{"text_format":"3","workbook":"xlsx","n_sheets":3,"sheets":["Activ-Protein processed Fig4","ABS iGc targets Supp FigS5","ABS mGc targets Supp FigS5"],"read":"whole","date_system":"1900"}

{"sheet":"Activ-Protein processed Fig4","index":0,"n_rows":159,"n_cols":38,"rows_kept":159,"merged":[[0,13,0,18],[0,21,0,23],[0,26,0,29]]}
["Compound identifier","Trivial name",null,"Final ABS IC50 (nM)","Final iGc IC50 (nM)","Final LGc IC50 (nM)","Final mGc IC50 (nM)",null,"FC iGC-ABS","FC LGc-ABS","FC mGc-ABS",null,"Target (implied/confirmed)","References",{"$nulls":5},"GeneID",null,"transcript expression (microarray) (Bozdech 2003, van Biljon 2019)",{"$nulls":4},"Proteome expression (Silvestrini 2010)",{"$nulls":3},"FC proteom (ABS/iGc)","FC proteom (ABS/mGc)",null,"Ratio: activity (iGc/ABS)/protein (ABS/iGc)","Ratio: activity (mGc/ABS)/protein (ABS/mGc)",null,"ABS/iGc cluster (based on ratio)","ABS/mGc cluster (based on ratio)"]
[{"$nulls":21},"ABS","iGc","mGc",null,null,"T","iGc","mGc","classification"]
["MMV1580857","Mupirocin",null,100.49,5000,null,5000,null,49.7561946462335,null,49.7561946462335,null,"isoleucine--tRNA ligase (cyto-IRS)","Validation of isoleucine utilization targets in Plasmodium falciparum. ES Istvan. 2011","Dual targeting of aminoacyl-tRNA synthetases to the apicoplast and cytosol in Plasmodium falciparum. KE Jackson. 2012",{"$nulls":4},"PF3D7_1332900",null,0.67,-0.18,-0.65,null,null,1.3845350808661399,2.2579551294528715,3.59886437939448,"shared 3 stages",0.6131809542210117,0.3847144362519968,null,81.14439025498434,129.33279845428532,null,1,1]
["MMV027634",null,null,37.74,5000,null,5000,null,132.485426603074,null,132.485426603074,null,"DHFR-TS","Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. Cowell. 2018","Using in Vitro Evolution and Whole Genome Analysis To Discover Next Generation Targets for Antimalarial Drug Discovery. MR Luth. 2018","Exploration of the Plasmodium falciparum Resistome and Druggable Genome Reveals New Mechanisms of Drug Resistance and Antimalarial Targets. A Cowell. 2018",{"$nulls":3},"PF3D7_0417200",null,0.11,0.52,0.13,null,null,1.15443469003188,0.6407679530676047,10.9377664171444,"gct V enriched",1.8016423644552657,0.10554574361931532,null,73.53591879103664,1000,null,1,2]
["MMV688533","MMV533",null,1.9,247.1,null,5000,null,130.052631578947,null,2631.57894736842,null,"EH domain-containing protein (EHD)"," The antimalarial MMV688533 provides potential for single-dose cures with a high barrier to Plasmodium falciparum parasite resistance James M Murithi 2021",{"$nulls":5},"PF3D7_0304200",null,0.52,-0.17,-0.37,null,null,0.8697210650705587,0.5334064717843519,1.97635144163132,"shared 3 stages",1.630503398583011,0.4400639717967739,null,79.76225728322284,1000,null,1,2]
["MMV1557821","SC83288",null,6.68,3903,null,5000,null,584.281437125749,null,748.502994011976,null,"mini-chromosome maintenance complex-binding protein","SC83288 is a clinical development candidate for the treatment of severe malaria S Pegoraro 2017","Target identification studies for SC83288: a novel drug for the treatment of severe malaria RV Celada 2022",{"$nulls":4},"PF3D7_1412100",null,1.16,0.17,0.19,null,null,0.22030595261377078,0.06444401261225294,0.0873356727196561,"enriched troph",3.418563551269049,2.522519673271926,null,170.91431192169878,296.7283077880233,null,1,3]
["MMV019555",null,null,20,1428,1547.9,470,null,71.4,77.395,23.5,null,"esterase","Combining stage specificity and metabolomic profiling to advance antimalarial drug discovery JM Murithi","Antiapicoplast and gametocytocidal screening to identify the mechanisms of action of compounds within the malaria box JD Bowman"," Evaluation of short-tether bis-THA AChE inhibitors. A further test of the dual binding site hypothesis PR Carlier",{"$nulls":5},1.01666666666667,-0.6,-0.753333333333333,"Average",null,0,0,23.6209240149463,"gct V enriched",1,0.05,null,71.4,470,null,1,4]
["MMV892604",null,null,151.9,5000,null,5000,null,32.916392363397,null,32.916392363397,null,"serine hydroxymethyltransferase (SHMT)","Provided from MMV",{"$nulls":5},"PF3D7_1235600",null,0.21,0.33,0.63,null,null,3.3570103694626154,12.41539811512397,47.9390091847749,"gct V enriched",0.2703908757765272,0.07002669488898779,null,121.73632808010035,470.0549185646822,null,1,4]
["MMV892604",null,null,151.9,5000,null,5000,null,32.916392363397,null,32.916392363397,null,"serine hydroxymethyltransferase (SHMT)","Provided from MMV",{"$nulls":5},"PF3D7_1456100",null,0.35,0.22,-0.21,null,null,3.3570103694626154,12.41539811512397,47.9390091847749,"gct V enriched",0.2703908757765272,0.07002669488898779,null,121.73632808010035,470.0549185646822,null,1,4]
["MMV1557821","SC83288",null,6.68,3903,null,5000,null,584.281437125749,null,748.502994011976,null,"Fe-S cluster assembly protein DRE2","SC83288 is a clinical development candidate for the treatment of severe malaria S Pegoraro 2017","Target identification studies for SC83288: a novel drug for the treatment of severe malaria RV Celada 2022",{"$nulls":4},"PF3D7_0824600",null,1.14,0.16,-0.15,null,null,1.2812367429334575,0.23330678076078387,1.05352502645715,"shared 3 stages",5.491639543246478,1.216142674125235,null,106.39471737439278,615.4730114625493,null,1,4]
["MMV1557821","SC83288",null,6.68,3903,null,5000,null,584.281437125749,null,748.502994011976,null,"fumarate hydratase (FH)","SC83288 is a clinical development candidate for the treatment of severe malaria S Pegoraro 2017","Target identification studies for SC83288: a novel drug for the treatment of severe malaria RV Celada 2022",{"$nulls":4},"PF3D7_0927300",null,0.23,0.16,0.19,null,null,0.16576703731775866,0.3188409631490102,3.01945033361513,"gct V enriched",0.5199050827113688,0.054899739688477986,null,1000,1000,null,2,2]
["MMV034055","ELQ-300",null,5,5000,null,5000,null,1000,null,1000,null,"mitochondrial cytochrome bc1 complex (Qi-site)","Nilsen A, LaCrue AN, White KL, Forquer IP, Cross RM, Marfurt J, Mather MW, Delves MJ, Shackleford DM, Saenz FE, Morrisey JM, Steuten J, Mutka T, Li Y, Wirjanata G, Ryan E, Duffy S, Kelly JX, Sebayang BF, Zeeman AM, Noviyanti R, Sinden RE, Kocken CH, Price RN, Avery VM, Angulo-Barturen I, Jimenez-Diaz MB, Ferrer S, Herreros E, Sanz LM, Gamo FJ, Bathurst I, Burrows JN, Siegl P, Guy RK, Winter RW, Vaidya AB, Charman SA, Kyle DE, Manetsch R, Riscoe MK. 2013. Quinolone-3-diarylethers: a new class of antimalarial drug. Sci Transl Med 5:177ra37.","Stickles AM, de Almeida MJ, Morrisey JM, Sheridan KA, Forquer IP, Nilsen A, Winter RW, Burrows JN, Fidock DA, Vaidya AB et al.. (2015) Subtle changes in endochin-like quinolone structure alter the site of inhibition within the cytochrome bc1 complex of Plasmodium falciparum. ",{"$nulls":6},0.848333333333333,0.98,0.81,"Average",null,0.4530828604879675,1.7006577915597767,7.360729507627478,"gct V enriched",0.2664162436067856,0.06155407015275662,null,1000,1000,null,2,2]
["MMV018912","DSM265",null,4.3,5000,null,5000,null,1162.79069767442,null,1162.79069767442,null,"PfDHODH","Phillips MA, Lotharius J, Marsh K, White J, Dayan A, White KL, Njoroge JW, El Mazouni F, Lao Y, Kokkonda S, Tomchick DR, Deng X, Laird T, Bhatia SN, March S, Ng CL, Fidock DA, Wittlin S, Lafuente-Monasterio M, Benito FJ, Alonso LM, Martinez MS, Jimenez-Diaz MB, Bazaga SF, Angulo-Barturen I, Haselden JN, Louttit J, Cui Y, Sridhar A, Zeeman AM, Kocken C, Sauerwein R, Dechering K, Avery VM, Duffy S, Delves M, Sinden R, Ruecker A, Wickham KS, Rochford R, Gahagen J, Iyer L, Riccio E, Mirsalis J, Bathhurst I, Rueckle T, Ding X, Campo B, Leroy D, Rogers MJ, etal. 2015. A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria. Sci Transl Med 7:296ra111.",{"$nulls":5},"PF3D7_0603300",null,0.75,-0.19,-0.43,null,null,1.15443469003188,0.7714114432536744,1.89426612471675,"shared 3 stages",1.4965226405803402,0.6094363801202974,null,776.9950591749799,1000,null,2,2]
["MMV000024","Pyrimethamine",null,2.5,5000,5000,5000,null,2000,2000,2000,null,"DHFR-TS","Basco LK, Eldin de Pecoulas P, Wilson CM, Le Bras J, Mazabraud A. 1995. Point mutations in the dihydrofolate reductase-thymidylate synthase gene and pyrimethamine and cycloguanil resistance in Plasmodium falciparum. Mol Biochem Parasitol 69:135–138.","Sirawaraporn W, Sathitkul T, Sirawaraporn R, Yuthavong Y, Santi DV. (1997) Antifolate-resistant mutants of Plasmodium falciparum dihydrofolate reductase. ","Yuthavong Y, Tarnchompoo B, Vilaivan T, Chitnumsub P, Kamchonwongpaisan S, Charman SA, McLennan DN, White KL, Vivas L, Bongard E et al.. (2012) Malarial dihydrofolate reductase as a paradigm for drug development against a resistance-compromised target. ",{"$nulls":3},"PF3D7_0417200",null,0.11,0.52,0.13,null,null,1.15443469003188,0.6407679530676047,10.9377664171444,"gct V enriched",1.8016423644552657,0.10554574361931532,null,1000,1000,null,2,2]
["MMV000046","Atovaquone",null,0.27,5000,34.79,1000,null,18518.5185185185,128.851851851852,3703.7037037037,null,"bc1 complex (Qo site)","Fry M, Pudney M. 1992. Site of action of the antimalarial hydroxynaphthoquinone, 2-[trans-4-(4′-chlorophenyl) cyclohexyl]-3-hydroxy-1,4-naphthoquinone (566C80). Biochem Pharmacol 43:1545–1553.","Birth D, Kao WC, Hunte C. 2014. Structural analysis of atovaquone- inhibited cytochrome bc1 complex reveals the molecular basis of anti- malarial drug action. Nat Commun 5:4029.","Srivastava IK, Rottenberg H, Vaidya AB. (1997) Atovaquone, a broad spectrum antiparasitic drug, collapses mitochondrial membrane potential in a malarial parasite. ","Vaidya AB, Lashgari MS, Pologe LG, Morrisey J. (1993) Structural features of Plasmodium cytochrome b that may underlie susceptibility to 8-aminoquinolines and hydroxynaphthoquinones. ",{"$nulls":4},0.848333333333333,0.98,0.81,"Average",null,0.4530828604879675,1.7006577915597767,7.360729507627478,"gct V enriched",0.2664162436067856,0.06155407015275662,null,1000,1000,null,2,2]
["MMV1576861","49c",null,0.6,1031,null,5000,null,1718.33333333333,null,8333.33333333333,null,"plasmepsin X (PMX)","Pino P, Caldelari R, Mukherjee B, Vahokoski J, Klages N, Maco B, Collins CR, Blackman MJ, Kursula I, Heussler V et al.. (2017) A multistage antimalarial targets the plasmepsins IX and X essential for invasion and egress. ","C.-L. Ciana, Novel in vivo active anti-malarials based on a hydroxy-ethyl-amine scaffold. 2013","W.A. Guiguemde, A.A. Shelat, D. Bouck, S. Duffy, G.J. Crowther, P.H. Davis, D.C. Smithson, M. Connelly, J. Clark, F. Zhu, M.B. Jiménez-Díaz, M.S. Martinez, E.B. Wilson, A.K. Tripathi, J. Gut, E.R. Sharlow. Chemical genetics of Plasmodium falciparum. 2010",{"$nulls":3},"PF3D7_0808200",null,1.26,-0.79,0.17,null,null,0,0,0.99526231496888,"gct V enriched",1,2,null,1000,1000,null,2,2]
["MMV884705","NMT-145",null,0.144,5000,null,5000,null,34722.2222222222,null,34722.2222222222,null,"glycylpeptide N-tetradecanoyltransferase (NMT)","Selective Inhibitors of Protozoan Protein N-myristoyltransferases as Starting Points for Tropical Disease Medicinal Chemistry Programs Andrew S. Bell 2012",{"$nulls":5},"PF3D7_1412800",null,0.91,-0.29,-0.56,null,null,2.1250813598006153,1.3648237269808132,2.98107170553497,"shared 3 stages",1.5570372333001579,0.7128581831342623,null,1000,1000,null,2,2]
["MMV666693",null,null,23.8,5000,438,730,null,210.084033613445,18.4033613445378,30.672268907563,null,"bc1 inhibitor","E.L. Allman, H.J. Painter, J. Samra, M. Carrasquilla, M. Llinas Metabolomic profiling of the malaria box reveals antimalarial target pathways 2016","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond Voorhis 2016","Small molecule screen for candidate antimalarials targeting Plasmodium Kinesin-5 L Liu","Metabolomics-based screening of the malaria box reveals both novel and established mechanisms of action DJ Creek","High-throughput luciferase-based assay for the discovery of therapeutics that prevent malaria J Swann",{"$nulls":3},0.848333333333333,0.98,0.81,"Average",null,0.4530828604879675,1.7006577915597767,7.360729507627478,"gct V enriched",0.2664162436067856,0.06155407015275662,null,788.5556479938843,498.2979814567044,null,2,4]
["MMV1557821","SC83288",null,6.68,3903,null,5000,null,584.281437125749,null,748.502994011976,null,"casein kinase 2, alpha subunit","SC83288 is a clinical development candidate for the treatment of severe malaria S Pegoraro 2017","Target identification studies for SC83288: a novel drug for the treatment of severe malaria RV Celada 2022",{"$nulls":4},"PF3D7_1108400",null,0.45,0.17,0.01,null,null,60.79064011727486,103.28083452179338,47.3293023857175,"shared 3 stages",0.5885955550102316,1.2844186804582942,null,992.6704885081775,582.7562347075973,null,2,4]
["MMV666023",null,null,36.8,2000,183.5,5000,null,54.3478260869565,4.98641304347826,135.869565217391,null,"bc1 inhibitor","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond Voorhis 2016","Screening the Medicines for Malaria Venture \"Malaria Box\" against the Plasmodium falciparum Aminopeptidases, M1, M17 and M18 A Paiardini","Malaria Box Compounds against Anopheles gambiae (Diptera: Culicidae) Carboxypeptidase B Activity to Block Malaria Transmission T Pomun","Metabolomics-based screening of the malaria box reveals both novel and established mechanisms of action DJ Creek",{"$nulls":4},0.848333333333333,0.98,0.81,"Average",null,0.4530828604879675,1.7006577915597767,7.360729507627478,"gct V enriched",0.2664162436067856,0.06155407015275662,null,203.99591763320052,1000,null,3,2]
["MMV1793799","ML10",null,18.15,5000,null,5000,null,275.482093663912,null,275.482093663912,null,"PKG"," A potent series targeting the malarial cGMP-dependent protein kinase clears infection and blocks transmission. DA Baker. 2017",{"$nulls":5},"PF3D7_1436600",null,0.47,-0.44,0.1,null,null,0,0.068244893498124,2.02530545710245,"gct V enriched",0.8,0.2,null,344.35261707988985,1000,null,3,2]
["MMV1557821","SC83288",null,6.68,3903,null,5000,null,584.281437125749,null,748.502994011976,null,"calcium-transporting ATPase (ATP6)","SC83288 is a clinical development candidate for the treatment of severe malaria S Pegoraro 2017","Target identification studies for SC83288: a novel drug for the treatment of severe malaria RV Celada 2022",{"$nulls":4},"PF3D7_0106300",null,0.39,-0.03,-0.13,null,null,1.6876027710717014,0.7605873874153525,3.93796931771435,"shared 3 stages",2.2188150881735713,0.4285464499381139,null,263.3303875748847,1000,null,3,2]
["MMV1557821","SC83288",null,6.68,3903,null,5000,null,584.281437125749,null,748.502994011976,null,"casein kinase II beta chain","SC83288 is a clinical development candidate for the treatment of severe malaria S Pegoraro 2017","Target identification studies for SC83288: a novel drug for the treatment of severe malaria RV Celada 2022",{"$nulls":4},"PF3D7_1103700",null,0.9,0.14,-0.56,null,null,3.2187487937519563,1.8900861310663797,4.08021804691302,"shared 3 stages",1.7029640823489616,0.7888668587668183,null,343.09674712565135,948.8331087733355,null,3,2]
["MMV1557821","SC83288",null,6.68,3903,null,5000,null,584.281437125749,null,748.502994011976,null,"casein kinase II beta chain","SC83288 is a clinical development candidate for the treatment of severe malaria S Pegoraro 2017","Target identification studies for SC83288: a novel drug for the treatment of severe malaria RV Celada 2022",{"$nulls":4},"PF3D7_1342400",null,0.4,0.07,-0.15,null,null,2.257613856055447,1.1731201409058445,1.37137370566166,"enriched troph",1.7029640823489616,1.6462426300978217,null,343.09674712565135,454.6735580328758,null,3,4]
["MMV000445",null,null,1.97,2000,1611,3586.66,null,1015.22842639594,817.766497461929,1820.63959390863,null,"phosphoethanolamine methyltransferase (PfPMT)","Open Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and Beyond Wesley C. Van Voorhis 2016",{"$nulls":5},"PF3D7_1343000",null,0.77,1.48,0.61,null,null,336.4138014225539,83.2557979663136,10.5478198468946,"enriched troph",4.040725206413509,31.89415502973328,null,251.24906409981827,57.083800847250586,null,3,5]
["MMV1557821","SC83288",null,6.68,3903,null,5000,null,584.281437125749,null,748.502994011976,null,"cytosolic iron-sulfur assembly component 2","SC83288 is a clinical development candidate for the treatment of severe malaria S Pegoraro 2017","Target identification studies for SC83288: a novel drug for the treatment of severe malaria RV Celada 2022",{"$nulls":4},"PF3D7_0703100",null,0.86,0.01,-0.27,null,null,0,0,0.701254279852589,"gct V enriched",0.3,0.4,null,1000,1000,null,4,2]
["MMV000147","P218",null,6,5000,null,5000,null,833.333333333333,null,833.333333333333,null,"DHFR-TS","Yuthavong Y, Tarnchompoo B, Vilaivan T, Chitnumsub P, Kamchonwongpaisan S, Charman SA, McLennan DN, White KL, Vivas L, Bongard E, Thongphanchang C, Taweechai S, Vanichtanankul J, Rattanajak R, Arwon U, Fantauzzi P, Yuvaniyama J, Charman WN, Matthews D. 2012. Malarial dihydrofolate reductase as a paradigm for drug development against a resistance-compromised target. Proc Natl Acad Sci U S A 109:16823–16828",{"$nulls":5},"PF3D7_0417200",null,0.11,0.52,0.13,null,null,1.15443469003188,0.6407679530676047,10.9377664171444,"gct V enriched",1.8016423644552657,0.10554574361931532,null,462.5409291956205,1000,null,4,2]
["MMV000130","Ganaplacide/KAF156",null,{"v":6,"d":"6.00"},{"v":3300,"d":"3300.00"},null,{"v":5000,"d":"5000.00"},null,{"v":550,"d":"550.0000"},null,{"v":833.3333333333334,"d":"833.33"},null,"CARL","Pan-active imidazolopiperazine antimalarials target the Plasmodium falciparum intracellular secretory pathway. GM LaMonte. 2020",{"$nulls":5},"PF3D7_0321900",null,0.31,-0.21,-0.06,null,null,0,0,0.0537249727360731,"gct V enriched",1,0.8,null,550,1000,null,4,2]
["MMV1793038","BRD7539",null,5.54,5000,null,5000,null,902.527075812274,null,902.527075812274,null,"PfDHODH","Discovery of Antimalarial Azetidine-2-carbonitriles That Inhibit P. falciparum Dihydroorotate Dehydrogenase. M Maetani. 2017","Diversity-oriented synthesis yields novel multistage antimalarial inhibitors. Nobutaka Kato. 2016","Painter, H. J., Morrisey, J. M., Mather, M. W. & Vaidya, A. B. Specific role of mitochondrial electron transport in blood-stage Plasmodium falciparum. Nature 446",{"$nulls":3},"PF3D7_0603300",null,0.75,-0.19,-0.43,null,null,1.15443469003188,0.7714114432536744,1.89426612471675,"shared 3 stages",1.4965226405803402,0.6094363801202974,null,603.0828076628906,1000,null,4,2]
["MMV007384",null,null,100,949,1113.5,870,null,9.49,11.135,8.7,null,"6-phosphogluconate dehydrogenase","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond Voorhis 2016","New insights into novel inhibitors against deoxyhypusine hydroxylase from Plasmodium falciparum: compounds with an iron chelating potential I von Koschitzky","Identification of β-hematin inhibitors in the MMV Malaria Box KY Fong","Characterization of Plasmodium falciparum 6-phosphogluconate dehydrogenase as an antimalarial drug target K Haeussler,","Bilayer Effects of Antimalarial Compounds Nicole B. Ramsey",null,"PF3D7_1454700",null,0.29,0.18,-0.08,null,null,1.7176232460629302,5.869374848204267,16.4332882219999,"gct V enriched",0.29264159991220123,0.10452097126632753,null,32.42874561527549,83.23688437444505,null,5,1]
["MMV666054",null,null,499.444167,2000,1075,5000,null,4.00445161270649,2.15239274182974,10.0111290317662,null,"MAPK2","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond Voorhis 2016","Screening the Medicines for Malaria Venture \"Malaria Box\" against the Plasmodium falciparum Aminopeptidases, M1, M17 and M18 A Paiardini",{"$nulls":4},"PF3D7_1113900",null,0.53,1.03,0.24,null,null,0,0,3.89390091847749,"gct V enriched",1,0.05,null,4.004451612706491,200.222580635324,null,5,1]
["MMV000787",null,null,407,2000,584,4574.65,null,4.91400491400491,1.43488943488943,11.2399262899263,null,"CytBC1","Combining stage specificity and metabolomic profiling to advance antimalarial drug discovery JM Murithi 2020","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond Voorhis 2016",{"$nulls":6},0.848333333333333,0.98,0.81,"Average",null,0.4530828604879675,1.7006577915597767,7.360729507627478,"gct V enriched",0.2664162436067856,0.06155407015275662,null,18.444839727031397,182.602486919753,null,5,1]
["MMV665969",null,null,393,5000,1881,5000,null,12.7226463104326,4.78625954198473,12.7226463104326,null,"DHFR-TS","MMV Malaria Box Activity Screening in Dormant Plasmodium falciparum Phenotypes S Galusic",{"$nulls":5},"PF3D7_0417200",null,0.11,0.52,0.13,null,null,1.15443469003188,0.6407679530676047,10.9377664171444,"gct V enriched",1.8016423644552657,0.10554574361931532,null,7.0616935755056565,120.54153842831329,null,5,1]
["MMV011438",null,null,50,1656,1129.5,820,null,33.12,22.59,16.4,null,"phosphopantothenoylcysteine decarboxylase","Istvan, E. S., Mallari, J. P., Corey, V. C., Dharia, N. V., Marshall, G. R., Winzeler, E. A., and Goldberg, D. E. (2017) Esterase mutation is a mechanism of resistance to antimalarial compounds. Nat. Commu","A novel approach for the discovery of chemically diverse anti-malarial compounds targeting the Plasmodium falciparum Coenzyme A synthesis pathway Sabine Fletcher",{"$nulls":4},"PF3D7_0816100",null,0.73,-0.05,0.35,null,null,0,2.1471274463127243,1.89426612471675,"gct I/II enriched",4,0.1,null,8.28,163.99999999999997,null,5,1]
["MMV652103",null,null,7.25,59.6,5,133.3,null,8.22068965517241,0.689655172413793,18.3862068965517,null,"PKG","Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): preparation and evaluation of pyrazole … JM Large","Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) TM Chapman","New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of Plasmodium Phosphatidylinositol-4-kinase and cGMP … PM Cheuka","Exploring the transmission-blocking activity of antiplasmodial 3, 6-diarylated imidazopyridazines D Coertzen",null,null,"PF3D7_1436600",null,0.47,-0.44,0.1,null,null,0,0.068244893498124,2.02530545710245,"gct V enriched",0.8,0.2,null,10.275862068965518,91.93103448275849,null,5,1]
["MMV006787",null,null,200.9,1645,1170,3713.2,null,8.18815331010453,5.82379293180687,18.4828272772524,null,"Hsp90","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond Voorhis 2016",{"$nulls":5},"PF3D7_0708400",null,0.47,0.14,-0.37,null,null,391.244342138169,487.5030361563116,2642.7611857491,"gct V enriched",0.8025474984174693,0.14804377491539,null,10.202702427271431,124.84704127421574,null,5,1]
["MMV000061","Methylene Blue",null,21.7,62.7,null,457,null,2.88940092165899,null,21.0599078341014,null,"glutathione reductase (GR)","Buchholz K, Schirmer RH, Eubel JK, Akoachere MB, Dandekar T, Becker K, Gromer S. 2008. Interactions of methylene blue with human disulfide reductases and their orthologues from Plasmodium falciparum. Antimicrob. Agents Chemother. 52:183–191.","Vennerstrom JL, Makler MT, Angerhofer CK, Williams JA. 1995. Antimalarial dyes revisited: xanthenes, azines, oxazines, and thiazines. Antimicrob Agents Chemother 39:2671–2677. https://doi.org/10.1128/AAC.39 .12.2671",{"$nulls":4},"PF3D7_1419800",null,0.71,0.64,-0.14,null,null,1.15443469003188,1.0570182237640764,9,"gct V enriched",1.0921615768561685,0.12827052111465334,null,2.645580088961053,164.18353688044354,null,5,1]
["MMV675615",null,null,4.47,163.2,72.1,104.2,null,36.510067114094,16.1297539149888,23.3109619686801,null,"PKG","Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): preparation and evaluation of pyrazole … JM Large","Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) TM Chapman","New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of Plasmodium Phosphatidylinositol-4-kinase and cGMP … PM Cheuka"," Potent Plasmodium falciparum gametocytocidal compounds identified by exploring the kinase inhibitor chemical space for dual active antimalarials Mariëtte E van der Watt, ",null,null,"PF3D7_1436600",null,0.47,-0.44,0.1,null,null,0,0.068244893498124,2.02530545710245,"gct V enriched",0.8,0.2,null,45.63758389261745,116.55480984340049,null,5,1]
["MMV030084",null,null,160.17,5000,null,5000,null,31.2168321158769,null,31.2168321158769,null,"PKG","Inhibition of resistance-refractory P. falciparum kinase PKG delivers prophylactic, blood stage, and transmission-blocking antiplasmodial activity. M. Vanaerschot, 2020",{"$nulls":5},"PF3D7_1436600",null,0.47,-0.44,0.1,null,null,0,0.068244893498124,2.02530545710245,"gct V enriched",0.8,0.2,null,39.021040144846104,156.0841605793845,null,5,1]
["MMV672652",null,null,0.56,10.8,3.3,18.1,null,19.2857142857143,5.89285714285714,32.3214285714286,null,"CDPK1","Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): preparation and evaluation of pyrazole … JM Large","Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) TM Chapman","New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of Plasmodium Phosphatidylinositol-4-kinase and cGMP … PM Cheuka",{"$nulls":3},"PF3D7_0217500",null,0.54,-0.07,0.86,null,null,1.8276642121903912,0.8228906159046369,5.07832312829723,"shared 3 stages",2.2210293529488925,0.35989521856266954,null,8.6832325111365,89.80788547431169,null,5,1]
["MMV672652",null,null,0.56,10.8,3.3,18.1,null,19.2857142857143,5.89285714285714,32.3214285714286,null,"PKG","Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): preparation and evaluation of pyrazole … JM Large","Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) TM Chapman","New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of Plasmodium Phosphatidylinositol-4-kinase and cGMP … PM Cheuka",{"$nulls":3},"PF3D7_1436600",null,0.47,-0.44,0.1,null,null,0,0.068244893498124,2.02530545710245,"gct V enriched",0.8,0.2,null,24.107142857142858,161.60714285714297,null,5,1]
["MMV674766",null,null,7.86,93.9,66.4,262.9,null,11.9465648854962,8.44783715012723,33.4478371501272,null,"CDPK1","Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): preparation and evaluation of pyrazole … JM Large","Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) TM Chapman","New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of Plasmodium Phosphatidylinositol-4-kinase and cGMP … PM Cheuka",{"$nulls":3},"PF3D7_0217500",null,0.54,-0.07,0.86,null,null,1.8276642121903912,0.8228906159046369,5.07832312829723,"shared 3 stages",2.2210293529488925,0.35989521856266954,null,5.3788415131184815,92.93770915798603,null,5,1]
["MMV674766",null,null,7.86,93.9,66.4,262.9,null,11.9465648854962,8.44783715012723,33.4478371501272,null,"PKG","Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): preparation and evaluation of pyrazole … JM Large","Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) TM Chapman","New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of Plasmodium Phosphatidylinositol-4-kinase and cGMP … PM Cheuka",{"$nulls":3},"PF3D7_1436600",null,0.47,-0.44,0.1,null,null,0,0.068244893498124,2.02530545710245,"gct V enriched",0.8,0.2,null,14.933206106870227,167.23918575063598,null,5,1]
["MMV666620",null,null,11.59,68.4,78.9,428,null,5.9016393442623,6.80759275237273,36.9283865401208,null,"CDPK1","Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): preparation and evaluation of pyrazole … JM Large","Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) TM Chapman","New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of Plasmodium Phosphatidylinositol-4-kinase and cGMP … PM Cheuka",{"$nulls":3},"PF3D7_0217500",null,0.54,-0.07,0.86,null,null,1.8276642121903912,0.8228906159046369,5.07832312829723,"shared 3 stages",2.2210293529488925,0.35989521856266954,null,2.6571640471237377,102.60871674706719,null,5,1]
["MMV666620",null,null,11.59,68.4,78.9,428,null,5.9016393442623,6.80759275237273,36.9283865401208,null,"PKG","Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): preparation and evaluation of pyrazole … JM Large","Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) TM Chapman","New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of Plasmodium Phosphatidylinositol-4-kinase and cGMP … PM Cheuka",{"$nulls":3},"PF3D7_1436600",null,0.47,-0.44,0.1,null,null,0,0.068244893498124,2.02530545710245,"gct V enriched",0.8,0.2,null,7.377049180327869,184.64193270060397,null,5,1]
["MMV669286",null,null,0.88,4.1,3,34.2,null,4.65909090909091,3.40909090909091,38.8636363636364,null,"CDPK1","Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): preparation and evaluation of pyrazole … JM Large","Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) TM Chapman","New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of Plasmodium Phosphatidylinositol-4-kinase and cGMP … PM Cheuka",{"$nulls":3},"PF3D7_0217500",null,0.54,-0.07,0.86,null,null,1.8276642121903912,0.8228906159046369,5.07832312829723,"shared 3 stages",2.2210293529488925,0.35989521856266954,null,2.097716945030451,107.98597580386851,null,5,1]
["MMV669286",null,null,0.88,4.1,3,34.2,null,4.65909090909091,3.40909090909091,38.8636363636364,null,"PKG","Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): preparation and evaluation of pyrazole … JM Large","Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) TM Chapman","New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of Plasmodium Phosphatidylinositol-4-kinase and cGMP … PM Cheuka",{"$nulls":3},"PF3D7_1436600",null,0.47,-0.44,0.1,null,null,0,0.068244893498124,2.02530545710245,"gct V enriched",0.8,0.2,null,5.823863636363638,194.318181818182,null,5,1]
["MMV000025","Pyronaridine",null,17,27,null,938.4,null,1.58823529411765,null,55.2,null,"DNA topoisomerase2 (TOP2)","Pyronaridine: An update of its pharmacological activities andmechanisms of action Christian Bailly 2021","Review of pyronaridine anti-malarial properties and product characteristics Simon L Croft 2012",{"$nulls":4},"PF3D7_1433500",null,0.79,-0.02,0.28,null,null,1.1250623353878415,0.9615132377040246,2.43332001828199,"shared 3 stages",1.1700955236709503,0.46235691439475163,null,1.3573552432154115,119.38828701688082,null,5,1]
["MMV000073","Cipargamin/KAE609/NITD609",null,0.5,1.03,null,27.7,null,2.06,null,55.4,null,"ATP4","Rottmann M, McNamara C, Yeung BK, Lee MC, Zou B, Russell B, Seitz P, Plouffe DM, Dharia NV, Tan J, Cohen SB, Spencer KR, Gonzalez-Paez GE, Lakshminarayana SB, Goh A, Suwanarusk R, Jegla T, Schmitt EK, Beck HP, Brun R, Nosten F, Renia L, Dartois V, Keller TH, Fidock DA, Winzeler EA, Diagana TT. 2010. Spiroindolones, a potent compound class for the treatment of malaria. Science 329:1175–1180.","N.J. Spillman, R.J. Allen, C.W. McNamara, B.K.S. Yeung, E.A. Winzeler, et al. Na+ regulation in the malaria parasite Plasmodium falciparum involves the cation ATPase PfATP4 and is a target of the spiroindolone antimalarials 2013","J.C. Van Pelt-Koops, H.E. Pett, W. Graumans, M. van der Vegte-Bolmer, G.J. van Gemert, M. Rottmann, et al. The spiroindolone drug candidate NITD609 potently inhibits gametocytogenesis and blocks Plasmodium falciparum transmission to anopheles mosquito vector 2012",{"$nulls":3},"PF3D7_1211900",null,0.33,-0.22,-0.49,null,null,1.7731908623980155,0.4394601472062679,2.59381366380463,"shared 3 stages",4.034929842149575,0.6836230709792325,null,0.5105417146243495,81.03880976492523,null,5,1]
["MMV000062","Pentamidine",null,10,697.28,812.56,700,null,69.728,81.256,70,null,"DNA topoisomerase2 (TOP2)","A. Stead, P.G. Bray, I.G. Edwards, H.P. DeKoning, B.C. Elford, P.A. Stocks, S.A. Ward Mol. Pharmacol., 59 (2001), pp. 1298-1306","A.E. Purfield, R.R. Tidwell, S.R. Meshnik Malar. J., 8 (2009), p. 104",{"$nulls":4},"PF3D7_1433500",null,0.79,-0.02,0.28,null,null,1.1250623353878415,0.9615132377040246,2.43332001828199,"shared 3 stages",1.1700955236709503,0.46235691439475163,null,59.59171588080413,151.39819005763871,null,5,1]
["MMV000062","Pentamidine",null,10,697.28,812.56,700,null,69.728,81.256,70,null,"calcium-transporting ATPase (ATP6)","A. Stead, P.G. Bray, I.G. Edwards, H.P. DeKoning, B.C. Elford, P.A. Stocks, S.A. Ward Mol. Pharmacol., 59 (2001), pp. 1298-1306","A.E. Purfield, R.R. Tidwell, S.R. Meshnik Malar. J., 8 (2009), p. 104",{"$nulls":4},"PF3D7_0106300",null,0.39,-0.03,-0.13,null,null,1.6876027710717014,0.7605873874153525,3.93796931771435,"shared 3 stages",2.2188150881735713,0.4285464499381139,null,31.3636364,163.34285352289967,null,5,1]
["MMV000662",null,null,36.7,1388,2000,3324.48,null,37.8201634877384,54.4959128065395,90.5852861035422,null,"ATP4","E.L. Allman, H.J. Painter, J. Samra, M. Carrasquilla, M. Llinas Metabolomic profiling of the malaria box reveals antimalarial target pathways 2016","Diverse chemotypes disrupt ion homeostasis in the malaria parasite AM Lehane 2014","Biochemical characterization and chemical inhibition of PfATP4-associated Na+-ATPase activity in Plasmodium falciparum membranes JEO Rosling 2018",{"$nulls":3},"PF3D7_1211900",null,0.33,-0.22,-0.49,null,null,1.7731908623980155,0.4394601472062679,2.59381366380463,"shared 3 stages",4.034929842149575,0.6836230709792325,null,9.373189861360773,132.50764924271266,null,5,1]
["MMV652007","AN3661",null,46.26,1086,null,5000,null,23.4760051880674,null,108.084738434933,null,"Cleavage and polyadenylation specificity factor subunit 3 (CPSF3)","A potent antimalarial benzoxaborole targets a Plasmodium falciparum cleavage and polyadenylation specificity factor homologue. Ebere Sonoiki. 2017",{"$nulls":5},"PF3D7_1438500",null,0.77,0.29,0.06,null,null,0.19077316861219132,0.1746748582396935,0,"enriched troph",1.0921615768561683,1.2,null,21.49499276072693,90.07061536244417,null,5,1]
["MMV652103",null,null,7.25,59.6,5,133.3,null,8.22068965517241,0.689655172413793,18.3862068965517,null,"CDPK4","Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): preparation and evaluation of pyrazole … JM Large","Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) TM Chapman","New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of Plasmodium Phosphatidylinositol-4-kinase and cGMP … PM Cheuka","Exploring the transmission-blocking activity of antiplasmodial 3, 6-diarylated imidazopyridazines D Coertzen",null,null,"PF3D7_0717500",null,0.32,0.52,0.27,null,null,0,0.40541168873881694,56.3615251044868,"gct V enriched",0.4,1E-3,null,20.551724137931036,1000,null,5,2]
["MMV672652",null,null,0.56,10.8,3.3,18.1,null,19.2857142857143,5.89285714285714,32.3214285714286,null,"CDPK4","Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): preparation and evaluation of pyrazole … JM Large","Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) TM Chapman","New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of Plasmodium Phosphatidylinositol-4-kinase and cGMP … PM Cheuka",{"$nulls":3},"PF3D7_0717500",null,0.32,0.52,0.27,null,null,0,0.40541168873881694,56.3615251044868,"gct V enriched",0.4,1E-3,null,48.214285714285715,1000,null,5,2]
["MMV666620",null,null,11.59,68.4,78.9,428,null,5.9016393442623,6.80759275237273,36.9283865401208,null,"CDPK4","Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): preparation and evaluation of pyrazole … JM Large","Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) TM Chapman","New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of Plasmodium Phosphatidylinositol-4-kinase and cGMP … PM Cheuka",{"$nulls":3},"PF3D7_0717500",null,0.32,0.52,0.27,null,null,0,0.40541168873881694,56.3615251044868,"gct V enriched",0.4,1E-3,null,14.754098360655737,1000,null,5,2]
["MMV669286",null,null,0.88,4.1,3,34.2,null,4.65909090909091,3.40909090909091,38.8636363636364,null,"CDPK4","Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): preparation and evaluation of pyrazole … JM Large","Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) TM Chapman","New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of Plasmodium Phosphatidylinositol-4-kinase and cGMP … PM Cheuka",{"$nulls":3},"PF3D7_0717500",null,0.32,0.52,0.27,null,null,0,0.40541168873881694,56.3615251044868,"gct V enriched",0.4,1E-3,null,11.647727272727275,1000,null,5,2]
["MMV666021",null,null,94.4,819,603,5000,null,8.67584745762712,6.38771186440678,52.9661016949153,null,"Mitochondrial electron transport chain (bc1 inhibitor) (Gamo)","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond Voorhis 2016","The relative rate of kill of the MMV Malaria Box compounds provides links to the mode of antimalarial action and highlights scaffolds of medicinal chemistry interest I Ullah",{"$nulls":6},0.848333333333333,0.98,0.81,"Average",null,0.4530828604879675,1.7006577915597767,7.360729507627478,"gct V enriched",0.2664162436067856,0.06155407015275662,null,32.565009325903375,860.4809001820862,null,5,2]
["MMV674850",null,null,2.65,4.47,28.7,208.8,null,1.68679245283019,10.8301886792453,78.7924528301887,null,"CDPK4","Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): preparation and evaluation of pyrazole … JM Large","Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) TM Chapman","New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of Plasmodium Phosphatidylinositol-4-kinase and cGMP … PM Cheuka",{"$nulls":3},"PF3D7_0717500",null,0.32,0.52,0.27,null,null,0,0.40541168873881694,56.3615251044868,"gct V enriched",0.4,1E-3,null,4.216981132075472,1000,null,5,2]
["MMV674253","AZ412/MMV253",null,9,141.97,null,5000,null,15.7744444444444,null,555.555555555556,null,"Vacuolar ATP synthase (V-type H+-ATPase) subunit D","Hameed PS, Solapure S, Patil V, Henrich PP, Magistrado PA, Bharath S, Murugan K, Viswanath P, Puttur J, Srivastava A, Bellale E, Panduga V, Shanbag G, Awasthy D, Landge S, Morayya S, Koushik K, Saralaya R, Raichurkar A, Rautela N, Roy Choudhury N, Ambady A, Nandishaiah R, Reddy J, Prabhakar KR, Menasinakai S, Rudrapatna S, Chatterji M, Jimenez-Diaz MB, Martinez MS, Sanz LM, Coburn-Flynn O, Fidock DA, Lukens AK, Wirth DF, Bandodkar B, Mukherjee K, McLaughlin RE, Waterson D, Rosenbrier-Ribeiro L, Hickling K, Balasubramanian V, Warner P, Hosagrahara V, Dudley A, Iyer PS, Narayanan S, Kavanagh S, Sambandamurthy VK. 2015. Triaminopyrimidine is a fast-killing and long-acting antimalarial clinical candidate. Nat Commun 6:6715.",{"$nulls":5},"PF3D7_1341900",null,0.35,0.76,0.31,null,null,1.76006068659215,1.255572788203053,28.7635144163132,"gct V enriched",1.4017990061023133,0.06119073841664958,null,11.253000163201081,1000,null,5,2]
["MMV688533","MMV533",null,1.9,247.1,null,5000,null,130.052631578947,null,2631.57894736842,null,"Plasmodium protein (PfACG1)"," The antimalarial MMV688533 provides potential for single-dose cures with a high barrier to Plasmodium falciparum parasite resistance James M Murithi 2021",{"$nulls":5},"PF3D7_0910300",null,1,1.02,0.36,null,null,0,1.0364555891885496,1.31012970008316,"gct V enriched",2,2,null,65.02631578947368,1000,null,5,2]
["MMV687815","BRD7929",null,1.07,12.45,null,5000,null,11.6355140186916,null,4672.89719626168,null,"phenylalanine-tRNA synthetase (PheRS/FRS)","Inhibition of Plasmodium falciparum phenylalanine tRNA synthetase provides opportunity for antimalarial drug development. Sharma. 2022","Novel antimalarial target identified. Crunkhorn. 2016","Kato N, Comer E, Sakata-Kato T, Sharma A, Sharma M, Maetani M, Bastien J, Brancucci NM, Bittker JA, Corey V et al.. (2016) Diversity-oriented synthesis yields novel multistage antimalarial inhibitors. ",{"$nulls":3},"PF3D7_1104000",null,0.3,0.21,0.02,null,null,1.2020793536038865,1.1006424132444954,3.64158883361278,"shared 3 stages",1.011326538489894,0.33009749549657885,null,11.50519992886339,1000,null,5,2]
["MMV000011","Doxycycline hydrochloride",null,1258.92541179416,5000,5000,5000,null,3.97164117362143,3.97164117362143,3.97164117362143,null,"targets ribosomes"," Multiple antibiotics exert delayed effects against the Plasmodium falciparum apicoplast Erica L Dahl 2007",{"$nulls":7},0.801709677419355,0.480787096774194,0.155325806451613,"Average",null,24.71297769631029,85.40557604207882,1459.5331009753745,"gct V enriched",0.28936023666808774,0.016932111837542525,null,13.725594156798824,234.56265891271494,null,5,3]
["MMV007116",null,null,351,5000,253,5000,null,14.2450142450142,0.720797720797721,14.2450142450142,null,"Mitochondrial electron transport chain (bc1 inhibitor)","E.L. Allman, H.J. Painter, J. Samra, M. Carrasquilla, M. Llinas Metabolomic profiling of the malaria box reveals antimalarial target pathways 2016","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond Voorhis 2016","Metabolomics-based screening of the malaria box reveals both novel and established mechanisms of action DJ Creek",{"$nulls":5},0.848333333333333,0.98,0.81,"Average",null,0.4530828604879675,1.7006577915597767,7.360729507627478,"gct V enriched",0.2664162436067856,0.06155407015275662,null,53.46901544801837,231.42278341079376,null,5,3]
["MMV1577530","MMV1577530",null,25.87,147.14,null,481.57,null,5.68766911480479,null,18.6149980672594,null,"proteosome","Provided from MMV",{"$nulls":7},0.414285714285714,0.289285714285714,0.119285714285714,"Average",null,4.371904224875087,14.744723143961812,53.195817261465585,"gct V enriched",0.296506362458589,0.08218511247578938,null,19.182283535649763,226.50085284902573,null,5,3]
["MMV011895","MMV011895",null,233,2156,null,5000,null,9.25321888412017,null,21.4592274678112,null,"6-phosphogluconate dehydrogenase","Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. Cowell. 2018","Identification of β-hematin inhibitors in the MMV Malaria Box KY Fong 2015","Characterization of Plasmodium falciparum 6-phosphogluconate dehydrogenase as an antimalarial drug target K Haeussler 2018",{"$nulls":3},"PF3D7_1454700",null,0.29,0.18,-0.08,null,null,1.7176232460629302,5.869374848204267,16.4332882219999,"gct V enriched",0.29264159991220123,0.10452097126632753,null,31.619629221875275,205.3102569543812,null,5,3]
["MMV665980",null,null,210.8,5000,5000,5000,null,23.719165085389,23.719165085389,23.719165085389,null,"phosphopantothenoylcysteine decarboxylase","A novel approach for the discovery of chemically diverse anti-malarial compounds targeting the Plasmodium falciparum Coenzyme A synthesis pathway S Fletcher",{"$nulls":5},"PF3D7_0816100",null,0.73,-0.05,0.35,null,null,0,2.1471274463127243,1.89426612471675,"gct I/II enriched",4,0.1,null,5.929791271347249,237.19165085389,null,5,3]
["MMV674850",null,null,2.65,4.47,28.7,208.8,null,1.68679245283019,10.8301886792453,78.7924528301887,null,"CDPK1","Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): preparation and evaluation of pyrazole … JM Large","Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) TM Chapman","New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of Plasmodium Phosphatidylinositol-4-kinase and cGMP … PM Cheuka",{"$nulls":3},"PF3D7_0217500",null,0.54,-0.07,0.86,null,null,1.8276642121903912,0.8228906159046369,5.07832312829723,"shared 3 stages",2.2210293529488925,0.35989521856266954,null,0.7594642774939513,218.93164667445657,null,5,3]
["MMV674850",null,null,2.65,4.47,28.7,208.8,null,1.68679245283019,10.8301886792453,78.7924528301887,null,"PKG","Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): preparation and evaluation of pyrazole … JM Large","Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) TM Chapman","New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of Plasmodium Phosphatidylinositol-4-kinase and cGMP … PM Cheuka",{"$nulls":3},"PF3D7_1436600",null,0.47,-0.44,0.1,null,null,0,0.068244893498124,2.02530545710245,"gct V enriched",0.8,0.2,null,2.108490566037736,393.96226415094344,null,5,3]
["MMV666023",null,null,36.8,2000,183.5,5000,null,54.3478260869565,4.98641304347826,135.869565217391,null,"PfA-M17 leucyl aminopeptidase","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond Voorhis 2016","Screening the Medicines for Malaria Venture \"Malaria Box\" against the Plasmodium falciparum Aminopeptidases, M1, M17 and M18 A Paiardini","Malaria Box Compounds against Anopheles gambiae (Diptera: Culicidae) Carboxypeptidase B Activity to Block Malaria Transmission T Pomun","Metabolomics-based screening of the malaria box reveals both novel and established mechanisms of action DJ Creek",null,null,"PF3D7_1446200",null,0.54,0.07,-0.73,null,null,5.684407499026659,6.582454249212135,12.6500780654601,"shared 3 stages",0.8635696176250729,0.4493575035356835,null,62.93392562422473,302.3640734789724,null,5,3]
["MMV666023",null,null,36.8,2000,183.5,5000,null,54.3478260869565,4.98641304347826,135.869565217391,null,"PfA-M1 alanyl aminopeptidase","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond Voorhis 2016","Screening the Medicines for Malaria Venture \"Malaria Box\" against the Plasmodium falciparum Aminopeptidases, M1, M17 and M18 A Paiardini","Malaria Box Compounds against Anopheles gambiae (Diptera: Culicidae) Carboxypeptidase B Activity to Block Malaria Transmission T Pomun","Metabolomics-based screening of the malaria box reveals both novel and established mechanisms of action DJ Creek",null,null,"PF3D7_1311800",null,0.56,0.06,-0.86,null,null,15.969688689965796,9.989022559815394,32.8385515342823,"shared 3 stages",1.5987238585494725,0.4863091684568973,null,33.99450492736531,279.3892733886086,null,5,3]
["MMV1557817","MIPS1778",null,32.83,1798,null,5000,null,54.7669814194334,null,152.299725860493,null,"PfA-M17 leucyl aminopeptidase","Characterising the M1 and M17 aminopeptidases in Plasmodium falciparum. R Edgar. 2018",{"$nulls":5},"PF3D7_1446200",null,0.54,0.07,-0.73,null,null,5.684407499026659,6.582454249212135,12.6500780654601,"shared 3 stages",0.8635696176250729,0.4493575035356835,null,63.41930088977617,338.92774608669436,null,5,3]
["MMV1557817","MIPS1778",null,32.83,1798,null,5000,null,54.7669814194334,null,152.299725860493,null,"PfA-M1 alanyl aminopeptidase","Characterising the M1 and M17 aminopeptidases in Plasmodium falciparum. R Edgar. 2018",{"$nulls":5},"PF3D7_1311800",null,0.56,0.06,-0.86,null,null,15.969688689965796,9.989022559815394,32.8385515342823,"shared 3 stages",1.5987238585494725,0.4863091684568973,null,34.25668612284532,313.1746957264937,null,5,3]
["MMV000031","Cycloheximide",null,198,912.61,476.67,2692.47,null,4.60914141414141,2.40742424242424,13.5983333333333,null,"60S ribosomal subunit","Geary TG, Jensen JB. 1983. Effects of antibiotics on Plasmodium falciparum in vitro. Am. J. Trop. Med. Hyg. 32:221–225.",{"$nulls":7},0.896,0.4648,0.1642,"Average",null,28.652939691617416,19.96706839095079,1136.2749488814245,"gct V enriched",1.4350098437386594,0.025216554954260003,null,3.211923203351085,539.262137829658,null,5,4]
["MMV000054","Quinine",null,29.25,374.94,1000,5000,null,12.8184615384615,34.1880341880342,170.940170940171,null,"purine nucleoside phosphorylase (PNP)","A. F. Cowman, D. Galatis, J. K. Thompson, Selection for mefloquine resistance in Plasmodium falciparum is linked to amplification of the pfmdr1 gene and cross-resistance to halofantrine and quinine. Proc. Natl. Acad. Sci. U.S.A. 91, 1143–1147 (1994).","K. N. Olafson, T. Q. Nguyen, J. D. Rimer, P. G. Vekilov, Antimalarials inhibit hematin crystallization by unique drug–surface site interactions. Proc. Natl. Acad. Sci. U.S.A. 114, 7531–7536 (2017).","M. W. Davidson, B. G. Griggs, D. W. Boykin, W. D. Wilson, Molecular structural effects involved in the interaction of quinolinemethanolamines with DNA. Implications for antimalarial action. J. Med. Chem. 20, 1117–1122 (1977).","Identifying purine nucleoside phosphorylase as the target of quinine using cellular thermal shift assay Jerzy M. Dziekan 2020",null,null,"PF3D7_0513300",null,0.88,0.31,-0.78,null,null,59.71899427057608,106.97270748410696,226.584592607479,"gct V enriched",0.5582638382734081,0.2635615845867752,null,22.9612965405503,648.5777174552179,null,5,4]
["MMV1581373","KAE609 analog",null,0.55,1.14,null,0.11,null,{"v":2.0727272727272723,"d":"2.07"},null,{"v":0.19999999999999998,"d":"0.2000"},null,"ATP4","Provided from MMV",{"$nulls":5},"PF3D7_1211900",null,0.33,-0.22,-0.49,null,null,1.7731908623980155,0.4394601472062679,2.59381366380463,"shared 3 stages",4.034929842149575,0.6836230709792325,null,0.5136959882363269,0.2925588800177806,null,5,5]
["MMV643121","M5717 (DDD107498)",null,{"v":1,"d":"1.00"},3.57,null,0.25,null,3.57,null,{"v":0.25,"d":"0.2500"},null,"eEF2","Baragaña B, Hallyburton I, Lee MC, Norcross NR, Grimaldi R, Otto TD, Proto WR, Blagborough AM, Meister S, Wirjanata G et al.. (2015) A novel multiple-stage antimalarial agent that inhibits protein synthesis. ",{"$nulls":5},"PF3D7_1451100",null,0.72,-0.3,-1,null,null,36.215096568022325,20.79857304540562,60.2680478057332,"shared 3 stages",1.741229866537512,0.6009004420511069,null,2.0502749628910584,0.4160422967016845,null,5,5]
["Epoxomycin","Epoxomycin",null,{"v":8,"d":"8.00"},{"v":12.1,"d":"12.10"},{"v":0.42000000000000004,"d":"0.42"},{"v":3.8,"d":"3.80"},null,{"v":1.5125,"d":"1.51"},{"v":0.052500000000000005,"d":"0.05"},{"v":0.475,"d":"0.4750"},null,"Proteosome subunit beta type-5","rasad R, Atul Kolla VK, Legac J, Singhal N, NavaleR, Rosenthal PJ & Sijwali PS (2013) BlockingPlasmodium falciparumdevelopment via dualinhibition of hemoglobin degradation and theubiquitin proteasome system by MG13",{"$nulls":5},"PF3D7_1011400",null,0.17,0.88,0.57,null,null,1.3957664804363776,5.489058493010015,6.35642254459642,"gct V enriched",0.2542815825726401,0.21958365269831148,null,5.948130354930157,2.163184709622296,null,5,5]
["GNF179","GNF179",null,4.31,19.92,9.15,{"v":3.3609999999999998,"d":"3.36"},null,{"v":4.621809744779584,"d":"4.62"},{"v":2.122969837587007,"d":"2.12"},{"v":0.779814385150812,"d":"0.7798"},null,"CARL","Pan-active imidazolopiperazine antimalarials target the Plasmodium falciparum intracellular secretory pathway GM LaMonte","Plasmodium falciparum Cyclic Amine Resistance Locus (PfCARL), a Resistance Mechanism for Two Distinct Compound Classes Pamela A. Magistrado","UDP-galactose and Acetyl-CoA transporters as Plasmodium multidrug resistance genes Michelle Yi-Xiu Lim",{"$nulls":3},"PF3D7_0321900",null,0.31,-0.21,-0.06,null,null,0,0,0.0537249727360731,"gct V enriched",1,0.8,null,4.621809744779584,0.974767981438515,null,5,5]
["GNF179","GNF179",null,4.31,19.92,9.15,{"v":3.3609999999999998,"d":"3.36"},null,{"v":4.621809744779584,"d":"4.62"},{"v":2.122969837587007,"d":"2.12"},{"v":0.779814385150812,"d":"0.7798"},null,"acetyl-CoA transporter 1","Pan-active imidazolopiperazine antimalarials target the Plasmodium falciparum intracellular secretory pathway GM LaMonte","Plasmodium falciparum Cyclic Amine Resistance Locus (PfCARL), a Resistance Mechanism for Two Distinct Compound Classes Pamela A. Magistrado","UDP-galactose and Acetyl-CoA transporters as Plasmodium multidrug resistance genes Michelle Yi-Xiu Lim",{"$nulls":3},"PF3D7_1036800",null,1.52,0,0.37,null,null,0,0,0.737800828749376,"gct V enriched",2,0.2,null,2.310904872389792,3.89907192575406,null,5,5]
["GNF179","GNF179",null,4.31,19.92,9.15,{"v":3.3609999999999998,"d":"3.36"},null,{"v":4.621809744779584,"d":"4.62"},{"v":2.122969837587007,"d":"2.12"},{"v":0.779814385150812,"d":"0.7798"},null,"UDP-galactose transporter","Pan-active imidazolopiperazine antimalarials target the Plasmodium falciparum intracellular secretory pathway GM LaMonte","Plasmodium falciparum Cyclic Amine Resistance Locus (PfCARL), a Resistance Mechanism for Two Distinct Compound Classes Pamela A. Magistrado","UDP-galactose and Acetyl-CoA transporters as Plasmodium multidrug resistance genes Michelle Yi-Xiu Lim",{"$nulls":3},"PF3D7_1113300",null,1.64,-0.02,0.24,null,null,1.2812367429334575,0,1.61015721568254,"shared 3 stages",1,0.7957215174111714,null,4.621809744779584,0.980009171660819,null,5,5]
["MMV665852","NSC 35217",null,5171.67,{"v":3978,"d":"3978.00"},null,{"v":5000,"d":"5000.00"},null,{"v":0.7691906096096619,"d":"0.77"},null,{"v":0.9668056933253668,"d":"0.9668"},null,"phospholipid-transporting ATPase 2 (ATP2)","Corey VC, Lukens AK, Istvan ES, et al. A broad analysis of resistance development in the malaria parasite. Nat Commun. 2016;7:11901.","Cowell AN, Istvan ES, Lukens AK, et al. Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. Science. 2018;359(6372):191-199.","Screening for potential prophylactics targeting sporozoite motility through the skin RG Douglas 2018",{"$nulls":3},"PF3D7_1219600",null,0.26,-0.16,-0.4,null,null,0,0,0.337940442708695,"gct V enriched",1,0.4,null,4.863813229571984,2.417014233313417,null,5,5]
["MMV665852","NSC 35217",null,5171.67,{"v":3978,"d":"3978.00"},null,{"v":5000,"d":"5000.00"},null,{"v":0.7691906096096619,"d":"0.77"},null,{"v":0.9668056933253668,"d":"0.9668"},null,"PKG","Corey VC, Lukens AK, Istvan ES, et al. A broad analysis of resistance development in the malaria parasite. Nat Commun. 2016;7:11901.","Cowell AN, Istvan ES, Lukens AK, et al. Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. Science. 2018;359(6372):191-199.","Screening for potential prophylactics targeting sporozoite motility through the skin RG Douglas 2018",{"$nulls":3},"PF3D7_1436600",null,0.47,-0.44,0.1,null,null,0,0.068244893498124,2.02530545710245,"gct V enriched",0.8,0.2,null,6.079766536964979,4.834028466626834,null,5,5]
["MMV667491",null,null,1230,891.5,696.4,1390.65,null,0.72479674796748,0.566178861788618,1.13060975609756,null,"phosphoethanolamine methyltransferase (PfPMT)","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond Voorhis 2016","Combining stage specificity and metabolomic profiling to advance antimalarial drug discovery JM Murithi",{"$nulls":4},"PF3D7_1343000",null,0.77,1.48,0.61,null,null,336.4138014225539,83.2557979663136,10.5478198468946,"enriched troph",4.040725206413509,31.89415502973328,null,0.17937293702057983,0.03544880731417875,null,5,5]
["MMV019918",null,null,280,824,406.9,320,null,2.94285714285714,1.45321428571429,1.14285714285714,null,"phosphoethanolamine methyltransferase (PfPMT)"," … and biological studies of the Malaria Box compound 1-[5-(4-bromo-2-chlorophenyl) furan-2-yl]-N-[(piperidin-4-yl) methyl] methanamine (MMV019918) and … A Vallone",{"$nulls":5},"PF3D7_1343000",null,0.77,1.48,0.61,null,null,336.4138014225539,83.2557979663136,10.5478198468946,"enriched troph",4.040725206413509,31.89415502973328,null,0.17937293702057983,0.03583280829329741,null,5,5]
["MMV1542945","ACT-451840",null,8.34,9.9,null,11.1,null,1.18705035971223,null,1.33093525179856,null,"MDR1","CRISPR‐Cas9‐modified pfmdr1 protects Plasmodium falciparum asexual blood stages and gametocytes against a class of piperazine‐containing compounds. CL Ng 2016","Brunner R, Aissaoui H, Boss C, Bozdech Z, Brun R, Corminboeuf O, Delahaye S, Fischli C, Heidmann B, Kaiser M et al.. (2012) Identification of a new chemical class of antimalarials. ","Brunner R, Ng CL, Aissaoui H, Akabas MH, Boss C, Brun R, Callaghan PS, Corminboeuf O, Fidock DA, Frame IJ et al.. (2013) UV-triggered affinity capture identifies interactions between the Plasmodium falciparum multidrug resistance protein 1 (PfMDR1) and antimalarial agents in live parasitized cells",{"$nulls":3},"PF3D7_0523000",null,0.55,-0.14,-0.37,null,null,4.185382762981795,2.6120056276710084,5.55996328108289,"shared 3 stages",1.6023636085017496,0.752771655385218,null,0.7408121061998858,1.768046448451193,null,5,5]
["MMV396749",null,null,928,1384.56,5000,1354.33,null,1.49198275862069,5.38793103448276,1.45940732758621,null,"ATP4","E.L. Allman, H.J. Painter, J. Samra, M. Carrasquilla, M. Llinas Metabolomic profiling of the malaria box reveals antimalarial target pathways 2016","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond Voorhis 2016","Diverse chemotypes disrupt ion homeostasis in the malaria parasite AM Lehane","Targeted phenotypic screening in Plasmodium falciparum and Toxoplasma gondii reveals novel modes of action of medicines for malaria venture malaria box … G Subramanian",null,null,"PF3D7_1211900",null,0.33,-0.22,-0.49,null,null,1.7731908623980155,0.4394601472062679,2.59381366380463,"shared 3 stages",4.034929842149575,0.6836230709792325,null,0.3697667163962009,2.1348128662418193,null,5,5]
["MMV019266",null,null,255,596,324,520,null,2.33725490196078,1.27058823529412,2.03921568627451,null,"phosphatidylserine decarboxylase (PSD)","E.L. Allman, H.J. Painter, J. Samra, M. Carrasquilla, M. Llinas Metabolomic profiling of the malaria box reveals antimalarial target pathways 2016","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond Voorhis 2016","Characterization of Plasmodium phosphatidylserine decarboxylase expressed in yeast and application for inhibitor screening JY Choi",{"$nulls":3},"PF3D7_0927900",null,0.6,-0.61,0.16,null,null,0.9628761074834958,0,0.584893192461114,"shared 3 stages",1.5,1.6462426300978217,null,1.558169934640523,1.2387090754376453,null,5,5]
["MMV019266",null,null,255,596,324,520,null,2.33725490196078,1.27058823529412,2.03921568627451,null,"PKG","E.L. Allman, H.J. Painter, J. Samra, M. Carrasquilla, M. Llinas Metabolomic profiling of the malaria box reveals antimalarial target pathways 2016","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond Voorhis 2016","Characterization of Plasmodium phosphatidylserine decarboxylase expressed in yeast and application for inhibitor screening JY Choi",{"$nulls":3},"PF3D7_1436600",null,0.47,-0.44,0.1,null,null,0,0.068244893498124,2.02530545710245,"gct V enriched",0.8,0.2,null,2.9215686274509802,10.19607843137255,null,5,5]
["MMV019721","MMV019721",null,844.3,3379,null,1841.33,null,4.00213194362194,null,2.18089541632121,null,"acetyl-CoA synthetase (ACAS)","Chemogenomics identifies acetyl-coenzyme A synthetase as a target for malaria treatment and prevention. RL Summers. 2022",{"$nulls":5},"PF3D7_0627800",null,0.29,-0.51,-0.45,null,null,0.5239278103274543,0.22331568211144429,0.148153621496883,"enriched troph",2.3461308465833195,3.5363820677071818,null,1.7058434526148691,0.6167024304970522,null,5,5]
["MMV019721","MMV019721",null,844.3,3379,null,1841.33,null,4.00213194362194,null,2.18089541632121,null,"acyl-CoA synthetase (ACS11)","Chemogenomics identifies acetyl-coenzyme A synthetase as a target for malaria treatment and prevention. RL Summers. 2022",{"$nulls":5},"PF3D7_1238800",null,0.54,-0.04,-0.19,null,null,3.175016900592523,1.578121624064757,2.78248990638938,"shared 3 stages",2.011896201266575,1.1410704108222605,null,1.9892338089323005,1.911271553128476,null,5,5]
["MMV019721","MMV019721",null,844.3,3379,null,1841.33,null,4.00213194362194,null,2.18089541632121,null,"acyl-CoA synthetase (ACS10)","Chemogenomics identifies acetyl-coenzyme A synthetase as a target for malaria treatment and prevention. RL Summers. 2022",{"$nulls":5},"PF3D7_0525100",null,0.84,-0.61,-0.77,null,null,6.499642624097776,6.443810658555231,5.39080484186031,"shared 3 stages",1.0086644329731227,1.2056905814187884,null,3.967753608427847,1.808835077532791,null,5,5]
["MMV019881",null,null,646,740.91,287.6,1502,null,1.14691950464396,0.445201238390093,2.32507739938081,null,"Hsp90","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond Voorhis 2016","Malaria Box Compounds against Anopheles gambiae (Diptera: Culicidae) Carboxypeptidase B Activity to Block Malaria Transmission Tippawan Pomun",{"$nulls":4},"PF3D7_0708400",null,0.47,0.14,-0.37,null,null,391.244342138169,487.5030361563116,2642.7611857491,"gct V enriched",0.8025474984174693,0.14804377491539,null,1.4290985977846236,15.705337159293855,null,5,5]
["MMV669810",null,null,0.45,2,1.4,1.2,null,4.44444444444444,3.11111111111111,2.66666666666667,null,"CDPK1"," Potent Plasmodium falciparum gametocytocidal compounds identified by exploring the kinase inhibitor chemical space for dual active antimalarials Mariëtte E van der Watt, ",{"$nulls":5},"PF3D7_0217500",null,0.54,-0.07,0.86,null,null,1.8276642121903912,0.8228906159046369,5.07832312829723,"shared 3 stages",2.2210293529488925,0.35989521856266954,null,2.001074158945037,7.409564031766418,null,5,5]
["MMV669810",null,null,0.45,2,1.4,1.2,null,4.44444444444444,3.11111111111111,2.66666666666667,null,"PKG"," Potent Plasmodium falciparum gametocytocidal compounds identified by exploring the kinase inhibitor chemical space for dual active antimalarials Mariëtte E van der Watt, ",{"$nulls":5},"PF3D7_1436600",null,0.47,-0.44,0.1,null,null,0,0.068244893498124,2.02530545710245,"gct V enriched",0.8,0.2,null,5.555555555555555,13.33333333333335,null,5,5]
["MMV669810",null,null,0.45,2,1.4,1.2,null,4.44444444444444,3.11111111111111,2.66666666666667,null,"PK7"," Potent Plasmodium falciparum gametocytocidal compounds identified by exploring the kinase inhibitor chemical space for dual active antimalarials Mariëtte E van der Watt, ",{"$nulls":5},"PF3D7_0213400",null,0.31,0.27,-0.31,null,null,0.2246523050636276,0,0.136463666385725,"not determined",1.1,1.6462426300978217,null,4.040404040404041,1.619850329418461,null,5,5]
["MMV670325",null,null,1365,4492,null,3715.67,null,3.29084249084249,null,2.72210256410256,null,"leucine--tRNA ligase (LeuRS)","Provided from MMV",{"$nulls":5},"PF3D7_0622800",null,0.36,-0.2,-0.48,null,null,1.2020793536038865,1.2476120887779127,2.62680169079642,"shared 3 stages",0.9635040926714429,0.4576208999010611,null,3.4154940449896727,5.948379028779249,null,5,5]
["MMV693183","MMV183",null,9.4,113,null,26.2,null,12.0212765957447,null,2.78723404255319,null,"acetyl-CoA synthetase (ACAS)","Preclinical characterization and target validation of the antimalarial pantothenamide MMV693183. LE de Vries. 2022",{"$nulls":5},"PF3D7_0627800",null,0.29,-0.51,-0.45,null,null,0.5239278103274543,0.22331568211144429,0.148153621496883,"enriched troph",2.3461308465833195,3.5363820677071818,null,5.123873041118451,0.7881597602264444,null,5,5]
["MMV019662",null,null,1729,4715.5,null,5000,null,2.7272990167727,null,2.89184499710816,null,"Niemann-Pick type C1-related protein (NCR1)","Diverse Chemical Compounds Target Plasmodium falciparum Plasma Membrane Lipid Homeostasis. S Bhatnagar. 2019","Plasmodium Niemann-Pick type C1-related protein is a druggable target required for parasite membrane homeostasis. ES Istvan. 2019","Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. Cowell. 2018",{"$nulls":3},"PF3D7_0107500",null,0.44,-0.6,-0.27,null,null,0.8720675920415234,0,0.0734188827013531,"enriched troph",1.8,11.877974166248805,null,1.5151661204292783,0.24346281248239457,null,5,5]
["MMV016838",null,null,1718,2000,null,5000,null,1.16414435389988,null,2.91036088474971,null,"eEF2","A novel multiple-stage antimalarial agent that inhibits protein synthesis. Beatriz Baragaña. 2015","Screening the Medicines for Malaria Venture Pathogen Box for invasion and egress inhibitors of the blood stage of Plasmodium falciparum reveals several inhibitory compounds\nAuthor links open overlay panelMadeline G.Dans. 2020",{"$nulls":4},"PF3D7_1451100",null,0.72,-0.3,-1,null,null,36.215096568022325,20.79857304540562,60.2680478057332,"shared 3 stages",1.741229866537512,0.6009004420511069,null,0.6685759165243471,4.8433329068880635,null,5,5]
["MMV665882",null,null,337,252,63,983.63,null,0.747774480712166,0.186943620178042,2.91878338278932,null,"Hsp90","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond Voorhis 2016","Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics",{"$nulls":4},"PF3D7_0708400",null,0.47,0.14,-0.37,null,null,391.244342138169,487.5030361563116,2642.7611857491,"gct V enriched",0.8025474984174693,0.14804377491539,null,0.9317510579581779,19.715677909844324,null,5,5]
["MMV665943",null,null,190,2000,1099,570,null,10.5263157894737,5.78421052631579,3,null,"Cysteine protease","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond Voorhis 2016",{"$nulls":7},0.868333333333333,0.2925,0.5025,"Average",null,0.798641256081183,0.19433860091901342,0.31856282249165724,"enriched troph",4.109534864944305,2.507013372855517,null,2.561437275850036,1.1966429985903768,null,5,5]
["MMV396797",null,null,477,3934.38,1768.9,1431.09,null,8.24817610062893,3.7083857442348,3.00018867924528,null,"Thioredoxin Reductase (PfTrxR)","E.L. Allman, H.J. Painter, J. Samra, M. Carrasquilla, M. Llinas Metabolomic profiling of the malaria box reveals antimalarial target pathways 2016","Preliminary LC-MS Based Screening for Inhibitors of Plasmodium falciparum Thioredoxin Reductase (PfTrxR) among a Set of Antimalarials from the Malaria Box NK Tiwari","The Medicines for Malaria Venture Malaria Box contains inhibitors of protein secretion in Plasmodium falciparum blood stage parasites O Looker",{"$nulls":3},"PF3D7_0923800",null,0.25,0.12,0.31,null,null,0.2942965475215916,0.2694624621099895,3.77058269614393,"gct V enriched",1.0921615768561683,0.07805068108506426,null,7.5521573688498025,38.438981409726544,null,5,5]
["MMV1578884","CRS-3123",null,1643.33,3776,null,5000,null,2.2977734234755,null,3.04260252049193,null,"methionine--tRNA ligase (cyto)","Inhibition of protein synthesis and malaria parasite development by drug targeting of methionyl-tRNA synthetases T Hussain 2015",{"$nulls":5},"PF3D7_1034900",null,0.43,0.01,0.05,null,null,2.488931895417541,5.890704031654335,15.5265353985669,"gct V enriched",0.42251857877139926,0.16030182082006972,null,5.438277838946104,18.98046138794075,null,5,5]
["MMV665941",null,null,255,769,157.9,843,null,3.0156862745098,0.61921568627451,3.30588235294118,null,"HT","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond Voorhis 2016","A novel fluorescence resonance energy transfer-based screen in high-throughput format to identify inhibitors of malarial and human glucose transporters TE Kraft",{"$nulls":4},"PF3D7_0204700",null,0.53,1.08,-0.46,null,null,3.0423154285688634,4.369138307018179,2.89860370254907,"shared 3 stages",0.6963193231219001,1.0495796392909493,null,4.330895573871453,3.14972035392616,null,5,5]
["MMV007273",null,null,1278,1361,5000,5000,null,1.06494522691706,3.91236306729264,3.91236306729264,null,"6-phosphogluconate dehydrogenase","Identification of β-hematin inhibitors in the MMV Malaria Box KY Fong","Characterization of Plasmodium falciparum 6-phosphogluconate dehydrogenase as an antimalarial drug target K Haeussler",{"$nulls":4},"PF3D7_1454700",null,0.29,0.18,-0.08,null,null,1.7176232460629302,5.869374848204267,16.4332882219999,"gct V enriched",0.29264159991220123,0.10452097126632753,null,3.6390766973545943,37.43136922564215,null,5,5]
["MMV000028","Trimethoprim",null,1258.92541179416,5000,5000,5000,null,3.97164117362143,3.97164117362143,3.97164117362143,null,"DHFR-TS","Antibacterial Agents That Interfere With Folate Synthesis. (2020). In Rang and Dale's Pharmacology (9th ed.). Edinburgh: Elsevier. ",{"$nulls":5},"PF3D7_0417200",null,0.11,0.52,0.13,null,null,1.15443469003188,0.6407679530676047,10.9377664171444,"gct V enriched",1.8016423644552657,0.10554574361931532,null,2.204455918654129,37.629572140269644,null,5,5]
["MMV666125",null,null,120,720.32,745,480,null,6.00266666666667,6.20833333333333,4,null,"Hsp90","Sun W, Tanaka TQ, Magle CT, Huang W, Southall N, Huang R, Dehdashti SJ, McKew JC et al (2014) Chemical signatures and new drug targets for gametocytocidal drug development. "," Characterization of Plasmodium falciparum 6-phosphogluconate dehydrogenase as an antimalarial drug target K Haeussler",{"$nulls":4},"PF3D7_0708400",null,0.47,0.14,-0.37,null,null,391.244342138169,487.5030361563116,2642.7611857491,"gct V enriched",0.8025474984174693,0.14804377491539,null,7.479515765114501,27.019035432500154,null,5,5]
["MMV666125",null,null,120,720.32,745,480,null,6.00266666666667,6.20833333333333,4,null,"6-phosphogluconate dehydrogenase","Sun W, Tanaka TQ, Magle CT, Huang W, Southall N, Huang R, Dehdashti SJ, McKew JC et al (2014) Chemical signatures and new drug targets for gametocytocidal drug development. "," Characterization of Plasmodium falciparum 6-phosphogluconate dehydrogenase as an antimalarial drug target K Haeussler",{"$nulls":4},"PF3D7_1454700",null,0.29,0.18,-0.08,null,null,1.7176232460629302,5.869374848204267,16.4332882219999,"gct V enriched",0.29264159991220123,0.10452097126632753,null,20.512007412710958,38.26983189629658,null,5,5]
["MMV023367",null,null,1192.27,2718,null,5000,null,2.27968497068617,null,4.19368096152717,null,"AP2 domain transcription factor","Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. Cowell. 2018",{"$nulls":5},"PF3D7_0613800",null,0.3,0.16,0.69,null,null,0.03482332457788821,0,0,"enriched troph",1.1,1.1,null,2.0724408824419727,3.812437237751973,null,5,5]
["MMV390048","MMV0048",null,24,171,null,101.4,null,7.125,null,4.225,null,"PKG"," Potent Plasmodium falciparum gametocytocidal compounds identified by exploring the kinase inhibitor chemical space for dual active antimalarials Mariëtte E van der Watt, ","Younis Y, Douelle F, Feng TS, Gonzalez Cabrera D, Le Manach C, Nchinda AT, Duffy S, White KL, Shackleford DM, Morizzi J, Mannila J, Katneni K, Bhamidipati R, Zabiulla KM, Joseph JT, Bashyam S, Waterson D, Witty MJ, Hardick D, Wittlin S, Avery V, Charman SA, Chibale K. 2012. 3,5-Diaryl-2-aminopyridines as a novel class of orally active antimalarials demonstrating single dose cure in mice and clinical candidate potential. J Med Chem 55:3479–3487.","Paquet T, Le Manach C, Cabrera DG, Younis Y, Henrich PP, Abraham TS, Lee MCS, Basak R, Ghidelli-Disse S, Lafuente-Monasterio MJ et al.. (2017)\nAntimalarial efficacy of MMV390048, an inhibitor of Plasmodium phosphatidylinositol 4-kinase. ",{"$nulls":3},"PF3D7_1436600",null,0.47,-0.44,0.1,null,null,0,0.068244893498124,2.02530545710245,"gct V enriched",0.8,0.2,null,8.90625,21.124999999999996,null,5,5]
["MMV020438",null,null,1150.27,4554,null,5000,null,3.95907047910491,null,4.34680553261408,null,"HT","Provided from MMV",{"$nulls":5},"PF3D7_0204700",null,0.53,1.08,-0.46,null,null,3.0423154285688634,4.369138307018179,2.89860370254907,"shared 3 stages",0.6963193231219001,1.0495796392909493,null,5.685711063359098,4.141472804817931,null,5,5]
["MMV665852",null,null,1028,5000,5000,5000,null,4.86381322957198,4.86381322957198,4.86381322957198,null,"phospholipid-transporting ATPase 2 (ATP2)","Corey VC, Lukens AK, Istvan ES, et al. A broad analysis of resistance development in the malaria parasite. Nat Commun. 2016;7:11901.","Cowell AN, Istvan ES, Lukens AK, et al. Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. Science. 2018;359(6372):191-199.","Screening for potential prophylactics targeting sporozoite motility through the skin RG Douglas 2018",{"$nulls":3},"PF3D7_1219600",null,0.26,-0.16,-0.4,null,null,0,0,0.337940442708695,"gct V enriched",1,0.4,null,4.863813229571984,12.159533073929948,null,5,5]
["MMV665852",null,null,1028,5000,5000,5000,null,4.86381322957198,4.86381322957198,4.86381322957198,null,"PKG","Corey VC, Lukens AK, Istvan ES, et al. A broad analysis of resistance development in the malaria parasite. Nat Commun. 2016;7:11901.","Cowell AN, Istvan ES, Lukens AK, et al. Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. Science. 2018;359(6372):191-199.","Screening for potential prophylactics targeting sporozoite motility through the skin RG Douglas 2018",{"$nulls":3},"PF3D7_1436600",null,0.47,-0.44,0.1,null,null,0,0.068244893498124,2.02530545710245,"gct V enriched",0.8,0.2,null,6.079766536964979,24.319066147859896,null,5,5]
["MMV665807",null,null,973.3,5000,5000,5000,null,5.13716223158327,5.13716223158327,5.13716223158327,null,"calcium-transporting ATPase (ATP6)","Selective Inhibition of Plasmodium falciparum ATPase 6 by Artemisinins and Identification of New Classes of Inhibitors after Expression in Yeast CM Moore","Screening of the open source malaria box reveals an early lead compound for the treatment of alveolar echinococcosis B Stadelmann",{"$nulls":4},"PF3D7_0106300",null,0.39,-0.03,-0.13,null,null,1.6876027710717014,0.7605873874153525,3.93796931771435,"shared 3 stages",2.2188150881735713,0.4285464499381139,null,2.3152728043741373,11.987410541669693,null,5,5]
["MMV000848",null,null,660,1997,2000,3600,null,3.02575757575758,3.03030303030303,5.45454545454545,null,"ATP4","E.L. Allman, H.J. Painter, J. Samra, M. Carrasquilla, M. Llinas Metabolomic profiling of the malaria box reveals antimalarial target pathways 2016","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond Voorhis 2016","Identification of an inhibitory pocket in falcilysin provides a new avenue for malaria drug development G Wirjanata",{"$nulls":3},"PF3D7_1211900",null,0.33,-0.22,-0.49,null,null,1.7731908623980155,0.4394601472062679,2.59381366380463,"shared 3 stages",4.034929842149575,0.6836230709792325,null,0.7498910003713048,7.978878545939464,null,5,5]
["MMV000848",null,null,660,1997,2000,3600,null,3.02575757575758,3.03030303030303,5.45454545454545,null,"Hsp90","E.L. Allman, H.J. Painter, J. Samra, M. Carrasquilla, M. Llinas Metabolomic profiling of the malaria box reveals antimalarial target pathways 2016","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond Voorhis 2016","Identification of an inhibitory pocket in falcilysin provides a new avenue for malaria drug development G Wirjanata",{"$nulls":3},"PF3D7_0708400",null,0.47,0.14,-0.37,null,null,391.244342138169,487.5030361563116,2642.7611857491,"gct V enriched",0.8025474984174693,0.14804377491539,null,3.7701912743158745,36.84413922613654,null,5,5]
["MMV000720",null,null,864.35955618131,5000,2427.4,5000,null,5.78462974608589,2.80832204912978,5.78462974608589,null,"6-phosphogluconate dehydrogenase","Characterization of Plasmodium falciparum 6-phosphogluconate dehydrogenase as an antimalarial drug target K Haeussler 2018",{"$nulls":5},"PF3D7_1454700",null,0.29,0.18,-0.08,null,null,1.7176232460629302,5.869374848204267,16.4332882219999,"gct V enriched",0.29264159991220123,0.10452097126632753,null,19.766942730703352,55.34420199125594,null,5,5]
["MMV011895",null,null,842,1286.53,5000,5000,null,1.52794536817102,5.93824228028504,5.93824228028504,null,"chloroquine resistance transporter (CRT)","Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. Cowell. 2018","Identification of β-hematin inhibitors in the MMV Malaria Box KY Fong 2015","Characterization of Plasmodium falciparum 6-phosphogluconate dehydrogenase as an antimalarial drug target K Haeussler 2018",{"$nulls":3},"PF3D7_0709000",null,0.71,-0.13,-0.9,null,null,2.488931895417541,0.18392148688178012,0.584893192461114,"enriched troph",13.532578153945444,4.255361367679134,null,0.6837735410692884,1.395473090813847,null,5,5]
["MMV011895",null,null,842,1286.53,5000,5000,null,1.52794536817102,5.93824228028504,5.93824228028504,null,"6-phosphogluconate dehydrogenase","Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. Cowell. 2018","Identification of β-hematin inhibitors in the MMV Malaria Box KY Fong 2015","Characterization of Plasmodium falciparum 6-phosphogluconate dehydrogenase as an antimalarial drug target K Haeussler 2018",{"$nulls":3},"PF3D7_1454700",null,0.29,0.18,-0.08,null,null,1.7176232460629302,5.869374848204267,16.4332882219999,"gct V enriched",0.29264159991220123,0.10452097126632753,null,31.619629221875275,56.813883456497344,null,5,5]
["MMV007224",null,null,320,654,948,1980,null,2.04375,2.9625,6.1875,null,"phospholipid-transporting ATPase 2 (ATP2)","Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. Cowell. 2018"," Lipid transport proteins in malaria, from Plasmodium parasites to their hosts M Ressurreição 2021"," Screening for potential prophylactics targeting sporozoite motility through the skin RG Douglas 2018","Generation of a mutator parasite to drive resistome discovery in Plasmodium falciparum K Kumpornsin",null,null,"PF3D7_1219600",null,0.26,-0.16,-0.4,null,null,0,0,0.337940442708695,"gct V enriched",1,0.4,null,2,15.46875,null,5,5]
["MMV1558277",null,null,759.3,5000,null,5000,null,6.58501251152377,null,6.58501251152377,null,"plasmepsin X (PMX)","Provided from MMV",{"$nulls":5},"PF3D7_0808200",null,1.26,-0.79,0.17,null,null,0,0,0.99526231496888,"gct V enriched",1,0.5,null,6.5850125115237725,13.17002502304754,null,5,5]
["MMV000788",null,null,697,2000,2000,5000,null,2.86944045911047,2.86944045911047,7.17360114777618,null,"Cysteine protease","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond Voorhis 2016",{"$nulls":7},0.868333333333333,0.2925,0.5025,"Average",null,0.798641256081183,0.19433860091901342,0.31856282249165724,"enriched troph",4.109534864944305,2.507013372855517,null,0.6982397165157918,2.861413196055419,null,5,5]
["MMV009952","(-)-Halofuginone",null,1.02,8.4,null,7.64,null,8.23529411764706,null,7.49019607843137,null,"proline--tRNA ligase (PRS)"," Elucidating the path to Plasmodium prolyl-tRNA synthetase inhibitors that overcome halofuginone resistance. MA Tye. 2022","Structure of prolyl-tRNA synthetase-halofuginone complex provides basis for development of drugs against malaria and toxoplasmosis. V Jain. 2015","Keller TL, Zocco D, Sundrud MS, Hendrick M, Edenius M, Yum J, Kim YJ, Lee HK, Cortese JF, Wirth DF et al.. (2012) Halofuginone and other febrifugine derivatives inhibit prolyl-tRNA synthetase. ",{"$nulls":3},"PF3D7_1213800",null,0.36,0.11,-0.31,null,null,1.5095069956043754,2.3943438818071816,10.0529514112602,"gct V enriched",0.6304470327232373,0.1501556044440435,null,13.062626501824314,49.88289385643706,null,5,5]
["MMV665794",null,null,90,656,416,680,null,7.28888888888889,4.62222222222222,7.55555555555556,null,"PKG","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond Voorhis 2016","Combining stage specificity and metabolomic profiling to advance antimalarial drug discovery JM Murithi","Malaria Box Compounds against Anopheles gambiae (Diptera: Culicidae) Carboxypeptidase B Activity to Block Malaria Transmission T Pomun","Generation of a mutator parasite to drive resistome discovery in Plasmodium falciparum K Kumpornsin",null,null,"PF3D7_1436600",null,0.47,-0.44,0.1,null,null,0,0.068244893498124,2.02530545710245,"gct V enriched",0.8,0.2,null,9.11111111111111,37.7777777777778,null,5,5]
["MMV665924",null,null,649.2,5000,null,5000,null,7.70178681454097,null,7.70178681454097,null,"acetyl-CoA synthetase (ACAS)","Chemogenomics identifies acetyl-coenzyme A synthetase as a target for malaria treatment and prevention. RL Summers. 2022",{"$nulls":5},"PF3D7_0627800",null,0.29,-0.51,-0.45,null,null,0.5239278103274543,0.22331568211144429,0.148153621496883,"enriched troph",2.3461308465833195,3.5363820677071818,null,3.2827609874176957,2.177871809969457,null,5,5]
["MMV665924",null,null,649.2,5000,null,5000,null,7.70178681454097,null,7.70178681454097,null,"acyl-CoA synthetase (ACS10)","Chemogenomics identifies acetyl-coenzyme A synthetase as a target for malaria treatment and prevention. RL Summers. 2022",{"$nulls":5},"PF3D7_0525100",null,0.84,-0.61,-0.77,null,null,6.499642624097776,6.443810658555231,5.39080484186031,"shared 3 stages",1.0086644329731227,1.2056905814187884,null,7.635628423854812,6.3878634645034245,null,5,5]
["MMV665878",null,null,139,819,null,1100,null,5.89208633093525,null,7.9136690647482,null,"ATP4","E.L. Allman, H.J. Painter, J. Samra, M. Carrasquilla, M. Llinas Metabolomic profiling of the malaria box reveals antimalarial target pathways 2016","Metabolomics-based screening of the malaria box reveals both novel and established mechanisms of action DJ Creek","Targeted phenotypic screening in Plasmodium falciparum and Toxoplasma gondii reveals novel modes of action of medicines for malaria venture malaria box … G Subramanian",{"$nulls":3},"PF3D7_1211900",null,0.33,-0.22,-0.49,null,null,1.7731908623980155,0.4394601472062679,2.59381366380463,"shared 3 stages",4.034929842149575,0.6836230709792325,null,1.460269834034163,11.576070792070455,null,5,5]
["MMV007384",null,null,100,949,1113.5,870,null,9.49,11.135,8.7,null,"Hsp90","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond Voorhis 2016","New insights into novel inhibitors against deoxyhypusine hydroxylase from Plasmodium falciparum: compounds with an iron chelating potential I von Koschitzky","Identification of β-hematin inhibitors in the MMV Malaria Box KY Fong","Characterization of Plasmodium falciparum 6-phosphogluconate dehydrogenase as an antimalarial drug target K Haeussler,","Bilayer Effects of Antimalarial Compounds Nicole B. Ramsey",null,"PF3D7_0708400",null,0.47,0.14,-0.37,null,null,391.244342138169,487.5030361563116,2642.7611857491,"gct V enriched",4.109534864944305,0.14804377491539,null,2.3092637760425996,58.76640206568783,null,5,5]
["MMV007384",null,null,100,949,1113.5,870,null,9.49,11.135,8.7,null,"phosphoethanolamine methyltransferase (PfPMT)","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond Voorhis 2016","New insights into novel inhibitors against deoxyhypusine hydroxylase from Plasmodium falciparum: compounds with an iron chelating potential I von Koschitzky","Identification of β-hematin inhibitors in the MMV Malaria Box KY Fong","Characterization of Plasmodium falciparum 6-phosphogluconate dehydrogenase as an antimalarial drug target K Haeussler,","Bilayer Effects of Antimalarial Compounds Nicole B. Ramsey",null,"PF3D7_1343000",null,0.77,1.48,0.61,null,null,336.4138014225539,83.2557979663136,10.5478198468946,"enriched troph",0.8025474984174693,31.89415502973328,null,11.82484528169757,0.2727772531327272,null,5,5]
["MMV007384",null,null,100,949,1113.5,870,null,9.49,11.135,8.7,null,"cysteine protease","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond Voorhis 2016","New insights into novel inhibitors against deoxyhypusine hydroxylase from Plasmodium falciparum: compounds with an iron chelating potential I von Koschitzky","Identification of β-hematin inhibitors in the MMV Malaria Box KY Fong","Characterization of Plasmodium falciparum 6-phosphogluconate dehydrogenase as an antimalarial drug target K Haeussler,","Bilayer Effects of Antimalarial Compounds Nicole B. Ramsey",null,"PF3D7_1302600",null,0.46,-0.08,-0.12,null,null,0.798641256081183,0.19433860091901342,0.31856282249165724,"enriched troph",4.040725206413509,2.507013372855517,null,2.3485883140326664,3.470264695912092,null,5,5]
["MMV006656",null,null,518.5,2420.18,5000,5000,null,4.66765670202507,9.64320154291225,9.64320154291225,null,"ATP4","Diverse chemotypes disrupt ion homeostasis in the malaria parasite AM Lehane 2014","A G358S mutation in the Plasmodium falciparum Na+ pump PfATP4 confers clinically-relevant resistance to cipargamin D Qiu",{"$nulls":4},"PF3D7_1211900",null,0.33,-0.22,-0.49,null,null,1.7731908623980155,0.4394601472062679,2.59381366380463,"shared 3 stages",4.034929842149575,0.6836230709792325,null,1.1568123572474356,14.106021215900709,null,5,5]
["MMV666054",null,null,499.444167,2000,1075,5000,null,4.00445161270649,2.15239274182974,10.0111290317662,null,"PfA-M1 alanyl aminopeptidase","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond Voorhis 2016","Screening the Medicines for Malaria Venture \"Malaria Box\" against the Plasmodium falciparum Aminopeptidases, M1, M17 and M18 A Paiardini",{"$nulls":4},"PF3D7_1311800",null,0.56,0.06,-0.86,null,null,15.969688689965796,9.989022559815394,32.8385515342823,"shared 3 stages",1.5987238585494725,0.4863091684568973,null,2.5047800414636607,20.585935205647907,null,5,5]
["MMV665971",null,null,489,359,228,5000,null,0.734151329243354,0.466257668711656,10.2249488752556,null,"phosphatidylserine decarboxylase (PSD)","Characterization of Plasmodium phosphatidylserine decarboxylase expressed in yeast and application for inhibitor screening JY Choi",{"$nulls":5},"PF3D7_0927900",null,0.6,-0.61,0.16,null,null,0.9628761074834958,0,0.584893192461114,"shared 3 stages",1.5,1.6462426300978217,null,0.4894342194955692,6.211082551451132,null,5,5]
["MMV000787",null,null,407,2000,584,4574.65,null,4.91400491400491,1.43488943488943,11.2399262899263,null,"PfDHODH","Combining stage specificity and metabolomic profiling to advance antimalarial drug discovery JM Murithi 2020","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond Voorhis 2016",{"$nulls":4},"PF3D7_0603300",null,0.75,-0.19,-0.43,null,null,1.15443469003188,0.7714114432536744,1.89426612471675,"shared 3 stages",1.4965226405803402,0.6094363801202974,null,3.283615483491315,18.443149533849024,null,5,5]
["MMV000787",null,null,407,2000,584,4574.65,null,4.91400491400491,1.43488943488943,11.2399262899263,null,"Cysteine protease","Combining stage specificity and metabolomic profiling to advance antimalarial drug discovery JM Murithi 2020","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond Voorhis 2016",{"$nulls":6},0.868333333333333,0.2925,0.5025,"Average",null,0.798641256081183,0.19433860091901342,0.31856282249165724,"enriched troph",4.109534864944305,2.507013372855517,null,1.1957569592420314,4.483393033170739,null,5,5]
["MMV007839",null,null,413.15,5000,null,5000,null,12.102142079148,null,12.102142079148,null,"formate nitrite transporter (PfFNT)"," Substrate-analogous inhibitors exert antimalarial action by targeting the Plasmodium lactate transporter PfFNT at nanomolar scale. A Golldack. 2017","Structural characterization of the Plasmodium falciparum lactate transporter PfFNT alone and in complex with antimalarial compound MMV007839 reveals its inhibition mechanism.    Xi Peng. 2021","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond Voorhis 2016",{"$nulls":3},"PF3D7_0316600",null,0.56,-0.12,-0.52,null,null,2.488931895417541,1.2779853366148883,1.51188643150958,"enriched troph",1.9475433904509365,1.6462426300978217,null,6.2140551725247395,7.351372062591331,null,5,5]
["MMV007839",null,null,413.15,5000,null,5000,null,12.102142079148,null,12.102142079148,null,"PKG"," Substrate-analogous inhibitors exert antimalarial action by targeting the Plasmodium lactate transporter PfFNT at nanomolar scale. A Golldack. 2017","Structural characterization of the Plasmodium falciparum lactate transporter PfFNT alone and in complex with antimalarial compound MMV007839 reveals its inhibition mechanism.    Xi Peng. 2021","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond Voorhis 2016",{"$nulls":3},"PF3D7_1436600",null,0.47,-0.44,0.1,null,null,0,0.068244893498124,2.02530545710245,"gct V enriched",0.8,0.2,null,15.127677598935012,60.51071039574,null,5,5]
["MMV390482","SJ733",null,30,102.7,null,367.5,null,3.42333333333333,null,12.25,null,"ATP4","Jimenez-Diaz MB, Ebert D, Salinas Y, Pradhan A, Lehane AM, Myrand-Lapierre ME, O'Loughlin KG, Shackleford DM, Justino de Almeida M, Carrillo AK, Clark JA, Dennis AS, Diep J, Deng X, Duffy S, Endsley AN, Fedewa G, Guiguemde WA, Gomez MG, Holbrook G, Horst J, Kim CC, Liu J, Lee MC, Matheny A, Martinez MS, Miller G, Rodriguez-Alejandre A, Sanz L, Sigal M, Spillman NJ, Stein PD, Wang Z, Zhu F, Waterson D, Knapp S, Shelat A, Avery VM, Fidock DA, Gamo FJ, Charman SA, Mirsalis JC, Ma H, Ferrer S, Kirk K, Angulo-Barturen I, Kyle DE, DeRisi JL, Floyd DM, Guy RK. 2014. (+)-SJ733, a clinical candidate for malaria that acts through ATP4 to induce rapid host-mediated clearance of Plasmodium. Proc Natl Acad Sci U S A 111:E5455–62.",{"$nulls":5},"PF3D7_1211900",null,0.33,-0.22,-0.49,null,null,1.7731908623980155,0.4394601472062679,2.59381366380463,"shared 3 stages",4.034929842149575,0.6836230709792325,null,0.8484244998692669,17.919231401089064,null,5,5]
["MMV1645159",null,null,388.83,4379,null,5000,null,11.2619911015097,null,12.8590900907852,null,"Plasmepsin V (PMV)","Provided from MMV",{"$nulls":5},"PF3D7_1323500",null,0.44,-0.25,-0.59,null,null,0.5122019514535665,0.3395699984187145,0.311133937421564,"enriched troph",1.5083839969336286,1.6462426300978215,null,7.466262652218528,7.8111754948425185,null,5,5]
["MMV029272",null,null,264.07,4042,null,3676,null,15.306547506343,null,13.9205513689552,null,"Dipeptidyl aminopeptidase 1 (DPAP1)","Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. Cowell. 2018",{"$nulls":5},"PF3D7_1116700",null,0.66,-0.38,-0.99,null,null,2.93452527859505,0,0.668100537200059,"enriched troph",4,4.392340845725623,null,3.826636876585754,3.1692784913315397,null,5,5]
["MMV668399","MMV668399",null,339.43,1770,null,5000,null,5.21462451757358,null,14.7305777332587,null,"inorganic anion exchanger, inorganic anion antiporter","Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. Cowell. 2018",{"$nulls":5},"PF3D7_1471200",null,0.26,0.44,-0.04,null,null,0,0,0.807768676963434,"gct V enriched",1,0.6,null,5.214624517573579,24.550962888764502,null,5,5]
["MMV674143","Cladosporin",null,65.89,199.4,null,1000.67,null,3.02625588101381,null,15.1869782971619,null,"lysine--tRNA ligase (KRS1)","Selective and Specific Inhibition of the Plasmodium falciparum Lysyl-tRNA Synthetase by the Fungal Secondary Metabolite Cladosporin. Hoepfner. 2012",{"$nulls":5},"PF3D7_1350100",null,0.52,-0.08,-0.33,null,null,2.488931895417541,4.157766611990654,5.68343917568615,"shared 3 stages",0.5986223200310637,0.4379270752232617,null,5.055367599485386,34.67924034936491,null,5,5]
["MMV000753",null,null,326,627,2000,5000,null,1.92331288343558,6.13496932515337,15.3374233128834,null,"CDPK1","Identification of β-hematin inhibitors in the MMV Malaria Box KY Fong 2015","Allosteric regulation of the inactive to active state conformational transition in CDPK1 protein of Plasmodium falciparum P Gupta 2022","K.Y. Fong, R.D. Sandlin, D.W. Wright\nIdentification of beta-hematin inhibitors in the MMV Malaria Box. International journal for parasitology",{"$nulls":3},"PF3D7_0217500",null,0.54,-0.07,0.86,null,null,1.8276642121903912,0.8228906159046369,5.07832312829723,"shared 3 stages",2.2210293529488925,0.35989521856266954,null,0.8659556348870279,42.616357544668666,null,5,5]
["MMV011438",null,null,50,1656,1129.5,820,null,33.12,22.59,16.4,null,"prodrug activation and resistance esterase (PARE)","Istvan, E. S., Mallari, J. P., Corey, V. C., Dharia, N. V., Marshall, G. R., Winzeler, E. A., and Goldberg, D. E. (2017) Esterase mutation is a mechanism of resistance to antimalarial compounds. Nat. Commu","A novel approach for the discovery of chemically diverse anti-malarial compounds targeting the Plasmodium falciparum Coenzyme A synthesis pathway Sabine Fletcher",{"$nulls":4},"PF3D7_0709700",null,0.74,0.63,0.46,null,null,2.9934994992897748,1.8671555457797142,1.23872113856834,"enriched troph",1.60324055810771,2.416604840335195,null,20.65816002003544,6.786380514625319,null,5,5]
["MMV011438",null,null,50,1656,1129.5,820,null,33.12,22.59,16.4,null,"phosphoethanolamine methyltransferase (PfPMT)","Istvan, E. S., Mallari, J. P., Corey, V. C., Dharia, N. V., Marshall, G. R., Winzeler, E. A., and Goldberg, D. E. (2017) Esterase mutation is a mechanism of resistance to antimalarial compounds. Nat. Commu","A novel approach for the discovery of chemically diverse anti-malarial compounds targeting the Plasmodium falciparum Coenzyme A synthesis pathway Sabine Fletcher",{"$nulls":4},"PF3D7_1343000",null,0.77,1.48,0.61,null,null,336.4138014225539,83.2557979663136,10.5478198468946,"enriched troph",4.040725206413509,31.89415502973328,null,8.196548467941192,0.5142007990088191,null,5,5]
["MMV011438",null,null,50,1656,1129.5,820,null,33.12,22.59,16.4,null,"pantothenate kinase 1","Istvan, E. S., Mallari, J. P., Corey, V. C., Dharia, N. V., Marshall, G. R., Winzeler, E. A., and Goldberg, D. E. (2017) Esterase mutation is a mechanism of resistance to antimalarial compounds. Nat. Commu","A novel approach for the discovery of chemically diverse anti-malarial compounds targeting the Plasmodium falciparum Coenzyme A synthesis pathway Sabine Fletcher",{"$nulls":4},"PF3D7_1420600",null,0.26,0.36,0.59,null,null,0.68726376397451,0,0,"enriched troph",1.5,1.5,null,22.08,10.933333333333332,null,5,5]
["MMV652103",null,null,7.25,59.6,5,133.3,null,8.22068965517241,0.689655172413793,18.3862068965517,null,"CDPK1","Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): preparation and evaluation of pyrazole … JM Large","Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) TM Chapman","New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of Plasmodium Phosphatidylinositol-4-kinase and cGMP … PM Cheuka","Exploring the transmission-blocking activity of antiplasmodial 3, 6-diarylated imidazopyridazines D Coertzen",null,null,"PF3D7_0217500",null,0.54,-0.07,0.86,null,null,1.8276642121903912,0.8228906159046369,5.07832312829723,"shared 3 stages",2.2210293529488925,0.35989521856266954,null,3.7012971684762683,51.08766648798936,null,5,5]
["MMV397264","21A092",null,10.58,62.1,null,213.3,null,5.8695652173913,null,20.1606805293006,null,"ATP4","Pyrazoleamide compounds are potent antimalarials that target Na+ homeostasis in intraerythrocytic Plasmodium falciparum. Akhil B. Vaidya. 2014",{"$nulls":5},"PF3D7_1211900",null,0.33,-0.22,-0.49,null,null,1.7731908623980155,0.4394601472062679,2.59381366380463,"shared 3 stages",4.034929842149575,0.6836230709792325,null,1.45468829620699,29.4909305802423,null,5,5]
["MMV011895","MMV011895",null,233,2156,null,5000,null,9.25321888412017,null,21.4592274678112,null,"chloroquine resistance transporter (CRT)","Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. Cowell. 2018","Identification of β-hematin inhibitors in the MMV Malaria Box KY Fong 2015","Characterization of Plasmodium falciparum 6-phosphogluconate dehydrogenase as an antimalarial drug target K Haeussler 2018",{"$nulls":3},"PF3D7_0709000",null,0.71,-0.13,-0.9,null,null,2.488931895417541,0.18392148688178012,0.584893192461114,"enriched troph",13.532578153945444,4.255361367679134,null,0.6837735410692884,5.042868422597684,null,5,5]
["MMV1792684","TCMDC-135051",null,115.67,840,null,2526,null,7.26203855796663,null,21.8379873778854,null,"cyclin-dependent-like kinase (CLK3)","Development of Potent PfCLK3 Inhibitors Based on TCMDC-135051 as a New Class of Antimalarials. A Mahindra. 2020","Validation of the protein kinase PfCLK3 as a multistage cross-species malarial drug target. Mahmood M. Alam. 2019",{"$nulls":4},"PF3D7_1114700",null,0.25,0.09,-0.02,null,null,0,0,0.0624678308940412,"not determined",1,0.8,null,7.262038557966629,27.29748422235675,null,5,5]
["MMV675615",null,null,4.47,163.2,72.1,104.2,null,36.510067114094,16.1297539149888,23.3109619686801,null,"CDPK1","Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): preparation and evaluation of pyrazole … JM Large","Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) TM Chapman","New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of Plasmodium Phosphatidylinositol-4-kinase and cGMP … PM Cheuka"," Potent Plasmodium falciparum gametocytocidal compounds identified by exploring the kinase inhibitor chemical space for dual active antimalarials Mariëtte E van der Watt, ",null,null,"PF3D7_0217500",null,0.54,-0.07,0.86,null,null,1.8276642121903912,0.8228906159046369,5.07832312829723,"shared 3 stages",2.2210293529488925,0.35989521856266954,null,16.438354164756547,64.77152450587754,null,5,5]
["MMV675615",null,null,4.47,163.2,72.1,104.2,null,36.510067114094,16.1297539149888,23.3109619686801,null,"PK7","Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): preparation and evaluation of pyrazole … JM Large","Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) TM Chapman","New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of Plasmodium Phosphatidylinositol-4-kinase and cGMP … PM Cheuka"," Potent Plasmodium falciparum gametocytocidal compounds identified by exploring the kinase inhibitor chemical space for dual active antimalarials Mariëtte E van der Watt, ",null,null,"PF3D7_0213400",null,0.31,0.27,-0.31,null,null,0.2246523050636276,0,0.136463666385725,"not determined",1.2,1.6462426300978217,null,30.425055928411638,14.16010103401036,null,5,5]
["MMV665980",null,null,210.8,5000,5000,5000,null,23.719165085389,23.719165085389,23.719165085389,null,"phosphoethanolamine methyltransferase (PfPMT)","A novel approach for the discovery of chemically diverse anti-malarial compounds targeting the Plasmodium falciparum Coenzyme A synthesis pathway S Fletcher",{"$nulls":5},"PF3D7_1343000",null,0.77,1.48,0.61,null,null,336.4138014225539,83.2557979663136,10.5478198468946,"enriched troph",4.040725206413509,31.89415502973328,null,5.870026758499076,0.7436837584590921,null,5,5]
["MMV006427",null,null,78.2,1960,5000,2237.62,null,25.0639386189258,63.9386189258312,28.6140664961637,null,"ATP4","E.L. Allman, H.J. Painter, J. Samra, M. Carrasquilla, M. Llinas Metabolomic profiling of the malaria box reveals antimalarial target pathways 2016","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond Voorhis 2016","Diverse chemotypes disrupt ion homeostasis in the malaria parasite AM Lehane",{"$nulls":3},"PF3D7_1211900",null,0.33,-0.22,-0.49,null,null,1.7731908623980155,0.4394601472062679,2.59381366380463,"shared 3 stages",4.034929842149575,0.6836230709792325,null,6.211740872692158,41.85649623435977,null,5,5]
["NITD246","KAF246",null,0.08,2.104,1.766,2.355,null,26.3,22.075,29.4375,null,"ATP4","McNamara CW, Lee MC, Lim CS, Lim SH, Roland J, Nagle A, Simon O, Yeung BK, Chatterjee AK, McCormack SL, Manary MJ, Zeeman AM, Dechering KJ, Kumar TR, Henrich PP, Gagaring K, Ibanez M, Kato N, Kuhen KL, Fischli C, Rottmann M, Plouffe DM, Bursulaya B, Meister S, Rameh L, Trappe J, Haasen D, Timmerman M, Sauerwein RW, Suwanarusk R, Russell B, Renia L, Nosten F, Tully DC, Kocken CH, Glynne RJ, Bodenreider C, Fidock DA, Diagana TT, Winzeler EA. 2013. Targeting Plasmodium PI(4)K to eliminate malaria. Nature 504:248–253.","Na+ extrusion imposes an acid load on the intraerythrocytic malaria parasite NJ Spillman",{"$nulls":4},"PF3D7_1211900",null,0.33,-0.22,-0.49,null,null,1.7731908623980155,0.4394601472062679,2.59381366380463,"shared 3 stages",4.034929842149575,0.6836230709792325,null,6.518081113893395,43.06101015261709,null,5,5]
["MMV674766",null,null,7.86,93.9,66.4,262.9,null,11.9465648854962,8.44783715012723,33.4478371501272,null,"PK7","Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): preparation and evaluation of pyrazole … JM Large","Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) TM Chapman","New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of Plasmodium Phosphatidylinositol-4-kinase and cGMP … PM Cheuka",{"$nulls":3},"PF3D7_0213400",null,0.31,0.27,-0.31,null,null,0.2246523050636276,0,0.136463666385725,"not determined",1.2,1.6462426300978217,null,9.955470737913485,20.31768375973819,null,5,5]
["MMV020243",null,null,134.258604,1058.32,5000,5000,null,7.88269778225908,37.2415610697099,37.2415610697099,null,"phosphatidylserine decarboxylase (PSD)","Characterization of Plasmodium phosphatidylserine decarboxylase expressed in yeast and application for inhibitor screening JY Choi","Identification of Novel Ezrin Inhibitors Targeting Metastatic Osteosarcoma by Screening Open Access Malaria BoxScreening MMV Malaria Box to Identify Novel Ezrin … H Çelik",{"$nulls":4},"PF3D7_0927900",null,0.6,-0.61,0.16,null,null,0.9628761074834958,0,0.584893192461114,"shared 3 stages",1.9,1.6462426300978217,null,4.148788306452148,22.622158112560214,null,5,5]
["MMV019313",null,null,115.85,3928,null,5000,null,33.9059128182995,null,43.1592576607682,null,"bifunctional farnesyl/geranylgeranyl diphosphate synthase (FPPS/GGPPS)","Specific inhibition of the bifunctional farnesyl/geranylgeranyl diphosphate synthase in malaria parasites via a new small-molecule binding site. JE Gisselberg. 2018","E.L. Allman, H.J. Painter, J. Samra, M. Carrasquilla, M. Llinas Metabolomic profiling of the malaria box reveals antimalarial target pathways 2016",{"$nulls":4},"PF3D7_1128400",null,0.43,0.1,0.13,null,null,1.793245727412536,2.644193071403792,1.51188643150958,"shared 3 stages",0.678182598239889,1.186098168512582,null,49.99525630161659,36.38759320815052,null,5,5]

{"sheet":"ABS iGc targets Supp FigS5","index":1,"n_rows":415,"n_cols":44,"rows_kept":415,"merged":[[0,13,0,18],[0,22,0,24],[0,27,0,30],[0,35,0,36],[0,42,0,43]]}
["Compound identifier","Trivial name",null,"Final ABS IC50 (nM)","Final iGc IC50 (nM)","Final LGc IC50 (nM)","Final mGc IC50 (nM)",null,"FC iGC-ABS","FC LGc-ABS","FC mGc-ABS",null,"Target (implied/confirmed)","References",{"$nulls":6},"GeneID",null,"transcript expression (microarray) (Bozdech 2003, van Biljon 2019)",{"$nulls":4},"Proteome expression (Silvestrini 2010)",{"$nulls":4},"FC proteom (ABS/iGc)","FC proteome (iGc/ABS)",null,"Proteome data (Lasonder 2016)",null,"Lasonder female","Lasonder male","F/M ratio",null,"Essential (P. falciparum data)","A = attenuated, difference in growth, D = different from wild type, U = no difference, I = invasion defect, S = cell cycle defect"]
[{"$nulls":22},"ABS","iGc","mGc",null,null,"T","iGc","mGc","classification",{"$nulls":5},"mGc (mixed)",{"$nulls":5},"ABS","Gc"]
["MMV1580488","ML324",null,{"v":2060,"d":"2060.00"},{"v":188,"d":"188.00"},{"v":77.39999999999999,"d":"77.40"},null,null,{"$f":"E3/D3","v":{"v":0.0912621359223301,"d":"0.09"}},{"$f":"F3/D3","v":{"v":0.03757281553398058,"d":"0.04"}},null,null,"Jmjc3","Matthews KA, Senagbe KM, Nötzel C, Gonzales CA, Tong X, Rijo-Ferreira F, Bhanu NV, Miguel-Blanco C, Lafuente-Monasterio MJ, Garcia BA et al.. (2020) Disruption of the Plasmodium falciparum Life Cycle through Transcriptional Reprogramming by Inhibitors of Jumonji Demethylases. ",{"$nulls":6},"PF3D7_1122200",null,0.76,0.34,0.21,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Not essential"]
["SD-70",null,null,{"v":3200,"d":"3200.00"},{"v":800,"d":"800.00"},{"$nulls":3},0.25,{"$nulls":3},"Jmjc3","Matthews KA, Senagbe KM, Nötzel C, Gonzales CA, Tong X, Rijo-Ferreira F, Bhanu NV, Miguel-Blanco C, Lafuente-Monasterio MJ, Garcia BA et al.. (2020) Disruption of the Plasmodium falciparum Life Cycle through Transcriptional Reprogramming by Inhibitors of Jumonji Demethylases. ",{"$nulls":6},"PF3D7_1122200",null,0.76,0.34,0.21,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Not essential"]
["MMV687273","SQ109",null,{"v":1390,"d":"1390.00"},{"v":383,"d":"383.00"},{"v":104.5,"d":"104.50"},null,null,{"v":0.2755395683453237,"d":"0.28"},{"$f":"F5/D5","v":{"v":0.07517985611510791,"d":"0.08"}},null,null,"V-type proton ATPase catalytic subunit A (vapA)","Reader J, van der Watt ME, Taylor D, Le Manach C, Mittal N, Ottilie S, Theron A, Moyo P, Erlank E, Nardini L et al.. (2021)Multistage and transmission-blocking targeted antimalarials discovered from the open-source MMV Pandemic Response Box. ",{"$nulls":6},"PF3D7_1311900",null,0.31,0.05,-0.27,null,null,5.707253085543619,4.157766611990654,52.0884444230989,"gct V enriched",null,{"$f":"AB5/AC5","v":1.372672787617365},{"$f":"AC5/AB5","v":0.7285057364149858},null,"Detected",4753861181.242787,6748000000,4641304567.199167,{"$f":"AL5/AM5","v":1.4539015706250311},null,"Not essential"]
["MMV667491",null,null,{"v":1230,"d":"1230.00"},{"v":891.5,"d":"891.50"},{"v":696.4,"d":"696.40"},{"v":1390.6499999999999,"d":"1390.65"},null,{"v":0.7247967479674797,"d":"0.72"},{"v":0.5661788617886179,"d":"0.57"},{"$f":"G6/D6","v":{"v":1.1306097560975608,"d":"1.13"}},null,"phosphoethanolamine methyltransferase (PfPMT) ","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond, van Voorhis 2016","Combining stage specificity and metabolomic profiling to advance antimalarial drug discovery JM Murithi",{"$nulls":5},"PF3D7_1343000",null,0.77,1.48,0.61,null,null,336.4138014225539,83.2557979663136,10.5478198468946,"enriched troph",null,4.040725206413509,0.247480328138321,null,"Detected",114835488.61768718,1894500000,446647232.3754124,4.241602460905097,null,"Not essential/Essential","A"]
["MMV665971",null,null,{"v":489,"d":"489.00"},{"v":359,"d":"359.00"},{"v":228,"d":"228.00"},{"v":5000,"d":"5000.00"},null,{"v":0.7341513292433538,"d":"0.73"},{"v":0.4662576687116564,"d":"0.47"},{"v":10.224948875255624,"d":"10.22"},null,"phosphatidylserine decarboxylase (PSD)","Characterization of Plasmodium phosphatidylserine decarboxylase expressed in yeast and application for inhibitor screening JY Choi",{"$nulls":6},"PF3D7_0927900",null,0.6,-0.61,0.16,null,null,0.9628761074834958,0,0.584893192461114,"shared 3 stages",null,1.5,0,null,"Not detected",{"$nulls":5},"Essential"]
["MMV665882",null,null,{"v":337,"d":"337.00"},{"v":252,"d":"252.00"},{"v":63,"d":"63.00"},983.63,null,{"v":0.7477744807121661,"d":"0.75"},{"v":0.18694362017804153,"d":"0.19"},{"v":2.9187833827893175,"d":"2.92"},null,"AP2 domain transcription factor","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond, van Voorhis 2016","Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics",{"$nulls":5},"PF3D7_0613800",null,0.3,0.16,0.69,null,null,0.03482332457788821,0,0,"enriched troph",null,1.1,0,null,"Not detected",{"$nulls":5},"Essential (ortholog)"]
["MMV665882",null,null,{"v":337,"d":"337.00"},{"v":252,"d":"252.00"},{"v":63,"d":"63.00"},983.63,null,{"v":0.7477744807121661,"d":"0.75"},{"v":0.18694362017804153,"d":"0.19"},{"v":2.9187833827893175,"d":"2.92"},null,"Hsp90","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond, van Voorhis 2016","Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics",{"$nulls":5},"PF3D7_0708400",null,0.47,0.14,-0.37,null,null,391.244342138169,487.5030361563116,2642.7611857491,"gct V enriched",null,0.8025474984174693,1.2460321687774047,null,"Detected",28102267024.51306,93040000000,24304490388.95642,3.8280991911797466,null,"Essential"]
["Barasertib (AZD1152-HQPA)","Barasertib (AZD1152-HQPA)",null,{"v":677.8,"d":"677.80"},{"v":518.1,"d":"518.10"},{"v":1000,"d":"1000.00"},null,null,{"v":0.7643847742696962,"d":"0.76"},{"v":1.475361463558572,"d":"1.48"},null,null,"ARK3","Activity of epigenetic inhibitors against Plasmodium falciparum asexual and sexual blood stages LN Vanheer 2020","Yang J, Ikezoe T, Nishioka C, Tasaka T, Taniguchi A, Kuwayama Y, Komatsu N, Bandobashi K, Togitani K, Koeffler HP et al.. (2007) AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo. ",{"$nulls":5},"PF3D7_1356800",null,0.75,0.37,1.21,{"$nulls":6},"Not detected",{"$nulls":3},"Translationally repressed",{"$nulls":5},"Essential/Not essential"]
["Barasertib (AZD1152-HQPA)","Barasertib (AZD1152-HQPA)",null,{"v":677.8,"d":"677.80"},{"v":518.1,"d":"518.10"},{"v":1000,"d":"1000.00"},null,null,{"v":0.7643847742696962,"d":"0.76"},{"v":1.475361463558572,"d":"1.48"},null,null,"ARK2","Activity of epigenetic inhibitors against Plasmodium falciparum asexual and sexual blood stages LN Vanheer 2020","Yang J, Ikezoe T, Nishioka C, Tasaka T, Taniguchi A, Kuwayama Y, Komatsu N, Bandobashi K, Togitani K, Koeffler HP et al.. (2007) AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo. ",{"$nulls":5},"PF3D7_0309200",null,0.15,1.22,0.88,{"$nulls":6},"Not detected",{"$nulls":3},"Detected",5668429.125041404,3214137.014789671,8530385.800486196,0.3767868288684527,null,"Essential"]
["Barasertib (AZD1152-HQPA)","Barasertib (AZD1152-HQPA)",null,{"v":677.8,"d":"677.80"},{"v":518.1,"d":"518.10"},{"v":1000,"d":"1000.00"},null,null,{"v":0.7643847742696962,"d":"0.76"},{"v":1.475361463558572,"d":"1.48"},null,null,"ARK1","Activity of epigenetic inhibitors against Plasmodium falciparum asexual and sexual blood stages LN Vanheer 2020","Yang J, Ikezoe T, Nishioka C, Tasaka T, Taniguchi A, Kuwayama Y, Komatsu N, Bandobashi K, Togitani K, Koeffler HP et al.. (2007) AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo. ",{"$nulls":5},"PF3D7_0605300",null,0.37,1.37,0.19,null,null,0,0,2.51119173421513,"gct V enriched",null,1,null,null,"Detected",77571928.73378326,10413000,135021045.8412919,0.07712131049732629,null,"Essential"]
["MMV665852","NSC 35217",null,5171.67,{"v":3978,"d":"3978.00"},null,{"v":5000,"d":"5000.00"},null,{"v":0.7691906096096619,"d":"0.77"},null,{"$f":"G13/D13","v":{"v":0.9668056933253668,"d":"0.97"}},null,"erythrocyte membrane protein 1 (PfEMP1)","Corey VC, Lukens AK, Istvan ES, et al. A broad analysis of resistance development in the malaria parasite. Nat Commun. 2016;7:11901.","Cowell AN, Istvan ES, Lukens AK, et al. Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. Science. 2018;359(6372):191-199.","Screening for potential prophylactics targeting sporozoite motility through the skin RG Douglas 2018",{"$nulls":4},"PF3D7_1219500",null,0.43,0.04,0.7,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Not essential"]
["MMV665852","NSC 35217",null,5171.67,{"v":3978,"d":"3978.00"},null,{"v":5000,"d":"5000.00"},null,{"v":0.7691906096096619,"d":"0.77"},null,{"$f":"G14/D14","v":{"v":0.9668056933253668,"d":"0.97"}},null,"phospholipid-transporting ATPase 2 (ATP2)","Corey VC, Lukens AK, Istvan ES, et al. A broad analysis of resistance development in the malaria parasite. Nat Commun. 2016;7:11901.","Cowell AN, Istvan ES, Lukens AK, et al. Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. Science. 2018;359(6372):191-199.","Screening for potential prophylactics targeting sporozoite motility through the skin RG Douglas 2018",{"$nulls":4},"PF3D7_1219600",null,0.26,-0.16,-0.4,null,null,0,0,0.337940442708695,"gct V enriched",null,1,null,null,"Detected",38850536.94093786,30051000,36855198.62823407,0.8153802209324819,null,"Essential"]
["MMV665852","NSC 35217",null,5171.67,{"v":3978,"d":"3978.00"},null,{"v":5000,"d":"5000.00"},null,{"v":0.7691906096096619,"d":"0.77"},null,{"$f":"G15/D15","v":{"v":0.9668056933253668,"d":"0.97"}},null,"PKG","Corey VC, Lukens AK, Istvan ES, et al. A broad analysis of resistance development in the malaria parasite. Nat Commun. 2016;7:11901.","Cowell AN, Istvan ES, Lukens AK, et al. Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. Science. 2018;359(6372):191-199.","Screening for potential prophylactics targeting sporozoite motility through the skin RG Douglas 2018",{"$nulls":4},"PF3D7_1436600",null,0.47,-0.44,0.1,null,null,0,0.068244893498124,2.02530545710245,"gct V enriched",null,0.8,null,null,"Detected",187255751.4074903,109730000,295371702.85639864,0.37149801060444715,null,"Essential"]
["MMV665953",null,null,{"v":2060,"d":"2060.00"},{"v":1645,"d":"1645.00"},{"v":5000,"d":"5000.00"},{"v":5000,"d":"5000.00"},null,{"v":0.7985436893203883,"d":"0.80"},{"$f":"F16/D16","v":{"v":2.4271844660194173,"d":"2.43"}},{"$f":"G16/D16","v":{"v":2.4271844660194173,"d":"2.43"}},null,"calmodulin (CAM)","The Medicines for Malaria Venture Malaria Box contains inhibitors of protein secretion in Plasmodium falciparum blood stage parasites O Looker","Comparison of ligand binding and conformational stability of human calmodulin with its homolog from the malaria parasite Plasmodium falciparum T Juhász,",{"$nulls":5},"PF3D7_1434200",null,0.66,-0.08,0.22,{"$nulls":6},"Not detected",{"$nulls":3},"Detected",10931146.987446235,236040000,342385661.2259073,0.6893980289795487,null,"Essential"]
["Trichostatin A","Trichostatin A",null,{"v":62.300000000000004,"d":"62.30"},{"v":53.900000000000006,"d":"53.90"},{"v":3795.5,"d":"3795.50"},null,null,{"v":0.8651685393258427,"d":"0.87"},{"v":60.922953451043334,"d":"60.92"},null,null,"HDAC1","Activity of epigenetic inhibitors against Plasmodium falciparum asexual and sexual blood stages LN Vanheer 2020","Lysine acetylation in sexual stage malaria parasites is a target for antimalarial small molecules K Trenholme",{"$nulls":5},"PF3D7_0925700",null,0.51,-0.22,-0.69,null,null,0.3649347020455916,0.15871401607333036,0.221677348996792,"enriched troph",null,2.299322461079817,0.43491072562757294,null,"Not detected",{"$nulls":5},"Essential"]
["ZM 447439",null,null,{"v":210.4,"d":"210.40"},{"v":189.4,"d":"189.40"},{"v":1000,"d":"1000.00"},null,null,{"v":0.9001901140684411,"d":"0.90"},{"v":4.752851711026616,"d":"4.75"},null,null,"ARK1","Activity of epigenetic inhibitors against Plasmodium falciparum asexual and sexual blood stages LN Vanheer 2020",{"$nulls":6},"PF3D7_0605300",null,0.37,1.37,0.19,null,null,0,0,2.51119173421513,"gct V enriched",null,1,null,null,"Detected",77571928.73378326,10413000,135021045.8412919,0.07712131049732629,null,"Essential"]
["ZM 447439",null,null,{"v":210.4,"d":"210.40"},{"v":189.4,"d":"189.40"},{"v":1000,"d":"1000.00"},null,null,{"v":0.9001901140684411,"d":"0.90"},{"v":4.752851711026616,"d":"4.75"},null,null,"NEK1","Activity of epigenetic inhibitors against Plasmodium falciparum asexual and sexual blood stages LN Vanheer 2020",{"$nulls":6},"PF3D7_1228300",null,0.07,0.23,0.17,null,null,0,0,0.197929810710521,"gct V enriched",null,1,null,null,"Detected",2783502.140783998,2836500,68353087.94929676,0.041497759429743264,null,"Essential/Not essential"]
["CX-6258 HCl","CX-6258 HCl",null,{"v":494.3,"d":"494.30"},{"v":472.2,"d":"472.20"},{"v":1000,"d":"1000.00"},null,null,{"v":0.9552903095286263,"d":"0.96"},{"v":2.0230629172567265,"d":"2.02"},null,null,"serine/threonine kinases","Activity of epigenetic inhibitors against Plasmodium falciparum asexual and sexual blood stages LN Vanheer 2020","Haddach M, Michaux J, Schwaebe MK, Pierre F, O'Brien SE, Borsan C, Tran J, Raffaele N, Ravula S, Drygin D et al.. (2012) Discovery of CX-6258. A Potent, Selective, and Orally Efficacious pan-Pim Kinases Inhibitor. ",{"$nulls":7},0.4972413793103446,0.43482758620689654,0.44137931034482764,"Average",null,0.15148991700512904,0.22907656310046898,0.6138576526621393,"gct V enriched","Average",0.6613069226933015,1.512157162860635,null,"Detected",275788067.42844534,422139337.5,306182163.24275047,1.3787195603726765,null,"Essential/Not essential"]
["MMV000050","Chlorproguanil",null,{"v":5000,"d":"5000.00"},{"v":5000,"d":"5000.00"},{"v":2002.6000000000001,"d":"2002.60"},{"v":4160,"d":"4160.00"},null,{"v":1,"d":"1.00"},{"v":0.40052000000000004,"d":"0.40"},{"$f":"G21/D21","v":{"v":0.832,"d":"0.83"}},null,"hydroxymethyldihydropterin pyrophosphokinase-dihydropteroate synthase (PfPPPK-DHPS)","Zhang Y, Meshnick SR. (1991) Inhibition of Plasmodium falciparum dihydropteroate synthetase and growth in vitro by sulfa drugs. ",{"$nulls":6},"PF3D7_0810800",null,0.54,-0.3,-0.18,null,null,1.438515492434979,0.5560138313090834,0.169989106589066,"enriched troph",null,2.587193719710401,0.38651918191573825,null,"Detected",8837958.65650243,66947000,11250583.590901198,5.950535761908631,null,"Essential"]
["MMV007224","MMV007224",null,{"v":5000,"d":"5000.00"},{"v":5000,"d":"5000.00"},null,{"v":5000,"d":"5000.00"},null,{"v":1,"d":"1.00"},null,{"v":1,"d":"1.00"},null,"phospholipid-transporting ATPase 2 (ATP2)","Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. Cowell. 2018"," Lipid transport proteins in malaria, from Plasmodium parasites to their hosts M Ressurreição 2021"," Screening for potential prophylactics targeting sporozoite motility through the skin RG Douglas 2018","Generation of a mutator parasite to drive resistome discovery in Plasmodium falciparum K Kumpornsin",{"$nulls":3},"PF3D7_1219600",null,0.26,-0.16,-0.4,null,null,0,0,0.337940442708695,"gct V enriched",null,1,null,null,"Detected",38850536.94093786,30051000,36855198.62823407,0.8153802209324819,null,"Essential"]
["MMV007224","MMV007224",null,{"v":5000,"d":"5000.00"},{"v":5000,"d":"5000.00"},null,{"v":5000,"d":"5000.00"},null,{"v":1,"d":"1.00"},null,{"v":1,"d":"1.00"},null,"amino acid transporter AAT1","Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. Cowell. 2018"," Lipid transport proteins in malaria, from Plasmodium parasites to their hosts M Ressurreição 2021"," Screening for potential prophylactics targeting sporozoite motility through the skin RG Douglas 2018","Generation of a mutator parasite to drive resistome discovery in Plasmodium falciparum K Kumpornsin",{"$nulls":3},"PF3D7_0629500",null,0.31,-0.31,-0.59,{"$nulls":6},"Not detected",{"$nulls":3},"Detected",3042923.6353463647,6972800,6511740.419343636,1.0708043550518,null,"Essential"]
["MMV007224","MMV007224",null,{"v":5000,"d":"5000.00"},{"v":5000,"d":"5000.00"},null,{"v":5000,"d":"5000.00"},null,{"v":1,"d":"1.00"},null,{"v":1,"d":"1.00"},null,"CCR4-associated factor 16 (CAF16)","Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. Cowell. 2018"," Lipid transport proteins in malaria, from Plasmodium parasites to their hosts M Ressurreição 2021"," Screening for potential prophylactics targeting sporozoite motility through the skin RG Douglas 2018","Generation of a mutator parasite to drive resistome discovery in Plasmodium falciparum K Kumpornsin",{"$nulls":3},"PF3D7_1434000",null,0.74,0.24,0.02,{"$nulls":6},"Not detected",{"$nulls":3},"Detected",249143.5242036318,7014000,11440745.83695086,0.6130719185585318,null,"Essential"]
["MMV007224","MMV007224",null,{"v":5000,"d":"5000.00"},{"v":5000,"d":"5000.00"},null,{"v":5000,"d":"5000.00"},null,{"v":1,"d":"1.00"},null,{"v":1,"d":"1.00"},null,"QRP1?","Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. Cowell. 2018"," Lipid transport proteins in malaria, from Plasmodium parasites to their hosts M Ressurreição 2021"," Screening for potential prophylactics targeting sporozoite motility through the skin RG Douglas 2018","Generation of a mutator parasite to drive resistome discovery in Plasmodium falciparum K Kumpornsin",{"$nulls":3},"PF3D7_1359900",null,0.59,-0.05,0.22,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Not essential"]
["MMV007224","MMV007224",null,{"v":5000,"d":"5000.00"},{"v":5000,"d":"5000.00"},null,{"v":5000,"d":"5000.00"},null,{"v":1,"d":"1.00"},null,{"v":1,"d":"1.00"},null,"thrombospondin-related anonymous protein (TRAP)","Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. Cowell. 2018"," Lipid transport proteins in malaria, from Plasmodium parasites to their hosts M Ressurreição 2021"," Screening for potential prophylactics targeting sporozoite motility through the skin RG Douglas 2018","Generation of a mutator parasite to drive resistome discovery in Plasmodium falciparum K Kumpornsin",{"$nulls":3},"PF3D7_1335900",null,0.82,0.91,0.81,{"$nulls":6},"Not detected",{"$nulls":3},"Translationally repressed",{"$nulls":5},"Not essential"]
["MMV000030","Thiostrepton",null,{"v":913,"d":"913.00"},{"v":959,"d":"959.00"},{"v":556,"d":"556.00"},{"v":3260.7400000000002,"d":"3260.74"},null,{"v":1.0503833515881709,"d":"1.05"},{"$f":"F27/D27","v":{"v":0.6089813800657174,"d":"0.61"}},{"v":3.5714567360350498,"d":"3.57"},null,"apicoplast ribosome","B. Clough, M. Strath, P. Preiser, P. Denny, I.R. Wilson Thiostrepton binds to malarial plastid rRNA FEBS Lett, 406 (1997)","M.J. Rogers, Y.V. Bukhman, T.F. McCutchan, D.E. Draper Interaction of thiostrepton with an RNA fragment derived from the plastid-encoded ribosomal RNA of the malaria parasite\nRNA, 3 (1997)","Aminake MN, Schoof S, Sologub L, Leubner M, Kirschner M, Arndt HD, Pradel G. 2011. Thiostrepton and derivatives exhibit antimalarial and gametocytocidal activity by dually targeting parasite proteasome and apicoplast. Antimicrob. Agents Chemother. 55:1338 –1348.",{"$nulls":6},0.8017096774193548,0.4807870967741935,0.15532580645161292,"Average",null,24.71297769631029,85.40557604207882,1459.5331009753745,"gct V enriched","Average",0.28936023666808774,3.4558998551934956,null,"Detected",1539680719.4419389,1132392260.2272727,592017901.0117464,1.9127669252771542,null,"Essential/Not essential"]
["MMV000030","Thiostrepton",null,{"v":913,"d":"913.00"},{"v":959,"d":"959.00"},{"v":556,"d":"556.00"},{"v":3260.7400000000002,"d":"3260.74"},null,{"v":1.0503833515881709,"d":"1.05"},{"v":0.6089813800657174,"d":"0.61"},{"v":3.5714567360350498,"d":"3.57"},null,"20S proteosome","B. Clough, M. Strath, P. Preiser, P. Denny, I.R. Wilson Thiostrepton binds to malarial plastid rRNA FEBS Lett, 406 (1997)","M.J. Rogers, Y.V. Bukhman, T.F. McCutchan, D.E. Draper Interaction of thiostrepton with an RNA fragment derived from the plastid-encoded ribosomal RNA of the malaria parasite\nRNA, 3 (1997)","Aminake MN, Schoof S, Sologub L, Leubner M, Kirschner M, Arndt HD, Pradel G. 2011. Thiostrepton and derivatives exhibit antimalarial and gametocytocidal activity by dually targeting parasite proteasome and apicoplast. Antimicrob. Agents Chemother. 55:1338 –1348.",{"$nulls":6},0.41428571428571426,0.2892857142857143,0.11928571428571429,"Average",null,4.371904224875087,14.744723143961812,53.195817261465585,"gct V enriched","Average",0.296506362458589,3.372608910338857,null,"Detected",1385888365.4679062,3846228571.428571,1162706304.4179296,3.307996659873671,null,"Essential/Not essential"]
["MMV007273",null,null,{"v":1278,"d":"1278.00"},{"v":1361,"d":"1361.00"},{"v":5000,"d":"5000.00"},{"v":5000,"d":"5000.00"},null,{"v":1.0649452269170578,"d":"1.06"},{"v":3.912363067292645,"d":"3.91"},{"v":3.912363067292645,"d":"3.91"},null,"6-phosphogluconate dehydrogenase","Identification of β-hematin inhibitors in the MMV Malaria Box KY Fong","Characterization of Plasmodium falciparum 6-phosphogluconate dehydrogenase as an antimalarial drug target K Haeussler",{"$nulls":5},"PF3D7_1454700",null,0.29,0.18,-0.08,null,null,1.7176232460629302,5.869374848204267,16.4332882219999,"gct V enriched",null,0.29264159991220123,3.4171491691544245,null,"Detected",1936470222.4009511,2758600000,3486288340.423685,0.7912713265893406,null,"Essential"]
["Vorinostat (SAHA, MK0683)","Vorinostat (SAHA, MK0683)",null,{"v":206.3,"d":"206.30"},{"v":233.1,"d":"233.10"},{"v":1000,"d":"1000.00"},null,null,{"v":1.1299079011148812,"d":"1.13"},{"v":4.847309743092583,"d":"4.85"},null,null,"HDAC1","Activity of epigenetic inhibitors against Plasmodium falciparum asexual and sexual blood stages LN Vanheer 2020","In silico identification of inhibitors against Plasmodium falciparum histone deacetylase 1 (PfHDAC-1) A Kumar",{"$nulls":5},"PF3D7_0925700",null,0.51,-0.22,-0.69,null,null,0.3649347020455916,0.15871401607333036,0.221677348996792,"enriched troph",null,2.299322461079817,0.43491072562757294,null,"Not detected",{"$nulls":5},"Essential"]
["MMV019881",null,null,{"v":646,"d":"646.00"},740.91,{"v":287.6,"d":"287.60"},{"v":1502,"d":"1502.00"},null,{"v":1.1469195046439629,"d":"1.15"},{"v":0.4452012383900929,"d":"0.45"},{"$f":"G31/D31","v":{"v":2.325077399380805,"d":"2.33"}},null,"Hsp90","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond, van Voorhis 2016","Malaria Box Compounds against Anopheles gambiae (Diptera: Culicidae) Carboxypeptidase B Activity to Block Malaria Transmission Tippawan Pomun",{"$nulls":5},"PF3D7_0708400",null,0.47,0.14,-0.37,null,null,391.244342138169,487.5030361563116,2642.7611857491,"gct V enriched",null,0.8025474984174693,1.2460321687774047,null,"Detected",28102267024.51306,93040000000,24304490388.95642,3.8280991911797466,null,"Essential"]
["MMV016838",null,null,{"v":1718,"d":"1718.00"},{"v":2000,"d":"2000.00"},null,{"v":5000,"d":"5000.00"},null,{"v":1.1641443538998837,"d":"1.16"},null,{"$f":"G32/D32","v":{"v":2.910360884749709,"d":"2.91"}},null,"eEF2","A novel multiple-stage antimalarial agent that inhibits protein synthesis. Beatriz Baragaña. 2015","Screening the Medicines for Malaria Venture Pathogen Box for invasion and egress inhibitors of the blood stage of Plasmodium falciparum reveals several inhibitory compounds\nAuthor links open overlay panelMadeline G.Dans. 2020",{"$nulls":5},"PF3D7_1451100",null,0.72,-0.3,-1,null,null,36.215096568022325,20.79857304540562,60.2680478057332,"shared 3 stages",null,1.741229866537512,0.5743067122944141,null,"Detected",8763016763.996223,19691000000,2265856301.007119,8.690312793113941,null,"Essential (ortholog)"]
["MMV1542945","ACT-451840",null,8.34,{"v":9.9,"d":"9.90"},null,{"v":11.1,"d":"11.10"},null,{"v":1.1870503597122304,"d":"1.19"},null,{"$f":"G33/D33","v":{"v":1.330935251798561,"d":"1.33"}},null,"MDR1","CRISPR‐Cas9‐modified pfmdr1 protects Plasmodium falciparum asexual blood stages and gametocytes against a class of piperazine‐containing compounds. CL Ng 2016","Brunner R, Aissaoui H, Boss C, Bozdech Z, Brun R, Corminboeuf O, Delahaye S, Fischli C, Heidmann B, Kaiser M et al.. (2012) Identification of a new chemical class of antimalarials. ","Brunner R, Ng CL, Aissaoui H, Akabas MH, Boss C, Brun R, Callaghan PS, Corminboeuf O, Fidock DA, Frame IJ et al.. (2013) UV-triggered affinity capture identifies interactions between the Plasmodium falciparum multidrug resistance protein 1 (PfMDR1) and antimalarial agents in live parasitized cells",{"$nulls":4},"PF3D7_0523000",null,0.55,-0.14,-0.37,null,null,4.185382762981795,2.6120056276710084,5.55996328108289,"shared 3 stages",null,1.6023636085017496,0.6240780773441461,null,"Detected",1075298324.2997518,2109100000,611327737.4544191,3.45003158008556,null,"Essential"]
["Lestaurtinib",null,null,{"v":136.1,"d":"136.10"},{"v":170.4,"d":"170.40"},{"v":950.4,"d":"950.40"},null,null,{"v":1.252020573108009,"d":"1.25"},{"$f":"F34/D34","v":{"v":6.983100661278471,"d":"6.98"}},null,null,"CDPK1","Activity of epigenetic inhibitors against Plasmodium falciparum asexual and sexual blood stages LN Vanheer 2020","Swords R, Freeman C, Giles F. 2012. Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia. ","Expression of the essential kinase PfCDPK1 from Plasmodium falciparum in Toxoplasma gondii facilitates the discovery of novel antimalarial drugs RY Gaji",{"$nulls":4},"PF3D7_0217500",null,0.54,-0.07,0.86,null,null,1.8276642121903912,0.8228906159046369,5.07832312829723,"shared 3 stages",null,2.2210293529488925,0.4502416857626333,null,"Detected",1326801430.219953,360430000,3411452182.6706023,0.10565295384496434,null,"Essential","I S","A"]
["MMV007907",null,null,{"v":350,"d":"350.00"},{"v":461,"d":"461.00"},{"v":231,"d":"231.00"},null,null,{"v":1.3171428571428572,"d":"1.32"},{"$f":"F35/D35","v":0.66},null,null,"autophagy-related protein 8 (ATG8)","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond, van Voorhis 2016","Characterization of Plasmodium Atg3-Atg8 interaction inhibitors identifies novel alternative mechanisms of action in Toxoplasma gondii JM Varberg",{"$nulls":5},"PF3D7_1019900",null,0.69,-0.17,1.04,null,null,0,1.1731201409058445,1.37137370566166,"gct V enriched",null,0.5,null,null,"Not detected",{"$nulls":5},"Essential","A"]
["MMV007907",null,null,{"v":350,"d":"350.00"},{"v":461,"d":"461.00"},{"v":231,"d":"231.00"},null,null,{"v":1.3171428571428572,"d":"1.32"},0.66,null,null,"autophagy-related protein 3 (ATG3)","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond, van Voorhis 2016","Characterization of Plasmodium Atg3-Atg8 interaction inhibitors identifies novel alternative mechanisms of action in Toxoplasma gondii JM Varberg",{"$nulls":5},"PF3D7_0905700",null,0.33,0.45,0.09,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential (ortholog)"]
["MMV000704",null,null,{"v":1091.05746,"d":"1091.06"},{"v":1462,"d":"1462.00"},{"v":5000,"d":"5000.00"},null,null,{"v":1.339984422085341,"d":"1.34"},{"v":4.582710061851372,"d":"4.58"},null,null,"phosphoethanolamine methyltransferase (PfPMT) ","Open Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and Beyond Wesley C. Van Open source drug discovery with the malaria box compound collection for neglected diseases and beyond, van Voorhis 2016 2016",{"$nulls":6},"PF3D7_1343000",null,0.77,1.48,0.61,null,null,336.4138014225539,83.2557979663136,10.5478198468946,"enriched troph",null,4.040725206413509,0.247480328138321,null,"Detected",114835488.61768718,1894500000,446647232.3754124,4.241602460905097,null,"Not essential/Essential","A"]
["Celastrol","Celastrol",null,{"v":820,"d":"820.00"},{"v":1160,"d":"1160.00"},{"v":282.4,"d":"282.40"},null,null,{"v":1.4146341463414633,"d":"1.41"},{"v":0.344390243902439,"d":"0.34"},null,null,"glutathione reductase (GR)","Antimalarial and antitumour activities of the steroidal quinone-methide celastrol and its combinations with artemiside, artemisone and methylene blue Ng 2022",{"$nulls":6},"PF3D7_1419800",null,0.71,0.64,-0.14,null,null,1.15443469003188,1.0570182237640764,9,"gct V enriched",null,1.0921615768561685,0.9156154374873182,null,"Not detected",{"$nulls":5},"Essential"]
["Celastrol","Celastrol",null,{"v":820,"d":"820.00"},{"v":1160,"d":"1160.00"},{"v":282.4,"d":"282.40"},null,null,{"v":1.4146341463414633,"d":"1.41"},{"v":0.344390243902439,"d":"0.34"},null,null,"Thioredoxin Reductase (PfTrxR)","Antimalarial and antitumour activities of the steroidal quinone-methide celastrol and its combinations with artemiside, artemisone and methylene blue Ng 2022",{"$nulls":6},"PF3D7_0923800",null,0.25,0.12,0.31,null,null,0.2942965475215916,0.2694624621099895,3.77058269614393,"gct V enriched",null,1.0921615768561683,0.9156154374873183,null,"Not detected",{"$nulls":5},"Essential/Not essential"]
["Triclosan","Triclosan",null,{"v":5.3,"d":"5.30"},{"v":7.5,"d":"7.50"},{"$nulls":3},{"v":1.4150943396226416,"d":"1.42"},{"$nulls":3},"P. falciparum enoyl reductase (PfENR)","Perozzo, R. et al. Structural elucidation of the specificity of the antibacterial agent triclosan for malarial enoyl acyl carrier protein reductase.","Freundlich, J. S. et al. X-ray structural analysis of Plasmodium falciparum enoyl acyl carrier protein reductase as a pathway toward the optimization of triclosan antimalarial efficacy.","Kumar, S. P., George, L. B., Jasrai, Y. T. & Pandya, H. A. Prioritization of active antimalarials using structural interaction profile of Plasmodium falciparum enoyl-acyl carrier protein reductase (PfENR)-triclosan derivatives. ","Plasmodium dihydrofolate reductase is a second enzyme target for the antimalarial action of triclosan E Bilsland",{"$nulls":3},"PF3D7_0615100",null,0.62,2.1,1.53,null,null,0,0.7051256087078136,0.333521432163324,"gct I/II enriched",null,0.7,null,null,"Translationally repressed",{"$nulls":5},"Not essential","U"]
["Triclosan","Triclosan",null,{"v":5.3,"d":"5.30"},{"v":7.5,"d":"7.50"},{"$nulls":3},{"v":1.4150943396226416,"d":"1.42"},{"$nulls":3},"DHFR-TS","Perozzo, R. et al. Structural elucidation of the specificity of the antibacterial agent triclosan for malarial enoyl acyl carrier protein reductase.","Freundlich, J. S. et al. X-ray structural analysis of Plasmodium falciparum enoyl acyl carrier protein reductase as a pathway toward the optimization of triclosan antimalarial efficacy.","Kumar, S. P., George, L. B., Jasrai, Y. T. & Pandya, H. A. Prioritization of active antimalarials using structural interaction profile of Plasmodium falciparum enoyl-acyl carrier protein reductase (PfENR)-triclosan derivatives. ","Plasmodium dihydrofolate reductase is a second enzyme target for the antimalarial action of triclosan E Bilsland",{"$nulls":3},"PF3D7_0417200",null,0.11,0.52,0.13,null,null,1.15443469003188,0.6407679530676047,10.9377664171444,"gct V enriched",null,1.8016423644552657,0.5550491150347446,null,"Detected",3107354809.595412,901370000,1885999900.5903804,0.47792685445945216,null,"Essential","A"]
["GSK1070916",null,null,{"v":535.2,"d":"535.20"},{"v":761.1,"d":"761.10"},{"v":1000,"d":"1000.00"},null,null,{"v":1.422085201793722,"d":"1.42"},{"$f":"F42/D42","v":{"v":1.8684603886397606,"d":"1.87"}},null,null,"ARK3","Activity of epigenetic inhibitors against Plasmodium falciparum asexual and sexual blood stages LN Vanheer 2020","Adams ND, Adams JL, Burgess JL, Chaudhari AM, Copeland RA, Donatelli CA, Drewry DH, Fisher KE, Hamajima T, Hardwicke MA et al.. (2010)Discovery of GSK1070916, a potent and selective inhibitor of Aurora B/C kinase. ",{"$nulls":5},"PF3D7_1356800",null,0.75,0.37,1.21,{"$nulls":6},"Not detected",{"$nulls":3},"Translationally repressed",{"$nulls":5},"Essential/Not essential"]
["GSK1070916",null,null,{"v":535.2,"d":"535.20"},{"v":761.1,"d":"761.10"},{"v":1000,"d":"1000.00"},null,null,{"v":1.422085201793722,"d":"1.42"},{"v":1.8684603886397606,"d":"1.87"},null,null,"ARK2","Activity of epigenetic inhibitors against Plasmodium falciparum asexual and sexual blood stages LN Vanheer 2020","Adams ND, Adams JL, Burgess JL, Chaudhari AM, Copeland RA, Donatelli CA, Drewry DH, Fisher KE, Hamajima T, Hardwicke MA et al.. (2010)Discovery of GSK1070916, a potent and selective inhibitor of Aurora B/C kinase. ",{"$nulls":5},"PF3D7_0309200",null,0.15,1.22,0.88,{"$nulls":6},"Not detected",{"$nulls":3},"Detected",5668429.125041404,3214137.014789671,8530385.800486196,0.3767868288684527,null,"Essential"]
["GSK1070916",null,null,{"v":535.2,"d":"535.20"},{"v":761.1,"d":"761.10"},{"v":1000,"d":"1000.00"},null,null,{"v":1.422085201793722,"d":"1.42"},{"v":1.8684603886397606,"d":"1.87"},null,null,"ARK1","Activity of epigenetic inhibitors against Plasmodium falciparum asexual and sexual blood stages LN Vanheer 2020","Adams ND, Adams JL, Burgess JL, Chaudhari AM, Copeland RA, Donatelli CA, Drewry DH, Fisher KE, Hamajima T, Hardwicke MA et al.. (2010)Discovery of GSK1070916, a potent and selective inhibitor of Aurora B/C kinase. ",{"$nulls":5},"PF3D7_0605300",null,0.37,1.37,0.19,null,null,0,0,2.51119173421513,"gct V enriched",null,1,null,null,"Detected",77571928.73378326,10413000,135021045.8412919,0.07712131049732629,null,"Essential"]
["GSK1070916",null,null,{"v":535.2,"d":"535.20"},{"v":761.1,"d":"761.10"},{"v":1000,"d":"1000.00"},null,null,{"v":1.422085201793722,"d":"1.42"},{"v":1.8684603886397606,"d":"1.87"},null,null,"serine/threonine kinases","Activity of epigenetic inhibitors against Plasmodium falciparum asexual and sexual blood stages LN Vanheer 2020","Adams ND, Adams JL, Burgess JL, Chaudhari AM, Copeland RA, Donatelli CA, Drewry DH, Fisher KE, Hamajima T, Hardwicke MA et al.. (2010)Discovery of GSK1070916, a potent and selective inhibitor of Aurora B/C kinase. ",{"$nulls":7},0.4972413793103446,0.43482758620689654,0.44137931034482764,"Average",null,0.15148991700512904,0.22907656310046898,0.6138576526621393,"gct V enriched","Average",0.6613069226933015,1.512157162860635,null,"Detected",275788067.42844534,422139337.5,306182163.24275047,1.3787195603726765,null,"Essential/Not essential"]
["MMV666597",null,null,{"v":551,"d":"551.00"},{"v":819,"d":"819.00"},{"v":465,"d":"465.00"},{"v":1927,"d":"1927.00"},null,{"v":1.486388384754991,"d":"1.49"},{"v":0.8439201451905626,"d":"0.84"},{"$f":"G46/D46","v":{"v":3.4972776769509983,"d":"3.50"}},null,"Saglin (thrombospondin-related anonymous protein?)","Transcriptome Analysis of Uninfected and Plasmodium vivax-infected Anopheles dirus at Ookinete and Oocyst Stages and Targeting Anopheles Carboxypeptidase B … T Boonkaew",{"$nulls":6},"PF3D7_1335900",null,0.82,0.91,0.81,{"$nulls":6},"Not detected",{"$nulls":3},"Translationally repressed",{"$nulls":5},"Not essential"]
["MMV396749",null,null,{"v":928,"d":"928.00"},1384.56,{"v":5000,"d":"5000.00"},1354.33,null,{"v":1.4919827586206895,"d":"1.49"},{"v":5.387931034482759,"d":"5.39"},{"$f":"G47/D47","v":{"v":1.4594073275862067,"d":"1.46"}},null,"ATP4","E.L. Allman, H.J. Painter, J. Samra, M. Carrasquilla, M. Llinas Metabolomic profiling of the malaria box reveals antimalarial target pathways 2016","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond, van Voorhis 2016","Diverse chemotypes disrupt ion homeostasis in the malaria parasite AM Lehane","Targeted phenotypic screening in Plasmodium falciparum and Toxoplasma gondii reveals novel modes of action of medicines for malaria venture malaria box … G Subramanian",{"$nulls":3},"PF3D7_1211900",null,0.33,-0.22,-0.49,null,null,1.7731908623980155,0.4394601472062679,2.59381366380463,"shared 3 stages",null,4.034929842149575,0.24783578379822793,null,"Detected",636393353.8483057,392860000,65708369.94269839,5.978842578846459,null,"Essential"]
["Epoxomycin","Epoxomycin",null,{"v":8,"d":"8.00"},{"v":12.1,"d":"12.10"},{"v":0.42000000000000004,"d":"0.42"},{"v":3.8,"d":"3.80"},null,{"v":1.5125,"d":"1.51"},{"v":0.052500000000000005,"d":"0.05"},{"$f":"G48/D48","v":{"v":0.475,"d":"0.48"}},null,"Proteosome subunit beta type-5","rasad R, Atul Kolla VK, Legac J, Singhal N, NavaleR, Rosenthal PJ & Sijwali PS (2013) BlockingPlasmodium falciparumdevelopment via dualinhibition of hemoglobin degradation and theubiquitin proteasome system by MG13",{"$nulls":6},"PF3D7_1011400",null,0.17,0.88,0.57,null,null,1.3957664804363776,5.489058493010015,6.35642254459642,"gct V enriched",null,0.2542815825726401,3.9326481685488646,null,"Detected",863717094.4504669,2420200000,905523359.9583262,2.672708520861772,null,"Essential (ortholog)"]
["MMV011895",null,null,{"v":842,"d":"842.00"},1286.53,{"v":5000,"d":"5000.00"},{"v":5000,"d":"5000.00"},null,{"v":1.5279453681710213,"d":"1.53"},{"v":5.938242280285036,"d":"5.94"},{"$f":"G49/D49","v":{"v":5.938242280285036,"d":"5.94"}},null,"chloroquine resistance transporter (CRT)","Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. Cowell. 2018","Identification of β-hematin inhibitors in the MMV Malaria Box KY Fong 2015","Characterization of Plasmodium falciparum 6-phosphogluconate dehydrogenase as an antimalarial drug target K Haeussler 2018",{"$nulls":4},"PF3D7_0709000",null,0.71,-0.13,-0.9,null,null,2.488931895417541,0.18392148688178012,0.584893192461114,"enriched troph",null,13.532578153945444,0.07389574910442682,null,"Detected",12619931.898450887,55641000,158501694.86890087,0.35104356484024674,null,"Essential","D"]
["MMV011895",null,null,{"v":842,"d":"842.00"},1286.53,{"v":5000,"d":"5000.00"},{"v":5000,"d":"5000.00"},null,{"v":1.5279453681710213,"d":"1.53"},{"v":5.938242280285036,"d":"5.94"},{"v":5.938242280285036,"d":"5.94"},null,"amino acid transporter AAT1","Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. Cowell. 2018","Identification of β-hematin inhibitors in the MMV Malaria Box KY Fong 2015","Characterization of Plasmodium falciparum 6-phosphogluconate dehydrogenase as an antimalarial drug target K Haeussler 2018",{"$nulls":4},"PF3D7_0629500",null,0.31,-0.31,-0.59,{"$nulls":6},"Not detected",{"$nulls":3},"Detected",3042923.6353463647,6972800,6511740.419343636,1.0708043550518,null,"Essential"]
["MMV011895",null,null,{"v":842,"d":"842.00"},1286.53,{"v":5000,"d":"5000.00"},{"v":5000,"d":"5000.00"},null,{"v":1.5279453681710213,"d":"1.53"},{"v":5.938242280285036,"d":"5.94"},{"v":5.938242280285036,"d":"5.94"},null,"6-phosphogluconate dehydrogenase","Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. Cowell. 2018","Identification of β-hematin inhibitors in the MMV Malaria Box KY Fong 2015","Characterization of Plasmodium falciparum 6-phosphogluconate dehydrogenase as an antimalarial drug target K Haeussler 2018",{"$nulls":4},"PF3D7_1454700",null,0.29,0.18,-0.08,null,null,1.7176232460629302,5.869374848204267,16.4332882219999,"gct V enriched",null,0.29264159991220123,3.4171491691544245,null,"Detected",1936470222.4009511,2758600000,3486288340.423685,0.7912713265893406,null,"Essential"]
["MMV000025","Pyronaridine",null,{"v":17,"d":"17.00"},{"v":27,"d":"27.00"},null,{"v":938.4,"d":"938.40"},null,{"v":1.588235294117647,"d":"1.59"},null,{"v":55.199999999999996,"d":"55.20"},null,"DNA topoisomerase2 (TOP2)","Pyronaridine: An update of its pharmacological activities andmechanisms of action Christian Bailly 2021","Review of pyronaridine anti-malarial properties and product characteristics Simon L Croft 2012",{"$nulls":5},"PF3D7_1433500",null,0.79,-0.02,0.28,null,null,1.1250623353878415,0.9615132377040246,2.43332001828199,"shared 3 stages",null,1.1700955236709503,0.8546310790615554,null,"Detected",563713858.0970031,244090000,3133698280.5174513,0.07789199155436709,null,"Not essential"]
["CLM-19",null,null,{"v":2.7,"d":"2.70"},{"v":4.5,"d":"4.50"},{"v":29,"d":"29.00"},null,null,{"v":1.6666666666666665,"d":"1.67"},{"$f":"F53/D53","v":{"v":10.74074074074074,"d":"10.74"}},null,null,"PK7","A novel pyrazolopyridine with in vivo activity in Plasmodium berghei-and Plasmodium falciparum-infected mouse models from structure–activity relationship studies around the core of recently identified antimalarial imidazopyridazines Le Manach 2015",{"$nulls":6},"PF3D7_0213400",null,0.31,0.27,-0.31,null,null,0.2246523050636276,0,0.136463666385725,"not determined",null,1.2,0,null,"Not detected",{"$nulls":5},"Not essential","A D"]
["MMV674850",null,null,2.65,4.47,{"v":28.7,"d":"28.70"},{"v":208.8,"d":"208.80"},null,{"v":1.6867924528301887,"d":"1.69"},{"v":10.830188679245284,"d":"10.83"},{"$f":"G54/D54","v":{"v":78.79245283018868,"d":"78.79"}},null,"CDPK1","Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): preparation and evaluation of pyrazole … JM Large","Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) TM Chapman","New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of Plasmodium Phosphatidylinositol-4-kinase and cGMP … PM Cheuka",{"$nulls":4},"PF3D7_0217500",null,0.54,-0.07,0.86,null,null,1.8276642121903912,0.8228906159046369,5.07832312829723,"shared 3 stages",null,2.2210293529488925,0.4502416857626333,null,"Detected",1326801430.219953,360430000,3411452182.6706023,{"$f":"AL54/AM54","v":0.10565295384496434},null,"Essential","I S","A"]
["MMV674850",null,null,2.65,4.47,{"v":28.7,"d":"28.70"},{"v":208.8,"d":"208.80"},null,{"v":1.6867924528301887,"d":"1.69"},{"v":10.830188679245284,"d":"10.83"},{"$f":"G55/D55","v":{"v":78.79245283018868,"d":"78.79"}},null,"CDPK4","Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): preparation and evaluation of pyrazole … JM Large","Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) TM Chapman","New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of Plasmodium Phosphatidylinositol-4-kinase and cGMP … PM Cheuka",{"$nulls":4},"PF3D7_0717500",null,0.32,0.52,0.27,null,null,0,0.40541168873881694,56.3615251044868,"gct V enriched",null,0.4,null,null,"Detected",1686711047.3126552,891260000,11247658017.88505,0.07923960691041598,null,"Not essential","U"]
["MMV674850",null,null,2.65,4.47,{"v":28.7,"d":"28.70"},{"v":208.8,"d":"208.80"},null,{"v":1.6867924528301887,"d":"1.69"},{"v":10.830188679245284,"d":"10.83"},{"$f":"G56/D56","v":{"v":78.79245283018868,"d":"78.79"}},null,"PI4K","Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): preparation and evaluation of pyrazole … JM Large","Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) TM Chapman","New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of Plasmodium Phosphatidylinositol-4-kinase and cGMP … PM Cheuka",{"$nulls":4},"PF3D7_0509800",null,0.29,-0.01,0.16,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV674850",null,null,2.65,4.47,{"v":28.7,"d":"28.70"},{"v":208.8,"d":"208.80"},null,{"v":1.6867924528301887,"d":"1.69"},{"v":10.830188679245284,"d":"10.83"},{"$f":"G57/D57","v":{"v":78.79245283018868,"d":"78.79"}},null,"PKG","Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): preparation and evaluation of pyrazole … JM Large","Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) TM Chapman","New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of Plasmodium Phosphatidylinositol-4-kinase and cGMP … PM Cheuka",{"$nulls":4},"PF3D7_1436600",null,0.47,-0.44,0.1,null,null,0,0.068244893498124,2.02530545710245,"gct V enriched",null,0.8,null,null,"Detected",187255751.4074903,109730000,295371702.85639864,0.37149801060444715,null,"Essential"]
["Belinostat (PXD101)","Belinostat (PXD101)",null,{"v":186.6,"d":"186.60"},{"v":326.1,"d":"326.10"},{"v":1000,"d":"1000.00"},null,null,{"v":1.7475884244372992,"d":"1.75"},{"v":5.359056806002144,"d":"5.36"},null,null,"HDAC1","Activity of epigenetic inhibitors against Plasmodium falciparum asexual and sexual blood stages LN Vanheer 2020","Bradner JE, West N, Grachan ML, Greenberg EF, Haggarty SJ, Warnow T, Mazitschek R. (2010) Chemical phylogenetics of histone deacetylases. ","Khan N, Jeffers M, Kumar S, Hackett C, Boldog F, Khramtsov N, Qian X, Mills E, Berghs SC, Carey N et al.. (2008) Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. ","Engel JA, Jones AJ, Avery VM et al (2015) Profiling the anti-protozoal activity of anti-cancer HDAC inhibitors against Plasmodium and Trypanosoma parasites. ",{"$nulls":3},"PF3D7_0925700",null,0.51,-0.22,-0.69,null,null,0.3649347020455916,0.15871401607333036,0.221677348996792,"enriched troph",null,2.299322461079817,0.43491072562757294,null,"Not detected",{"$nulls":5},"Essential"]
["MMV000839",null,null,{"v":1080,"d":"1080.00"},{"v":2000,"d":"2000.00"},{"v":2000,"d":"2000.00"},null,null,{"v":1.8518518518518519,"d":"1.85"},{"v":1.8518518518518519,"d":"1.85"},null,null,"Hsp90","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond, van Voorhis 2016",{"$nulls":6},"PF3D7_0708400",null,0.47,0.14,-0.37,null,null,391.244342138169,487.5030361563116,2642.7611857491,"gct V enriched",null,0.8025474984174693,1.2460321687774047,null,"Detected",28102267024.51306,93040000000,24304490388.95642,3.8280991911797466,null,"Essential"]
["PC29",null,null,{"v":12,"d":"12.00"},{"v":22.8,"d":"22.80"},{"v":42.3,"d":"42.30"},null,null,{"v":1.9000000000000001,"d":"1.90"},{"v":3.525,"d":"3.53"},null,null,"PI4K","New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of Plasmodium Phosphatidylinositol-4-kinase and cGMP … PM Cheuka",{"$nulls":6},"PF3D7_0509800",null,0.29,-0.01,0.16,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV000753",null,null,{"v":326,"d":"326.00"},{"v":627,"d":"627.00"},{"v":2000,"d":"2000.00"},{"v":5000,"d":"5000.00"},null,{"v":1.9233128834355828,"d":"1.92"},{"v":6.134969325153374,"d":"6.13"},{"$f":"G61/D61","v":{"v":15.337423312883436,"d":"15.34"}},null,"CDPK1","Identification of β-hematin inhibitors in the MMV Malaria Box KY Fong 2015","Allosteric regulation of the inactive to active state conformational transition in CDPK1 protein of Plasmodium falciparum P Gupta 2022","K.Y. Fong, R.D. Sandlin, D.W. Wright\nIdentification of beta-hematin inhibitors in the MMV Malaria Box. International journal for parasitology",{"$nulls":4},"PF3D7_0217500",null,0.54,-0.07,0.86,null,null,1.8276642121903912,0.8228906159046369,5.07832312829723,"shared 3 stages",null,2.2210293529488925,0.4502416857626333,null,"Detected",1326801430.219953,360430000,3411452182.6706023,0.10565295384496434,null,"Essential","I S","A"]
["MMV007224",null,null,{"v":320,"d":"320.00"},{"v":654,"d":"654.00"},{"v":948,"d":"948.00"},{"v":1980,"d":"1980.00"},null,{"v":2.04375,"d":"2.04"},{"$f":"F62/D62","v":{"v":2.9625,"d":"2.96"}},{"v":6.1875,"d":"6.19"},null,"phospholipid-transporting ATPase 2 (ATP2)","Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. Cowell. 2018"," Lipid transport proteins in malaria, from Plasmodium parasites to their hosts M Ressurreição 2021"," Screening for potential prophylactics targeting sporozoite motility through the skin RG Douglas 2018","Generation of a mutator parasite to drive resistome discovery in Plasmodium falciparum K Kumpornsin",{"$nulls":3},"PF3D7_1219600",null,0.26,-0.16,-0.4,null,null,0,0,0.337940442708695,"gct V enriched",null,1,null,null,"Detected",38850536.94093786,30051000,36855198.62823407,0.8153802209324819,null,"Essential"]
["MMV007224",null,null,{"v":320,"d":"320.00"},{"v":654,"d":"654.00"},{"v":948,"d":"948.00"},{"v":1980,"d":"1980.00"},null,{"v":2.04375,"d":"2.04"},{"$f":"F63/D63","v":{"v":2.9625,"d":"2.96"}},{"v":6.1875,"d":"6.19"},null,"amino acid transporter AAT1","Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. Cowell. 2018"," Lipid transport proteins in malaria, from Plasmodium parasites to their hosts M Ressurreição 2021"," Screening for potential prophylactics targeting sporozoite motility through the skin RG Douglas 2018","Generation of a mutator parasite to drive resistome discovery in Plasmodium falciparum K Kumpornsin",{"$nulls":3},"PF3D7_0629500",null,0.31,-0.31,-0.59,{"$nulls":6},"Not detected",{"$nulls":3},"Detected",3042923.6353463647,6972800,6511740.419343636,1.0708043550518,null,"Essential"]
["MMV007224",null,null,{"v":320,"d":"320.00"},{"v":654,"d":"654.00"},{"v":948,"d":"948.00"},{"v":1980,"d":"1980.00"},null,{"v":2.04375,"d":"2.04"},{"$f":"F64/D64","v":{"v":2.9625,"d":"2.96"}},{"v":6.1875,"d":"6.19"},null,"CCR4-associated factor 16 (CAF16)","Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. Cowell. 2018"," Lipid transport proteins in malaria, from Plasmodium parasites to their hosts M Ressurreição 2021"," Screening for potential prophylactics targeting sporozoite motility through the skin RG Douglas 2018","Generation of a mutator parasite to drive resistome discovery in Plasmodium falciparum K Kumpornsin",{"$nulls":3},"PF3D7_1434000",null,0.74,0.24,0.02,{"$nulls":6},"Not detected",{"$nulls":3},"Detected",249143.5242036318,7014000,11440745.83695086,0.6130719185585318,null,"Essential"]
["MMV007224",null,null,{"v":320,"d":"320.00"},{"v":654,"d":"654.00"},{"v":948,"d":"948.00"},{"v":1980,"d":"1980.00"},null,{"v":2.04375,"d":"2.04"},{"$f":"F65/D65","v":{"v":2.9625,"d":"2.96"}},{"v":6.1875,"d":"6.19"},null,"QRP1?","Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. Cowell. 2018"," Lipid transport proteins in malaria, from Plasmodium parasites to their hosts M Ressurreição 2021"," Screening for potential prophylactics targeting sporozoite motility through the skin RG Douglas 2018","Generation of a mutator parasite to drive resistome discovery in Plasmodium falciparum K Kumpornsin",{"$nulls":3},"PF3D7_1359900",null,0.59,-0.05,0.22,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Not essential"]
["MMV007224",null,null,{"v":320,"d":"320.00"},{"v":654,"d":"654.00"},{"v":948,"d":"948.00"},{"v":1980,"d":"1980.00"},null,{"v":2.04375,"d":"2.04"},{"$f":"F66/D66","v":{"v":2.9625,"d":"2.96"}},{"v":6.1875,"d":"6.19"},null,"thrombospondin-related anonymous protein (TRAP)","Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. Cowell. 2018"," Lipid transport proteins in malaria, from Plasmodium parasites to their hosts M Ressurreição 2021"," Screening for potential prophylactics targeting sporozoite motility through the skin RG Douglas 2018","Generation of a mutator parasite to drive resistome discovery in Plasmodium falciparum K Kumpornsin",{"$nulls":3},"PF3D7_1335900",null,0.82,0.91,0.81,{"$nulls":6},"Not detected",{"$nulls":3},"Translationally repressed",{"$nulls":5},"Not essential"]
["MMV000073","Cipargamin/KAE609/NITD609",null,{"v":0.5,"d":"0.50"},1.03,null,{"v":27.7,"d":"27.70"},null,{"$f":"E67/D67","v":2.06},null,{"$f":"G67/D67","v":{"v":55.4,"d":"55.40"}},null,"ATP4","Rottmann M, McNamara C, Yeung BK, Lee MC, Zou B, Russell B, Seitz P, Plouffe DM, Dharia NV, Tan J, Cohen SB, Spencer KR, Gonzalez-Paez GE, Lakshminarayana SB, Goh A, Suwanarusk R, Jegla T, Schmitt EK, Beck HP, Brun R, Nosten F, Renia L, Dartois V, Keller TH, Fidock DA, Winzeler EA, Diagana TT. 2010. Spiroindolones, a potent compound class for the treatment of malaria. Science 329:1175–1180.","N.J. Spillman, R.J. Allen, C.W. McNamara, B.K.S. Yeung, E.A. Winzeler, et al. Na+ regulation in the malaria parasite Plasmodium falciparum involves the cation ATPase PfATP4 and is a target of the spiroindolone antimalarials 2013","J.C. Van Pelt-Koops, H.E. Pett, W. Graumans, M. van der Vegte-Bolmer, G.J. van Gemert, M. Rottmann, et al. The spiroindolone drug candidate NITD609 potently inhibits gametocytogenesis and blocks Plasmodium falciparum transmission to anopheles mosquito vector 2012",{"$nulls":4},"PF3D7_1211900",null,0.33,-0.22,-0.49,null,null,1.7731908623980155,0.4394601472062679,2.59381366380463,"shared 3 stages",null,4.034929842149575,0.24783578379822793,null,"Detected",636393353.8483057,392860000,65708369.94269839,5.978842578846459,null,"Essential"]
["Abexinostat (PCI-24781)","Abexinostat (PCI-24781)",null,{"v":54.4,"d":"54.40"},{"v":112.19999999999999,"d":"112.20"},{"v":1000,"d":"1000.00"},null,null,{"v":2.0625,"d":"2.06"},{"$f":"F68/D68","v":{"v":18.38235294117647,"d":"18.38"}},null,null,"HDAC1","Activity of epigenetic inhibitors against Plasmodium falciparum asexual and sexual blood stages LN Vanheer 2020","Buggy JJ, Cao ZA, Bass KE, Verner E, Balasubramanian S, Liu L, Schultz BE, Young PR, Dalrymple SA. (2006) CRA-024781: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo. ",{"$nulls":5},"PF3D7_0925700",null,0.51,-0.22,-0.69,null,null,0.3649347020455916,0.15871401607333036,0.221677348996792,"enriched troph",null,2.299322461079817,0.43491072562757294,null,"Not detected",{"$nulls":5},"Essential"]
["MMV1581373","KAE609 analog",null,0.55,1.14,null,0.11,null,{"v":2.0727272727272723,"d":"2.07"},null,{"$f":"G69/D69","v":{"v":0.19999999999999998,"d":"0.20"}},null,"ATP4",{"$nulls":7},"PF3D7_1211900",null,0.33,-0.22,-0.49,null,null,1.7731908623980155,0.4394601472062679,2.59381366380463,"shared 3 stages",null,{"$f":"AB69/AC69","v":4.034929842149575},{"$f":"AC69/AB69","v":0.24783578379822793},null,"Detected",636393353.8483057,392860000,65708369.94269839,5.978842578846459,null,"Essential"]
["MMV666692",null,null,{"v":387,"d":"387.00"},{"v":830,"d":"830.00"},{"v":594,"d":"594.00"},null,null,{"v":2.144702842377261,"d":"2.14"},{"$f":"F70/D70","v":{"v":1.5348837209302326,"d":"1.53"}},null,null,"Saglin (thrombospondin-related anonymous protein?)","Transcriptome Analysis of Uninfected and Plasmodium vivax-infected Anopheles dirus at Ookinete and Oocyst Stages and Targeting Anopheles Carboxypeptidase B … T Boonkaew",{"$nulls":6},"PF3D7_1335900",null,0.82,0.91,0.81,{"$nulls":6},"Not detected",{"$nulls":3},"Translationally repressed",{"$nulls":5},"Not essential"]
["MMV023367",null,null,1192.27,{"v":2718,"d":"2718.00"},null,{"v":5000,"d":"5000.00"},null,{"v":2.27968497068617,"d":"2.28"},null,{"$f":"G71/D71","v":{"v":4.193680961527171,"d":"4.19"}},null,"ABCI3","Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. Cowell. 2018",{"$nulls":6},"PF3D7_0319700",null,0.37,-0.27,-0.58,{"$nulls":6},"Not detected",{"$nulls":3},"Detected",2589313.0859880405,1486100,10695894.947039416,0.13894115521500583,null,"Essential (ortholog)"]
["MMV023367",null,null,1192.27,{"v":2718,"d":"2718.00"},null,{"v":5000,"d":"5000.00"},null,{"v":2.27968497068617,"d":"2.28"},null,{"$f":"G72/D72","v":{"v":4.193680961527171,"d":"4.19"}},null,"amino acid transporter A","Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. Cowell. 2018",{"$nulls":6},"PF3D7_1132500",null,0.34,0.73,0.67,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Not essential"]
["MMV023367",null,null,1192.27,{"v":2718,"d":"2718.00"},null,{"v":5000,"d":"5000.00"},null,{"v":2.27968497068617,"d":"2.28"},null,{"$f":"G73/D73","v":{"v":4.193680961527171,"d":"4.19"}},null,"amino acid transporter B","Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. Cowell. 2018",{"$nulls":6},"PF3D7_1208400",null,0.32,0.7,0.71,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Not essential"]
["MMV023367",null,null,1192.27,{"v":2718,"d":"2718.00"},null,{"v":5000,"d":"5000.00"},null,{"v":2.27968497068617,"d":"2.28"},null,{"$f":"G74/D74","v":{"v":4.193680961527171,"d":"4.19"}},null,"amino acid transporter AAT1","Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. Cowell. 2018",{"$nulls":6},"PF3D7_0629500",null,0.31,-0.31,-0.59,{"$nulls":6},"Not detected",{"$nulls":3},"Detected",3042923.6353463647,6972800,6511740.419343636,1.0708043550518,null,"Essential"]
["MMV023367",null,null,1192.27,{"v":2718,"d":"2718.00"},null,{"v":5000,"d":"5000.00"},null,{"v":2.27968497068617,"d":"2.28"},null,{"$f":"G75/D75","v":{"v":4.193680961527171,"d":"4.19"}},null,"AP2 domain transcription factor","Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. Cowell. 2018",{"$nulls":6},"PF3D7_0613800",null,0.3,0.16,0.69,null,null,0.03482332457788821,0,0,"enriched troph",null,1.1,0,null,"Not detected",{"$nulls":5},"Essential (ortholog)"]
["MMV019127",null,null,{"v":625,"d":"625.00"},{"v":1436,"d":"1436.00"},{"v":935,"d":"935.00"},null,null,{"v":2.2976,"d":"2.30"},{"$f":"F76/D76","v":{"v":1.496,"d":"1.50"}},null,null,"PKG","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond, van Voorhis 2016","Targeted phenotypic screening in Plasmodium falciparum and Toxoplasma gondii reveals novel modes of action of medicines for malaria venture malaria box … G Subramanian",{"$nulls":5},"PF3D7_1436600",null,0.47,-0.44,0.1,null,null,0,0.068244893498124,2.02530545710245,"gct V enriched",null,0.8,null,null,"Detected",187255751.4074903,109730000,295371702.85639864,0.37149801060444715,null,"Essential"]
["MMV1578884","CRS-3123",null,1643.33,{"v":3776,"d":"3776.00"},null,{"v":5000,"d":"5000.00"},null,{"v":2.2977734234755043,"d":"2.30"},null,{"$f":"G77/D77","v":{"v":3.0426025204919283,"d":"3.04"}},null,"methionine--tRNA ligase (cyto)","Inhibition of protein synthesis and malaria parasite development by drug targeting of methionyl-tRNA synthetases T Hussain 2015",{"$nulls":6},"PF3D7_1034900",null,0.43,0.01,0.05,null,null,2.488931895417541,5.890704031654335,15.5265353985669,"gct V enriched",null,0.42251857877139926,2.3667598307932467,null,"Detected",3091188099.450991,3090600000,2027422100.1910057,1.5243988904475447,null,"Essential"]
["MMV1578884","CRS-3123",null,1643.33,{"v":3776,"d":"3776.00"},null,{"v":5000,"d":"5000.00"},null,{"v":2.2977734234755043,"d":"2.30"},null,{"$f":"G78/D78","v":{"v":3.0426025204919283,"d":"3.04"}},null,"methionine--tRNA ligase (apic)","Inhibition of protein synthesis and malaria parasite development by drug targeting of methionyl-tRNA synthetases T Hussain 2015",{"$nulls":6},"PF3D7_1005000",null,0.42,0.36,0.4,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV642944",null,null,20.16,{"v":46.800000000000004,"d":"46.80"},{"v":51.9,"d":"51.90"},{"v":96.8,"d":"96.80"},null,{"v":2.3214285714285716,"d":"2.32"},{"$f":"F79/D79","v":{"v":2.574404761904762,"d":"2.57"}},{"$f":"G79/D79","v":{"v":4.801587301587301,"d":"4.80"}},null,"PI4K"," Potent Plasmodium falciparum gametocytocidal compounds identified by exploring the kinase inhibitor chemical space for dual active antimalarials Mariëtte E van der Watt, ","Probing the distinct chemosensitivity of Plasmodium vivax liver stage parasites and demonstration of 8-aminoquinoline radical cure activity in vitro SP Maher 2021","UCT943, a Next-Generation Plasmodium falciparum PI4K Inhibitor Preclinical Candidate for the Treatment of Malaria Christel Brunschwig 2018",{"$nulls":4},"PF3D7_0509800",null,0.29,-0.01,0.16,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV665820",null,null,{"v":520,"d":"520.00"},{"v":1214,"d":"1214.00"},{"v":2000,"d":"2000.00"},null,null,{"v":2.3346153846153848,"d":"2.33"},{"v":3.8461538461538463,"d":"3.85"},null,null,"phosphopantetheine adenylyltransferase (PPAT)","Biological characterization of chemically diverse compounds targeting the Plasmodium falciparum coenzyme A synthesis pathway S Fletcher",{"$nulls":6},"PF3D7_0704700",null,0.2,0.12,0.72,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Not essential"]
["MMV665820",null,null,{"v":520,"d":"520.00"},{"v":1214,"d":"1214.00"},{"v":2000,"d":"2000.00"},null,null,{"v":2.3346153846153848,"d":"2.33"},{"v":3.8461538461538463,"d":"3.85"},null,null,"dephospho-CoA kinase (DPCK)","Biological characterization of chemically diverse compounds targeting the Plasmodium falciparum coenzyme A synthesis pathway S Fletcher",{"$nulls":6},"PF3D7_1443700",null,0.27,0.6,0.55,{"$nulls":6},"Not detected",{"$nulls":3},"Detected",600796.7779038273,3685300,5879231.533252301,0.626833622584234,null,"Essential"]
["MMV019266",null,null,{"v":255,"d":"255.00"},{"v":596,"d":"596.00"},{"v":324,"d":"324.00"},{"v":520,"d":"520.00"},null,{"v":2.3372549019607844,"d":"2.34"},{"v":1.2705882352941176,"d":"1.27"},{"$f":"G82/D82","v":{"v":2.0392156862745097,"d":"2.04"}},null,"phosphatidylserine decarboxylase (PSD)","E.L. Allman, H.J. Painter, J. Samra, M. Carrasquilla, M. Llinas Metabolomic profiling of the malaria box reveals antimalarial target pathways 2016","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond, van Voorhis 2016","Characterization of Plasmodium phosphatidylserine decarboxylase expressed in yeast and application for inhibitor screening JY Choi",{"$nulls":4},"PF3D7_0927900",null,0.6,-0.61,0.16,null,null,0.9628761074834958,0,0.584893192461114,"shared 3 stages",null,1.5,0,null,"Not detected",{"$nulls":5},"Essential"]
["MMV019266",null,null,{"v":255,"d":"255.00"},{"v":596,"d":"596.00"},{"v":324,"d":"324.00"},{"v":520,"d":"520.00"},null,{"v":2.3372549019607844,"d":"2.34"},{"v":1.2705882352941176,"d":"1.27"},{"$f":"G83/D83","v":{"v":2.0392156862745097,"d":"2.04"}},null,"PKG","E.L. Allman, H.J. Painter, J. Samra, M. Carrasquilla, M. Llinas Metabolomic profiling of the malaria box reveals antimalarial target pathways 2016","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond, van Voorhis 2016","Characterization of Plasmodium phosphatidylserine decarboxylase expressed in yeast and application for inhibitor screening JY Choi",{"$nulls":4},"PF3D7_1436600",null,0.47,-0.44,0.1,null,null,0,0.068244893498124,2.02530545710245,"gct V enriched",null,0.8,null,null,"Detected",187255751.4074903,109730000,295371702.85639864,0.37149801060444715,null,"Essential"]
["MMV666116",null,null,{"v":548,"d":"548.00"},{"v":1314,"d":"1314.00"},{"v":662,"d":"662.00"},null,null,{"v":2.397810218978102,"d":"2.40"},{"v":1.2080291970802919,"d":"1.21"},null,null,"DHFR-TS","E.L. Allman, H.J. Painter, J. Samra, M. Carrasquilla, M. Llinas Metabolomic profiling of the malaria box reveals antimalarial target pathways 2016","MMV Malaria Box Activity Screening in Dormant Plasmodium falciparum Phenotypes S Galusic",{"$nulls":5},"PF3D7_0417200",null,0.11,0.52,0.13,null,null,1.15443469003188,0.6407679530676047,10.9377664171444,"gct V enriched",null,1.8016423644552657,0.5550491150347446,null,"Detected",3107354809.595412,901370000,1885999900.5903804,0.47792685445945216,null,"Essential","A"]
["MMV665789",null,null,{"v":592,"d":"592.00"},{"v":1592,"d":"1592.00"},{"v":1321,"d":"1321.00"},null,null,{"v":2.689189189189189,"d":"2.69"},{"v":2.231418918918919,"d":"2.23"},null,null,"MDR1","E.L. Allman, H.J. Painter, J. Samra, M. Carrasquilla, M. Llinas Metabolomic profiling of the malaria box reveals antimalarial target pathways 2016","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond, van Voorhis 2016","Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics AN Cowell",{"$nulls":4},"PF3D7_0523000",null,0.55,-0.14,-0.37,null,null,4.185382762981795,2.6120056276710084,5.55996328108289,"shared 3 stages",null,1.6023636085017496,0.6240780773441461,null,"Detected",1075298324.2997518,2109100000,611327737.4544191,3.45003158008556,null,"Essential"]
["MMV665789",null,null,{"v":592,"d":"592.00"},{"v":1592,"d":"1592.00"},{"v":1321,"d":"1321.00"},null,null,{"v":2.689189189189189,"d":"2.69"},{"v":2.231418918918919,"d":"2.23"},null,null,"amino acid transporter AAT1","E.L. Allman, H.J. Painter, J. Samra, M. Carrasquilla, M. Llinas Metabolomic profiling of the malaria box reveals antimalarial target pathways 2016","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond, van Voorhis 2016","Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics AN Cowell",{"$nulls":4},"PF3D7_0629500",null,0.31,-0.31,-0.59,{"$nulls":6},"Not detected",{"$nulls":3},"Detected",3042923.6353463647,6972800,6511740.419343636,1.0708043550518,null,"Essential"]
["MMV019662",null,null,{"v":1729,"d":"1729.00"},{"v":4715.5,"d":"4715.50"},null,{"v":5000,"d":"5000.00"},null,{"v":2.727299016772701,"d":"2.73"},null,{"$f":"G87/D87","v":{"v":2.891844997108155,"d":"2.89"}},null,"Niemann-Pick type C1-related protein (NCR1)","Diverse Chemical Compounds Target Plasmodium falciparum Plasma Membrane Lipid Homeostasis. S Bhatnagar. 2019","Plasmodium Niemann-Pick type C1-related protein is a druggable target required for parasite membrane homeostasis. ES Istvan. 2019","Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. Cowell. 2018",{"$nulls":4},"PF3D7_0107500",null,0.44,-0.6,-0.27,null,null,0.8720675920415234,0,0.0734188827013531,"enriched troph",null,1.8,0,null,"Not detected",{"$nulls":5},"Essential"]
["MMV665929",null,null,{"v":720,"d":"720.00"},{"v":2000,"d":"2000.00"},{"v":2000,"d":"2000.00"},null,null,{"v":2.7777777777777777,"d":"2.78"},{"$f":"F88/D88","v":{"v":2.7777777777777777,"d":"2.78"}},null,null,"DHFR-TS","E.L. Allman, H.J. Painter, J. Samra, M. Carrasquilla, M. Llinas Metabolomic profiling of the malaria box reveals antimalarial target pathways 2016","Novel approaches to treating and preventing malaria J Nogueira Varela","Cheminformatic analysis of antimalarial chemical space illuminates therapeutic mechanisms and offers strategies for therapy development JN Varela",{"$nulls":4},"PF3D7_0417200",null,0.11,0.52,0.13,null,null,1.15443469003188,0.6407679530676047,10.9377664171444,"gct V enriched",null,1.8016423644552657,0.5550491150347446,null,"Detected",3107354809.595412,901370000,1885999900.5903804,0.47792685445945216,null,"Essential","A"]
["MMV000634",null,null,{"v":634.1999999999999,"d":"634.20"},{"v":1790,"d":"1790.00"},{"v":2000,"d":"2000.00"},null,null,{"v":2.822453484705141,"d":"2.82"},{"v":3.1535793125197102,"d":"3.15"},null,null,"phospholipase","Metabolomics-based screening of the malaria box reveals both novel and established mechanisms of action DJ Creek 2016","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond, van Voorhis 2016",{"$nulls":7},1.2342857142857144,0.23285714285714285,0.42857142857142855,"Average",null,0,1.1731201409058445,0,"gct I/II enriched","Average",0.07,null,null,"Detected",36808252.5369794,4311923.045510044,1382391.761590554,3.119175884373636]
["MMV000634",null,null,{"v":634.1999999999999,"d":"634.20"},{"v":1790,"d":"1790.00"},{"v":2000,"d":"2000.00"},null,null,{"v":2.822453484705141,"d":"2.82"},{"v":3.1535793125197102,"d":"3.15"},null,null,"PKG","Metabolomics-based screening of the malaria box reveals both novel and established mechanisms of action DJ Creek 2016","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond, van Voorhis 2016",{"$nulls":5},"PF3D7_1436600",null,0.47,-0.44,0.1,null,null,0,0.068244893498124,2.02530545710245,"gct V enriched",null,0.06,null,null,"Detected",187255751.4074903,109730000,295371702.85639864,0.37149801060444715,null,"Essential"]
["MMV000634",null,null,{"v":634.1999999999999,"d":"634.20"},{"v":1790,"d":"1790.00"},{"v":2000,"d":"2000.00"},null,null,{"v":2.822453484705141,"d":"2.82"},{"v":3.1535793125197102,"d":"3.15"},null,null,"Fatty acid pathway","Metabolomics-based screening of the malaria box reveals both novel and established mechanisms of action DJ Creek 2016","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond, van Voorhis 2016",{"$nulls":7},0.42826086956521753,0.7691304347826086,0.5582608695652173,"Average",null,0.28334024779249645,4.761770573690979,1.319018667303425,"gct I/II enriched","Average",0.05950312880632375,16.805838954366447,null,"Detected",132017292.1949855,1079994333.3333333,70963557.24778607,15.21899937403472,null,"Essential/Non essential"]
["MMV000788",null,null,{"v":697,"d":"697.00"},{"v":2000,"d":"2000.00"},{"v":2000,"d":"2000.00"},{"v":5000,"d":"5000.00"},null,{"v":2.8694404591104736,"d":"2.87"},{"v":2.8694404591104736,"d":"2.87"},{"$f":"G92/D92","v":{"v":7.173601147776184,"d":"7.17"}},null,"Cysteine protease","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond, van Voorhis 2016",{"$nulls":8},0.8683333333333333,0.2925,0.5025000000000001,"Average",null,0.798641256081183,0.19433860091901342,0.31856282249165724,"enriched troph","Average",4.109534864944305,0.24333654120575338,null,"Detected",57370296.82134489,79529333.33333333,145189284.43913874,0.5477631055249872,null,"Essential/Non essential","S U"]
["MMV000061","Methylene Blue",null,{"v":21.7,"d":"21.70"},{"v":62.7,"d":"62.70"},null,{"v":457,"d":"457.00"},null,{"v":2.889400921658986,"d":"2.89"},null,{"$f":"G93/D93","v":{"v":21.059907834101384,"d":"21.06"}},null,"glutathione reductase (GR)","Buchholz K, Schirmer RH, Eubel JK, Akoachere MB, Dandekar T, Becker K, Gromer S. 2008. Interactions of methylene blue with human disulfide reductases and their orthologues from Plasmodium falciparum. Antimicrob. Agents Chemother. 52:183–191.","Vennerstrom JL, Makler MT, Angerhofer CK, Williams JA. 1995. Antimalarial dyes revisited: xanthenes, azines, oxazines, and thiazines. Antimicrob Agents Chemother 39:2671–2677. https://doi.org/10.1128/AAC.39 .12.2671",{"$nulls":5},"PF3D7_1419800",null,0.71,0.64,-0.14,null,null,1.15443469003188,1.0570182237640764,9,"gct V enriched",null,1.0921615768561685,0.9156154374873182,null,"Not detected",{"$nulls":5},"Essential"]
["B-II.4","B-II.4",null,129.97,{"v":382.1,"d":"382.10"},{"v":5000,"d":"5000.00"},null,null,{"v":2.9399092098176505,"d":"2.94"},{"$f":"F94/D94","v":{"v":38.47041624990383,"d":"38.47"}},null,null,"PfDHODH","Comprehensive review in current developments of benzimidazole‐based medicinal chemistry RS Keri","Benzimidazole derivatives are potent against multiple life cycle stages of Plasmodium falciparum malaria parasites Leshabane 2021",{"$nulls":5},"PF3D7_0603300",null,0.75,-0.19,-0.43,null,null,1.15443469003188,0.7714114432536744,1.89426612471675,"shared 3 stages",null,1.4965226405803402,0.6682157508904827,null,"Detected",133919747.91061999,21091000,31021606.034033686,0.679880982849861,null,"Essential"]
["MMV019918",null,null,{"v":280,"d":"280.00"},{"v":824,"d":"824.00"},{"v":406.9,"d":"406.90"},{"v":320,"d":"320.00"},null,{"v":2.942857142857143,"d":"2.94"},{"$f":"F95/D95","v":{"v":1.4532142857142856,"d":"1.45"}},{"$f":"G95/D95","v":{"v":1.1428571428571428,"d":"1.14"}},null,"phosphoethanolamine methyltransferase (PfPMT) "," … and biological studies of the Malaria Box compound 1-[5-(4-bromo-2-chlorophenyl) furan-2-yl]-N-[(piperidin-4-yl) methyl] methanamine (MMV019918) and … A Vallone",{"$nulls":6},"PF3D7_1343000",null,0.77,1.48,0.61,null,null,336.4138014225539,83.2557979663136,10.5478198468946,"enriched troph",null,4.040725206413509,0.247480328138321,null,"Detected",114835488.61768718,1894500000,446647232.3754124,4.241602460905097,null,"Not essential/Essential","A"]
["ACT-451840","ACT-451840",null,{"v":0.6,"d":"0.60"},{"v":1.8,"d":"1.80"},{"$nulls":3},{"v":3,"d":"3.00"},{"$nulls":3},"MDR1","CRISPR‐Cas9‐modified pfmdr1 protects Plasmodium falciparum asexual blood stages and gametocytes against a class of piperazine‐containing compounds. CL Ng 2016",{"$nulls":6},"PF3D7_0523000",null,0.55,-0.14,-0.37,null,null,4.185382762981795,2.6120056276710084,5.55996328108289,"shared 3 stages",null,1.6023636085017496,0.6240780773441461,null,"Detected",1075298324.2997518,2109100000,611327737.4544191,3.45003158008556,null,"Essential"]
["MMV665941",null,null,{"v":255,"d":"255.00"},{"v":769,"d":"769.00"},{"v":157.9,"d":"157.90"},{"v":843,"d":"843.00"},null,{"v":3.015686274509804,"d":"3.02"},{"$f":"F97/D97","v":{"v":0.6192156862745098,"d":"0.62"}},{"$f":"G97/D97","v":{"v":3.3058823529411763,"d":"3.31"}},null,"HT","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond, van Voorhis 2016","A novel fluorescence resonance energy transfer-based screen in high-throughput format to identify inhibitors of malarial and human glucose transporters TE Kraft",{"$nulls":5},"PF3D7_0204700",null,0.53,1.08,-0.46,null,null,3.0423154285688634,4.369138307018179,2.89860370254907,"shared 3 stages",null,0.6963193231219001,1.4361227195542532,null,"Detected",552024808.196664,783670000,843559723.476298,0.9290035763804686,null,"Essential"]
["MMV000848",null,null,{"v":660,"d":"660.00"},{"v":1997,"d":"1997.00"},{"v":2000,"d":"2000.00"},{"v":3600,"d":"3600.00"},null,{"v":3.025757575757576,"d":"3.03"},{"$f":"F98/D98","v":{"v":3.0303030303030303,"d":"3.03"}},{"v":5.454545454545454,"d":"5.45"},null,"falcilysin","E.L. Allman, H.J. Painter, J. Samra, M. Carrasquilla, M. Llinas Metabolomic profiling of the malaria box reveals antimalarial target pathways 2016","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond, van Voorhis 2016","Identification of an inhibitory pocket in falcilysin provides a new avenue for malaria drug development G Wirjanata",{"$nulls":4},"PF3D7_1360800",null,0.16,0.01,-0.26,null,null,3.4082006913994385,7.891611972108679,54.4102033000949,"gct V enriched",null,0.4318763648599349,2.3154774869986636,null,"Detected",3539472589.7821445,17515000000,2581642652.3702035,6.784440125328537,null,"Essential"]
["MMV000848",null,null,{"v":660,"d":"660.00"},{"v":1997,"d":"1997.00"},{"v":2000,"d":"2000.00"},{"v":3600,"d":"3600.00"},null,{"v":3.025757575757576,"d":"3.03"},{"$f":"F99/D99","v":{"v":3.0303030303030303,"d":"3.03"}},{"v":5.454545454545454,"d":"5.45"},null,"ATP4","E.L. Allman, H.J. Painter, J. Samra, M. Carrasquilla, M. Llinas Metabolomic profiling of the malaria box reveals antimalarial target pathways 2016","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond, van Voorhis 2016","Identification of an inhibitory pocket in falcilysin provides a new avenue for malaria drug development G Wirjanata",{"$nulls":4},"PF3D7_1211900",null,0.33,-0.22,-0.49,null,null,1.7731908623980155,0.4394601472062679,2.59381366380463,"shared 3 stages",null,4.034929842149575,0.24783578379822793,null,"Detected",636393353.8483057,392860000,65708369.94269839,5.978842578846459,null,"Essential"]
["MMV000848",null,null,{"v":660,"d":"660.00"},{"v":1997,"d":"1997.00"},{"v":2000,"d":"2000.00"},{"v":3600,"d":"3600.00"},null,{"v":3.025757575757576,"d":"3.03"},{"$f":"F100/D100","v":{"v":3.0303030303030303,"d":"3.03"}},{"v":5.454545454545454,"d":"5.45"},null,"Hsp90","E.L. Allman, H.J. Painter, J. Samra, M. Carrasquilla, M. Llinas Metabolomic profiling of the malaria box reveals antimalarial target pathways 2016","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond, van Voorhis 2016","Identification of an inhibitory pocket in falcilysin provides a new avenue for malaria drug development G Wirjanata",{"$nulls":4},"PF3D7_0708400",null,0.47,0.14,-0.37,null,null,391.244342138169,487.5030361563116,2642.7611857491,"gct V enriched",null,0.8025474984174693,1.2460321687774047,null,"Detected",28102267024.51306,93040000000,24304490388.95642,3.8280991911797466,null,"Essential"]
["MMV674143","Cladosporin",null,65.89,{"v":199.4,"d":"199.40"},null,1000.67,null,{"v":3.026255881013811,"d":"3.03"},null,{"v":15.186978297161936,"d":"15.19"},null,"lysine--tRNA ligase (KRS1)","Selective and Specific Inhibition of the Plasmodium falciparum Lysyl-tRNA Synthetase by the Fungal Secondary Metabolite Cladosporin. Hoepfner. 2012",{"$nulls":6},"PF3D7_1350100",null,0.52,-0.08,-0.33,null,null,2.488931895417541,4.157766611990654,5.68343917568615,"shared 3 stages",null,0.5986223200310637,1.6705023627386764,null,"Detected",1071857595.901668,2153200000,1024886739.0171906,2.1009150748352927]
["MMV674143","Cladosporin",null,65.89,{"v":199.4,"d":"199.40"},null,1000.67,null,{"v":3.026255881013811,"d":"3.03"},null,{"v":15.186978297161936,"d":"15.19"},null,"lysine--tRNA ligase (KRS2)","Selective and Specific Inhibition of the Plasmodium falciparum Lysyl-tRNA Synthetase by the Fungal Secondary Metabolite Cladosporin. Hoepfner. 2012",{"$nulls":6},"PF3D7_1416800",null,0.63,1.22,0.84,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV009015",null,null,{"v":676.5,"d":"676.50"},{"v":2049,"d":"2049.00"},{"v":5000,"d":"5000.00"},null,null,{"v":3.0288248337028825,"d":"3.03"},{"$f":"F103/D103","v":{"v":7.390983000739098,"d":"7.39"}},null,null,"lysophospholipase (LPL3?)","A Plasmodium Falciparum Lysophospholipase Regulates Host Fatty Acid Chanelling Through Parasite Lipid Storage to Enable Controlled Asexual Schizogonic … PK Sheokand",{"$nulls":6},"PF3D7_1476800",null,0.58,0.16,0.53,null,null,0,0,0.105295141126022,"not determined",null,1,null,null,"Not detected",{"$nulls":5},"Essential","U"]
["MMV009015",null,null,{"v":676.5,"d":"676.50"},{"v":2049,"d":"2049.00"},{"v":5000,"d":"5000.00"},null,null,{"v":3.0288248337028825,"d":"3.03"},{"$f":"F104/D104","v":{"v":7.390983000739098,"d":"7.39"}},null,null,"phospholipase","A Plasmodium Falciparum Lysophospholipase Regulates Host Fatty Acid Chanelling Through Parasite Lipid Storage to Enable Controlled Asexual Schizogonic … PK Sheokand",{"$nulls":8},1.2342857142857144,0.23285714285714285,0.42857142857142855,"Average",null,0,1.1731201409058445,0,"gct I/II enriched","Average",0.08,null,null,"Detected",36808252.5369794,4311923.045510044,1382391.761590554,3.119175884373636]
["WEHI-842","WEHI-842",null,{"v":1580,"d":"1580.00"},{"v":5000,"d":"5000.00"},{"v":5000,"d":"5000.00"},null,null,{"v":3.1645569620253164,"d":"3.16"},{"$f":"F105/D105","v":{"v":3.1645569620253164,"d":"3.16"}},null,null,"Plasmepsin V (PMV)","Inhibition of plasmepsin V activity blocks Plasmodium falciparum gametocytogenesis and transmission to mosquitoes Jennison 2019",{"$nulls":6},"PF3D7_1323500",null,0.44,-0.25,-0.59,null,null,0.5122019514535665,0.3395699984187145,0.311133937421564,"enriched troph",null,1.5083839969336286,0.6629611571276844,null,"Detected",15395138.5844669,16127000,287542.8694651849,56.08555006074537,null,"Essential","S"]
["MMV665786",null,null,{"v":408,"d":"408.00"},{"v":1308,"d":"1308.00"},{"v":2000,"d":"2000.00"},null,null,{"v":3.2058823529411766,"d":"3.21"},{"$f":"F106/D106","v":{"v":4.901960784313726,"d":"4.90"}},null,null,"PKG","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond, van Voorhis 2016",{"$nulls":6},"PF3D7_1436600",null,0.47,-0.44,0.1,null,null,0,0.068244893498124,2.02530545710245,"gct V enriched",null,0.8,null,null,"Detected",187255751.4074903,109730000,295371702.85639864,0.37149801060444715,null,"Essential"]
["MMV000015","Mefloquine",null,{"v":16,"d":"16.00"},{"v":51.7,"d":"51.70"},{"v":100,"d":"100.00"},{"v":131.95000000000002,"d":"131.95"},null,{"v":3.23125,"d":"3.23"},{"$f":"F107/D107","v":6.25},{"$f":"G107/D107","v":{"v":8.246875000000001,"d":"8.25"}},null,"80S ribosome","Wong W, Bai XC, Sleebs BE, Triglia T, Brown A, Thompson JK, Jackson KE, Hanssen E, Marapana DS, Fernandez IS et al.. (2017) Mefloquine targets the Plasmodium falciparum 80S ribosome to inhibit protein synthesis. ",{"$nulls":11},"Not detected",{"$nulls":5},"Not detected",{"$nulls":3},"Not detected"]
["MMV670325",null,null,{"v":1365,"d":"1365.00"},{"v":4492,"d":"4492.00"},null,3715.67,null,{"v":3.2908424908424907,"d":"3.29"},null,{"v":2.7221025641025642,"d":"2.72"},null,"leucine--tRNA ligase (LeuRS)","Provided from MMV",{"$nulls":6},"PF3D7_0622800",null,0.36,-0.2,-0.48,null,null,1.2020793536038865,1.2476120887779127,2.62680169079642,"shared 3 stages",null,0.9635040926714429,1.037878310643567,null,"Detected",595387412.6656642,382780000,1257820862.562945,0.3043199643071945,null,"Essential (ortholog)"]
["MMV390482","SJ733",null,{"v":30,"d":"30.00"},{"v":102.7,"d":"102.70"},null,{"v":367.5,"d":"367.50"},null,{"v":3.4233333333333333,"d":"3.42"},null,12.25,null,"ATP4","Jimenez-Diaz MB, Ebert D, Salinas Y, Pradhan A, Lehane AM, Myrand-Lapierre ME, O'Loughlin KG, Shackleford DM, Justino de Almeida M, Carrillo AK, Clark JA, Dennis AS, Diep J, Deng X, Duffy S, Endsley AN, Fedewa G, Guiguemde WA, Gomez MG, Holbrook G, Horst J, Kim CC, Liu J, Lee MC, Matheny A, Martinez MS, Miller G, Rodriguez-Alejandre A, Sanz L, Sigal M, Spillman NJ, Stein PD, Wang Z, Zhu F, Waterson D, Knapp S, Shelat A, Avery VM, Fidock DA, Gamo FJ, Charman SA, Mirsalis JC, Ma H, Ferrer S, Kirk K, Angulo-Barturen I, Kyle DE, DeRisi JL, Floyd DM, Guy RK. 2014. (+)-SJ733, a clinical candidate for malaria that acts through ATP4 to induce rapid host-mediated clearance of Plasmodium. Proc Natl Acad Sci U S A 111:E5455–62.",{"$nulls":6},"PF3D7_1211900",null,0.33,-0.22,-0.49,null,null,1.7731908623980155,0.4394601472062679,2.59381366380463,"shared 3 stages",null,4.034929842149575,0.24783578379822793,null,"Detected",636393353.8483057,392860000,65708369.94269839,5.978842578846459,null,"Essential"]
["MMV643121","M5717 (DDD107498)",null,{"v":1,"d":"1.00"},3.57,null,0.25,null,3.57,null,0.25,null,"eEF2","Baragaña B, Hallyburton I, Lee MC, Norcross NR, Grimaldi R, Otto TD, Proto WR, Blagborough AM, Meister S, Wirjanata G et al.. (2015) A novel multiple-stage antimalarial agent that inhibits protein synthesis. ",{"$nulls":6},"PF3D7_1451100",null,0.72,-0.3,-1,null,null,36.215096568022325,20.79857304540562,60.2680478057332,"shared 3 stages",null,1.741229866537512,0.5743067122944141,null,"Detected",8763016763.996223,19691000000,2265856301.007119,8.690312793113941,null,"Essential (ortholog)"]
["DDD107498","M5717",null,{"v":1,"d":"1.00"},3.57,{"v":1.606,"d":"1.61"},0.25,null,3.57,{"$f":"F111/D111","v":{"v":1.606,"d":"1.61"}},0.25,null,"eEF2","Baragaña B, Hallyburton I, Lee MC, Norcross NR, Grimaldi R, Otto TD, Proto WR, Blagborough AM, Meister S, Wirjanata G et al.. (2015) A novel multiple-stage antimalarial agent that inhibits protein synthesis. ",{"$nulls":6},"PF3D7_1451100",null,0.72,-0.3,-1,null,null,36.215096568022325,20.79857304540562,60.2680478057332,"shared 3 stages",null,1.741229866537512,0.5743067122944141,null,"Detected",8763016763.996223,19691000000,2265856301.007119,8.690312793113941,null,"Essential (ortholog)"]
["MMV000004","DHA",null,{"v":0.24000000000000002,"d":"0.24"},{"v":0.9,"d":"0.90"},2.17,{"v":1500,"d":"1500.00"},null,3.75,{"$f":"F112/D112","v":{"v":9.041666666666666,"d":"9.04"}},{"v":6249.999999999999,"d":"6250.00"},null,"PI3K","Wang J, Zhang CJ, Chia WN, Loh CCY, Li Z, Lee YM, et al. Haem-activated promiscuous targeting of artemisinin in Plasmodium falciparum. Nat Commun. 2015;6:10111.","Tilley L, Straimer J, Gnädig NF, Ralph SA, Fidock DA. Artemisinin action and resistance in Plasmodium falciparum. Trends Parasitol. 2016;32:682–96."," High-throughput assay and discovery of small molecules that interrupt malaria transmission DM Plouffe 2016","Antimalarial and anticancer properties of artesunate and other artemisinins: current development P Khanal 2021","Coertzen, D., Reader, J., van der Watt, M., Nondaba, S. H., Gibhard, L., Wiesner, L., et al. (2018). Artemisone and Artemiside Are Potent Panreactive Antimalarial Agents That Also Synergize Redox Imbalance in Plasmodium Falciparum Transmissible Gametocyte Stages. Antimicrob. Agents Chemother. 62, 1–17. doi: 10.1128/AAC.02214-17","Klonis, N., Crespo-Ortiz, M. P., Bottova, I., Abu-Bakar, N., Kenny, S., Rosenthal, P. J., et al. (2011). Artemisinin Activity Against Plasmodium Falciparum Requires Hemoglobin Uptake and Digestion. Proc. Natl. Acad. Sci. U.S.A. 108, 11405–11410. doi: 10.1073/pnas.1104063108",null,"PF3D7_0515300",null,0.56,0.18,0.29,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV000004","DHA",null,{"v":0.24000000000000002,"d":"0.24"},{"v":0.9,"d":"0.90"},2.17,{"v":1500,"d":"1500.00"},null,3.75,{"v":9.041666666666666,"d":"9.04"},{"v":6249.999999999999,"d":"6250.00"},null,"proteosome","Wang J, Zhang CJ, Chia WN, Loh CCY, Li Z, Lee YM, et al. Haem-activated promiscuous targeting of artemisinin in Plasmodium falciparum. Nat Commun. 2015;6:10111.","Tilley L, Straimer J, Gnädig NF, Ralph SA, Fidock DA. Artemisinin action and resistance in Plasmodium falciparum. Trends Parasitol. 2016;32:682–96."," High-throughput assay and discovery of small molecules that interrupt malaria transmission DM Plouffe 2016","Antimalarial and anticancer properties of artesunate and other artemisinins: current development P Khanal 2021","Coertzen, D., Reader, J., van der Watt, M., Nondaba, S. H., Gibhard, L., Wiesner, L., et al. (2018). Artemisone and Artemiside Are Potent Panreactive Antimalarial Agents That Also Synergize Redox Imbalance in Plasmodium Falciparum Transmissible Gametocyte Stages. Antimicrob. Agents Chemother. 62, 1–17. doi: 10.1128/AAC.02214-17","Klonis, N., Crespo-Ortiz, M. P., Bottova, I., Abu-Bakar, N., Kenny, S., Rosenthal, P. J., et al. (2011). Artemisinin Activity Against Plasmodium Falciparum Requires Hemoglobin Uptake and Digestion. Proc. Natl. Acad. Sci. U.S.A. 108, 11405–11410. doi: 10.1073/pnas.1104063108",{"$nulls":3},0.41428571428571426,0.2892857142857143,0.11928571428571429,"Average",null,4.371904224875087,14.744723143961812,53.195817261465585,"gct V enriched","Average",0.296506362458589,3.372608910338857,null,"Detected",1385888365.4679062,3846228571.428571,1162706304.4179296,3.307996659873671,null,"Essential/Non essential"]
["MMV396703",null,null,{"v":406,"d":"406.00"},{"v":1531,"d":"1531.00"},{"v":3722,"d":"3722.00"},null,null,{"v":3.770935960591133,"d":"3.77"},{"v":9.167487684729064,"d":"9.17"},null,null,"PKG","E.L. Allman, H.J. Painter, J. Samra, M. Carrasquilla, M. Llinas Metabolomic profiling of the malaria box reveals antimalarial target pathways 2016","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond, van Voorhis 2016",{"$nulls":5},"PF3D7_1436600",null,0.47,-0.44,0.1,null,null,0,0.068244893498124,2.02530545710245,"gct V enriched",null,0.8,null,null,"Detected",187255751.4074903,109730000,295371702.85639864,0.37149801060444715,null,"Essential"]
["MMV020438",null,null,1150.27,{"v":4554,"d":"4554.00"},null,{"v":5000,"d":"5000.00"},null,{"v":3.959070479104906,"d":"3.96"},null,{"$f":"G115/D115","v":{"v":4.346805532614082,"d":"4.35"}},null,"HT","Provided from MMV",{"$nulls":6},"PF3D7_0204700",null,0.53,1.08,-0.46,null,null,3.0423154285688634,4.369138307018179,2.89860370254907,"shared 3 stages",null,0.6963193231219001,1.4361227195542532,null,"Detected",552024808.196664,783670000,843559723.476298,0.9290035763804686,null,"Essential"]
["MMV000011","Doxycycline hydrochloride",null,{"v":1258.92541179416,"d":"1258.93"},{"v":5000,"d":"5000.00"},{"v":5000,"d":"5000.00"},{"v":5000,"d":"5000.00"},null,{"v":3.97164117362143,"d":"3.97"},{"$f":"F116/D116","v":{"v":3.97164117362143,"d":"3.97"}},{"v":3.97164117362143,"d":"3.97"},null,"ribosomes"," Multiple antibiotics exert delayed effects against the Plasmodium falciparum apicoplast Erica L Dahl 2007",{"$nulls":8},0.8017096774193548,0.4807870967741935,0.15532580645161292,"Average",null,24.71297769631029,85.40557604207882,1459.5331009753745,"gct V enriched","Average",0.28936023666808774,3.4558998551934956,null,"Detected",1539680719.4419389,1132392260.2272727,592017901.0117464,1.9127669252771542,null,"Essential/Non essential"]
["MMV000028","Trimethoprim",null,{"v":1258.92541179416,"d":"1258.93"},{"v":5000,"d":"5000.00"},{"v":5000,"d":"5000.00"},{"v":5000,"d":"5000.00"},null,{"v":3.97164117362143,"d":"3.97"},{"$f":"F117/D117","v":{"v":3.97164117362143,"d":"3.97"}},{"v":3.97164117362143,"d":"3.97"},null,"DHFR-TS","Antibacterial Agents That Interfere With Folate Synthesis. (2020). In Rang and Dale's Pharmacology (9th ed.). Edinburgh: Elsevier. ",{"$nulls":6},"PF3D7_0417200",null,0.11,0.52,0.13,null,null,1.15443469003188,0.6407679530676047,10.9377664171444,"gct V enriched",null,1.8016423644552657,0.5550491150347446,null,"Detected",3107354809.595412,901370000,1885999900.5903804,0.47792685445945216,null,"Essential","A"]
["MMV019721","MMV019721",null,{"v":844.3,"d":"844.30"},{"v":3379,"d":"3379.00"},null,1841.33,null,{"v":4.002131943621936,"d":"4.00"},null,{"v":2.180895416321213,"d":"2.18"},null,"acetyl-CoA synthetase (ACAS)","Chemogenomics identifies acetyl-coenzyme A synthetase as a target for malaria treatment and prevention. RL Summers. 2022",{"$nulls":6},"PF3D7_0627800",null,0.29,-0.51,-0.45,null,null,0.5239278103274543,0.22331568211144429,0.148153621496883,"enriched troph",null,2.3461308465833195,0.42623368660631367,null,"Detected",7752479.546805608,5327800,13142844.217746137,{"$f":"AL118/AM118","v":0.40537648561687534},null,"Essential","A"]
["MMV019721","MMV019721",null,{"v":844.3,"d":"844.30"},{"v":3379,"d":"3379.00"},null,1841.33,null,{"v":4.002131943621936,"d":"4.00"},null,{"v":2.180895416321213,"d":"2.18"},null,"acyl-CoA synthetase (ACS11)","Chemogenomics identifies acetyl-coenzyme A synthetase as a target for malaria treatment and prevention. RL Summers. 2022",{"$nulls":6},"PF3D7_1238800",null,0.54,-0.04,-0.19,null,null,3.175016900592523,1.578121624064757,2.78248990638938,"shared 3 stages",null,2.011896201266575,0.49704353503448984,null,"Detected",370910521.31342447,1014900000,531968643.8183713,1.9078192141462285,null,"Essential"]
["MMV019721","MMV019721",null,{"v":844.3,"d":"844.30"},{"v":3379,"d":"3379.00"},null,1841.33,null,{"v":4.002131943621936,"d":"4.00"},null,{"v":2.180895416321213,"d":"2.18"},null,"acyl-CoA synthetase (ACS10)","Chemogenomics identifies acetyl-coenzyme A synthetase as a target for malaria treatment and prevention. RL Summers. 2022",{"$nulls":6},"PF3D7_0525100",null,0.84,-0.61,-0.77,null,null,6.499642624097776,6.443810658555231,5.39080484186031,"shared 3 stages",null,1.0086644329731227,0.991409994553309,null,"Detected",337785262.1603665,1807600000,394712460.1927418,4.579536199889236,null,"Essential"]
["MMV666054",null,null,{"v":499.444167,"d":"499.44"},{"v":2000,"d":"2000.00"},{"v":1075,"d":"1075.00"},{"v":5000,"d":"5000.00"},null,{"v":4.004451612706491,"d":"4.00"},{"$f":"F121/D121","v":{"v":2.152392741829739,"d":"2.15"}},{"v":10.011129031766227,"d":"10.01"},null,"MAPK2","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond, van Voorhis 2016","Screening the Medicines for Malaria Venture \"Malaria Box\" against the Plasmodium falciparum Aminopeptidases, M1, M17 and M18 A Paiardini",{"$nulls":5},"PF3D7_1113900",null,0.53,1.03,0.24,null,null,0,0,3.89390091847749,"gct V enriched",null,1,null,null,"Detected",159395278.0361576,174890000,1931170747.9597151,0.09056164514959206,null,"Essential/Not essential","U","A"]
["MMV666054",null,null,{"v":499.444167,"d":"499.44"},{"v":2000,"d":"2000.00"},{"v":1075,"d":"1075.00"},{"v":5000,"d":"5000.00"},null,{"v":4.004451612706491,"d":"4.00"},{"v":2.152392741829739,"d":"2.15"},{"v":10.011129031766227,"d":"10.01"},null,"PfA-M1 alanyl aminopeptidase","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond, van Voorhis 2016","Screening the Medicines for Malaria Venture \"Malaria Box\" against the Plasmodium falciparum Aminopeptidases, M1, M17 and M18 A Paiardini",{"$nulls":5},"PF3D7_1311800",null,0.56,0.06,-0.86,null,null,15.969688689965796,9.989022559815394,32.8385515342823,"shared 3 stages",null,1.5987238585494725,0.6254988906635217,null,"Detected",2472328320.453194,15872000000,1421009325.403716,11.169525573303808,null,"Essential"]
["MMV020500",null,null,{"v":62.400925,"d":"62.40"},{"v":252,"d":"252.00"},{"v":235,"d":"235.00"},null,null,{"v":4.038401674334154,"d":"4.04"},{"v":3.7659698153512946,"d":"3.77"},null,null,"deoxyhypusine synthase (DHS)","E.L. Allman, H.J. Painter, J. Samra, M. Carrasquilla, M. Llinas Metabolomic profiling of the malaria box reveals antimalarial target pathways 2016","Metabolomics-based screening of the malaria box reveals both novel and established mechanisms of action DJ Creek","Target evaluation of deoxyhypusine synthase from Theileria parva the neglected animal parasite and its relationship to Plasmodium JT Njuguna",{"$nulls":4},"PF3D7_1412600",null,0.81,0.46,-0.3,null,null,0.13604011411551692,0,0.610262027560939,"gct V enriched",null,1.1,0,null,"Detected",18192497.90537469,43611000,215673242.75047752,0.20220867198837275,null,"Essential"]
["MMV665875",null,null,{"v":140.053664,"d":"140.05"},{"v":588,"d":"588.00"},{"v":372,"d":"372.00"},null,null,{"v":4.198390696868881,"d":"4.20"},{"v":2.656124726590516,"d":"2.66"},null,null,"Cysteine protease","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond, van Voorhis 2016",{"$nulls":8},0.8683333333333333,0.2925,0.5025000000000001,"Average",null,0.798641256081183,0.19433860091901342,0.31856282249165724,"enriched troph","Average",4.109534864944305,0.24333654120575338,null,"Detected",57370296.82134489,79529333.33333333,145189284.43913874,0.5477631055249872,null,"Essential/Non essential","S U"]
["SC81458","SC81458",null,{"v":18,"d":"18.00"},{"v":76.6,"d":"76.60"},{"v":1800,"d":"1800.00"},null,null,{"v":4.2555555555555555,"d":"4.26"},{"v":100,"d":"100.00"},null,null,"calcium-transporting ATPase (ATP6)","SC83288 is a clinical development candidate for the treatment of severe malaria Stefano Pegoraro",{"$nulls":6},"PF3D7_0106300",null,0.39,-0.03,-0.13,null,null,1.6876027710717014,0.7605873874153525,3.93796931771435,"shared 3 stages",null,2.2188150881735713,0.4506910040994696,null,"Detected",1029579056.5443927,1600300000,889900800.0520924,1.7982903261872814,null,"Essential"]
["SC81458","SC81458",null,{"v":18,"d":"18.00"},{"v":76.6,"d":"76.60"},{"v":1800,"d":"1800.00"},null,null,{"v":4.2555555555555555,"d":"4.26"},{"v":100,"d":"100.00"},null,null,"fumarate hydratase (FH)","SC83288 is a clinical development candidate for the treatment of severe malaria Stefano Pegoraro",{"$nulls":6},"PF3D7_0927300",null,0.23,0.16,0.19,null,null,0.16576703731775866,0.3188409631490102,3.01945033361513,"gct V enriched",null,0.5199050827113688,1.9234280126381478,null,"Detected",289907290.8347029,323510000,31981193.98333044,10.115632335947906,null,"Essential"]
["SC81458","SC81458",null,{"v":18,"d":"18.00"},{"v":76.6,"d":"76.60"},{"v":1800,"d":"1800.00"},null,null,{"v":4.2555555555555555,"d":"4.26"},{"v":100,"d":"100.00"},null,null,"mini-chromosome maintenance complex-binding protein","SC83288 is a clinical development candidate for the treatment of severe malaria Stefano Pegoraro",{"$nulls":6},"PF3D7_1412100",null,1.16,0.17,0.19,null,null,0.22030595261377078,0.06444401261225294,0.0873356727196561,"enriched troph",null,3.418563551269049,0.2925205236066994,null,"Detected",477492.16995597084,2276900,32190079.896683455,0.07073297137838384,null,"Essential","A"]
["SC81458","SC81458",null,{"v":18,"d":"18.00"},{"v":76.6,"d":"76.60"},{"v":1800,"d":"1800.00"},null,null,{"v":4.2555555555555555,"d":"4.26"},{"v":100,"d":"100.00"},null,null,"casein kinase 2, alpha subunit","SC83288 is a clinical development candidate for the treatment of severe malaria Stefano Pegoraro",{"$nulls":6},"PF3D7_1108400",null,0.45,0.17,0.01,null,null,60.79064011727486,103.28083452179338,47.3293023857175,"shared 3 stages",null,0.5885955550102316,1.6989594832781518,null,"Detected",1725313191.9432108,3068800000,905698894.339295,3.388322564132842,null,"Essential","I","D"]
["SC81458","SC81458",null,{"v":18,"d":"18.00"},{"v":76.6,"d":"76.60"},{"v":1800,"d":"1800.00"},null,null,{"v":4.2555555555555555,"d":"4.26"},{"v":100,"d":"100.00"},null,null,"casein kinase II beta chain","SC83288 is a clinical development candidate for the treatment of severe malaria Stefano Pegoraro",{"$nulls":6},"PF3D7_1103700",null,0.9,0.14,-0.56,null,null,3.2187487937519563,1.8900861310663797,4.08021804691302,"shared 3 stages",null,1.7029640823489616,0.5872114452470794,null,"Detected",299234964.12211066,248990000,101464723.34606703,2.453956328750502,null,"Essential"]
["SC81458","SC81458",null,{"v":18,"d":"18.00"},{"v":76.6,"d":"76.60"},{"v":1800,"d":"1800.00"},null,null,{"v":4.2555555555555555,"d":"4.26"},{"v":100,"d":"100.00"},null,null,"casein kinase II beta chain","SC83288 is a clinical development candidate for the treatment of severe malaria Stefano Pegoraro",{"$nulls":6},"PF3D7_1103700",null,0.9,0.14,-0.56,null,null,3.2187487937519563,1.8900861310663797,4.08021804691302,"shared 3 stages",null,1.7029640823489616,0.5872114452470794,null,"Detected",299234964.12211066,248990000,101464723.34606703,2.453956328750502,null,"Essential"]
["SC81458","SC81458",null,{"v":18,"d":"18.00"},{"v":76.6,"d":"76.60"},{"v":1800,"d":"1800.00"},null,null,{"$f":"E131/D131","v":{"v":4.2555555555555555,"d":"4.26"}},{"v":100,"d":"100.00"},null,null,"iron-sulfur cluster assembly protein SufA","SC83288 is a clinical development candidate for the treatment of severe malaria Stefano Pegoraro",{"$nulls":6},"PF3D7_0522700",null,0.46,0.62,0.91,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["SC81458","SC81458",null,{"v":18,"d":"18.00"},{"v":76.6,"d":"76.60"},{"v":1800,"d":"1800.00"},null,null,{"v":4.2555555555555555,"d":"4.26"},{"v":100,"d":"100.00"},null,null,"iron-sulfur cluster assembly protein SufD","SC83288 is a clinical development candidate for the treatment of severe malaria Stefano Pegoraro",{"$nulls":6},"PF3D7_1103400",null,0.4,0.62,0.39,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["SC81458","SC81458",null,{"v":18,"d":"18.00"},{"v":76.6,"d":"76.60"},{"v":1800,"d":"1800.00"},null,null,{"v":4.2555555555555555,"d":"4.26"},{"v":100,"d":"100.00"},null,null,"iron-sulfur cluster assembly protein SufC","SC83288 is a clinical development candidate for the treatment of severe malaria Stefano Pegoraro",{"$nulls":6},"PF3D7_1413500",null,0.41,-0.05,0.12,null,null,0,0.36959173644292936,0,"gct I/II enriched",null,0.3,null,null,"Not detected",{"$nulls":5},"Essential","R"]
["SC81458","SC81458",null,{"v":18,"d":"18.00"},{"v":76.6,"d":"76.60"},{"v":1800,"d":"1800.00"},null,null,{"v":4.2555555555555555,"d":"4.26"},{"v":100,"d":"100.00"},null,null,"iron-sulfur cluster assembly protein ISCU","SC83288 is a clinical development candidate for the treatment of severe malaria Stefano Pegoraro",{"$nulls":6},"PF3D7_1454500",null,0.61,0.46,-0.06,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["SC81458","SC81458",null,{"v":18,"d":"18.00"},{"v":76.6,"d":"76.60"},{"v":1800,"d":"1800.00"},null,null,{"v":4.2555555555555555,"d":"4.26"},{"v":100,"d":"100.00"},null,null,"cytosolic iron-sulfur assembly component 2","SC83288 is a clinical development candidate for the treatment of severe malaria Stefano Pegoraro",{"$nulls":6},"PF3D7_0703100",null,0.86,0.01,-0.27,null,null,0,0,0.701254279852589,"gct V enriched",null,1,null,null,"Detected",25954875.437983003,11308000,53060532.6792846,0.21311508627983985,null,"Essential"]
["SC81458","SC81458",null,{"v":18,"d":"18.00"},{"v":76.6,"d":"76.60"},{"v":1800,"d":"1800.00"},null,null,{"v":4.2555555555555555,"d":"4.26"},{"v":100,"d":"100.00"},null,null,"cytosolic iron-sulfur protein assembly protein 1","SC83288 is a clinical development candidate for the treatment of severe malaria Stefano Pegoraro",{"$nulls":6},"PF3D7_1209400",null,0.5,-0.02,0.36,{"$nulls":6},"Not detected",{"$nulls":3},"Detected",1273809.0091756743,203910,10904780.86039243,0.018699137801166405,null,"Essential (ortholog)"]
["SC81458","SC81458",null,{"v":18,"d":"18.00"},{"v":76.6,"d":"76.60"},{"v":1800,"d":"1800.00"},null,null,{"v":4.2555555555555555,"d":"4.26"},{"v":100,"d":"100.00"},null,null,"Fe-S cluster assembly protein DRE2","SC83288 is a clinical development candidate for the treatment of severe malaria Stefano Pegoraro",{"$nulls":6},"PF3D7_0824600",null,1.14,0.16,-0.15,null,null,1.2812367429334575,0.23330678076078387,1.05352502645715,"shared 3 stages",null,{"$f":"AB137/AC137","v":5.491639543246478},{"$f":"AC137/AB137","v":0.18209498131205323},null,"Detected",52525311.32636291,5585300,31361557.61851016,0.1780938328363976,null,"Essential"]
["MMV669810",null,null,0.45,{"v":2,"d":"2.00"},{"v":1.4,"d":"1.40"},{"v":1.2,"d":"1.20"},null,{"v":4.444444444444445,"d":"4.44"},{"v":3.1111111111111107,"d":"3.11"},{"$f":"G138/D138","v":{"v":2.6666666666666665,"d":"2.67"}},null,"CDPK1"," Potent Plasmodium falciparum gametocytocidal compounds identified by exploring the kinase inhibitor chemical space for dual active antimalarials Mariëtte E van der Watt, ",{"$nulls":6},"PF3D7_0217500",null,0.54,-0.07,0.86,null,null,1.8276642121903912,0.8228906159046369,5.07832312829723,"shared 3 stages",null,2.2210293529488925,0.4502416857626333,null,"Detected",1326801430.219953,360430000,3411452182.6706023,0.10565295384496434,null,"Essential","I S","A"]
["MMV669810",null,null,0.45,{"v":2,"d":"2.00"},{"v":1.4,"d":"1.40"},{"v":1.2,"d":"1.20"},null,{"v":4.444444444444445,"d":"4.44"},{"v":3.1111111111111107,"d":"3.11"},{"v":2.6666666666666665,"d":"2.67"},null,"PI4K"," Potent Plasmodium falciparum gametocytocidal compounds identified by exploring the kinase inhibitor chemical space for dual active antimalarials Mariëtte E van der Watt, ",{"$nulls":6},"PF3D7_0509800",null,0.29,-0.01,0.16,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV669810",null,null,0.45,{"v":2,"d":"2.00"},{"v":1.4,"d":"1.40"},{"v":1.2,"d":"1.20"},null,{"v":4.444444444444445,"d":"4.44"},{"v":3.1111111111111107,"d":"3.11"},{"v":2.6666666666666665,"d":"2.67"},null,"PKG"," Potent Plasmodium falciparum gametocytocidal compounds identified by exploring the kinase inhibitor chemical space for dual active antimalarials Mariëtte E van der Watt, ",{"$nulls":6},"PF3D7_1436600",null,0.47,-0.44,0.1,null,null,0,0.068244893498124,2.02530545710245,"gct V enriched",null,0.8,null,null,"Detected",187255751.4074903,109730000,295371702.85639864,0.37149801060444715,null,"Essential"]
["MMV669810",null,null,0.45,{"v":2,"d":"2.00"},{"v":1.4,"d":"1.40"},{"v":1.2,"d":"1.20"},null,{"v":4.444444444444445,"d":"4.44"},{"v":3.1111111111111107,"d":"3.11"},{"v":2.6666666666666665,"d":"2.67"},null,"PK7"," Potent Plasmodium falciparum gametocytocidal compounds identified by exploring the kinase inhibitor chemical space for dual active antimalarials Mariëtte E van der Watt, ",{"$nulls":6},"PF3D7_0213400",null,0.31,0.27,-0.31,null,null,0.2246523050636276,0,0.136463666385725,"not determined",null,1.1,0,null,"Not detected",{"$nulls":5},"Not essential","A D"]
["MMV000031","Cycloheximide",null,{"v":198,"d":"198.00"},912.61,{"v":476.66999999999996,"d":"476.67"},{"v":2692.4700000000003,"d":"2692.47"},null,{"v":4.609141414141415,"d":"4.61"},{"v":2.4074242424242422,"d":"2.41"},{"v":13.598333333333334,"d":"13.60"},null,"60S ribosomal subunit","Geary TG, Jensen JB. 1983. Effects of antibiotics on Plasmodium falciparum in vitro. Am. J. Trop. Med. Hyg. 32:221–225.",{"$nulls":8},0.8960000000000001,0.4647999999999999,0.1642,"Average",null,28.652939691617416,19.96706839095079,1136.2749488814245,"gct V enriched","Average",1.4350098437386594,0.6968593312187186,null,"Detected",1241256245.4378562,846791520.4545455,502040263.24940014,1.6867004151694547,null,"Essential/Non essential"]
["GNF179","GNF179",null,4.31,19.92,9.15,{"v":3.3609999999999998,"d":"3.36"},null,{"v":4.621809744779584,"d":"4.62"},{"v":2.122969837587007,"d":"2.12"},{"v":0.779814385150812,"d":"0.78"},null,"inhibit protein trafficking, block the establishment of new permeation pathways, and cause ER expansion. - similar to KAF156","Pan-active imidazolopiperazine antimalarials target the Plasmodium falciparum intracellular secretory pathway GM LaMonte","Plasmodium falciparum Cyclic Amine Resistance Locus (PfCARL), a Resistance Mechanism for Two Distinct Compound Classes Pamela A. Magistrado","UDP-galactose and Acetyl-CoA transporters as Plasmodium multidrug resistance genes Michelle Yi-Xiu Lim",{"$nulls":9},"Not detected",{"$nulls":5},"Not detected"]
["GNF179","GNF179",null,4.31,19.92,9.15,{"v":3.3609999999999998,"d":"3.36"},null,{"v":4.621809744779584,"d":"4.62"},{"v":2.122969837587007,"d":"2.12"},{"v":0.779814385150812,"d":"0.78"},null,"CARL","Pan-active imidazolopiperazine antimalarials target the Plasmodium falciparum intracellular secretory pathway GM LaMonte","Plasmodium falciparum Cyclic Amine Resistance Locus (PfCARL), a Resistance Mechanism for Two Distinct Compound Classes Pamela A. Magistrado","UDP-galactose and Acetyl-CoA transporters as Plasmodium multidrug resistance genes Michelle Yi-Xiu Lim",{"$nulls":4},"PF3D7_0321900",null,0.31,-0.21,-0.06,null,null,0,0,0.0537249727360731,"gct V enriched",null,1,null,null,"Not detected",{"$nulls":5},"Essential"]
["GNF179","GNF179",null,4.31,19.92,9.15,{"v":3.3609999999999998,"d":"3.36"},null,{"v":4.621809744779584,"d":"4.62"},{"v":2.122969837587007,"d":"2.12"},{"v":0.779814385150812,"d":"0.78"},null,"UDP-galactose transporter","Pan-active imidazolopiperazine antimalarials target the Plasmodium falciparum intracellular secretory pathway GM LaMonte","Plasmodium falciparum Cyclic Amine Resistance Locus (PfCARL), a Resistance Mechanism for Two Distinct Compound Classes Pamela A. Magistrado","UDP-galactose and Acetyl-CoA transporters as Plasmodium multidrug resistance genes Michelle Yi-Xiu Lim",{"$nulls":4},"PF3D7_1113300",null,1.64,-0.02,0.24,null,null,1.2812367429334575,0,1.61015721568254,"shared 3 stages",null,2,0,null,"Detected",44784143.763331816,138230000,1149223.5922035074,{"$f":"AL145/AM145","v":120.28120631857153},null,"Essential"]
["GNF179","GNF179",null,4.31,19.92,9.15,{"v":3.3609999999999998,"d":"3.36"},null,{"v":4.621809744779584,"d":"4.62"},{"v":2.122969837587007,"d":"2.12"},{"v":0.779814385150812,"d":"0.78"},null,"acetyl-CoA transporter 1","Pan-active imidazolopiperazine antimalarials target the Plasmodium falciparum intracellular secretory pathway GM LaMonte","Plasmodium falciparum Cyclic Amine Resistance Locus (PfCARL), a Resistance Mechanism for Two Distinct Compound Classes Pamela A. Magistrado","UDP-galactose and Acetyl-CoA transporters as Plasmodium multidrug resistance genes Michelle Yi-Xiu Lim",{"$nulls":4},"PF3D7_1036800",null,1.52,0,0.37,null,null,0,0,0.737800828749376,"gct V enriched",null,1,null,null,"Detected",15362145.29845788,3550600,31982949.32714013,0.11101540272857287,null,"Not essential","A"]
["MMV669286",null,null,0.88,{"v":4.1000000000000005,"d":"4.10"},{"v":3,"d":"3.00"},{"v":34.2,"d":"34.20"},null,{"v":4.65909090909091,"d":"4.66"},{"v":3.409090909090909,"d":"3.41"},{"v":38.86363636363637,"d":"38.86"},null,"CDPK1","Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): preparation and evaluation of pyrazole … JM Large","Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) TM Chapman","New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of Plasmodium Phosphatidylinositol-4-kinase and cGMP … PM Cheuka",{"$nulls":4},"PF3D7_0217500",null,0.54,-0.07,0.86,null,null,1.8276642121903912,0.8228906159046369,5.07832312829723,"shared 3 stages",null,2.2210293529488925,0.4502416857626333,null,"Detected",1326801430.219953,360430000,3411452182.6706023,0.10565295384496434,null,"Essential","I S","A"]
["MMV669286",null,null,0.88,{"v":4.1000000000000005,"d":"4.10"},{"v":3,"d":"3.00"},{"v":34.2,"d":"34.20"},null,{"v":4.65909090909091,"d":"4.66"},{"v":3.409090909090909,"d":"3.41"},{"v":38.86363636363637,"d":"38.86"},null,"CDPK4","Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): preparation and evaluation of pyrazole … JM Large","Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) TM Chapman","New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of Plasmodium Phosphatidylinositol-4-kinase and cGMP … PM Cheuka",{"$nulls":4},"PF3D7_0717500",null,0.32,0.52,0.27,null,null,0,0.40541168873881694,56.3615251044868,"gct V enriched",null,0.4,null,null,"Detected",1686711047.3126552,891260000,11247658017.88505,0.07923960691041598,null,"Not essential","U"]
["MMV669286",null,null,0.88,{"v":4.1000000000000005,"d":"4.10"},{"v":3,"d":"3.00"},{"v":34.2,"d":"34.20"},null,{"v":4.65909090909091,"d":"4.66"},{"v":3.409090909090909,"d":"3.41"},{"v":38.86363636363637,"d":"38.86"},null,"PI4K","Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): preparation and evaluation of pyrazole … JM Large","Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) TM Chapman","New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of Plasmodium Phosphatidylinositol-4-kinase and cGMP … PM Cheuka",{"$nulls":4},"PF3D7_0509800",null,0.29,-0.01,0.16,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV669286",null,null,0.88,{"v":4.1000000000000005,"d":"4.10"},{"v":3,"d":"3.00"},{"v":34.2,"d":"34.20"},null,{"v":4.65909090909091,"d":"4.66"},{"v":3.409090909090909,"d":"3.41"},{"v":38.86363636363637,"d":"38.86"},null,"PKG","Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): preparation and evaluation of pyrazole … JM Large","Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) TM Chapman","New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of Plasmodium Phosphatidylinositol-4-kinase and cGMP … PM Cheuka",{"$nulls":4},"PF3D7_1436600",null,0.47,-0.44,0.1,null,null,0,0.068244893498124,2.02530545710245,"gct V enriched",null,0.8,null,null,"Detected",187255751.4074903,109730000,295371702.85639864,0.37149801060444715,null,"Essential"]
["MMV006656",null,null,{"v":518.5,"d":"518.50"},{"v":2420.1800000000003,"d":"2420.18"},{"v":5000,"d":"5000.00"},{"v":5000,"d":"5000.00"},null,{"v":4.667656702025073,"d":"4.67"},{"v":9.643201542912246,"d":"9.64"},{"v":9.643201542912246,"d":"9.64"},null,"ATP4","Diverse chemotypes disrupt ion homeostasis in the malaria parasite AM Lehane 2014","A G358S mutation in the Plasmodium falciparum Na+ pump PfATP4 confers clinically-relevant resistance to cipargamin D Qiu",{"$nulls":5},"PF3D7_1211900",null,0.33,-0.22,-0.49,null,null,1.7731908623980155,0.4394601472062679,2.59381366380463,"shared 3 stages",null,4.034929842149575,0.24783578379822793,null,"Detected",636393353.8483057,392860000,65708369.94269839,5.978842578846459,null,"Essential"]
["MMV665934",null,null,{"v":1070,"d":"1070.00"},{"v":5000,"d":"5000.00"},{"v":5000,"d":"5000.00"},null,null,{"v":4.672897196261682,"d":"4.67"},{"v":4.672897196261682,"d":"4.67"},null,null,"Mitochondrial electron transport chain (bc1 inhibitor) (Gamo)","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond, van Voorhis 2016","The relative rate of kill of the MMV Malaria Box compounds provides links to the mode of antimalarial action and highlights scaffolds of medicinal chemistry interest I Ullah",{"$nulls":7},0.8483333333333333,0.9800000000000001,0.8099999999999999,"Average",null,0.4530828604879675,1.7006577915597767,7.360729507627478,"gct V enriched","Average",0.2664162436067856,3.7535248844508895,null,"Detected",692838621.0520334,545915000,215905094.41200727,2.528495223731227,null,"Essential/Non essential"]
["CLM-22",null,null,{"v":0.42000000000000004,"d":"0.42"},{"v":2,"d":"2.00"},{"v":1.4,"d":"1.40"},null,null,{"v":4.761904761904762,"d":"4.76"},{"v":3.3333333333333326,"d":"3.33"},null,null,"PK7","A novel pyrazolopyridine with in vivo activity in Plasmodium berghei-and Plasmodium falciparum-infected mouse models from structure–activity relationship studies around the core of recently identified antimalarial imidazopyridazines Le Manach 2015",{"$nulls":6},"PF3D7_0213400",null,0.31,0.27,-0.31,null,null,0.2246523050636276,0,0.136463666385725,"not determined",null,1.1,0,null,"Not detected",{"$nulls":5},"Not essential","A D"]
["MMV668436",null,null,163.91,{"v":781.5999999999999,"d":"781.60"},{"v":5000,"d":"5000.00"},null,null,{"v":4.7684705021048135,"d":"4.77"},{"v":30.504545177231407,"d":"30.50"},null,null,"DHFR-TS","Rosowsky A., Chen K. K., Lin M.: 2,4-Diaminothieno(2,3-d)pyrimidines as antifolates and antimalarials.",{"$nulls":6},"PF3D7_0417200",null,0.11,0.52,0.13,null,null,1.15443469003188,0.6407679530676047,10.9377664171444,"gct V enriched",null,1.8016423644552657,0.5550491150347446,null,"Detected",3107354809.595412,901370000,1885999900.5903804,0.47792685445945216,null,"Essential","A"]
["MMV665852",null,null,{"v":1028,"d":"1028.00"},{"v":5000,"d":"5000.00"},{"v":5000,"d":"5000.00"},{"v":5000,"d":"5000.00"},null,{"v":4.863813229571984,"d":"4.86"},{"v":4.863813229571984,"d":"4.86"},{"$f":"G155/D155","v":{"v":4.863813229571984,"d":"4.86"}},null,"phospholipid-transporting ATPase 2 (ATP2)","Corey VC, Lukens AK, Istvan ES, et al. A broad analysis of resistance development in the malaria parasite. Nat Commun. 2016;7:11901.","Cowell AN, Istvan ES, Lukens AK, et al. Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. Science. 2018;359(6372):191-199.","Screening for potential prophylactics targeting sporozoite motility through the skin RG Douglas 2018",{"$nulls":4},"PF3D7_1219600",null,0.26,-0.16,-0.4,null,null,0,0,0.337940442708695,"gct V enriched",null,1,null,null,"Detected",38850536.94093786,30051000,36855198.62823407,0.8153802209324819,null,"Essential"]
["MMV665852",null,null,{"v":1028,"d":"1028.00"},{"v":5000,"d":"5000.00"},{"v":5000,"d":"5000.00"},{"v":5000,"d":"5000.00"},null,{"v":4.863813229571984,"d":"4.86"},{"v":4.863813229571984,"d":"4.86"},{"$f":"G156/D156","v":{"v":4.863813229571984,"d":"4.86"}},null,"PKG","Corey VC, Lukens AK, Istvan ES, et al. A broad analysis of resistance development in the malaria parasite. Nat Commun. 2016;7:11901.","Cowell AN, Istvan ES, Lukens AK, et al. Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. Science. 2018;359(6372):191-199.","Screening for potential prophylactics targeting sporozoite motility through the skin RG Douglas 2018",{"$nulls":4},"PF3D7_1436600",null,0.47,-0.44,0.1,null,null,0,0.068244893498124,2.02530545710245,"gct V enriched",null,0.8,null,null,"Detected",187255751.4074903,109730000,295371702.85639864,0.37149801060444715,null,"Essential"]
["MMV000787",null,null,{"v":407,"d":"407.00"},{"v":2000,"d":"2000.00"},{"v":584,"d":"584.00"},{"v":4574.650000000001,"d":"4574.65"},null,{"v":4.914004914004914,"d":"4.91"},{"v":1.434889434889435,"d":"1.43"},{"$f":"G157/D157","v":{"v":11.239926289926292,"d":"11.24"}},null,"PfDHODH","Combining stage specificity and metabolomic profiling to advance antimalarial drug discovery JM Murithi 2020","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond, van Voorhis 2016",{"$nulls":5},"PF3D7_0603300",null,0.75,-0.19,-0.43,null,null,1.15443469003188,0.7714114432536744,1.89426612471675,"shared 3 stages",null,1.4965226405803402,0.6682157508904827,null,"Detected",133919747.91061999,21091000,31021606.034033686,0.679880982849861,null,"Essential"]
["MMV000787",null,null,{"v":407,"d":"407.00"},{"v":2000,"d":"2000.00"},{"v":584,"d":"584.00"},{"v":4574.650000000001,"d":"4574.65"},null,{"v":4.914004914004914,"d":"4.91"},{"v":1.434889434889435,"d":"1.43"},{"$f":"G158/D158","v":{"v":11.239926289926292,"d":"11.24"}},null,"Cysteine protease","Combining stage specificity and metabolomic profiling to advance antimalarial drug discovery JM Murithi 2020","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond, van Voorhis 2016",{"$nulls":7},0.8683333333333333,0.2925,0.5025000000000001,"Average",null,0.798641256081183,0.19433860091901342,0.31856282249165724,"enriched troph","Average",4.109534864944305,0.24333654120575338,null,"Detected",57370296.82134489,79529333.33333333,145189284.43913874,0.5477631055249872,null,"Essential/Non essential","S U"]
["MMV000787",null,null,{"v":407,"d":"407.00"},{"v":2000,"d":"2000.00"},{"v":584,"d":"584.00"},{"v":4574.650000000001,"d":"4574.65"},null,{"v":4.914004914004914,"d":"4.91"},{"v":1.434889434889435,"d":"1.43"},{"$f":"G159/D159","v":{"v":11.239926289926292,"d":"11.24"}},null," CytBC1","Combining stage specificity and metabolomic profiling to advance antimalarial drug discovery JM Murithi 2020","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond, van Voorhis 2016",{"$nulls":7},0.8483333333333333,0.9800000000000001,0.8099999999999999,"Average",null,0.4530828604879675,1.7006577915597767,7.360729507627478,"gct V enriched","Average",0.2664162436067856,3.7535248844508895,null,"Detected",692838621.0520334,545915000,215905094.41200727,2.528495223731227,null,"Essential/Non essential"]
["MMV665807",null,null,{"v":973.3000000000001,"d":"973.30"},{"v":5000,"d":"5000.00"},{"v":5000,"d":"5000.00"},{"v":5000,"d":"5000.00"},null,{"v":5.1371622315832735,"d":"5.14"},{"$f":"F160/D160","v":{"v":5.1371622315832735,"d":"5.14"}},{"$f":"G160/D160","v":{"v":5.1371622315832735,"d":"5.14"}},null,"calcium-transporting ATPase (ATP6)","Selective Inhibition of Plasmodium falciparum ATPase 6 by Artemisinins and Identification of New Classes of Inhibitors after Expression in Yeast CM Moore","Screening of the open source malaria box reveals an early lead compound for the treatment of alveolar echinococcosis B Stadelmann",{"$nulls":5},"PF3D7_0106300",null,0.39,-0.03,-0.13,null,null,1.6876027710717014,0.7605873874153525,3.93796931771435,"shared 3 stages",null,2.2188150881735713,0.4506910040994696,null,"Detected",1029579056.5443927,1600300000,889900800.0520924,1.7982903261872814,null,"Essential"]
["MMV668399","MMV668399",null,339.43,{"v":1770,"d":"1770.00"},null,{"v":5000,"d":"5000.00"},null,{"v":5.214624517573579,"d":"5.21"},null,{"v":14.730577733258698,"d":"14.73"},null,"inorganic anion exchanger, inorganic anion antiporter","Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. Cowell. 2018",{"$nulls":6},"PF3D7_1471200",null,0.26,0.44,-0.04,null,null,0,0,0.807768676963434,"gct V enriched",null,1,null,null,"Detected",64874226.94688254,78503000,147852609.0901198,0.5309544449915692,null,"Essential"]
["MMV668399","MMV668399",null,339.43,{"v":1770,"d":"1770.00"},null,{"v":5000,"d":"5000.00"},null,{"v":5.214624517573579,"d":"5.21"},null,{"v":14.730577733258698,"d":"14.73"},null,"amino acid transporter AAT1","Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. Cowell. 2018",{"$nulls":6},"PF3D7_0629500",null,0.31,-0.31,-0.59,{"$nulls":6},"Not detected",{"$nulls":3},"Detected",3042923.6353463647,6972800,6511740.419343636,1.0708043550518,null,"Essential"]
["MMV668399","MMV668399",null,339.43,{"v":1770,"d":"1770.00"},null,{"v":5000,"d":"5000.00"},null,{"v":5.214624517573579,"d":"5.21"},null,{"v":14.730577733258698,"d":"14.73"},null,"Forkhead-associated domain (FHA)","Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. Cowell. 2018",{"$nulls":6},"PF3D7_0909700",null,0.98,1.04,0.42,null,null,0,0.2766043115290483,0,"gct I/II enriched",null,0.2,null,null,"Not detected",{"$nulls":5},"Not essential","V"]
["MMV643110",null,null,{"v":23.240000000000002,"d":"23.24"},{"v":122.1,"d":"122.10"},71.51,{"v":92.7,"d":"92.70"},null,{"v":5.253872633390705,"d":"5.25"},{"$f":"F164/D164","v":{"v":3.0770223752151464,"d":"3.08"}},{"v":3.98881239242685,"d":"3.99"},null,"PI4K"," Potent Plasmodium falciparum gametocytocidal compounds identified by exploring the kinase inhibitor chemical space for dual active antimalarials Mariëtte E van der Watt, ",{"$nulls":6},"PF3D7_0509800",null,0.29,-0.01,0.16,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV1577530","MMV1577530",null,25.87,147.14,null,481.57,null,{"v":5.687669114804793,"d":"5.69"},null,{"v":18.61499806725937,"d":"18.61"},null,"proteosome","Provided from MMV",{"$nulls":8},0.41428571428571426,0.2892857142857143,0.11928571428571429,"Average",null,4.371904224875087,14.744723143961812,53.195817261465585,"gct V enriched","Average",0.296506362458589,3.372608910338857,null,"Detected",1385888365.4679062,3846228571.428571,1162706304.4179296,3.307996659873671,null,"Essential/Non essential"]
["MMV000720",null,null,{"v":864.35955618131,"d":"864.36"},{"v":5000,"d":"5000.00"},{"v":2427.4,"d":"2427.40"},{"v":5000,"d":"5000.00"},null,{"v":5.784629746085885,"d":"5.78"},{"$f":"F166/D166","v":{"v":2.808322049129776,"d":"2.81"}},{"v":5.784629746085885,"d":"5.78"},null,"6-phosphogluconate dehydrogenase","Characterization of Plasmodium falciparum 6-phosphogluconate dehydrogenase as an antimalarial drug target K Haeussler 2018",{"$nulls":6},"PF3D7_1454700",null,0.29,0.18,-0.08,null,null,1.7176232460629302,5.869374848204267,16.4332882219999,"gct V enriched",null,0.29264159991220123,3.4171491691544245,null,"Detected",1936470222.4009511,2758600000,3486288340.423685,0.7912713265893406,null,"Essential"]
["MMV397264","21A092",null,10.58,{"v":62.1,"d":"62.10"},null,{"v":213.3,"d":"213.30"},null,{"v":5.869565217391305,"d":"5.87"},null,{"v":20.160680529300567,"d":"20.16"},null,"ATP4","Pyrazoleamide compounds are potent antimalarials that target Na+ homeostasis in intraerythrocytic Plasmodium falciparum. Akhil B. Vaidya. 2014",{"$nulls":6},"PF3D7_1211900",null,0.33,-0.22,-0.49,null,null,1.7731908623980155,0.4394601472062679,2.59381366380463,"shared 3 stages",null,4.034929842149575,0.24783578379822793,null,"Detected",636393353.8483057,392860000,65708369.94269839,5.978842578846459,null,"Essential"]
["MMV665878",null,null,{"v":139,"d":"139.00"},{"v":819,"d":"819.00"},null,{"v":1100,"d":"1100.00"},null,{"v":5.892086330935252,"d":"5.89"},null,{"v":7.913669064748201,"d":"7.91"},null,"ATP4","E.L. Allman, H.J. Painter, J. Samra, M. Carrasquilla, M. Llinas Metabolomic profiling of the malaria box reveals antimalarial target pathways 2016","Metabolomics-based screening of the malaria box reveals both novel and established mechanisms of action DJ Creek","Targeted phenotypic screening in Plasmodium falciparum and Toxoplasma gondii reveals novel modes of action of medicines for malaria venture malaria box … G Subramanian",{"$nulls":4},"PF3D7_1211900",null,0.33,-0.22,-0.49,null,null,1.7731908623980155,0.4394601472062679,2.59381366380463,"shared 3 stages",null,4.034929842149575,0.24783578379822793,null,"Detected",636393353.8483057,392860000,65708369.94269839,5.978842578846459,null,"Essential"]
["KS9",null,null,{"v":390,"d":"390.00"},{"v":2300,"d":"2300.00"},{"v":1020,"d":"1020.00"},null,null,{"v":5.897435897435898,"d":"5.90"},{"$f":"F169/D169","v":{"v":2.6153846153846154,"d":"2.62"}},null,null,"bc1 complex","Antimalarial pyrido [1,2-a] benzimidazoles: Lead optimization, parasite life cycle stage profile, mechanistic evaluation, killing kinetics, and in vivo oral efficacy in a mouse model Singh 2017",{"$nulls":8},0.8483333333333333,0.9800000000000001,0.8099999999999999,"Average",null,0.4530828604879675,1.7006577915597767,7.360729507627478,"gct V enriched","Average",0.2664162436067856,3.7535248844508895,null,"Detected",692838621.0520334,545915000,215905094.41200727,2.528495223731227,null,"Essential/Non essential"]
["MMV666620",null,null,11.59,{"v":68.4,"d":"68.40"},{"v":78.89999999999999,"d":"78.90"},{"v":428,"d":"428.00"},null,{"v":5.901639344262295,"d":"5.90"},{"v":6.807592752372734,"d":"6.81"},{"$f":"G170/D170","v":{"v":36.9283865401208,"d":"36.93"}},null,"CDPK1","Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): preparation and evaluation of pyrazole … JM Large","Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) TM Chapman","New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of Plasmodium Phosphatidylinositol-4-kinase and cGMP … PM Cheuka",{"$nulls":4},"PF3D7_0217500",null,0.54,-0.07,0.86,null,null,1.8276642121903912,0.8228906159046369,5.07832312829723,"shared 3 stages",null,2.2210293529488925,0.4502416857626333,null,"Detected",1326801430.219953,360430000,3411452182.6706023,0.10565295384496434,null,"Essential","I S","A"]
["MMV666620",null,null,11.59,{"v":68.4,"d":"68.40"},{"v":78.89999999999999,"d":"78.90"},{"v":428,"d":"428.00"},null,{"v":5.901639344262295,"d":"5.90"},{"v":6.807592752372734,"d":"6.81"},{"v":36.9283865401208,"d":"36.93"},null,"CDPK4","Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): preparation and evaluation of pyrazole … JM Large","Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) TM Chapman","New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of Plasmodium Phosphatidylinositol-4-kinase and cGMP … PM Cheuka",{"$nulls":4},"PF3D7_0717500",null,0.32,0.52,0.27,null,null,0,0.40541168873881694,56.3615251044868,"gct V enriched",null,0.4,null,null,"Detected",1686711047.3126552,891260000,11247658017.88505,0.07923960691041598,null,"Not essential","U"]
["MMV666620",null,null,11.59,{"v":68.4,"d":"68.40"},{"v":78.89999999999999,"d":"78.90"},{"v":428,"d":"428.00"},null,{"v":5.901639344262295,"d":"5.90"},{"v":6.807592752372734,"d":"6.81"},{"v":36.9283865401208,"d":"36.93"},null,"PI4K","Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): preparation and evaluation of pyrazole … JM Large","Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) TM Chapman","New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of Plasmodium Phosphatidylinositol-4-kinase and cGMP … PM Cheuka",{"$nulls":4},"PF3D7_0509800",null,0.29,-0.01,0.16,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV666620",null,null,11.59,{"v":68.4,"d":"68.40"},{"v":78.89999999999999,"d":"78.90"},{"v":428,"d":"428.00"},null,{"v":5.901639344262295,"d":"5.90"},{"v":6.807592752372734,"d":"6.81"},{"v":36.9283865401208,"d":"36.93"},null,"PKG","Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): preparation and evaluation of pyrazole … JM Large","Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) TM Chapman","New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of Plasmodium Phosphatidylinositol-4-kinase and cGMP … PM Cheuka",{"$nulls":4},"PF3D7_1436600",null,0.47,-0.44,0.1,null,null,0,0.068244893498124,2.02530545710245,"gct V enriched",null,0.8,null,null,"Detected",187255751.4074903,109730000,295371702.85639864,0.37149801060444715,null,"Essential"]
["MMV000025","Pyronaridine",null,{"v":4.5,"d":"4.50"},{"v":27,"d":"27.00"},{"v":1866,"d":"1866.00"},{"v":938,"d":"938.00"},null,{"v":6,"d":"6.00"},{"v":414.6666666666667,"d":"414.67"},{"v":208.44444444444446,"d":"208.44"},null,"DNA topoisomerase2 (TOP2)","Pyronaridine: An update of its pharmacological activities andmechanisms of action Christian Bailly 2021","Review of pyronaridine anti-malarial properties and product characteristics Simon L Croft 2012",{"$nulls":5},"PF3D7_1433500",null,0.79,-0.02,0.28,null,null,1.1250623353878415,0.9615132377040246,2.43332001828199,"shared 3 stages",null,1.1700955236709503,0.8546310790615554,null,"Detected",563713858.0970031,244090000,3133698280.5174513,0.07789199155436709,null,"Not essential"]
["MMV666125",null,null,{"v":120,"d":"120.00"},{"v":720.3199999999999,"d":"720.32"},{"v":745,"d":"745.00"},{"v":480,"d":"480.00"},null,{"v":6.002666666666666,"d":"6.00"},{"v":6.208333333333333,"d":"6.21"},{"v":4,"d":"4.00"},null,"Hsp90","Sun W, Tanaka TQ, Magle CT, Huang W, Southall N, Huang R, Dehdashti SJ, McKew JC et al (2014) Chemical signatures and new drug targets for gametocytocidal drug development. "," Characterization of Plasmodium falciparum 6-phosphogluconate dehydrogenase as an antimalarial drug target K Haeussler",{"$nulls":5},"PF3D7_0708400",null,0.47,0.14,-0.37,null,null,391.244342138169,487.5030361563116,2642.7611857491,"gct V enriched",null,0.8025474984174693,1.2460321687774047,null,"Detected",28102267024.51306,93040000000,24304490388.95642,3.8280991911797466,null,"Essential"]
["MMV666125",null,null,{"v":120,"d":"120.00"},{"v":720.3199999999999,"d":"720.32"},{"v":745,"d":"745.00"},{"v":480,"d":"480.00"},null,{"v":6.002666666666666,"d":"6.00"},{"v":6.208333333333333,"d":"6.21"},{"v":4,"d":"4.00"},null,"6-phosphogluconate dehydrogenase","Sun W, Tanaka TQ, Magle CT, Huang W, Southall N, Huang R, Dehdashti SJ, McKew JC et al (2014) Chemical signatures and new drug targets for gametocytocidal drug development. "," Characterization of Plasmodium falciparum 6-phosphogluconate dehydrogenase as an antimalarial drug target K Haeussler",{"$nulls":5},"PF3D7_1454700",null,0.29,0.18,-0.08,null,null,1.7176232460629302,5.869374848204267,16.4332882219999,"gct V enriched",null,0.29264159991220123,3.4171491691544245,null,"Detected",1936470222.4009511,2758600000,3486288340.423685,0.7912713265893406,null,"Essential"]
["PC22",null,null,{"v":94,"d":"94.00"},{"v":570,"d":"570.00"},{"v":780,"d":"780.00"},null,null,{"v":6.0638297872340425,"d":"6.06"},{"v":8.297872340425531,"d":"8.30"},null,null,"PI4K","New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of Plasmodium Phosphatidylinositol-4-kinase and cGMP … PM Cheuka",{"$nulls":6},"PF3D7_0509800",null,0.29,-0.01,0.16,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV1558277",null,null,{"v":759.3,"d":"759.30"},{"v":5000,"d":"5000.00"},null,{"v":5000,"d":"5000.00"},null,{"v":6.5850125115237725,"d":"6.59"},null,{"$f":"G178/D178","v":{"v":6.5850125115237725,"d":"6.59"}},null,"plasmepsin X (PMX)","Provided from MMV",{"$nulls":6},"PF3D7_0808200",null,1.26,-0.79,0.17,null,null,0,0,0.99526231496888,"gct V enriched",null,1,null,null,"Detected",90439310.2773018,149530000,3295189.911008856,45.37826469437687,null,"Essential/Not essential","D I"]
["MMV009063",null,null,{"v":293,"d":"293.00"},{"v":2000,"d":"2000.00"},{"v":897,"d":"897.00"},null,null,{"v":6.825938566552901,"d":"6.83"},{"$f":"F179/D179","v":{"v":3.061433447098976,"d":"3.06"}},null,null,"ATP4","E.L. Allman, H.J. Painter, J. Samra, M. Carrasquilla, M. Llinas Metabolomic profiling of the malaria box reveals antimalarial target pathways 2016","Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics AN Cowell",{"$nulls":5},"PF3D7_1211900",null,0.33,-0.22,-0.49,null,null,1.7731908623980155,0.4394601472062679,2.59381366380463,"shared 3 stages",null,4.034929842149575,0.24783578379822793,null,"Detected",636393353.8483057,392860000,65708369.94269839,5.978842578846459,null,"Essential"]
["MMV009063",null,null,{"v":293,"d":"293.00"},{"v":2000,"d":"2000.00"},{"v":897,"d":"897.00"},null,null,{"v":6.825938566552901,"d":"6.83"},{"v":3.061433447098976,"d":"3.06"},null,null,"MDR1","E.L. Allman, H.J. Painter, J. Samra, M. Carrasquilla, M. Llinas Metabolomic profiling of the malaria box reveals antimalarial target pathways 2016","Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics AN Cowell",{"$nulls":5},"PF3D7_0523000",null,0.55,-0.14,-0.37,null,null,4.185382762981795,2.6120056276710084,5.55996328108289,"shared 3 stages",null,1.6023636085017496,0.6240780773441461,null,"Detected",1075298324.2997518,2109100000,611327737.4544191,3.45003158008556,null,"Essential"]
["MMV675081",null,null,24.42,{"v":168,"d":"168.00"},{"v":845,"d":"845.00"},null,null,{"v":6.879606879606879,"d":"6.88"},{"v":34.6027846027846,"d":"34.60"},null,null,"PI4K"," Potent Plasmodium falciparum gametocytocidal compounds identified by exploring the kinase inhibitor chemical space for dual active antimalarials Mariëtte E van der Watt, ",{"$nulls":6},"PF3D7_0509800",null,0.29,-0.01,0.16,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV665915",null,null,{"v":212,"d":"212.00"},{"v":1463,"d":"1463.00"},{"v":2000,"d":"2000.00"},null,null,{"v":6.900943396226415,"d":"6.90"},{"v":9.433962264150944,"d":"9.43"},null,null,"C4,C9-fatty acid incorporation into neutral lipids - lipid synthesis, ALA pathway","Leveraging a Fluorescent Fatty Acid Probe to Discover Cell-Permeable Inhibitors of Plasmodium falciparum Glycerolipid Biosynthesis C Dapper","Metabolomics-based screening of the malaria box reveals both novel and established mechanisms of action DJ Creek",{"$nulls":7},0.6671428571428571,0.3242857142857143,-0.021428571428571432,"Average",null,37.646519513211814,9.332753816591573,5.0591843940321946,"enriched troph","Average",4.03380612550656,0.24790482459650223,null,"Detected",681055108.2316326,2380578564.492525,834388396.6381606,2.8530820587679897,null,"Essential/Not essential"]
["MMV665915",null,null,{"v":212,"d":"212.00"},{"v":1463,"d":"1463.00"},{"v":2000,"d":"2000.00"},null,null,{"v":6.900943396226415,"d":"6.90"},{"v":9.433962264150944,"d":"9.43"},null,null,"acyl-CoA synthetase (ACS11)","Leveraging a Fluorescent Fatty Acid Probe to Discover Cell-Permeable Inhibitors of Plasmodium falciparum Glycerolipid Biosynthesis C Dapper","Metabolomics-based screening of the malaria box reveals both novel and established mechanisms of action DJ Creek",{"$nulls":5},"PF3D7_1238800",null,0.54,-0.04,-0.19,null,null,3.175016900592523,1.578121624064757,2.78248990638938,"shared 3 stages",null,2.011896201266575,0.49704353503448984,null,"Detected",370910521.31342447,1014900000,531968643.8183713,1.9078192141462285,null,"Essential"]
["MMV665915",null,null,{"v":212,"d":"212.00"},{"v":1463,"d":"1463.00"},{"v":2000,"d":"2000.00"},null,null,{"v":6.900943396226415,"d":"6.90"},{"v":9.433962264150944,"d":"9.43"},null,null,"Fatty acid pathway","Leveraging a Fluorescent Fatty Acid Probe to Discover Cell-Permeable Inhibitors of Plasmodium falciparum Glycerolipid Biosynthesis C Dapper","Metabolomics-based screening of the malaria box reveals both novel and established mechanisms of action DJ Creek",{"$nulls":7},0.42826086956521753,0.7691304347826086,0.5582608695652173,"Average",null,0.28334024779249645,4.761770573690979,1.319018667303425,"gct I/II enriched","Average",0.05950312880632375,16.805838954366447,null,"Detected",132017292.1949855,1079994333.3333333,70963557.24778607,15.21899937403472,null,"Essential/Not essential"]
["MMV000963",null,null,{"v":212.5,"d":"212.50"},{"v":1476,"d":"1476.00"},{"v":2000,"d":"2000.00"},null,null,{"v":6.945882352941177,"d":"6.95"},{"v":9.411764705882353,"d":"9.41"},null,null,"PKG","E.L. Allman, H.J. Painter, J. Samra, M. Carrasquilla, M. Llinas Metabolomic profiling of the malaria box reveals antimalarial target pathways 2016","Evaluation of 4-amino 2-anilinoquinazolines against Plasmodium and other apicomplexan parasites in vitro and in a P. falciparum humanized NOD-scid IL2Rγnull PR Gilson 2019","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond, van Voorhis 2016",{"$nulls":4},"PF3D7_1436600",null,0.47,-0.44,0.1,null,null,0,0.068244893498124,2.02530545710245,"gct V enriched",null,0.8,null,null,"Detected",187255751.4074903,109730000,295371702.85639864,0.37149801060444715,null,"Essential"]
["MMV390048","MMV0048",null,{"v":24,"d":"24.00"},{"v":171,"d":"171.00"},null,{"v":101.4,"d":"101.40"},null,{"v":7.125,"d":"7.13"},null,{"$f":"G186/D186","v":{"v":4.2250000000000005,"d":"4.23"}},null,"PI4K"," Potent Plasmodium falciparum gametocytocidal compounds identified by exploring the kinase inhibitor chemical space for dual active antimalarials Mariëtte E van der Watt, ","Younis Y, Douelle F, Feng TS, Gonzalez Cabrera D, Le Manach C, Nchinda AT, Duffy S, White KL, Shackleford DM, Morizzi J, Mannila J, Katneni K, Bhamidipati R, Zabiulla KM, Joseph JT, Bashyam S, Waterson D, Witty MJ, Hardick D, Wittlin S, Avery V, Charman SA, Chibale K. 2012. 3,5-Diaryl-2-aminopyridines as a novel class of orally active antimalarials demonstrating single dose cure in mice and clinical candidate potential. J Med Chem 55:3479–3487.","Paquet T, Le Manach C, Cabrera DG, Younis Y, Henrich PP, Abraham TS, Lee MCS, Basak R, Ghidelli-Disse S, Lafuente-Monasterio MJ et al.. (2017)\nAntimalarial efficacy of MMV390048, an inhibitor of Plasmodium phosphatidylinositol 4-kinase. ",{"$nulls":4},"PF3D7_0509800",null,0.29,-0.01,0.16,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV390048","MMV0048",null,{"v":24,"d":"24.00"},{"v":171,"d":"171.00"},null,{"v":101.4,"d":"101.40"},null,{"v":7.125,"d":"7.13"},null,{"$f":"G187/D187","v":{"v":4.2250000000000005,"d":"4.23"}},null,"PI3K"," Potent Plasmodium falciparum gametocytocidal compounds identified by exploring the kinase inhibitor chemical space for dual active antimalarials Mariëtte E van der Watt, ","Younis Y, Douelle F, Feng TS, Gonzalez Cabrera D, Le Manach C, Nchinda AT, Duffy S, White KL, Shackleford DM, Morizzi J, Mannila J, Katneni K, Bhamidipati R, Zabiulla KM, Joseph JT, Bashyam S, Waterson D, Witty MJ, Hardick D, Wittlin S, Avery V, Charman SA, Chibale K. 2012. 3,5-Diaryl-2-aminopyridines as a novel class of orally active antimalarials demonstrating single dose cure in mice and clinical candidate potential. J Med Chem 55:3479–3487.","Paquet T, Le Manach C, Cabrera DG, Younis Y, Henrich PP, Abraham TS, Lee MCS, Basak R, Ghidelli-Disse S, Lafuente-Monasterio MJ et al.. (2017)\nAntimalarial efficacy of MMV390048, an inhibitor of Plasmodium phosphatidylinositol 4-kinase. ",{"$nulls":4},"PF3D7_0515300",null,0.56,0.18,0.29,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV390048","MMV0048",null,{"v":24,"d":"24.00"},{"v":171,"d":"171.00"},null,{"v":101.4,"d":"101.40"},null,{"v":7.125,"d":"7.13"},null,{"$f":"G188/D188","v":{"v":4.2250000000000005,"d":"4.23"}},null,"PKG"," Potent Plasmodium falciparum gametocytocidal compounds identified by exploring the kinase inhibitor chemical space for dual active antimalarials Mariëtte E van der Watt, ","Younis Y, Douelle F, Feng TS, Gonzalez Cabrera D, Le Manach C, Nchinda AT, Duffy S, White KL, Shackleford DM, Morizzi J, Mannila J, Katneni K, Bhamidipati R, Zabiulla KM, Joseph JT, Bashyam S, Waterson D, Witty MJ, Hardick D, Wittlin S, Avery V, Charman SA, Chibale K. 2012. 3,5-Diaryl-2-aminopyridines as a novel class of orally active antimalarials demonstrating single dose cure in mice and clinical candidate potential. J Med Chem 55:3479–3487.","Paquet T, Le Manach C, Cabrera DG, Younis Y, Henrich PP, Abraham TS, Lee MCS, Basak R, Ghidelli-Disse S, Lafuente-Monasterio MJ et al.. (2017)\nAntimalarial efficacy of MMV390048, an inhibitor of Plasmodium phosphatidylinositol 4-kinase. ",{"$nulls":4},"PF3D7_1436600",null,0.47,-0.44,0.1,null,null,0,0.068244893498124,2.02530545710245,"gct V enriched",null,0.8,null,null,"Detected",187255751.4074903,109730000,295371702.85639864,0.37149801060444715,null,"Essential"]
["MMV1792684","TCMDC-135051",null,115.67,{"v":840,"d":"840.00"},null,{"v":2526,"d":"2526.00"},null,{"v":7.262038557966629,"d":"7.26"},null,{"$f":"G189/D189","v":{"v":21.837987377885362,"d":"21.84"}},null,"cyclin-dependent-like kinase (CLK3)","Development of Potent PfCLK3 Inhibitors Based on TCMDC-135051 as a New Class of Antimalarials. A Mahindra. 2020","Validation of the protein kinase PfCLK3 as a multistage cross-species malarial drug target. Mahmood M. Alam. 2019",{"$nulls":5},"PF3D7_1114700",null,0.25,0.09,-0.02,null,null,0,0,0.0624678308940412,"not determined",null,1,null,null,"Detected",2546751.7470364026,7551700,2549578.3721132143,2.9619407203163495,null,"Essential"]
["MMV674594",null,null,89.06,{"v":649,"d":"649.00"},{"v":1860,"d":"1860.00"},null,null,{"v":7.287222097462385,"d":"7.29"},{"$f":"F190/D190","v":{"v":20.884796766225016,"d":"20.88"}},null,null,"PI4K"," Potent Plasmodium falciparum gametocytocidal compounds identified by exploring the kinase inhibitor chemical space for dual active antimalarials Mariëtte E van der Watt, ",{"$nulls":6},"PF3D7_0509800",null,0.29,-0.01,0.16,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV665794",null,null,{"v":90,"d":"90.00"},{"v":656,"d":"656.00"},{"v":416,"d":"416.00"},{"v":680,"d":"680.00"},null,{"v":7.288888888888889,"d":"7.29"},{"v":4.622222222222222,"d":"4.62"},{"$f":"G191/D191","v":{"v":7.555555555555555,"d":"7.56"}},null,"PKG","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond, van Voorhis 2016","Combining stage specificity and metabolomic profiling to advance antimalarial drug discovery JM Murithi","Malaria Box Compounds against Anopheles gambiae (Diptera: Culicidae) Carboxypeptidase B Activity to Block Malaria Transmission T Pomun","Generation of a mutator parasite to drive resistome discovery in Plasmodium falciparum K Kumpornsin",{"$nulls":3},"PF3D7_1436600",null,0.47,-0.44,0.1,null,null,0,0.068244893498124,2.02530545710245,"gct V enriched",null,0.8,null,null,"Detected",187255751.4074903,109730000,295371702.85639864,0.37149801060444715,null,"Essential"]
["MMV665794",null,null,{"v":90,"d":"90.00"},{"v":656,"d":"656.00"},{"v":416,"d":"416.00"},{"v":680,"d":"680.00"},null,{"v":7.288888888888889,"d":"7.29"},{"v":4.622222222222222,"d":"4.62"},{"$f":"G192/D192","v":{"v":7.555555555555555,"d":"7.56"}},null,"QRP1?","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond, van Voorhis 2016","Combining stage specificity and metabolomic profiling to advance antimalarial drug discovery JM Murithi","Malaria Box Compounds against Anopheles gambiae (Diptera: Culicidae) Carboxypeptidase B Activity to Block Malaria Transmission T Pomun","Generation of a mutator parasite to drive resistome discovery in Plasmodium falciparum K Kumpornsin",{"$nulls":3},"PF3D7_1359900",null,0.59,-0.05,0.22,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Not essential"]
["MMV020549",null,null,{"v":274,"d":"274.00"},{"v":2027.0000000000002,"d":"2027.00"},{"v":5000,"d":"5000.00"},null,null,{"v":7.397810218978103,"d":"7.40"},{"v":18.248175182481752,"d":"18.25"},null,null,"Hsp90","E.L. Allman, H.J. Painter, J. Samra, M. Carrasquilla, M. Llinas Metabolomic profiling of the malaria box reveals antimalarial target pathways 2016","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond, van Voorhis 2016","Bilayer effects of antimalarial compounds NB Ramsey","Identification of Novel Ezrin Inhibitors Targeting Metastatic Osteosarcoma by Screening Open Access Malaria BoxScreening MMV Malaria Box to Identify Novel Ezrin … H Çelik",{"$nulls":3},"PF3D7_0708400",null,0.47,0.14,-0.37,null,null,391.244342138169,487.5030361563116,2642.7611857491,"gct V enriched",null,0.8025474984174693,1.2460321687774047,null,"Detected",28102267024.51306,93040000000,24304490388.95642,{"$f":"AL193/AM193","v":3.8280991911797466},null,"Essential"]
["MMV665924",null,null,{"v":649.2,"d":"649.20"},{"v":5000,"d":"5000.00"},null,{"v":5000,"d":"5000.00"},null,{"v":7.701786814540973,"d":"7.70"},null,{"$f":"G194/D194","v":{"v":7.701786814540973,"d":"7.70"}},null,"acetyl-CoA synthetase (ACAS)","Chemogenomics identifies acetyl-coenzyme A synthetase as a target for malaria treatment and prevention. RL Summers. 2022",{"$nulls":6},"PF3D7_0627800",null,0.29,-0.51,-0.45,null,null,0.5239278103274543,0.22331568211144429,0.148153621496883,"enriched troph",null,2.3461308465833195,0.42623368660631367,null,"Detected",7752479.546805608,5327800,13142844.217746137,0.40537648561687534,null,"Essential","A"]
["MMV665924",null,null,{"v":649.2,"d":"649.20"},{"v":5000,"d":"5000.00"},null,{"v":5000,"d":"5000.00"},null,{"v":7.701786814540973,"d":"7.70"},null,{"v":7.701786814540973,"d":"7.70"},null,"acyl-CoA synthetase (ACS10)","Chemogenomics identifies acetyl-coenzyme A synthetase as a target for malaria treatment and prevention. RL Summers. 2022",{"$nulls":6},"PF3D7_0525100",null,0.84,-0.61,-0.77,null,null,6.499642624097776,6.443810658555231,5.39080484186031,"shared 3 stages",null,1.0086644329731227,0.991409994553309,null,"Detected",337785262.1603665,1807600000,394712460.1927418,4.579536199889236,null,"Essential"]
["MMV020243",null,null,{"v":134.258604,"d":"134.26"},1058.32,{"v":5000,"d":"5000.00"},{"v":5000,"d":"5000.00"},null,{"v":7.88269778225908,"d":"7.88"},{"$f":"F196/D196","v":{"v":37.24156106970992,"d":"37.24"}},{"v":37.24156106970992,"d":"37.24"},null,"phosphatidylserine decarboxylase (PSD)","Characterization of Plasmodium phosphatidylserine decarboxylase expressed in yeast and application for inhibitor screening JY Choi","Identification of Novel Ezrin Inhibitors Targeting Metastatic Osteosarcoma by Screening Open Access Malaria BoxScreening MMV Malaria Box to Identify Novel Ezrin … H Çelik",{"$nulls":5},"PF3D7_0927900",null,0.6,-0.61,0.16,null,null,0.9628761074834958,0,0.584893192461114,"shared 3 stages",null,1.9,0,null,"Not detected",{"$nulls":5},"Essential"]
["MMV006787",null,null,{"v":200.9,"d":"200.90"},{"v":1645,"d":"1645.00"},{"v":1170,"d":"1170.00"},{"v":3713.2000000000003,"d":"3713.20"},null,{"v":8.188153310104529,"d":"8.19"},{"v":5.823792931806869,"d":"5.82"},{"$f":"G197/D197","v":{"v":18.482827277252365,"d":"18.48"}},null,"Hsp90","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond, van Voorhis 2016",{"$nulls":6},"PF3D7_0708400",null,0.47,0.14,-0.37,null,null,391.244342138169,487.5030361563116,2642.7611857491,"gct V enriched",null,{"$f":"AB197/AC197","v":0.8025474984174693},1.2460321687774047,null,"Detected",28102267024.51306,93040000000,24304490388.95642,3.8280991911797466,null,"Essential"]
["CLM-1",null,null,{"v":7.3,"d":"7.30"},{"v":60,"d":"60.00"},{"v":27,"d":"27.00"},null,null,{"v":8.219178082191782,"d":"8.22"},{"v":3.6986301369863015,"d":"3.70"},null,null,"PK7","A novel pyrazolopyridine with in vivo activity in Plasmodium berghei-and Plasmodium falciparum-infected mouse models from structure–activity relationship studies around the core of recently identified antimalarial imidazopyridazines Le Manach 2015",{"$nulls":6},"PF3D7_0213400",null,0.31,0.27,-0.31,null,null,0.2246523050636276,0,0.136463666385725,"not determined",null,1.1,0,null,"Not detected",{"$nulls":5},"Not essential","A D"]
["MMV652103",null,null,7.25,{"v":59.6,"d":"59.60"},{"v":5,"d":"5.00"},{"v":133.3,"d":"133.30"},null,{"v":8.220689655172414,"d":"8.22"},{"v":0.6896551724137931,"d":"0.69"},{"$f":"G199/D199","v":{"v":18.386206896551727,"d":"18.39"}},null,"CDPK1","Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): preparation and evaluation of pyrazole … JM Large","Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) TM Chapman","New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of Plasmodium Phosphatidylinositol-4-kinase and cGMP … PM Cheuka","Exploring the transmission-blocking activity of antiplasmodial 3, 6-diarylated imidazopyridazines D Coertzen",{"$nulls":3},"PF3D7_0217500",null,0.54,-0.07,0.86,null,null,1.8276642121903912,0.8228906159046369,5.07832312829723,"shared 3 stages",null,2.2210293529488925,0.4502416857626333,null,"Detected",1326801430.219953,360430000,3411452182.6706023,0.10565295384496434,null,"Essential","I S","A"]
["MMV652103",null,null,7.25,{"v":59.6,"d":"59.60"},{"v":5,"d":"5.00"},{"v":133.3,"d":"133.30"},null,{"$f":"E200/D200","v":{"v":8.220689655172414,"d":"8.22"}},{"v":0.6896551724137931,"d":"0.69"},{"v":18.386206896551727,"d":"18.39"},null,"CDPK4","Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): preparation and evaluation of pyrazole … JM Large","Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) TM Chapman","New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of Plasmodium Phosphatidylinositol-4-kinase and cGMP … PM Cheuka","Exploring the transmission-blocking activity of antiplasmodial 3, 6-diarylated imidazopyridazines D Coertzen",{"$nulls":3},"PF3D7_0717500",null,0.32,0.52,0.27,null,null,0,0.40541168873881694,56.3615251044868,"gct V enriched",null,0.4,null,null,"Detected",1686711047.3126552,891260000,11247658017.88505,0.07923960691041598,null,"Not essential","U"]
["MMV652103",null,null,7.25,{"v":59.6,"d":"59.60"},{"v":5,"d":"5.00"},{"v":133.3,"d":"133.30"},null,{"v":8.220689655172414,"d":"8.22"},{"v":0.6896551724137931,"d":"0.69"},{"v":18.386206896551727,"d":"18.39"},null,"PI4K","Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): preparation and evaluation of pyrazole … JM Large","Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) TM Chapman","New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of Plasmodium Phosphatidylinositol-4-kinase and cGMP … PM Cheuka","Exploring the transmission-blocking activity of antiplasmodial 3, 6-diarylated imidazopyridazines D Coertzen",{"$nulls":3},"PF3D7_0509800",null,0.29,-0.01,0.16,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV652103",null,null,7.25,{"v":59.6,"d":"59.60"},{"v":5,"d":"5.00"},{"v":133.3,"d":"133.30"},null,{"v":8.220689655172414,"d":"8.22"},{"v":0.6896551724137931,"d":"0.69"},{"v":18.386206896551727,"d":"18.39"},null,"PKG","Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): preparation and evaluation of pyrazole … JM Large","Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) TM Chapman","New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of Plasmodium Phosphatidylinositol-4-kinase and cGMP … PM Cheuka","Exploring the transmission-blocking activity of antiplasmodial 3, 6-diarylated imidazopyridazines D Coertzen",{"$nulls":3},"PF3D7_1436600",null,0.47,-0.44,0.1,null,null,0,0.068244893498124,2.02530545710245,"gct V enriched",null,0.8,null,null,"Detected",187255751.4074903,109730000,295371702.85639864,0.37149801060444715,null,"Essential"]
["MMV009952","(-)-Halofuginone",null,1.02,{"v":8.4,"d":"8.40"},null,7.64,null,{"v":8.23529411764706,"d":"8.24"},null,{"v":7.490196078431372,"d":"7.49"},null,"proline--tRNA ligase (PRS)"," Elucidating the path to Plasmodium prolyl-tRNA synthetase inhibitors that overcome halofuginone resistance. MA Tye. 2022","Structure of prolyl-tRNA synthetase-halofuginone complex provides basis for development of drugs against malaria and toxoplasmosis. V Jain. 2015","Keller TL, Zocco D, Sundrud MS, Hendrick M, Edenius M, Yum J, Kim YJ, Lee HK, Cortese JF, Wirth DF et al.. (2012) Halofuginone and other febrifugine derivatives inhibit prolyl-tRNA synthetase. ",{"$nulls":4},"PF3D7_1213800",null,0.36,0.11,-0.31,null,null,1.5095069956043754,2.3943438818071816,10.0529514112602,"gct V enriched",null,0.6304470327232373,{"$f":"AC203/AB203","v":1.5861760752215235},null,"Detected",943089513.9350281,1304100000,503052280.12675816,2.592374692490004,null,"Essential"]
["MMV009952","(-)-Halofuginone",null,1.02,{"v":8.4,"d":"8.40"},null,7.64,null,{"v":8.23529411764706,"d":"8.24"},null,{"v":7.490196078431372,"d":"7.49"},null,"proline--tRNA ligase (aPRS)"," Elucidating the path to Plasmodium prolyl-tRNA synthetase inhibitors that overcome halofuginone resistance. MA Tye. 2022","Structure of prolyl-tRNA synthetase-halofuginone complex provides basis for development of drugs against malaria and toxoplasmosis. V Jain. 2015","Keller TL, Zocco D, Sundrud MS, Hendrick M, Edenius M, Yum J, Kim YJ, Lee HK, Cortese JF, Wirth DF et al.. (2012) Halofuginone and other febrifugine derivatives inhibit prolyl-tRNA synthetase. ",{"$nulls":4},"PF3D7_0925300",null,0.27,0.71,0.76,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV396797",null,null,{"v":477,"d":"477.00"},3934.38,{"v":1768.8999999999999,"d":"1768.90"},1431.09,null,{"v":8.248176100628932,"d":"8.25"},{"$f":"F205/D205","v":{"v":3.7083857442348007,"d":"3.71"}},{"v":3.0001886792452828,"d":"3.00"},null,"Thioredoxin Reductase (PfTrxR)","E.L. Allman, H.J. Painter, J. Samra, M. Carrasquilla, M. Llinas Metabolomic profiling of the malaria box reveals antimalarial target pathways 2016","Preliminary LC-MS Based Screening for Inhibitors of Plasmodium falciparum Thioredoxin Reductase (PfTrxR) among a Set of Antimalarials from the Malaria Box NK Tiwari","The Medicines for Malaria Venture Malaria Box contains inhibitors of protein secretion in Plasmodium falciparum blood stage parasites O Looker",{"$nulls":4},"PF3D7_0923800",null,0.25,0.12,0.31,null,null,0.2942965475215916,0.2694624621099895,3.77058269614393,"gct V enriched",null,1.0921615768561683,0.9156154374873183,null,"Not detected",{"$nulls":5},"Essential/Not essential"]
["MMV666021",null,null,{"v":94.39999999999999,"d":"94.40"},{"v":819,"d":"819.00"},{"v":603,"d":"603.00"},{"v":5000,"d":"5000.00"},null,{"v":8.67584745762712,"d":"8.68"},{"v":6.38771186440678,"d":"6.39"},{"v":52.96610169491526,"d":"52.97"},null,"Mitochondrial electron transport chain (bc1 inhibitor) (Gamo)","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond, van Voorhis 2016","The relative rate of kill of the MMV Malaria Box compounds provides links to the mode of antimalarial action and highlights scaffolds of medicinal chemistry interest I Ullah",{"$nulls":7},0.8483333333333333,0.9800000000000001,0.8099999999999999,"Average",null,0.4530828604879675,1.7006577915597767,7.360729507627478,"gct V enriched","Average",0.2664162436067856,3.7535248844508895,null,"Detected",692838621.0520334,545915000,215905094.41200727,2.528495223731227,null,"Essential/Non essential"]
["MMV020788",null,null,{"v":22.599999999999998,"d":"22.60"},{"v":197,"d":"197.00"},{"v":105,"d":"105.00"},null,null,{"v":8.716814159292037,"d":"8.72"},{"v":4.646017699115045,"d":"4.65"},null,null,"enoyl-acyl carrier reductase (ENR)","Metabolomics-based screening of the malaria box reveals both novel and established mechanisms of action DJ Creek","Prioritization of active antimalarials using structural interaction profile of Plasmodium falciparum enoyl-acyl carrier protein reductase (PfENR)-triclosan derivatives SP Kumar",{"$nulls":5},"PF3D7_0615100",null,0.62,2.1,1.53,null,null,0,0.7051256087078136,0.333521432163324,"gct I/II enriched",null,0.7,null,null,"Translationally repressed",{"$nulls":5},"Not essential","U"]
["MMV020788",null,null,{"v":22.599999999999998,"d":"22.60"},{"v":197,"d":"197.00"},{"v":105,"d":"105.00"},null,null,{"v":8.716814159292037,"d":"8.72"},{"v":4.646017699115045,"d":"4.65"},null,null,"acyl carrier protein (ACP)","Metabolomics-based screening of the malaria box reveals both novel and established mechanisms of action DJ Creek","Prioritization of active antimalarials using structural interaction profile of Plasmodium falciparum enoyl-acyl carrier protein reductase (PfENR)-triclosan derivatives SP Kumar",{"$nulls":5},"PF3D7_0208500",null,0.24,0.27,0.36,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["CLM13",null,null,{"v":19,"d":"19.00"},{"v":168,"d":"168.00"},{"v":845,"d":"845.00"},null,null,{"v":8.842105263157896,"d":"8.84"},{"v":44.473684210526315,"d":"44.47"},null,null,"PI4K","Identification of a potential antimalarial drug candidate from a series of 2-aminopyrazines by optimization of aqueous solubility and potency across the parasite life cycle Le Manach 2016",{"$nulls":6},"PF3D7_0509800",null,0.29,-0.01,0.16,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV011895","MMV011895",null,{"v":233,"d":"233.00"},{"v":2156,"d":"2156.00"},null,{"v":5000,"d":"5000.00"},null,{"v":9.253218884120171,"d":"9.25"},null,{"$f":"G210/D210","v":{"v":21.459227467811157,"d":"21.46"}},null,"chloroquine resistance transporter (CRT)","Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. Cowell. 2018","Identification of β-hematin inhibitors in the MMV Malaria Box KY Fong 2015","Characterization of Plasmodium falciparum 6-phosphogluconate dehydrogenase as an antimalarial drug target K Haeussler 2018",{"$nulls":4},"PF3D7_0709000",null,0.71,-0.13,-0.9,null,null,2.488931895417541,0.18392148688178012,0.584893192461114,"enriched troph",null,13.532578153945444,0.07389574910442682,null,"Detected",12619931.898450887,55641000,158501694.86890087,0.35104356484024674,null,"Essential","D"]
["MMV011895","MMV011895",null,{"v":233,"d":"233.00"},{"v":2156,"d":"2156.00"},null,{"v":5000,"d":"5000.00"},null,{"v":9.253218884120171,"d":"9.25"},null,{"$f":"G211/D211","v":{"v":21.459227467811157,"d":"21.46"}},null,"6-phosphogluconate dehydrogenase","Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. Cowell. 2018","Identification of β-hematin inhibitors in the MMV Malaria Box KY Fong 2015","Characterization of Plasmodium falciparum 6-phosphogluconate dehydrogenase as an antimalarial drug target K Haeussler 2018",{"$nulls":4},"PF3D7_1454700",null,0.29,0.18,-0.08,null,null,1.7176232460629302,5.869374848204267,16.4332882219999,"gct V enriched",null,0.29264159991220123,3.4171491691544245,null,"Detected",1936470222.4009511,2758600000,3486288340.423685,0.7912713265893406,null,"Essential"]
["MMV011895","MMV011895",null,{"v":233,"d":"233.00"},{"v":2156,"d":"2156.00"},null,{"v":5000,"d":"5000.00"},null,{"v":9.253218884120171,"d":"9.25"},null,{"$f":"G212/D212","v":{"v":21.459227467811157,"d":"21.46"}},null,"amino acid transporter AAT1","Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. Cowell. 2018","Identification of β-hematin inhibitors in the MMV Malaria Box KY Fong 2015","Characterization of Plasmodium falciparum 6-phosphogluconate dehydrogenase as an antimalarial drug target K Haeussler 2018",{"$nulls":4},"PF3D7_0629500",null,0.31,-0.31,-0.59,{"$nulls":6},"Not detected",{"$nulls":3},"Detected",3042923.6353463647,6972800,6511740.419343636,1.0708043550518,null,"Essential"]
["MMV000570",null,null,{"v":194,"d":"194.00"},{"v":1801,"d":"1801.00"},{"v":469,"d":"469.00"},null,null,{"v":9.283505154639176,"d":"9.28"},{"$f":"F213/D213","v":{"v":2.417525773195876,"d":"2.42"}},null,null,"phosphopantetheine adenylyltransferase (PPAT)","A novel approach for the discovery of chemically diverse anti-malarial compounds targeting the Plasmodium falciparum Coenzyme A synthesis pathway Sabine Fletcher 2014","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond, van Voorhis 2016",{"$nulls":5},"PF3D7_0704700",null,0.2,0.12,0.72,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Not essential"]
["MMV000570",null,null,{"v":194,"d":"194.00"},{"v":1801,"d":"1801.00"},{"v":469,"d":"469.00"},null,null,{"v":9.283505154639176,"d":"9.28"},{"v":2.417525773195876,"d":"2.42"},null,null,"phosphoethanolamine methyltransferase (PfPMT) ","A novel approach for the discovery of chemically diverse anti-malarial compounds targeting the Plasmodium falciparum Coenzyme A synthesis pathway Sabine Fletcher 2014","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond, van Voorhis 2016",{"$nulls":5},"PF3D7_1343000",null,0.77,1.48,0.61,null,null,336.4138014225539,83.2557979663136,10.5478198468946,"enriched troph",null,4.040725206413509,0.247480328138321,null,"Detected",114835488.61768718,1894500000,446647232.3754124,4.241602460905097,null,"Not essential/Essential","A"]
["MMV000570",null,null,{"v":194,"d":"194.00"},{"v":1801,"d":"1801.00"},{"v":469,"d":"469.00"},null,null,{"v":9.283505154639176,"d":"9.28"},{"v":2.417525773195876,"d":"2.42"},null,null,"pantothenate kinase 1","A novel approach for the discovery of chemically diverse anti-malarial compounds targeting the Plasmodium falciparum Coenzyme A synthesis pathway Sabine Fletcher 2014","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond, van Voorhis 2016",{"$nulls":5},"PF3D7_1420600",null,0.26,0.36,0.59,null,null,0.68726376397451,0,0,"enriched troph",null,1.4,0,null,"Detected",266001.2984578802,721950,3593539.8471956938,0.2009021830002501,null,"Essential"]
["MMV000570",null,null,{"v":194,"d":"194.00"},{"v":1801,"d":"1801.00"},{"v":469,"d":"469.00"},null,null,{"v":9.283505154639176,"d":"9.28"},{"v":2.417525773195876,"d":"2.42"},null,null,"pantothenate kinase 2","A novel approach for the discovery of chemically diverse anti-malarial compounds targeting the Plasmodium falciparum Coenzyme A synthesis pathway Sabine Fletcher 2014","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond, van Voorhis 2016",{"$nulls":5},"PF3D7_1437400",null,0.33,-0.07,-0.18,{"$nulls":6},"Not detected",{"$nulls":3},"Detected",1234946.8745992319,2466955.0532793016,1141968.171123459,2.1602660351315497,null,"Not essential"]
["MMV000570",null,null,{"v":194,"d":"194.00"},{"v":1801,"d":"1801.00"},{"v":469,"d":"469.00"},null,null,{"v":9.283505154639176,"d":"9.28"},{"v":2.417525773195876,"d":"2.42"},null,null,"phosphopantothenoylcysteine synthetase","A novel approach for the discovery of chemically diverse anti-malarial compounds targeting the Plasmodium falciparum Coenzyme A synthesis pathway Sabine Fletcher 2014","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond, van Voorhis 2016",{"$nulls":5},"PF3D7_0412300",null,0.72,-0.49,-0.31,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Not essential"]
["MMV000570",null,null,{"v":194,"d":"194.00"},{"v":1801,"d":"1801.00"},{"v":469,"d":"469.00"},null,null,{"v":9.283505154639176,"d":"9.28"},{"v":2.417525773195876,"d":"2.42"},null,null,"phosphopantothenoylcysteine decarboxylase","A novel approach for the discovery of chemically diverse anti-malarial compounds targeting the Plasmodium falciparum Coenzyme A synthesis pathway Sabine Fletcher 2014","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond, van Voorhis 2016",{"$nulls":5},"PF3D7_0816100",null,0.73,-0.05,0.35,null,null,0,2.1471274463127243,1.89426612471675,"gct I/II enriched",null,0.02,null,null,"Detected",61310952.05790817,26538000,43158638.24882792,0.6148942848242137,null,"Essential"]
["MMV000570",null,null,{"v":194,"d":"194.00"},{"v":1801,"d":"1801.00"},{"v":469,"d":"469.00"},null,null,{"v":9.283505154639176,"d":"9.28"},{"v":2.417525773195876,"d":"2.42"},null,null,"dephospho-CoA kinase","A novel approach for the discovery of chemically diverse anti-malarial compounds targeting the Plasmodium falciparum Coenzyme A synthesis pathway Sabine Fletcher 2014","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond, van Voorhis 2016",{"$nulls":5},"PF3D7_1443700",null,0.27,0.6,0.55,{"$nulls":6},"Not detected",{"$nulls":3},"Detected",600796.7779038273,3685300,5879231.533252301,0.626833622584234,null,"Essential"]
["MMV007384",null,null,{"v":100,"d":"100.00"},{"v":949,"d":"949.00"},{"v":1113.5,"d":"1113.50"},{"v":870,"d":"870.00"},null,9.49,{"v":11.135,"d":"11.14"},{"$f":"G220/D220","v":{"v":8.7,"d":"8.70"}},null,"6-phosphogluconate dehydrogenase","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond, van Voorhis 2016","New insights into novel inhibitors against deoxyhypusine hydroxylase from Plasmodium falciparum: compounds with an iron chelating potential I von Koschitzky","Identification of β-hematin inhibitors in the MMV Malaria Box KY Fong","Characterization of Plasmodium falciparum 6-phosphogluconate dehydrogenase as an antimalarial drug target K Haeussler,","Bilayer Effects of Antimalarial Compounds Nicole B. Ramsey",null,null,"PF3D7_1454700",null,0.29,0.18,-0.08,null,null,1.7176232460629302,5.869374848204267,16.4332882219999,"gct V enriched",null,0.29264159991220123,3.4171491691544245,null,"Detected",1936470222.4009511,2758600000,3486288340.423685,0.7912713265893406,null,"Essential"]
["MMV007384",null,null,{"v":100,"d":"100.00"},{"v":949,"d":"949.00"},{"v":1113.5,"d":"1113.50"},{"v":870,"d":"870.00"},null,9.49,{"v":11.135,"d":"11.14"},{"v":8.7,"d":"8.70"},null,"cysteine protease","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond, van Voorhis 2016","New insights into novel inhibitors against deoxyhypusine hydroxylase from Plasmodium falciparum: compounds with an iron chelating potential I von Koschitzky","Identification of β-hematin inhibitors in the MMV Malaria Box KY Fong","Characterization of Plasmodium falciparum 6-phosphogluconate dehydrogenase as an antimalarial drug target K Haeussler,","Bilayer Effects of Antimalarial Compounds Nicole B. Ramsey",{"$nulls":4},0.8683333333333333,0.2925,0.5025000000000001,"Average",null,0.798641256081183,0.19433860091901342,0.31856282249165724,"enriched troph","Average",4.109534864944305,0.24333654120575338,null,"Detected",57370296.82134489,79529333.33333333,145189284.43913874,0.5477631055249872,null,"Essential/Non essential","S U"]
["MMV007384",null,null,{"v":100,"d":"100.00"},{"v":949,"d":"949.00"},{"v":1113.5,"d":"1113.50"},{"v":870,"d":"870.00"},null,9.49,{"v":11.135,"d":"11.14"},{"v":8.7,"d":"8.70"},null,"Hsp90","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond, van Voorhis 2016","New insights into novel inhibitors against deoxyhypusine hydroxylase from Plasmodium falciparum: compounds with an iron chelating potential I von Koschitzky","Identification of β-hematin inhibitors in the MMV Malaria Box KY Fong","Characterization of Plasmodium falciparum 6-phosphogluconate dehydrogenase as an antimalarial drug target K Haeussler,","Bilayer Effects of Antimalarial Compounds Nicole B. Ramsey",null,null,"PF3D7_0708400",null,0.47,0.14,-0.37,null,null,391.244342138169,487.5030361563116,2642.7611857491,"gct V enriched",null,0.8025474984174693,1.2460321687774047,null,"Detected",28102267024.51306,93040000000,24304490388.95642,3.8280991911797466,null,"Essential"]
["MMV007384",null,null,{"v":100,"d":"100.00"},{"v":949,"d":"949.00"},{"v":1113.5,"d":"1113.50"},{"v":870,"d":"870.00"},null,9.49,{"v":11.135,"d":"11.14"},{"v":8.7,"d":"8.70"},null,"phosphoethanolamine methyltransferase (PfPMT) ","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond, van Voorhis 2016","New insights into novel inhibitors against deoxyhypusine hydroxylase from Plasmodium falciparum: compounds with an iron chelating potential I von Koschitzky","Identification of β-hematin inhibitors in the MMV Malaria Box KY Fong","Characterization of Plasmodium falciparum 6-phosphogluconate dehydrogenase as an antimalarial drug target K Haeussler,","Bilayer Effects of Antimalarial Compounds Nicole B. Ramsey",null,null,"PF3D7_1343000",null,0.77,1.48,0.61,null,null,336.4138014225539,83.2557979663136,10.5478198468946,"enriched troph",null,4.040725206413509,0.247480328138321,null,"Detected",114835488.61768718,1894500000,446647232.3754124,4.241602460905097,null,"Not essential Essential","A"]
["MMV007384",null,null,{"v":100,"d":"100.00"},{"v":949,"d":"949.00"},{"v":1113.5,"d":"1113.50"},{"v":870,"d":"870.00"},null,9.49,{"v":11.135,"d":"11.14"},{"v":8.7,"d":"8.70"},null,"deoxyhypusine hydroxylase (DOHH)","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond, van Voorhis 2016","New insights into novel inhibitors against deoxyhypusine hydroxylase from Plasmodium falciparum: compounds with an iron chelating potential I von Koschitzky","Identification of β-hematin inhibitors in the MMV Malaria Box KY Fong","Characterization of Plasmodium falciparum 6-phosphogluconate dehydrogenase as an antimalarial drug target K Haeussler,","Bilayer Effects of Antimalarial Compounds Nicole B. Ramsey",null,null,"PF3D7_1302600",null,0.46,-0.08,-0.12,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV1576861",null,null,519.35,{"v":5000,"d":"5000.00"},null,{"v":5000,"d":"5000.00"},null,{"v":9.62741888899586,"d":"9.63"},null,{"$f":"G225/D225","v":{"v":9.62741888899586,"d":"9.63"}},null,"Plasmepsin IX (PMIX)","Pino P, Caldelari R, Mukherjee B, Vahokoski J, Klages N, Maco B, Collins CR, Blackman MJ, Kursula I, Heussler V et al.. (2017) A multistage antimalarial targets the plasmepsins IX and X essential for invasion and egress. ","C.-L. Ciana, Novel in vivo active anti-malarials based on a hydroxy-ethyl-amine scaffold. 2013","W.A. Guiguemde, A.A. Shelat, D. Bouck, S. Duffy, G.J. Crowther, P.H. Davis, D.C. Smithson, M. Connelly, J. Clark, F. Zhu, M.B. Jiménez-Díaz, M.S. Martinez, E.B. Wilson, A.K. Tripathi, J. Gut, E.R. Sharlow. Chemical genetics of Plasmodium falciparum. 2010",{"$nulls":4},"PF3D7_1430200",null,0.33,1.1,0.72,{"$nulls":6},"Not detected",{"$nulls":3},"Translationally repressed",{"$nulls":5},"Essential","I"]
["MMV1576861",null,null,519.35,{"v":5000,"d":"5000.00"},null,{"v":5000,"d":"5000.00"},null,{"v":9.62741888899586,"d":"9.63"},null,{"$f":"G226/D226","v":{"v":9.62741888899586,"d":"9.63"}},null,"plasmepsin X (PMX)","Pino P, Caldelari R, Mukherjee B, Vahokoski J, Klages N, Maco B, Collins CR, Blackman MJ, Kursula I, Heussler V et al.. (2017) A multistage antimalarial targets the plasmepsins IX and X essential for invasion and egress. ","C.-L. Ciana, Novel in vivo active anti-malarials based on a hydroxy-ethyl-amine scaffold. 2013","W.A. Guiguemde, A.A. Shelat, D. Bouck, S. Duffy, G.J. Crowther, P.H. Davis, D.C. Smithson, M. Connelly, J. Clark, F. Zhu, M.B. Jiménez-Díaz, M.S. Martinez, E.B. Wilson, A.K. Tripathi, J. Gut, E.R. Sharlow. Chemical genetics of Plasmodium falciparum. 2010",{"$nulls":4},"PF3D7_0808200",null,1.26,-0.79,0.17,null,null,0,0,0.99526231496888,"gct V enriched",null,1,null,null,"Detected",90439310.2773018,149530000,3295189.911008856,45.37826469437687,null,"Essential/Not essential","D I"]
["MMV390048",null,null,22.12,{"v":214,"d":"214.00"},{"v":140.3,"d":"140.30"},{"v":897,"d":"897.00"},null,{"v":9.674502712477395,"d":"9.67"},{"$f":"F227/D227","v":{"v":6.342676311030742,"d":"6.34"}},{"$f":"G227/D227","v":{"v":40.55153707052441,"d":"40.55"}},null,"PI4K"," Potent Plasmodium falciparum gametocytocidal compounds identified by exploring the kinase inhibitor chemical space for dual active antimalarials Mariëtte E van der Watt, ","Younis Y, Douelle F, Feng TS, Gonzalez Cabrera D, Le Manach C, Nchinda AT, Duffy S, White KL, Shackleford DM, Morizzi J, Mannila J, Katneni K, Bhamidipati R, Zabiulla KM, Joseph JT, Bashyam S, Waterson D, Witty MJ, Hardick D, Wittlin S, Avery V, Charman SA, Chibale K. 2012. 3,5-Diaryl-2-aminopyridines as a novel class of orally active antimalarials demonstrating single dose cure in mice and clinical candidate potential. J Med Chem 55:3479–3487.","Paquet T, Le Manach C, Cabrera DG, Younis Y, Henrich PP, Abraham TS, Lee MCS, Basak R, Ghidelli-Disse S, Lafuente-Monasterio MJ et al.. (2017)\nAntimalarial efficacy of MMV390048, an inhibitor of Plasmodium phosphatidylinositol 4-kinase. ",{"$nulls":4},"PF3D7_0509800",null,0.29,-0.01,0.16,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV390048",null,null,22.12,{"v":214,"d":"214.00"},{"v":140.3,"d":"140.30"},{"v":897,"d":"897.00"},null,{"v":9.674502712477395,"d":"9.67"},{"v":6.342676311030742,"d":"6.34"},{"$f":"G228/D228","v":{"v":40.55153707052441,"d":"40.55"}},null,"PI3K"," Potent Plasmodium falciparum gametocytocidal compounds identified by exploring the kinase inhibitor chemical space for dual active antimalarials Mariëtte E van der Watt, ","Younis Y, Douelle F, Feng TS, Gonzalez Cabrera D, Le Manach C, Nchinda AT, Duffy S, White KL, Shackleford DM, Morizzi J, Mannila J, Katneni K, Bhamidipati R, Zabiulla KM, Joseph JT, Bashyam S, Waterson D, Witty MJ, Hardick D, Wittlin S, Avery V, Charman SA, Chibale K. 2012. 3,5-Diaryl-2-aminopyridines as a novel class of orally active antimalarials demonstrating single dose cure in mice and clinical candidate potential. J Med Chem 55:3479–3487.","Paquet T, Le Manach C, Cabrera DG, Younis Y, Henrich PP, Abraham TS, Lee MCS, Basak R, Ghidelli-Disse S, Lafuente-Monasterio MJ et al.. (2017)\nAntimalarial efficacy of MMV390048, an inhibitor of Plasmodium phosphatidylinositol 4-kinase. ",{"$nulls":4},"PF3D7_0515300",null,0.56,0.18,0.29,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV390048",null,null,22.12,{"v":214,"d":"214.00"},{"v":140.3,"d":"140.30"},{"v":897,"d":"897.00"},null,{"v":9.674502712477395,"d":"9.67"},{"v":6.342676311030742,"d":"6.34"},{"$f":"G229/D229","v":{"v":40.55153707052441,"d":"40.55"}},null,"PKG"," Potent Plasmodium falciparum gametocytocidal compounds identified by exploring the kinase inhibitor chemical space for dual active antimalarials Mariëtte E van der Watt, ","Younis Y, Douelle F, Feng TS, Gonzalez Cabrera D, Le Manach C, Nchinda AT, Duffy S, White KL, Shackleford DM, Morizzi J, Mannila J, Katneni K, Bhamidipati R, Zabiulla KM, Joseph JT, Bashyam S, Waterson D, Witty MJ, Hardick D, Wittlin S, Avery V, Charman SA, Chibale K. 2012. 3,5-Diaryl-2-aminopyridines as a novel class of orally active antimalarials demonstrating single dose cure in mice and clinical candidate potential. J Med Chem 55:3479–3487.","Paquet T, Le Manach C, Cabrera DG, Younis Y, Henrich PP, Abraham TS, Lee MCS, Basak R, Ghidelli-Disse S, Lafuente-Monasterio MJ et al.. (2017)\nAntimalarial efficacy of MMV390048, an inhibitor of Plasmodium phosphatidylinositol 4-kinase. ",{"$nulls":4},"PF3D7_1436600",null,0.47,-0.44,0.1,null,null,0,0.068244893498124,2.02530545710245,"gct V enriched",null,0.8,null,null,"Detected",187255751.4074903,109730000,295371702.85639864,0.37149801060444715,null,"Essential"]
["MMV001246",null,null,{"v":206,"d":"206.00"},{"v":2000,"d":"2000.00"},{"v":781,"d":"781.00"},null,null,{"v":9.70873786407767,"d":"9.71"},{"v":3.79126213592233,"d":"3.79"},null,null,"autophagy-related protein 8 (ATG8)","Characterization of Plasmodium Atg3-Atg8 interaction inhibitors identifies novel alternative mechanisms of action in Toxoplasma gondii JM Varberg 2018","Open Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and Beyond Wesley C. Van Open source drug discovery with the malaria box compound collection for neglected diseases and beyond, van Voorhis 2016",{"$nulls":5},"PF3D7_1019900",null,0.69,-0.17,1.04,null,null,0,1.1731201409058445,1.37137370566166,"gct V enriched",null,0.03,null,null,"Not detected",{"$nulls":5},"Essential","A"]
["MMV001246",null,null,{"v":206,"d":"206.00"},{"v":2000,"d":"2000.00"},{"v":781,"d":"781.00"},null,null,{"v":9.70873786407767,"d":"9.71"},{"v":3.79126213592233,"d":"3.79"},null,null,"autophagy-related protein 3 (ATG3)","Characterization of Plasmodium Atg3-Atg8 interaction inhibitors identifies novel alternative mechanisms of action in Toxoplasma gondii JM Varberg 2018","Open Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and Beyond Wesley C. Van Open source drug discovery with the malaria box compound collection for neglected diseases and beyond, van Voorhis 2016",{"$nulls":5},"PF3D7_0905700",null,0.33,0.45,0.09,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential (ortholog)"]
["MMV665943",null,null,{"v":190,"d":"190.00"},{"v":2000,"d":"2000.00"},{"v":1099,"d":"1099.00"},{"v":570,"d":"570.00"},null,{"v":10.526315789473685,"d":"10.53"},{"v":5.78421052631579,"d":"5.78"},{"$f":"G232/D232","v":{"v":3,"d":"3.00"}},null,"Cysteine protease","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond, van Voorhis 2016",{"$nulls":8},0.8683333333333333,0.2925,0.5025000000000001,"Average",null,0.798641256081183,0.19433860091901342,0.31856282249165724,"enriched troph","Average",4.109534864944305,0.24333654120575338,null,"Detected",57370296.82134489,79529333.33333333,145189284.43913874,0.5477631055249872,null,"Essential/Non essential","S U"]
["MMV1645159",null,null,388.83,{"v":4379,"d":"4379.00"},null,{"v":5000,"d":"5000.00"},null,{"v":11.261991101509658,"d":"11.26"},null,{"$f":"G233/D233","v":{"v":12.859090090785177,"d":"12.86"}},null,"Plasmepsin V (PMV)","Provided from MMV",{"$nulls":6},"PF3D7_1323500",null,0.44,-0.25,-0.59,null,null,0.5122019514535665,0.3395699984187145,0.311133937421564,"enriched troph",null,1.5083839969336286,0.6629611571276844,null,"Detected",15395138.5844669,16127000,287542.8694651849,56.08555006074537,null,"Essential","S"]
["KS45",null,null,{"v":110,"d":"110.00"},{"v":1260,"d":"1260.00"},{"v":590,"d":"590.00"},null,null,{"v":11.454545454545455,"d":"11.45"},{"$f":"F234/D234","v":{"v":5.363636363636363,"d":"5.36"}},null,null,"cytochrome b","Antimalarial pyrido [1,2-a] benzimidazoles: Lead optimization, parasite life cycle stage profile, mechanistic evaluation, killing kinetics, and in vivo oral efficacy in a mouse model Singh 2017",{"$nulls":8},0.8483333333333333,0.9800000000000001,0.8099999999999999,"Average",null,0.4530828604879675,1.7006577915597767,7.360729507627478,"gct V enriched","Average",0.2664162436067856,3.7535248844508895,null,"Detected",692838621.0520334,545915000,215905094.41200727,2.528495223731227,null,"Essential/Non essential"]
["MMV687815","BRD7929",null,1.07,12.45,null,{"v":5000,"d":"5000.00"},null,{"v":11.635514018691588,"d":"11.64"},null,{"$f":"G235/D235","v":{"v":4672.8971962616815,"d":"4672.90"}},null,"phenylalanine-tRNA synthetase (PheRS/FRS)","Inhibition of Plasmodium falciparum phenylalanine tRNA synthetase provides opportunity for antimalarial drug development. Sharma. 2022","Novel antimalarial target identified. Crunkhorn. 2016","Kato N, Comer E, Sakata-Kato T, Sharma A, Sharma M, Maetani M, Bastien J, Brancucci NM, Bittker JA, Corey V et al.. (2016) Diversity-oriented synthesis yields novel multistage antimalarial inhibitors. ",{"$nulls":6},0.355,0.16,0.027500000000000004,"Average",null,1.265931292439404,1.2517532609494102,2.85076926040999,"gct V enriched","Average",1.011326538489894,0.988800315171392,null,"Detected",299187830.85638356,277380000,216855174.24900156,1.2791025206597169,null,"Essential"]
["CLM-18",null,null,{"v":8,"d":"8.00"},{"v":94,"d":"94.00"},{"v":66,"d":"66.00"},null,null,11.75,{"$f":"F236/D236","v":8.25},null,null,"PK7","A novel pyrazolopyridine with in vivo activity in Plasmodium berghei-and Plasmodium falciparum-infected mouse models from structure–activity relationship studies around the core of recently identified antimalarial imidazopyridazines Le Manach 2015",{"$nulls":6},"PF3D7_0213400",null,0.31,0.27,-0.31,null,null,0.2246523050636276,0,0.136463666385725,"not determined",null,1.2,0,null,"Not detected",{"$nulls":5},"Not essential","A D"]
["KDU691","KDU691",null,{"v":29.9,"d":"29.90"},353.75,{"v":220.4,"d":"220.40"},{"v":149.85999999999999,"d":"149.86"},null,{"v":11.831103678929766,"d":"11.83"},{"v":7.37123745819398,"d":"7.37"},{"$f":"G237/D237","v":{"v":5.012040133779264,"d":"5.01"}},null,"PI4K","McNamara CW, et al. Targeting Plasmodium PI(4)K to eliminate malaria. Nature. 2013;504:248–253.",{"$nulls":6},"PF3D7_0509800",null,0.29,-0.01,0.16,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV674766",null,null,7.86,{"v":93.89999999999999,"d":"93.90"},{"v":66.4,"d":"66.40"},{"v":262.90000000000003,"d":"262.90"},null,{"v":11.946564885496182,"d":"11.95"},{"v":8.447837150127226,"d":"8.45"},{"v":33.44783715012723,"d":"33.45"},null,"CDPK1","Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): preparation and evaluation of pyrazole … JM Large","Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) TM Chapman","New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of Plasmodium Phosphatidylinositol-4-kinase and cGMP … PM Cheuka",{"$nulls":4},"PF3D7_0217500",null,0.54,-0.07,0.86,null,null,1.8276642121903912,0.8228906159046369,5.07832312829723,"shared 3 stages",null,2.2210293529488925,0.4502416857626333,null,"Detected",1326801430.219953,360430000,3411452182.6706023,0.10565295384496434,null,"Essential","I S","A"]
["MMV674766",null,null,7.86,{"v":93.89999999999999,"d":"93.90"},{"v":66.4,"d":"66.40"},{"v":262.90000000000003,"d":"262.90"},null,{"v":11.946564885496182,"d":"11.95"},{"v":8.447837150127226,"d":"8.45"},{"v":33.44783715012723,"d":"33.45"},null,"PI4K","Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): preparation and evaluation of pyrazole … JM Large","Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) TM Chapman","New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of Plasmodium Phosphatidylinositol-4-kinase and cGMP … PM Cheuka",{"$nulls":4},"PF3D7_0509800",null,0.29,-0.01,0.16,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV674766",null,null,7.86,{"v":93.89999999999999,"d":"93.90"},{"v":66.4,"d":"66.40"},{"v":262.90000000000003,"d":"262.90"},null,{"v":11.946564885496182,"d":"11.95"},{"v":8.447837150127226,"d":"8.45"},{"v":33.44783715012723,"d":"33.45"},null,"PKG","Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): preparation and evaluation of pyrazole … JM Large","Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) TM Chapman","New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of Plasmodium Phosphatidylinositol-4-kinase and cGMP … PM Cheuka",{"$nulls":4},"PF3D7_1436600",null,0.47,-0.44,0.1,null,null,0,0.068244893498124,2.02530545710245,"gct V enriched",null,0.8,null,null,"Detected",187255751.4074903,109730000,295371702.85639864,0.37149801060444715,null,"Essential"]
["MMV674766",null,null,7.86,{"v":93.89999999999999,"d":"93.90"},{"v":66.4,"d":"66.40"},{"v":262.90000000000003,"d":"262.90"},null,{"v":11.946564885496182,"d":"11.95"},{"v":8.447837150127226,"d":"8.45"},{"v":33.44783715012723,"d":"33.45"},null,"PK7","Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): preparation and evaluation of pyrazole … JM Large","Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) TM Chapman","New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of Plasmodium Phosphatidylinositol-4-kinase and cGMP … PM Cheuka",{"$nulls":4},"PF3D7_0213400",null,0.31,0.27,-0.31,null,null,0.2246523050636276,0,0.136463666385725,"not determined",null,1.2,0,null,"Not detected",{"$nulls":5},"Not essential","A D"]
["MMV693183","MMV183",null,{"v":9.4,"d":"9.40"},{"v":113,"d":"113.00"},null,{"v":26.2,"d":"26.20"},null,{"v":12.02127659574468,"d":"12.02"},null,{"v":2.7872340425531914,"d":"2.79"},null,"acetyl-CoA synthetase (ACAS)","Preclinical characterization and target validation of the antimalarial pantothenamide MMV693183. LE de Vries. 2022",{"$nulls":6},"PF3D7_0627800",null,0.29,-0.51,-0.45,null,null,0.5239278103274543,0.22331568211144429,0.148153621496883,"enriched troph",null,2.3461308465833195,0.42623368660631367,null,"Detected",7752479.546805608,5327800,13142844.217746137,{"$f":"AL242/AM242","v":0.40537648561687534},null,"Essential","A"]
["MMV668434",null,null,42.54,{"v":513.7,"d":"513.70"},{"v":5000,"d":"5000.00"},null,null,{"v":12.075693464974144,"d":"12.08"},{"$f":"F243/D243","v":{"v":117.53643629525153,"d":"117.54"}},null,null,"DHFR-TS","Rosowsky A., Chen K. K., Lin M.: 2,4-Diaminothieno(2,3-d)pyrimidines as antifolates and antimalarials.",{"$nulls":6},"PF3D7_0417200",null,0.11,0.52,0.13,null,null,1.15443469003188,0.6407679530676047,10.9377664171444,"gct V enriched",null,1.8016423644552657,0.5550491150347446,null,"Detected",3107354809.595412,901370000,1885999900.5903804,0.47792685445945216,null,"Essential","A"]
["MMV007839",null,null,413.15,{"v":5000,"d":"5000.00"},null,{"v":5000,"d":"5000.00"},null,{"v":12.10214207914801,"d":"12.10"},null,{"$f":"G244/D244","v":{"v":12.10214207914801,"d":"12.10"}},null,"formate nitrite transporter (PfFNT)"," Substrate-analogous inhibitors exert antimalarial action by targeting the Plasmodium lactate transporter PfFNT at nanomolar scale. A Golldack. 2017","Structural characterization of the Plasmodium falciparum lactate transporter PfFNT alone and in complex with antimalarial compound MMV007839 reveals its inhibition mechanism.    Xi Peng. 2021","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond, van Voorhis 2016",{"$nulls":4},"PF3D7_0316600",null,0.56,-0.12,-0.52,null,null,2.488931895417541,1.2779853366148883,1.51188643150958,"enriched troph",null,1.9475433904509365,0.5134673789057191,null,"Detected",102868352.44955763,394100000,150216472.08716792,2.6235471684577365,null,"Not essential"]
["MMV007839",null,null,413.15,{"v":5000,"d":"5000.00"},null,{"v":5000,"d":"5000.00"},null,{"v":12.10214207914801,"d":"12.10"},null,{"$f":"G245/D245","v":{"v":12.10214207914801,"d":"12.10"}},null,"PKG"," Substrate-analogous inhibitors exert antimalarial action by targeting the Plasmodium lactate transporter PfFNT at nanomolar scale. A Golldack. 2017","Structural characterization of the Plasmodium falciparum lactate transporter PfFNT alone and in complex with antimalarial compound MMV007839 reveals its inhibition mechanism.    Xi Peng. 2021","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond, van Voorhis 2016",{"$nulls":4},"PF3D7_1436600",null,0.47,-0.44,0.1,null,null,0,0.068244893498124,2.02530545710245,"gct V enriched",null,0.8,null,null,"Detected",187255751.4074903,109730000,295371702.85639864,0.37149801060444715,null,"Essential"]
["MMV006587",null,null,{"v":108.89999999999999,"d":"108.90"},{"v":1360,"d":"1360.00"},{"v":5000,"d":"5000.00"},null,null,{"v":12.488521579430671,"d":"12.49"},{"$f":"F246/D246","v":{"v":45.91368227731864,"d":"45.91"}},null,null,"Saglin (thrombospondin-related anonymous protein?)","Transcriptome Analysis of Uninfected and Plasmodium vivax-infected Anopheles dirus at Ookinete and Oocyst Stages and Targeting Anopheles Carboxypeptidase B T Boonkaew Thesis",{"$nulls":6},"PF3D7_1335900",null,0.82,0.91,0.81,{"$nulls":6},"Not detected",{"$nulls":3},"Translationally repressed",{"$nulls":5},"Not essential"]
["MMV665969",null,null,{"v":393,"d":"393.00"},{"v":5000,"d":"5000.00"},{"v":1881,"d":"1881.00"},{"v":5000,"d":"5000.00"},null,{"v":12.72264631043257,"d":"12.72"},{"$f":"F247/D247","v":{"v":4.786259541984733,"d":"4.79"}},{"$f":"G247/D247","v":{"v":12.72264631043257,"d":"12.72"}},null,"DHFR-TS","MMV Malaria Box Activity Screening in Dormant Plasmodium falciparum Phenotypes S Galusic",{"$nulls":6},"PF3D7_0417200",null,0.11,0.52,0.13,null,null,1.15443469003188,0.6407679530676047,10.9377664171444,"gct V enriched",null,1.8016423644552657,0.5550491150347446,null,"Detected",3107354809.595412,901370000,1885999900.5903804,0.47792685445945216,null,"Essential","A"]
["MMV000054","Quinine",null,29.25,374.94,{"v":1000,"d":"1000.00"},{"v":5000,"d":"5000.00"},null,{"v":12.818461538461538,"d":"12.82"},{"$f":"F248/D248","v":{"v":34.18803418803419,"d":"34.19"}},{"$f":"G248/D248","v":{"v":170.94017094017093,"d":"170.94"}},null,"purine nucleoside phosphorylase (PNP)","A. F. Cowman, D. Galatis, J. K. Thompson, Selection for mefloquine resistance in Plasmodium falciparum is linked to amplification of the pfmdr1 gene and cross-resistance to halofantrine and quinine. Proc. Natl. Acad. Sci. U.S.A. 91, 1143–1147 (1994).","K. N. Olafson, T. Q. Nguyen, J. D. Rimer, P. G. Vekilov, Antimalarials inhibit hematin crystallization by unique drug–surface site interactions. Proc. Natl. Acad. Sci. U.S.A. 114, 7531–7536 (2017).","M. W. Davidson, B. G. Griggs, D. W. Boykin, W. D. Wilson, Molecular structural effects involved in the interaction of quinolinemethanolamines with DNA. Implications for antimalarial action. J. Med. Chem. 20, 1117–1122 (1977).","Identifying purine nucleoside phosphorylase as the target of quinine using cellular thermal shift assay Jerzy M. Dziekan 2020",{"$nulls":3},"PF3D7_0513300",null,0.88,0.31,-0.78,null,null,59.71899427057608,106.97270748410696,226.584592607479,"gct V enriched",null,0.5582638382734081,1.7912677330002036,null,"Detected",3876334039.934259,5361900000,1379349165.6537595,3.887268092454793,null,"Not essential"]
["MMV000004","Artenimol (DHA)",null,1.45,{"v":20.5,"d":"20.50"},null,{"v":2103.3,"d":"2103.30"},null,{"v":14.13793103448276,"d":"14.14"},null,{"$f":"G249/D249","v":{"v":1450.5517241379312,"d":"1450.55"}},null,"PI3K","Wang J, Zhang CJ, Chia WN, Loh CCY, Li Z, Lee YM, et al. Haem-activated promiscuous targeting of artemisinin in Plasmodium falciparum. Nat Commun. 2015;6:10111.","Tilley L, Straimer J, Gnädig NF, Ralph SA, Fidock DA. Artemisinin action and resistance in Plasmodium falciparum. Trends Parasitol. 2016;32:682–96."," High-throughput assay and discovery of small molecules that interrupt malaria transmission DM Plouffe 2016","Antimalarial and anticancer properties of artesunate and other artemisinins: current development P Khanal 2021","Coertzen, D., Reader, J., van der Watt, M., Nondaba, S. H., Gibhard, L., Wiesner, L., et al. (2018). Artemisone and Artemiside Are Potent Panreactive Antimalarial Agents That Also Synergize Redox Imbalance in Plasmodium Falciparum Transmissible Gametocyte Stages. Antimicrob. Agents Chemother. 62, 1–17. doi: 10.1128/AAC.02214-17","Klonis, N., Crespo-Ortiz, M. P., Bottova, I., Abu-Bakar, N., Kenny, S., Rosenthal, P. J., et al. (2011). Artemisinin Activity Against Plasmodium Falciparum Requires Hemoglobin Uptake and Digestion. Proc. Natl. Acad. Sci. U.S.A. 108, 11405–11410. doi: 10.1073/pnas.1104063108",null,"PF3D7_0515300",null,0.56,0.18,0.29,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV000004","Artenimol (DHA)",null,1.45,{"v":20.5,"d":"20.50"},null,{"v":2103.3,"d":"2103.30"},null,{"v":14.13793103448276,"d":"14.14"},null,{"v":1450.5517241379312,"d":"1450.55"},null,"proteosome","Wang J, Zhang CJ, Chia WN, Loh CCY, Li Z, Lee YM, et al. Haem-activated promiscuous targeting of artemisinin in Plasmodium falciparum. Nat Commun. 2015;6:10111.","Tilley L, Straimer J, Gnädig NF, Ralph SA, Fidock DA. Artemisinin action and resistance in Plasmodium falciparum. Trends Parasitol. 2016;32:682–96."," High-throughput assay and discovery of small molecules that interrupt malaria transmission DM Plouffe 2016","Antimalarial and anticancer properties of artesunate and other artemisinins: current development P Khanal 2021","Coertzen, D., Reader, J., van der Watt, M., Nondaba, S. H., Gibhard, L., Wiesner, L., et al. (2018). Artemisone and Artemiside Are Potent Panreactive Antimalarial Agents That Also Synergize Redox Imbalance in Plasmodium Falciparum Transmissible Gametocyte Stages. Antimicrob. Agents Chemother. 62, 1–17. doi: 10.1128/AAC.02214-17","Klonis, N., Crespo-Ortiz, M. P., Bottova, I., Abu-Bakar, N., Kenny, S., Rosenthal, P. J., et al. (2011). Artemisinin Activity Against Plasmodium Falciparum Requires Hemoglobin Uptake and Digestion. Proc. Natl. Acad. Sci. U.S.A. 108, 11405–11410. doi: 10.1073/pnas.1104063108",{"$nulls":3},0.41428571428571426,0.2892857142857143,0.11928571428571429,"Average",null,4.371904224875087,14.744723143961812,53.195817261465585,"gct V enriched","Average",0.296506362458589,3.372608910338857,null,"Detected",1385888365.4679062,3846228571.428571,1162706304.4179296,3.307996659873671,null,"Essential/Non essential"]
["MMV007116",null,null,{"v":351,"d":"351.00"},{"v":5000,"d":"5000.00"},{"v":253,"d":"253.00"},{"v":5000,"d":"5000.00"},null,{"v":14.245014245014245,"d":"14.25"},{"$f":"F251/D251","v":{"v":0.7207977207977208,"d":"0.72"}},{"v":14.245014245014245,"d":"14.25"},null,"Mitochondrial electron transport chain (bc1 inhibitor)","E.L. Allman, H.J. Painter, J. Samra, M. Carrasquilla, M. Llinas Metabolomic profiling of the malaria box reveals antimalarial target pathways 2016","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond, van Voorhis 2016","Metabolomics-based screening of the malaria box reveals both novel and established mechanisms of action DJ Creek",{"$nulls":6},0.8483333333333333,0.9800000000000001,0.8099999999999999,"Average",null,0.4530828604879675,1.7006577915597767,7.360729507627478,"gct V enriched","Average",0.2664162436067856,3.7535248844508895,null,"Detected",692838621.0520334,545915000,215905094.41200727,2.528495223731227,null,"Essential/Non essential"]
["CLM9i",null,null,{"v":22,"d":"22.00"},{"v":323,"d":"323.00"},{"v":137,"d":"137.00"},null,null,{"v":14.681818181818182,"d":"14.68"},{"v":6.2272727272727275,"d":"6.23"},null,null,"PI4K","Identification of a potential antimalarial drug candidate from a series of 2-aminopyrazines by optimization of aqueous solubility and potency across the parasite life cycle Le Manach 2016",{"$nulls":6},"PF3D7_0509800",null,0.29,-0.01,0.16,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV668808",null,null,{"v":93.75999999999999,"d":"93.76"},{"v":1390,"d":"1390.00"},{"v":342.2,"d":"342.20"},null,null,{"v":14.825085324232083,"d":"14.83"},{"v":3.6497440273037545,"d":"3.65"},null,null,"PI4K"," Potent Plasmodium falciparum gametocytocidal compounds identified by exploring the kinase inhibitor chemical space for dual active antimalarials Mariëtte E van der Watt, ",{"$nulls":6},"PF3D7_0509800",null,0.29,-0.01,0.16,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV007127",null,null,{"v":337,"d":"337.00"},{"v":5000,"d":"5000.00"},{"v":875,"d":"875.00"},null,null,{"v":14.836795252225519,"d":"14.84"},{"v":2.5964391691394657,"d":"2.60"},null,null,"BC-1 inhibitor","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond, van Voorhis 2016",{"$nulls":8},0.8483333333333333,0.9800000000000001,0.8099999999999999,"Average",null,0.4530828604879675,1.7006577915597767,7.360729507627478,"gct V enriched","Average",0.2664162436067856,3.7535248844508895,null,"Detected",692838621.0520334,545915000,215905094.41200727,2.528495223731227,null,"Essential/Non essential"]
["Decoquinate","Decoquinate",null,{"v":2.4,"d":"2.40"},{"v":36,"d":"36.00"},{"$nulls":3},{"v":15,"d":"15.00"},{"$nulls":3},"cytochrome bc1 complex. "," Drug Screen Targeted at Plasmodium Liver Stages Identifies a Potent Multistage Antimalarial Drug Filipa P. da Cruz",{"$nulls":8},0.8483333333333333,0.9800000000000001,0.8099999999999999,"Average",null,0.4530828604879675,1.7006577915597767,7.360729507627478,"gct V enriched","Average",0.2664162436067856,3.7535248844508895,null,"Detected",692838621.0520334,545915000,215905094.41200727,2.528495223731227,null,"Essential/Non essential"]
["KS8",null,null,{"v":120,"d":"120.00"},{"v":1800,"d":"1800.00"},{"v":740,"d":"740.00"},null,null,{"v":15,"d":"15.00"},{"$f":"F256/D256","v":{"v":6.166666666666667,"d":"6.17"}},null,null,"cytochrome b","Antimalarial pyrido [1,2-a] benzimidazoles: Lead optimization, parasite life cycle stage profile, mechanistic evaluation, killing kinetics, and in vivo oral efficacy in a mouse model Singh 2017",{"$nulls":8},0.8483333333333333,0.9800000000000001,0.8099999999999999,"Average",null,0.4530828604879675,1.7006577915597767,7.360729507627478,"gct V enriched","Average",0.2664162436067856,3.7535248844508895,null,"Detected",692838621.0520334,545915000,215905094.41200727,2.528495223731227,null,"Essential/Non essential"]
["MMV668647",null,null,21.47,{"v":322.90000000000003,"d":"322.90"},{"v":136.9,"d":"136.90"},null,null,{"v":15.039590125756872,"d":"15.04"},{"$f":"F257/D257","v":{"v":6.376339077782953,"d":"6.38"}},null,null,"PI4K"," Potent Plasmodium falciparum gametocytocidal compounds identified by exploring the kinase inhibitor chemical space for dual active antimalarials Mariëtte E van der Watt, ",{"$nulls":6},"PF3D7_0509800",null,0.29,-0.01,0.16,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV670393",null,null,{"v":248.42000000000002,"d":"248.42"},{"v":3790,"d":"3790.00"},{"v":4267,"d":"4267.00"},null,null,{"v":15.256420578053296,"d":"15.26"},{"$f":"F258/D258","v":{"v":17.1765558328637,"d":"17.18"}},null,null,"PI4K"," Potent Plasmodium falciparum gametocytocidal compounds identified by exploring the kinase inhibitor chemical space for dual active antimalarials Mariëtte E van der Watt, ",{"$nulls":6},"PF3D7_0509800",null,0.29,-0.01,0.16,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV029272",null,null,264.07,{"v":4042,"d":"4042.00"},null,{"v":3676,"d":"3676.00"},null,{"v":15.306547506343016,"d":"15.31"},null,{"$f":"G259/D259","v":{"v":13.920551368955202,"d":"13.92"}},null,"ABCI3","Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. Cowell. 2018",{"$nulls":6},"PF3D7_0319700",null,0.37,-0.27,-0.58,{"$nulls":6},"Not detected",{"$nulls":3},"Detected",2589313.0859880405,1486100,10695894.947039416,0.13894115521500583,null,"Essential (ortholog)"]
["MMV029272",null,null,264.07,{"v":4042,"d":"4042.00"},null,{"v":3676,"d":"3676.00"},null,{"v":15.306547506343016,"d":"15.31"},null,{"$f":"G260/D260","v":{"v":13.920551368955202,"d":"13.92"}},null,"Dipeptidyl aminopeptidase 1 (DPAP1)","Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. Cowell. 2018",{"$nulls":6},"PF3D7_1116700",null,0.66,-0.38,-0.99,null,null,2.93452527859505,0,0.668100537200059,"enriched troph",null,4,{"$f":"AC260/AB260","v":0},null,"Not detected",{"$nulls":5},"Essential/Not essential"]
["MMV674253","AZ412/MMV253",null,{"v":9,"d":"9.00"},141.97,null,{"v":5000,"d":"5000.00"},null,{"v":15.774444444444445,"d":"15.77"},null,{"$f":"G261/D261","v":{"v":555.5555555555555,"d":"555.56"}},null,"Vacuolar ATP synthase (V-type H+-ATPase) subunit D","Hameed PS, Solapure S, Patil V, Henrich PP, Magistrado PA, Bharath S, Murugan K, Viswanath P, Puttur J, Srivastava A, Bellale E, Panduga V, Shanbag G, Awasthy D, Landge S, Morayya S, Koushik K, Saralaya R, Raichurkar A, Rautela N, Roy Choudhury N, Ambady A, Nandishaiah R, Reddy J, Prabhakar KR, Menasinakai S, Rudrapatna S, Chatterji M, Jimenez-Diaz MB, Martinez MS, Sanz LM, Coburn-Flynn O, Fidock DA, Lukens AK, Wirth DF, Bandodkar B, Mukherjee K, McLaughlin RE, Waterson D, Rosenbrier-Ribeiro L, Hickling K, Balasubramanian V, Warner P, Hosagrahara V, Dudley A, Iyer PS, Narayanan S, Kavanagh S, Sambandamurthy VK. 2015. Triaminopyrimidine is a fast-killing and long-acting antimalarial clinical candidate. Nat Commun 6:6715.",{"$nulls":6},"PF3D7_1341900",null,0.35,0.76,0.31,null,null,1.76006068659215,1.255572788203053,28.7635144163132,"gct V enriched",null,{"$f":"AB261/AC261","v":1.4017990061023133},0.7133690319702031,null,"Detected",717038371.5075008,250510000,745494515.9749957,0.3360319823042162,null,"Essential"]
["PC28",null,null,{"v":24,"d":"24.00"},{"v":390,"d":"390.00"},{"v":120,"d":"120.00"},null,null,16.25,{"$f":"F262/D262","v":{"v":5,"d":"5.00"}},null,null,"PI4K","New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of Plasmodium Phosphatidylinositol-4-kinase and cGMP … PM Cheuka",{"$nulls":6},"PF3D7_0509800",null,0.29,-0.01,0.16,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["PC28",null,null,{"v":24,"d":"24.00"},{"v":390,"d":"390.00"},{"v":120,"d":"120.00"},null,null,16.25,{"v":5,"d":"5.00"},null,null,"PKG","New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of Plasmodium Phosphatidylinositol-4-kinase and cGMP … PM Cheuka",{"$nulls":6},"PF3D7_1436600",null,0.47,-0.44,0.1,null,null,0,0.068244893498124,2.02530545710245,"gct V enriched",null,0.8,null,null,"Detected",187255751.4074903,109730000,295371702.85639864,0.37149801060444715,null,"Essential"]
["MMV084434",null,null,{"v":266,"d":"266.00"},{"v":5000,"d":"5000.00"},{"v":892,"d":"892.00"},null,null,{"$f":"E264/D264","v":{"v":18.796992481203006,"d":"18.80"}},{"v":3.3533834586466167,"d":"3.35"},null,null,"Mitochondrial electron transport chain (bc1 inhibitor) (Gamo)","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond, van Voorhis 2016",{"$nulls":8},0.8483333333333333,0.9800000000000001,0.8099999999999999,"Average",null,0.4530828604879675,1.7006577915597767,7.360729507627478,"gct V enriched","Average",0.2664162436067856,3.7535248844508895,null,"Detected",692838621.0520334,545915000,215905094.41200727,2.528495223731227,null,"Essential/Non essential"]
["MMV672652",null,null,{"v":0.5599999999999999,"d":"0.56"},{"v":10.8,"d":"10.80"},{"v":3.3,"d":"3.30"},{"v":18.1,"d":"18.10"},null,{"v":19.28571428571429,"d":"19.29"},{"v":5.892857142857143,"d":"5.89"},{"$f":"G265/D265","v":{"v":32.32142857142858,"d":"32.32"}},null,"CDPK1","Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): preparation and evaluation of pyrazole … JM Large","Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) TM Chapman","New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of Plasmodium Phosphatidylinositol-4-kinase and cGMP … PM Cheuka",{"$nulls":4},"PF3D7_0217500",null,0.54,-0.07,0.86,null,null,1.8276642121903912,0.8228906159046369,5.07832312829723,"shared 3 stages",null,2.2210293529488925,0.4502416857626333,null,"Detected",1326801430.219953,360430000,3411452182.6706023,0.10565295384496434,null,"Essential","I S","A"]
["MMV672652",null,null,{"v":0.5599999999999999,"d":"0.56"},{"v":10.8,"d":"10.80"},{"v":3.3,"d":"3.30"},{"v":18.1,"d":"18.10"},null,{"v":19.28571428571429,"d":"19.29"},{"v":5.892857142857143,"d":"5.89"},{"$f":"G266/D266","v":{"v":32.32142857142858,"d":"32.32"}},null,"CDPK4","Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): preparation and evaluation of pyrazole … JM Large","Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) TM Chapman","New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of Plasmodium Phosphatidylinositol-4-kinase and cGMP … PM Cheuka",{"$nulls":4},"PF3D7_0717500",null,0.32,0.52,0.27,null,null,0,0.40541168873881694,56.3615251044868,"gct V enriched",null,0.4,null,null,"Detected",1686711047.3126552,891260000,11247658017.88505,0.07923960691041598,null,"Not essential","U"]
["MMV672652",null,null,{"v":0.5599999999999999,"d":"0.56"},{"v":10.8,"d":"10.80"},{"v":3.3,"d":"3.30"},{"v":18.1,"d":"18.10"},null,{"v":19.28571428571429,"d":"19.29"},{"v":5.892857142857143,"d":"5.89"},{"$f":"G267/D267","v":{"v":32.32142857142858,"d":"32.32"}},null,"PI4K","Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): preparation and evaluation of pyrazole … JM Large","Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) TM Chapman","New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of Plasmodium Phosphatidylinositol-4-kinase and cGMP … PM Cheuka",{"$nulls":4},"PF3D7_0509800",null,0.29,-0.01,0.16,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV672652",null,null,{"v":0.5599999999999999,"d":"0.56"},{"v":10.8,"d":"10.80"},{"v":3.3,"d":"3.30"},{"v":18.1,"d":"18.10"},null,{"v":19.28571428571429,"d":"19.29"},{"v":5.892857142857143,"d":"5.89"},{"$f":"G268/D268","v":{"v":32.32142857142858,"d":"32.32"}},null,"PKG","Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): preparation and evaluation of pyrazole … JM Large","Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) TM Chapman","New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of Plasmodium Phosphatidylinositol-4-kinase and cGMP … PM Cheuka",{"$nulls":4},"PF3D7_1436600",null,0.47,-0.44,0.1,null,null,0,0.068244893498124,2.02530545710245,"gct V enriched",null,0.8,null,null,"Detected",187255751.4074903,109730000,295371702.85639864,0.37149801060444715,null,"Essential"]
["CLM14",null,null,{"v":33,"d":"33.00"},{"v":649,"d":"649.00"},{"v":729,"d":"729.00"},null,null,{"v":19.666666666666668,"d":"19.67"},{"v":22.09090909090909,"d":"22.09"},null,null,"PI4K","Identification of a potential antimalarial drug candidate from a series of 2-aminopyrazines by optimization of aqueous solubility and potency across the parasite life cycle Le Manach 2016",{"$nulls":6},"PF3D7_0509800",null,0.29,-0.01,0.16,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV670997",null,null,{"v":20.080000000000002,"d":"20.08"},{"v":442.3,"d":"442.30"},{"v":5000,"d":"5000.00"},null,null,{"v":22.026892430278885,"d":"22.03"},{"v":249.003984063745,"d":"249.00"},null,null,"DHFR-TS","Rosowsky A., Chen K. K., Lin M.: 2,4-Diaminothieno(2,3-d)pyrimidines as antifolates and antimalarials.",{"$nulls":6},"PF3D7_0417200",null,0.11,0.52,0.13,null,null,1.15443469003188,0.6407679530676047,10.9377664171444,"gct V enriched",null,1.8016423644552657,0.5550491150347446,null,"Detected",3107354809.595412,901370000,1885999900.5903804,0.47792685445945216,null,"Essential","A"]
["MMV642944","CC_642944",null,13.78,{"v":306.6,"d":"306.60"},null,{"v":319.1,"d":"319.10"},null,{"v":22.249637155297535,"d":"22.25"},null,{"$f":"G271/D271","v":{"v":23.156748911465897,"d":"23.16"}},null,"PI4K"," Potent Plasmodium falciparum gametocytocidal compounds identified by exploring the kinase inhibitor chemical space for dual active antimalarials Mariëtte E van der Watt, ","Probing the distinct chemosensitivity of Plasmodium vivax liver stage parasites and demonstration of 8-aminoquinoline radical cure activity in vitro SP Maher 2021","UCT943, a Next-Generation Plasmodium falciparum PI4K Inhibitor Preclinical Candidate for the Treatment of Malaria Christel Brunschwig 2018",{"$nulls":4},"PF3D7_0509800",null,0.29,-0.01,0.16,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV642943",null,null,{"v":5.7299999999999995,"d":"5.73"},{"v":134,"d":"134.00"},{"v":66,"d":"66.00"},{"v":125.6,"d":"125.60"},null,{"v":23.385689354275744,"d":"23.39"},{"$f":"F272/D272","v":{"v":11.518324607329843,"d":"11.52"}},{"$f":"G272/D272","v":{"v":21.919720767888307,"d":"21.92"}},null,"PI4K","UCT943, a Next-Generation Plasmodium falciparum PI4K Inhibitor Preclinical Candidate for the Treatment of Malaria Christel Brunschwig 2018","Potent Plasmodium falciparum gametocytocidal compounds identified by exploring the kinase inhibitor chemical space for dual active antimalarials ME van der Wat",{"$nulls":5},"PF3D7_0509800",null,0.29,-0.01,0.16,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV652007","AN3661",null,46.26,{"v":1086,"d":"1086.00"},null,{"v":5000,"d":"5000.00"},null,{"v":23.476005188067447,"d":"23.48"},null,{"v":108.08473843493299,"d":"108.08"},null,"Cleavage and polyadenylation specificity factor subunit 3 (CPSF3)","A potent antimalarial benzoxaborole targets a Plasmodium falciparum cleavage and polyadenylation specificity factor homologue. Ebere Sonoiki. 2017",{"$nulls":6},"PF3D7_1438500",null,0.77,0.29,0.06,null,null,0.19077316861219132,0.1746748582396935,0,"enriched troph",null,1.0921615768561683,0.9156154374873183,null,"Detected",2165066.561177746,11106000,3262072.4244660535,3.4045841277781763,null,"Essential"]
["MMV665980",null,null,{"v":210.79999999999998,"d":"210.80"},{"v":5000,"d":"5000.00"},{"v":5000,"d":"5000.00"},{"v":5000,"d":"5000.00"},null,{"v":23.719165085388997,"d":"23.72"},{"$f":"F274/D274","v":{"v":23.719165085388997,"d":"23.72"}},{"v":23.719165085388997,"d":"23.72"},null,"phosphoethanolamine methyltransferase (PfPMT) ","A novel approach for the discovery of chemically diverse anti-malarial compounds targeting the Plasmodium falciparum Coenzyme A synthesis pathway S Fletcher",{"$nulls":6},"PF3D7_1343000",null,0.77,1.48,0.61,null,null,336.4138014225539,83.2557979663136,10.5478198468946,"enriched troph",null,4.040725206413509,0.247480328138321,null,"Detected",114835488.61768718,1894500000,446647232.3754124,4.241602460905097,null,"Not essential/Essential","A"]
["MMV665980",null,null,{"v":210.79999999999998,"d":"210.80"},{"v":5000,"d":"5000.00"},{"v":5000,"d":"5000.00"},{"v":5000,"d":"5000.00"},null,{"v":23.719165085388997,"d":"23.72"},{"v":23.719165085388997,"d":"23.72"},{"v":23.719165085388997,"d":"23.72"},null,"pantothenate kinase 1","A novel approach for the discovery of chemically diverse anti-malarial compounds targeting the Plasmodium falciparum Coenzyme A synthesis pathway S Fletcher",{"$nulls":6},"PF3D7_1420600",null,0.26,0.36,0.59,null,null,0.68726376397451,0,0,"enriched troph",null,1.6,0,null,"Detected",266001.2984578802,721950,3593539.8471956938,0.2009021830002501,null,"Essential"]
["MMV665980",null,null,{"v":210.79999999999998,"d":"210.80"},{"v":5000,"d":"5000.00"},{"v":5000,"d":"5000.00"},{"v":5000,"d":"5000.00"},null,{"v":23.719165085388997,"d":"23.72"},{"v":23.719165085388997,"d":"23.72"},{"v":23.719165085388997,"d":"23.72"},null,"pantothenate kinase 2","A novel approach for the discovery of chemically diverse anti-malarial compounds targeting the Plasmodium falciparum Coenzyme A synthesis pathway S Fletcher",{"$nulls":6},"PF3D7_1437400",null,0.33,-0.07,-0.18,{"$nulls":6},"Not detected",{"$nulls":3},"Detected",1234946.8745992319,2466955.0532793016,1141968.171123459,2.1602660351315497,null,"Not essential"]
["MMV665980",null,null,{"v":210.79999999999998,"d":"210.80"},{"v":5000,"d":"5000.00"},{"v":5000,"d":"5000.00"},{"v":5000,"d":"5000.00"},null,{"v":23.719165085388997,"d":"23.72"},{"v":23.719165085388997,"d":"23.72"},{"v":23.719165085388997,"d":"23.72"},null,"phosphopantothenoylcysteine synthetase","A novel approach for the discovery of chemically diverse anti-malarial compounds targeting the Plasmodium falciparum Coenzyme A synthesis pathway S Fletcher",{"$nulls":6},"PF3D7_0412300",null,0.72,-0.49,-0.31,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Not essential"]
["MMV665980",null,null,{"v":210.79999999999998,"d":"210.80"},{"v":5000,"d":"5000.00"},{"v":5000,"d":"5000.00"},{"v":5000,"d":"5000.00"},null,{"v":23.719165085388997,"d":"23.72"},{"v":23.719165085388997,"d":"23.72"},{"v":23.719165085388997,"d":"23.72"},null,"phosphopantothenoylcysteine decarboxylase","A novel approach for the discovery of chemically diverse anti-malarial compounds targeting the Plasmodium falciparum Coenzyme A synthesis pathway S Fletcher",{"$nulls":6},"PF3D7_0816100",null,0.73,-0.05,0.35,null,null,0,2.1471274463127243,1.89426612471675,"gct I/II enriched",null,4,null,null,"Detected",61310952.05790817,26538000,43158638.24882792,0.6148942848242137,null,"Essential"]
["MMV665980",null,null,{"v":210.79999999999998,"d":"210.80"},{"v":5000,"d":"5000.00"},{"v":5000,"d":"5000.00"},{"v":5000,"d":"5000.00"},null,{"v":23.719165085388997,"d":"23.72"},{"v":23.719165085388997,"d":"23.72"},{"v":23.719165085388997,"d":"23.72"},null,"phosphopantetheine adenylyltransferase (PPAT)","A novel approach for the discovery of chemically diverse anti-malarial compounds targeting the Plasmodium falciparum Coenzyme A synthesis pathway S Fletcher",{"$nulls":6},"PF3D7_0704700",null,0.2,0.12,0.72,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Not essential"]
["MMV665980",null,null,{"v":210.79999999999998,"d":"210.80"},{"v":5000,"d":"5000.00"},{"v":5000,"d":"5000.00"},{"v":5000,"d":"5000.00"},null,{"v":23.719165085388997,"d":"23.72"},{"v":23.719165085388997,"d":"23.72"},{"v":23.719165085388997,"d":"23.72"},null,"dephospho-CoA kinase","A novel approach for the discovery of chemically diverse anti-malarial compounds targeting the Plasmodium falciparum Coenzyme A synthesis pathway S Fletcher",{"$nulls":6},"PF3D7_1443700",null,0.27,0.6,0.55,{"$nulls":6},"Not detected",{"$nulls":3},"Detected",600796.7779038273,3685300,5879231.533252301,0.626833622584234,null,"Essential"]
["CLM3",null,null,{"v":5.4,"d":"5.40"},{"v":134,"d":"134.00"},{"v":66,"d":"66.00"},null,null,{"v":24.814814814814813,"d":"24.81"},{"v":12.222222222222221,"d":"12.22"},null,null,"PI4K","Identification of a potential antimalarial drug candidate from a series of 2-aminopyrazines by optimization of aqueous solubility and potency across the parasite life cycle Le Manach 2016",{"$nulls":6},"PF3D7_0509800",null,0.29,-0.01,0.16,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["SC83288","SC83288",null,{"v":8,"d":"8.00"},{"v":199,"d":"199.00"},{"v":5000,"d":"5000.00"},null,null,{"v":24.875,"d":"24.88"},{"v":625,"d":"625.00"},null,null,"calcium-transporting ATPase (ATP6)","SC83288 is a clinical development candidate for the treatment of severe malaria S Pegoraro 2017","Target identification studies for SC83288: a novel drug for the treatment of severe malaria RV Celada 2022",{"$nulls":5},"PF3D7_0106300",null,0.39,-0.03,-0.13,null,null,1.6876027710717014,0.7605873874153525,3.93796931771435,"shared 3 stages",null,2.2188150881735713,0.4506910040994696,null,"Detected",1029579056.5443927,1600300000,889900800.0520924,1.7982903261872814,null,"Essential"]
["SC83288","SC83288",null,{"v":8,"d":"8.00"},{"v":199,"d":"199.00"},{"v":5000,"d":"5000.00"},null,null,{"v":24.875,"d":"24.88"},{"v":625,"d":"625.00"},null,null,"fumarate hydratase (FH)","SC83288 is a clinical development candidate for the treatment of severe malaria S Pegoraro 2017","Target identification studies for SC83288: a novel drug for the treatment of severe malaria RV Celada 2022",{"$nulls":5},"PF3D7_0927300",null,0.23,0.16,0.19,null,null,0.16576703731775866,0.3188409631490102,3.01945033361513,"gct V enriched",null,0.5199050827113688,1.9234280126381478,null,"Detected",289907290.8347029,323510000,31981193.98333044,10.115632335947906,null,"Essential"]
["SC83288","SC83288",null,{"v":8,"d":"8.00"},{"v":199,"d":"199.00"},{"v":5000,"d":"5000.00"},null,null,{"v":24.875,"d":"24.88"},{"v":625,"d":"625.00"},null,null,"mini-chromosome maintenance complex-binding protein","SC83288 is a clinical development candidate for the treatment of severe malaria S Pegoraro 2017","Target identification studies for SC83288: a novel drug for the treatment of severe malaria RV Celada 2022",{"$nulls":5},"PF3D7_1412100",null,1.16,0.17,0.19,null,null,0.22030595261377078,0.06444401261225294,0.0873356727196561,"enriched troph",null,3.418563551269049,0.2925205236066994,null,"Detected",477492.16995597084,2276900,32190079.896683455,0.07073297137838384,null,"Essential","A"]
["SC83288","SC83288",null,{"v":8,"d":"8.00"},{"v":199,"d":"199.00"},{"v":5000,"d":"5000.00"},null,null,{"v":24.875,"d":"24.88"},{"v":625,"d":"625.00"},null,null,"casein kinase 2, alpha subunit","SC83288 is a clinical development candidate for the treatment of severe malaria S Pegoraro 2017","Target identification studies for SC83288: a novel drug for the treatment of severe malaria RV Celada 2022",{"$nulls":5},"PF3D7_1108400",null,0.45,0.17,0.01,null,null,60.79064011727486,103.28083452179338,47.3293023857175,"shared 3 stages",null,0.5885955550102316,1.6989594832781518,null,"Detected",1725313191.9432108,3068800000,905698894.339295,3.388322564132842,null,"Essential","I","D"]
["SC83288","SC83288",null,{"v":8,"d":"8.00"},{"v":199,"d":"199.00"},{"v":5000,"d":"5000.00"},null,null,{"v":24.875,"d":"24.88"},{"v":625,"d":"625.00"},null,null,"casein kinase II beta chain","SC83288 is a clinical development candidate for the treatment of severe malaria S Pegoraro 2017","Target identification studies for SC83288: a novel drug for the treatment of severe malaria RV Celada 2022",{"$nulls":5},"PF3D7_1103700",null,0.9,0.14,-0.56,null,null,3.2187487937519563,1.8900861310663797,4.08021804691302,"shared 3 stages",null,1.7029640823489616,0.5872114452470794,null,"Detected",299234964.12211066,248990000,101464723.34606703,2.453956328750502,null,"Essential"]
["SC83288","SC83288",null,{"v":8,"d":"8.00"},{"v":199,"d":"199.00"},{"v":5000,"d":"5000.00"},null,null,{"v":24.875,"d":"24.88"},{"v":625,"d":"625.00"},null,null,"casein kinase II beta chain","SC83288 is a clinical development candidate for the treatment of severe malaria S Pegoraro 2017","Target identification studies for SC83288: a novel drug for the treatment of severe malaria RV Celada 2022",{"$nulls":5},"PF3D7_1103700",null,0.9,0.14,-0.56,null,null,3.2187487937519563,1.8900861310663797,4.08021804691302,"shared 3 stages",null,1.7029640823489616,0.5872114452470794,null,"Detected",299234964.12211066,248990000,101464723.34606703,2.453956328750502,null,"Essential"]
["SC83288","SC83288",null,{"v":8,"d":"8.00"},{"v":199,"d":"199.00"},{"v":5000,"d":"5000.00"},null,null,{"v":24.875,"d":"24.88"},{"v":625,"d":"625.00"},null,null,"iron-sulfur cluster assembly protein SufA","SC83288 is a clinical development candidate for the treatment of severe malaria S Pegoraro 2017","Target identification studies for SC83288: a novel drug for the treatment of severe malaria RV Celada 2022",{"$nulls":5},"PF3D7_0522700",null,0.46,0.62,0.91,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["SC83288","SC83288",null,{"v":8,"d":"8.00"},{"v":199,"d":"199.00"},{"v":5000,"d":"5000.00"},null,null,{"v":24.875,"d":"24.88"},{"v":625,"d":"625.00"},null,null,"iron-sulfur cluster assembly protein SufD","SC83288 is a clinical development candidate for the treatment of severe malaria S Pegoraro 2017","Target identification studies for SC83288: a novel drug for the treatment of severe malaria RV Celada 2022",{"$nulls":5},"PF3D7_1103400",null,0.4,0.62,0.39,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["SC83288","SC83288",null,{"v":8,"d":"8.00"},{"v":199,"d":"199.00"},{"v":5000,"d":"5000.00"},null,null,{"v":24.875,"d":"24.88"},{"v":625,"d":"625.00"},null,null,"iron-sulfur cluster assembly protein SufC","SC83288 is a clinical development candidate for the treatment of severe malaria S Pegoraro 2017","Target identification studies for SC83288: a novel drug for the treatment of severe malaria RV Celada 2022",{"$nulls":5},"PF3D7_1413500",null,0.41,-0.05,0.12,null,null,0,0.36959173644292936,0,"gct I/II enriched",null,0.3,null,null,"Not detected",{"$nulls":5},"Essential"]
["SC83288","SC83288",null,{"v":8,"d":"8.00"},{"v":199,"d":"199.00"},{"v":5000,"d":"5000.00"},null,null,{"v":24.875,"d":"24.88"},{"v":625,"d":"625.00"},null,null,"iron-sulfur cluster assembly protein ISCU","SC83288 is a clinical development candidate for the treatment of severe malaria S Pegoraro 2017","Target identification studies for SC83288: a novel drug for the treatment of severe malaria RV Celada 2022",{"$nulls":5},"PF3D7_1454500",null,0.61,0.46,-0.06,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["SC83288","SC83288",null,{"v":8,"d":"8.00"},{"v":199,"d":"199.00"},{"v":5000,"d":"5000.00"},null,null,{"v":24.875,"d":"24.88"},{"v":625,"d":"625.00"},null,null,"cytosolic iron-sulfur assembly component 2","SC83288 is a clinical development candidate for the treatment of severe malaria S Pegoraro 2017","Target identification studies for SC83288: a novel drug for the treatment of severe malaria RV Celada 2022",{"$nulls":5},"PF3D7_0703100",null,0.86,0.01,-0.27,null,null,0,0,0.701254279852589,"gct V enriched",null,1,null,null,"Detected",25954875.437983003,11308000,53060532.6792846,0.21311508627983985,null,"Essential"]
["SC83288","SC83288",null,{"v":8,"d":"8.00"},{"v":199,"d":"199.00"},{"v":5000,"d":"5000.00"},null,null,{"v":24.875,"d":"24.88"},{"v":625,"d":"625.00"},null,null,"cytosolic iron-sulfur protein assembly protein 1","SC83288 is a clinical development candidate for the treatment of severe malaria S Pegoraro 2017","Target identification studies for SC83288: a novel drug for the treatment of severe malaria RV Celada 2022",{"$nulls":5},"PF3D7_1209400",null,0.5,-0.02,0.36,{"$nulls":6},"Not detected",{"$nulls":3},"Detected",1273809.0091756743,203910,10904780.86039243,0.018699137801166405,null,"Essential (ortholog)"]
["SC83288","SC83288",null,{"v":8,"d":"8.00"},{"v":199,"d":"199.00"},{"v":5000,"d":"5000.00"},null,null,{"v":24.875,"d":"24.88"},{"v":625,"d":"625.00"},null,null,"Fe-S cluster assembly protein DRE2","SC83288 is a clinical development candidate for the treatment of severe malaria S Pegoraro 2017","Target identification studies for SC83288: a novel drug for the treatment of severe malaria RV Celada 2022",{"$nulls":5},"PF3D7_0824600",null,1.14,0.16,-0.15,null,null,1.2812367429334575,0.23330678076078387,1.05352502645715,"shared 3 stages",null,5.491639543246478,0.18209498131205323,null,"Detected",52525311.32636291,5585300,31361557.61851016,0.1780938328363976,null,"Essential"]
["MMV006427",null,null,{"v":78.2,"d":"78.20"},{"v":1960,"d":"1960.00"},{"v":5000,"d":"5000.00"},{"v":2237.6200000000003,"d":"2237.62"},null,{"v":25.06393861892583,"d":"25.06"},{"v":63.9386189258312,"d":"63.94"},{"$f":"G295/D295","v":{"v":28.614066496163687,"d":"28.61"}},null,"ATP4","E.L. Allman, H.J. Painter, J. Samra, M. Carrasquilla, M. Llinas Metabolomic profiling of the malaria box reveals antimalarial target pathways 2016","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond, van Voorhis 2016","Diverse chemotypes disrupt ion homeostasis in the malaria parasite AM Lehane",{"$nulls":4},"PF3D7_1211900",null,0.33,-0.22,-0.49,null,null,1.7731908623980155,0.4394601472062679,2.59381366380463,"shared 3 stages",null,4.034929842149575,0.24783578379822793,null,"Detected",636393353.8483057,392860000,65708369.94269839,5.978842578846459,null,"Essential"]
["MMV672643",null,null,{"v":42.4,"d":"42.40"},{"v":1071,"d":"1071.00"},{"v":460,"d":"460.00"},null,null,{"v":25.25943396226415,"d":"25.26"},{"v":10.849056603773585,"d":"10.85"},null,null,"PI4K"," Potent Plasmodium falciparum gametocytocidal compounds identified by exploring the kinase inhibitor chemical space for dual active antimalarials Mariëtte E van der Watt, ",{"$nulls":6},"PF3D7_0509800",null,0.29,-0.01,0.16,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV668308",null,null,194.24,{"v":5000,"d":"5000.00"},{"v":5000,"d":"5000.00"},null,null,{"v":25.74135090609555,"d":"25.74"},{"v":25.74135090609555,"d":"25.74"},null,null,"DHFR-TS","Rosowsky A., Chen K. K., Lin M.: 2,4-Diaminothieno(2,3-d)pyrimidines as antifolates and antimalarials.",{"$nulls":6},"PF3D7_0417200",null,0.11,0.52,0.13,null,null,1.15443469003188,0.6407679530676047,10.9377664171444,"gct V enriched",null,1.8016423644552657,0.5550491150347446,null,"Detected",3107354809.595412,901370000,1885999900.5903804,0.47792685445945216,null,"Essential","A"]
["NITD246","KAF246",null,0.08,{"v":2.104,"d":"2.10"},{"v":1.766,"d":"1.77"},{"v":2.355,"d":"2.36"},null,{"v":26.3,"d":"26.30"},{"v":22.075,"d":"22.08"},{"$f":"G298/D298","v":{"v":29.4375,"d":"29.44"}},null,"ATP4","McNamara CW, Lee MC, Lim CS, Lim SH, Roland J, Nagle A, Simon O, Yeung BK, Chatterjee AK, McCormack SL, Manary MJ, Zeeman AM, Dechering KJ, Kumar TR, Henrich PP, Gagaring K, Ibanez M, Kato N, Kuhen KL, Fischli C, Rottmann M, Plouffe DM, Bursulaya B, Meister S, Rameh L, Trappe J, Haasen D, Timmerman M, Sauerwein RW, Suwanarusk R, Russell B, Renia L, Nosten F, Tully DC, Kocken CH, Glynne RJ, Bodenreider C, Fidock DA, Diagana TT, Winzeler EA. 2013. Targeting Plasmodium PI(4)K to eliminate malaria. Nature 504:248–253.","Na+ extrusion imposes an acid load on the intraerythrocytic malaria parasite NJ Spillman",{"$nulls":5},"PF3D7_1211900",null,0.33,-0.22,-0.49,null,null,1.7731908623980155,0.4394601472062679,2.59381366380463,"shared 3 stages",null,4.034929842149575,0.24783578379822793,null,"Detected",636393353.8483057,392860000,65708369.94269839,5.978842578846459,null,"Essential"]
["MMV019406",null,null,{"v":38.750999,"d":"38.75"},{"v":1052,"d":"1052.00"},{"v":418,"d":"418.00"},null,null,{"v":27.147687211883234,"d":"27.15"},{"v":10.786818683048661,"d":"10.79"},null,null,"Hsp90","Metabolomics-Based Screening of the Malaria Box Reveals both Novel and Established Mechanisms of Action Darren J. Creek"," New insight-guided approaches to detect, cure, prevent and eliminate malaria S Kumar",{"$nulls":5},"PF3D7_0708400",null,0.47,0.14,-0.37,null,null,391.244342138169,487.5030361563116,2642.7611857491,"gct V enriched",null,0.8025474984174693,1.2460321687774047,null,"Detected",28102267024.51306,93040000000,24304490388.95642,3.8280991911797466,null,"Essential"]
["CLM-31",null,null,{"v":6,"d":"6.00"},{"v":163,"d":"163.00"},{"v":72,"d":"72.00"},null,null,{"v":27.166666666666668,"d":"27.17"},{"v":12,"d":"12.00"},null,null,"PK7","A novel pyrazolopyridine with in vivo activity in Plasmodium berghei-and Plasmodium falciparum-infected mouse models from structure–activity relationship studies around the core of recently identified antimalarial imidazopyridazines Le Manach 2015",{"$nulls":6},"PF3D7_0213400",null,0.31,0.27,-0.31,null,null,0.2246523050636276,0,0.136463666385725,"not determined",null,1.2,0,null,"Not detected",{"$nulls":5},"Not essential","A D"]
["MMV670401",null,null,42.11,{"v":1168.5,"d":"1168.50"},{"v":238.4,"d":"238.40"},null,null,{"v":27.74875326525766,"d":"27.75"},{"v":5.661363096651627,"d":"5.66"},null,null,"PI4K"," Potent Plasmodium falciparum gametocytocidal compounds identified by exploring the kinase inhibitor chemical space for dual active antimalarials Mariëtte E van der Watt, ",{"$nulls":6},"PF3D7_0509800",null,0.29,-0.01,0.16,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["KS54",null,null,{"v":30,"d":"30.00"},{"v":880,"d":"880.00"},{"v":810,"d":"810.00"},null,null,{"v":29.333333333333332,"d":"29.33"},{"v":27,"d":"27.00"},null,null,"cytochrome b","Antimalarial pyrido [1,2-a] benzimidazoles: Lead optimization, parasite life cycle stage profile, mechanistic evaluation, killing kinetics, and in vivo oral efficacy in a mouse model Singh 2017",{"$nulls":8},0.8483333333333333,0.9800000000000001,0.8099999999999999,"Average",null,0.4530828604879675,1.7006577915597767,7.360729507627478,"gct V enriched","Average",0.2664162436067856,3.7535248844508895,null,"Detected",692838621.0520334,545915000,215905094.41200727,2.528495223731227,null,"Essential/Non essential"]
["PC18",null,null,{"v":19,"d":"19.00"},{"v":559,"d":"559.00"},{"v":158,"d":"158.00"},null,null,{"v":29.42105263157895,"d":"29.42"},{"v":8.31578947368421,"d":"8.32"},null,null,"PI4K","New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of Plasmodium Phosphatidylinositol-4-kinase and cGMP … PM Cheuka",{"$nulls":6},"PF3D7_0509800",null,0.29,-0.01,0.16,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV030084",null,null,160.17,{"v":5000,"d":"5000.00"},null,{"v":5000,"d":"5000.00"},null,{"v":31.216832115876883,"d":"31.22"},null,{"$f":"G304/D304","v":{"v":31.216832115876883,"d":"31.22"}},null,"PKG","Inhibition of resistance-refractory P. falciparum kinase PKG delivers prophylactic, blood stage, and transmission-blocking antiplasmodial activity. M. Vanaerschot, 2020",{"$nulls":6},"PF3D7_1436600",null,0.47,-0.44,0.1,null,null,0,0.068244893498124,2.02530545710245,"gct V enriched",null,0.8,null,null,"Detected",187255751.4074903,109730000,295371702.85639864,0.37149801060444715,null,"Essential"]
["MMV030084",null,null,160.17,{"v":5000,"d":"5000.00"},null,{"v":5000,"d":"5000.00"},null,{"v":31.216832115876883,"d":"31.22"},null,{"$f":"G305/D305","v":{"v":31.216832115876883,"d":"31.22"}},null,"tyrosine kinase-like protein (TKL3)","Inhibition of resistance-refractory P. falciparum kinase PKG delivers prophylactic, blood stage, and transmission-blocking antiplasmodial activity. M. Vanaerschot, 2020",{"$nulls":6},"PF3D7_1349300",null,0.11,0.43,0.37,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential/Not essential"]
["BRD3444",null,null,{"v":9,"d":"9.00"},{"v":282,"d":"282.00"},{"v":663,"d":"663.00"},null,null,{"v":31.333333333333332,"d":"31.33"},{"$f":"F306/D306","v":{"v":73.66666666666667,"d":"73.67"}},null,null,"phenylalanine-tRNA synthetase (PheRS/FRS)","Diversity-oriented synthesis yields novel multistage antimalarial inhibitors Nobutaka Kato",{"$nulls":8},0.355,0.16,0.027500000000000004,"Average",null,1.265931292439404,1.2517532609494102,2.85076926040999,"gct V enriched","Average",1.011326538489894,0.988800315171392,null,"Detected",299187830.85638356,277380000,216855174.24900156,1.2791025206597169,null,"Essential"]
["MMV892604",null,null,{"v":151.9,"d":"151.90"},{"v":5000,"d":"5000.00"},null,{"v":5000,"d":"5000.00"},null,{"v":32.91639236339697,"d":"32.92"},null,{"$f":"G307/D307","v":{"v":32.91639236339697,"d":"32.92"}},null,"serine hydroxymethyltransferase (SHMT)","Provided from MMV",{"$nulls":6},"PF3D7_1235600",null,0.21,0.33,0.63,null,null,3.3570103694626154,12.41539811512397,47.9390091847749,"gct V enriched",null,0.2703908757765272,3.6983496470734485,null,"Detected",4524227910.619995,15584000000,9004913743.705505,{"$f":"AL307/AM307","v":1.7306106914009387},null,"Essential"]
["MMV892604",null,null,{"v":151.9,"d":"151.90"},{"v":5000,"d":"5000.00"},null,{"v":5000,"d":"5000.00"},null,{"v":32.91639236339697,"d":"32.92"},null,{"v":32.91639236339697,"d":"32.92"},null,"serine hydroxymethyltransferase (SHMT)","Provided from MMV",{"$nulls":6},"PF3D7_1235600",null,0.21,0.33,0.63,null,null,3.3570103694626154,12.41539811512397,47.9390091847749,"gct V enriched",null,0.2703908757765272,3.6983496470734485,null,"Detected",4524227910.619995,15584000000,9004913743.705505,1.7306106914009387,null,"Essential"]
["MMV011438",null,null,{"v":50,"d":"50.00"},{"v":1656,"d":"1656.00"},{"v":1129.5,"d":"1129.50"},{"v":820,"d":"820.00"},null,33.12,{"$f":"F309/D309","v":22.59},{"v":16.4,"d":"16.40"},null,"phosphoethanolamine methyltransferase (PfPMT) ","Istvan, E. S., Mallari, J. P., Corey, V. C., Dharia, N. V., Marshall, G. R., Winzeler, E. A., and Goldberg, D. E. (2017) Esterase mutation is a mechanism of resistance to antimalarial compounds. Nat. Commu","A novel approach for the discovery of chemically diverse anti-malarial compounds targeting the Plasmodium falciparum Coenzyme A synthesis pathway Sabine Fletcher",{"$nulls":5},"PF3D7_1343000",null,0.77,1.48,0.61,null,null,336.4138014225539,83.2557979663136,10.5478198468946,"enriched troph",null,4.040725206413509,0.247480328138321,null,"Detected",114835488.61768718,1894500000,446647232.3754124,4.241602460905097,null,"Not essential/Essential","A"]
["MMV011438",null,null,{"v":50,"d":"50.00"},{"v":1656,"d":"1656.00"},{"v":1129.5,"d":"1129.50"},{"v":820,"d":"820.00"},null,33.12,22.59,{"v":16.4,"d":"16.40"},null,"pantothenate kinase 1","Istvan, E. S., Mallari, J. P., Corey, V. C., Dharia, N. V., Marshall, G. R., Winzeler, E. A., and Goldberg, D. E. (2017) Esterase mutation is a mechanism of resistance to antimalarial compounds. Nat. Commu","A novel approach for the discovery of chemically diverse anti-malarial compounds targeting the Plasmodium falciparum Coenzyme A synthesis pathway Sabine Fletcher",{"$nulls":5},"PF3D7_1420600",null,0.26,0.36,0.59,null,null,0.68726376397451,0,0,"enriched troph",null,1.5,0,null,"Detected",266001.2984578802,721950,3593539.8471956938,0.2009021830002501,null,"Essential"]
["MMV011438",null,null,{"v":50,"d":"50.00"},{"v":1656,"d":"1656.00"},{"v":1129.5,"d":"1129.50"},{"v":820,"d":"820.00"},null,33.12,22.59,{"v":16.4,"d":"16.40"},null,"pantothenate kinase 2","Istvan, E. S., Mallari, J. P., Corey, V. C., Dharia, N. V., Marshall, G. R., Winzeler, E. A., and Goldberg, D. E. (2017) Esterase mutation is a mechanism of resistance to antimalarial compounds. Nat. Commu","A novel approach for the discovery of chemically diverse anti-malarial compounds targeting the Plasmodium falciparum Coenzyme A synthesis pathway Sabine Fletcher",{"$nulls":5},"PF3D7_1437400",null,0.33,-0.07,-0.18,{"$nulls":6},"Not detected",{"$nulls":3},"Detected",1234946.8745992319,2466955.0532793016,1141968.171123459,2.1602660351315497,null,"Not essential"]
["MMV011438",null,null,{"v":50,"d":"50.00"},{"v":1656,"d":"1656.00"},{"v":1129.5,"d":"1129.50"},{"v":820,"d":"820.00"},null,33.12,22.59,{"v":16.4,"d":"16.40"},null,"phosphopantothenoylcysteine synthetase","Istvan, E. S., Mallari, J. P., Corey, V. C., Dharia, N. V., Marshall, G. R., Winzeler, E. A., and Goldberg, D. E. (2017) Esterase mutation is a mechanism of resistance to antimalarial compounds. Nat. Commu","A novel approach for the discovery of chemically diverse anti-malarial compounds targeting the Plasmodium falciparum Coenzyme A synthesis pathway Sabine Fletcher",{"$nulls":5},"PF3D7_0412300",null,0.72,-0.49,-0.31,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Not essential"]
["MMV011438",null,null,{"v":50,"d":"50.00"},{"v":1656,"d":"1656.00"},{"v":1129.5,"d":"1129.50"},{"v":820,"d":"820.00"},null,33.12,22.59,{"v":16.4,"d":"16.40"},null,"phosphopantothenoylcysteine decarboxylase","Istvan, E. S., Mallari, J. P., Corey, V. C., Dharia, N. V., Marshall, G. R., Winzeler, E. A., and Goldberg, D. E. (2017) Esterase mutation is a mechanism of resistance to antimalarial compounds. Nat. Commu","A novel approach for the discovery of chemically diverse anti-malarial compounds targeting the Plasmodium falciparum Coenzyme A synthesis pathway Sabine Fletcher",{"$nulls":5},"PF3D7_0816100",null,0.73,-0.05,0.35,null,null,0,2.1471274463127243,1.89426612471675,"gct I/II enriched",null,4,null,null,"Detected",61310952.05790817,26538000,43158638.24882792,0.6148942848242137,null,"Essential"]
["MMV011438",null,null,{"v":50,"d":"50.00"},{"v":1656,"d":"1656.00"},{"v":1129.5,"d":"1129.50"},{"v":820,"d":"820.00"},null,33.12,22.59,{"v":16.4,"d":"16.40"},null,"phosphopantetheine adenylyltransferase (PPAT)","Istvan, E. S., Mallari, J. P., Corey, V. C., Dharia, N. V., Marshall, G. R., Winzeler, E. A., and Goldberg, D. E. (2017) Esterase mutation is a mechanism of resistance to antimalarial compounds. Nat. Commu","A novel approach for the discovery of chemically diverse anti-malarial compounds targeting the Plasmodium falciparum Coenzyme A synthesis pathway Sabine Fletcher",{"$nulls":5},"PF3D7_0704700",null,0.2,0.12,0.72,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Not essential"]
["MMV011438",null,null,{"v":50,"d":"50.00"},{"v":1656,"d":"1656.00"},{"v":1129.5,"d":"1129.50"},{"v":820,"d":"820.00"},null,33.12,22.59,{"v":16.4,"d":"16.40"},null,"dephospho-CoA kinase","Istvan, E. S., Mallari, J. P., Corey, V. C., Dharia, N. V., Marshall, G. R., Winzeler, E. A., and Goldberg, D. E. (2017) Esterase mutation is a mechanism of resistance to antimalarial compounds. Nat. Commu","A novel approach for the discovery of chemically diverse anti-malarial compounds targeting the Plasmodium falciparum Coenzyme A synthesis pathway Sabine Fletcher",{"$nulls":5},"PF3D7_1443700",null,0.27,0.6,0.55,{"$nulls":6},"Not detected",{"$nulls":3},"Detected",600796.7779038273,3685300,5879231.533252301,0.626833622584234,null,"Essential"]
["MMV011438",null,null,{"v":50,"d":"50.00"},{"v":1656,"d":"1656.00"},{"v":1129.5,"d":"1129.50"},{"v":820,"d":"820.00"},null,33.12,22.59,{"v":16.4,"d":"16.40"},null,"prodrug activation and resistance esterase (PARE)","Istvan, E. S., Mallari, J. P., Corey, V. C., Dharia, N. V., Marshall, G. R., Winzeler, E. A., and Goldberg, D. E. (2017) Esterase mutation is a mechanism of resistance to antimalarial compounds. Nat. Commu","A novel approach for the discovery of chemically diverse anti-malarial compounds targeting the Plasmodium falciparum Coenzyme A synthesis pathway Sabine Fletcher",{"$nulls":5},"PF3D7_0709700",null,0.74,0.63,0.46,null,null,2.9934994992897748,1.8671555457797142,1.23872113856834,"enriched troph",null,1.60324055810771,0.6237367155807803,null,"Detected",24136474.046228625,42612000,32565723.47195694,1.3084923489169258,null,"Not essential","U"]
["MMV666101",null,null,{"v":148,"d":"148.00"},{"v":5000,"d":"5000.00"},{"v":333,"d":"333.00"},null,null,{"v":33.78378378378378,"d":"33.78"},2.25,null,null,"Saglin (thrombospondin-related anonymous protein?)","Transcriptome Analysis of Uninfected and Plasmodium vivax-infected Anopheles dirus at Ookinete and Oocyst Stages and Targeting Anopheles Carboxypeptidase B … T Boonkaew",{"$nulls":6},"PF3D7_1335900",null,0.82,0.91,0.81,{"$nulls":6},"Not detected",{"$nulls":3},"Translationally repressed",{"$nulls":5},"Not essential"]
["MMV019313",null,null,115.85,{"v":3928,"d":"3928.00"},null,{"v":5000,"d":"5000.00"},null,{"v":33.90591281829953,"d":"33.91"},null,{"$f":"G318/D318","v":{"v":43.15925766076824,"d":"43.16"}},null,"protein farnesyltransferase subunit beta (FTB)","Specific inhibition of the bifunctional farnesyl/geranylgeranyl diphosphate synthase in malaria parasites via a new small-molecule binding site. JE Gisselberg. 2018","E.L. Allman, H.J. Painter, J. Samra, M. Carrasquilla, M. Llinas Metabolomic profiling of the malaria box reveals antimalarial target pathways 2016",{"$nulls":5},"PF3D7_1147500",null,0.9,-0.08,-0.56,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV019313",null,null,115.85,{"v":3928,"d":"3928.00"},null,{"v":5000,"d":"5000.00"},null,{"v":33.90591281829953,"d":"33.91"},null,{"$f":"G319/D319","v":{"v":43.15925766076824,"d":"43.16"}},null,"protein farnesyltransferase subunit alpha","Specific inhibition of the bifunctional farnesyl/geranylgeranyl diphosphate synthase in malaria parasites via a new small-molecule binding site. JE Gisselberg. 2018","E.L. Allman, H.J. Painter, J. Samra, M. Carrasquilla, M. Llinas Metabolomic profiling of the malaria box reveals antimalarial target pathways 2016",{"$nulls":5},"PF3D7_1242600",null,0.63,-0.21,-0.65,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV019313",null,null,115.85,{"v":3928,"d":"3928.00"},null,{"v":5000,"d":"5000.00"},null,{"v":33.90591281829953,"d":"33.91"},null,{"$f":"G320/D320","v":{"v":43.15925766076824,"d":"43.16"}},null,"bifunctional farnesyl/geranylgeranyl diphosphate synthase (FPPS/GGPPS)","Specific inhibition of the bifunctional farnesyl/geranylgeranyl diphosphate synthase in malaria parasites via a new small-molecule binding site. JE Gisselberg. 2018","E.L. Allman, H.J. Painter, J. Samra, M. Carrasquilla, M. Llinas Metabolomic profiling of the malaria box reveals antimalarial target pathways 2016",{"$nulls":5},"PF3D7_1128400",null,0.43,0.1,0.13,null,null,1.793245727412536,2.644193071403792,1.51188643150958,"shared 3 stages",null,0.678182598239889,1.4745291350667724,null,"Detected",242208425.91880268,194550000,99808849.0189269,1.9492259645545775,null,"Essential"]
["MMV006087",null,null,7.16,{"v":249,"d":"249.00"},{"v":372,"d":"372.00"},null,null,{"v":34.77653631284916,"d":"34.78"},{"$f":"F321/D321","v":{"v":51.95530726256983,"d":"51.96"}},null,null,"enoyl-acyl carrier reductase (ENR)","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond, van Voorhis 2016","D.J. Creek, H.H. Chua, S.A. Cobbold, B. Nijagal, J.I. Macrae, B.K. Dickerman, P.R. Gilson, S.A. Ralph, M.J. McConville Metabolomics-based screening of the Malaria Box reveals both novel and established mechanisms of action 2016","Prioritization of active antimalarials using structural interaction profile of Plasmodium falciparum enoyl-acyl carrier protein reductase (PfENR)-triclosan derivatives S.P. Kumar",{"$nulls":4},"PF3D7_0615100",null,0.62,2.1,1.53,null,null,0,0.7051256087078136,0.333521432163324,"gct I/II enriched",null,0.5,null,null,"Translationally repressed",{"$nulls":5},"Not essential","U"]
["MMV675615",null,null,4.47,{"v":163.20000000000002,"d":"163.20"},{"v":72.1,"d":"72.10"},{"v":104.2,"d":"104.20"},null,{"v":36.510067114093964,"d":"36.51"},{"v":16.129753914988815,"d":"16.13"},{"$f":"G322/D322","v":{"v":23.31096196868009,"d":"23.31"}},null,"CDPK1","Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): preparation and evaluation of pyrazole … JM Large","Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) TM Chapman","New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of Plasmodium Phosphatidylinositol-4-kinase and cGMP … PM Cheuka"," Potent Plasmodium falciparum gametocytocidal compounds identified by exploring the kinase inhibitor chemical space for dual active antimalarials Mariëtte E van der Watt, ",{"$nulls":3},"PF3D7_0217500",null,0.54,-0.07,0.86,null,null,1.8276642121903912,0.8228906159046369,5.07832312829723,"shared 3 stages",null,2.2210293529488925,0.4502416857626333,null,"Detected",1326801430.219953,360430000,3411452182.6706023,0.10565295384496434,null,"Essential","I S","A"]
["MMV675615",null,null,4.47,{"v":163.20000000000002,"d":"163.20"},{"v":72.1,"d":"72.10"},{"v":104.2,"d":"104.20"},null,{"v":36.510067114093964,"d":"36.51"},{"v":16.129753914988815,"d":"16.13"},{"v":23.31096196868009,"d":"23.31"},null,"PI4K","Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): preparation and evaluation of pyrazole … JM Large","Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) TM Chapman","New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of Plasmodium Phosphatidylinositol-4-kinase and cGMP … PM Cheuka"," Potent Plasmodium falciparum gametocytocidal compounds identified by exploring the kinase inhibitor chemical space for dual active antimalarials Mariëtte E van der Watt, ",{"$nulls":3},"PF3D7_0509800",null,0.29,-0.01,0.16,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV675615",null,null,4.47,{"v":163.20000000000002,"d":"163.20"},{"v":72.1,"d":"72.10"},{"v":104.2,"d":"104.20"},null,{"v":36.510067114093964,"d":"36.51"},{"v":16.129753914988815,"d":"16.13"},{"v":23.31096196868009,"d":"23.31"},null,"PKG","Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): preparation and evaluation of pyrazole … JM Large","Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) TM Chapman","New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of Plasmodium Phosphatidylinositol-4-kinase and cGMP … PM Cheuka"," Potent Plasmodium falciparum gametocytocidal compounds identified by exploring the kinase inhibitor chemical space for dual active antimalarials Mariëtte E van der Watt, ",{"$nulls":3},"PF3D7_1436600",null,0.47,-0.44,0.1,null,null,0,0.068244893498124,2.02530545710245,"gct V enriched",null,0.8,null,null,"Detected",187255751.4074903,109730000,295371702.85639864,0.37149801060444715,null,"Essential"]
["MMV675615",null,null,4.47,{"v":163.20000000000002,"d":"163.20"},{"v":72.1,"d":"72.10"},{"v":104.2,"d":"104.20"},null,{"v":36.510067114093964,"d":"36.51"},{"v":16.129753914988815,"d":"16.13"},{"v":23.31096196868009,"d":"23.31"},null,"PK7","Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): preparation and evaluation of pyrazole … JM Large","Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) TM Chapman","New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of Plasmodium Phosphatidylinositol-4-kinase and cGMP … PM Cheuka"," Potent Plasmodium falciparum gametocytocidal compounds identified by exploring the kinase inhibitor chemical space for dual active antimalarials Mariëtte E van der Watt, ",{"$nulls":3},"PF3D7_0213400",null,0.31,0.27,-0.31,null,null,0.2246523050636276,0,0.136463666385725,"not determined",null,1.2,{"$f":"AC325/AB325","v":0},null,"Not detected",{"$nulls":5},"Not essential","A D"]
["MMV000662",null,null,{"v":36.7,"d":"36.70"},{"v":1388,"d":"1388.00"},{"v":2000,"d":"2000.00"},3324.48,null,{"v":37.82016348773842,"d":"37.82"},{"v":54.49591280653951,"d":"54.50"},{"v":90.58528610354223,"d":"90.59"},null,"ATP4","E.L. Allman, H.J. Painter, J. Samra, M. Carrasquilla, M. Llinas Metabolomic profiling of the malaria box reveals antimalarial target pathways 2016","Diverse chemotypes disrupt ion homeostasis in the malaria parasite AM Lehane 2014","Biochemical characterization and chemical inhibition of PfATP4-associated Na+-ATPase activity in Plasmodium falciparum membranes JEO Rosling 2018",{"$nulls":4},"PF3D7_1211900",null,0.33,-0.22,-0.49,null,null,1.7731908623980155,0.4394601472062679,2.59381366380463,"shared 3 stages",null,{"$f":"AB326/AC326","v":4.034929842149575},0.24783578379822793,null,"Detected",636393353.8483057,392860000,65708369.94269839,5.978842578846459,null,"Essential"]
["MMV667530",null,null,129.73,{"v":5000,"d":"5000.00"},null,{"v":5000,"d":"5000.00"},null,{"v":38.54158637169506,"d":"38.54"},null,{"v":38.54158637169506,"d":"38.54"},null,"2-C-Methyl-D-erythritol 4-Phosphate Cytidyltransferase (IspD)","Provided from MMV",{"$nulls":6},"PF3D7_0106900",null,0.39,1.03,0.97,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV642943",null,null,5.38,{"v":208.7,"d":"208.70"},null,{"v":125.6,"d":"125.60"},null,{"v":38.79182156133829,"d":"38.79"},null,{"$f":"G328/D328","v":{"v":23.345724907063197,"d":"23.35"}},null,"PI4K","UCT943, a Next-Generation Plasmodium falciparum PI4K Inhibitor Preclinical Candidate for the Treatment of Malaria Christel Brunschwig 2018","Potent Plasmodium falciparum gametocytocidal compounds identified by exploring the kinase inhibitor chemical space for dual active antimalarials ME van der Wat",{"$nulls":5},"PF3D7_0509800",null,0.29,-0.01,0.16,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV665827",null,null,{"v":119,"d":"119.00"},{"v":5000,"d":"5000.00"},{"v":337,"d":"337.00"},{"v":5000,"d":"5000.00"},null,{"v":42.016806722689076,"d":"42.02"},{"$f":"F329/D329","v":{"v":2.831932773109244,"d":"2.83"}},{"$f":"G329/D329","v":{"v":42.016806722689076,"d":"42.02"}},null,"Mitochondrial electron transport chain (bc1 inhibitor)","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond, van Voorhis 2016","In vitro multistage malaria transmission blocking activity of selected malaria box compounds HM Malebo","Metabolomics-based screening of the malaria box reveals both novel and established mechanisms of action DJ Creek",{"$nulls":6},0.8483333333333333,0.9800000000000001,0.8099999999999999,"Average",null,0.4530828604879675,1.7006577915597767,7.360729507627478,"gct V enriched","Average",0.2664162436067856,3.7535248844508895,null,"Detected",692838621.0520334,545915000,215905094.41200727,2.528495223731227,null,"Essential/Non essential"]
["MMV000061","Methylene blue",null,{"v":0.3,"d":"0.30"},{"v":13.299999999999999,"d":"13.30"},{"v":30,"d":"30.00"},{"v":80,"d":"80.00"},null,{"$f":"E330/D330","v":{"v":44.33333333333333,"d":"44.33"}},{"v":100,"d":"100.00"},{"$f":"G330/D330","v":{"v":266.6666666666667,"d":"266.67"}},null,"glutathione reductase (GR)","Buchholz K, Schirmer RH, Eubel JK, Akoachere MB, Dandekar T, Becker K, Gromer S. 2008. Interactions of methylene blue with human disulfide reductases and their orthologues from Plasmodium falciparum. Antimicrob. Agents Chemother. 52:183–191.","Vennerstrom JL, Makler MT, Angerhofer CK, Williams JA. 1995. Antimalarial dyes revisited: xanthenes, azines, oxazines, and thiazines. Antimicrob Agents Chemother 39:2671–2677. https://doi.org/10.1128/AAC.39 .12.2671",{"$nulls":5},"PF3D7_1419800",null,0.71,0.64,-0.14,null,null,1.15443469003188,1.0570182237640764,9,"gct V enriched",null,1.0921615768561685,0.9156154374873182,null,"Not detected",{"$nulls":5},"Essential"]
["MMV670930",null,null,14.27,{"v":639.8000000000001,"d":"639.80"},{"v":189.9,"d":"189.90"},null,null,{"v":44.83531885073582,"d":"44.84"},{"v":13.307638402242468,"d":"13.31"},null,null,"PI4K"," Potent Plasmodium falciparum gametocytocidal compounds identified by exploring the kinase inhibitor chemical space for dual active antimalarials Mariëtte E van der Watt, ",{"$nulls":6},"PF3D7_0509800",null,0.29,-0.01,0.16,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["CLM9f",null,null,{"v":9.2,"d":"9.20"},{"v":415,"d":"415.00"},{"v":45,"d":"45.00"},null,null,{"v":45.108695652173914,"d":"45.11"},{"v":4.891304347826087,"d":"4.89"},null,null,"PI4K","Identification of a potential antimalarial drug candidate from a series of 2-aminopyrazines by optimization of aqueous solubility and potency across the parasite life cycle Le Manach 2016",{"$nulls":6},"PF3D7_0509800",null,0.29,-0.01,0.16,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV674192",null,null,9.17,{"v":415.9,"d":"415.90"},45.24,null,null,{"v":45.35441657579062,"d":"45.35"},{"v":4.933478735005453,"d":"4.93"},null,null,"PI4K"," Potent Plasmodium falciparum gametocytocidal compounds identified by exploring the kinase inhibitor chemical space for dual active antimalarials Mariëtte E van der Watt, ",{"$nulls":6},"PF3D7_0509800",null,0.29,-0.01,0.16,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV030084",null,null,{"v":109,"d":"109.00"},{"v":5000,"d":"5000.00"},{"v":5000,"d":"5000.00"},null,null,{"v":45.87155963302752,"d":"45.87"},{"v":45.87155963302752,"d":"45.87"},null,null,"PKG","Inhibition of resistance-refractory P. falciparum kinase PKG delivers prophylactic, blood stage, and transmission-blocking antiplasmodial activity. M. Vanaerschot, 2020",{"$nulls":6},"PF3D7_1436600",null,0.47,-0.44,0.1,null,null,0,0.068244893498124,2.02530545710245,"gct V enriched",null,0.8,null,null,"Detected",187255751.4074903,109730000,295371702.85639864,{"$f":"AL334/AM334","v":0.37149801060444715},null,"Essential"]
["MMV030084",null,null,{"v":109,"d":"109.00"},{"v":5000,"d":"5000.00"},{"v":5000,"d":"5000.00"},null,null,{"v":45.87155963302752,"d":"45.87"},{"v":45.87155963302752,"d":"45.87"},null,null,"tyrosine kinase-like protein (TKL3)","Inhibition of resistance-refractory P. falciparum kinase PKG delivers prophylactic, blood stage, and transmission-blocking antiplasmodial activity. M. Vanaerschot, 2020",{"$nulls":6},"PF3D7_1349300",null,0.11,0.43,0.37,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential/Not essential"]
["MMV673927",null,null,{"v":15,"d":"15.00"},{"v":697.3000000000001,"d":"697.30"},146.05,null,null,{"v":46.48666666666667,"d":"46.49"},{"$f":"F336/D336","v":{"v":9.736666666666668,"d":"9.74"}},null,null,"PI4K"," Potent Plasmodium falciparum gametocytocidal compounds identified by exploring the kinase inhibitor chemical space for dual active antimalarials Mariëtte E van der Watt, ",{"$nulls":6},"PF3D7_0509800",null,0.29,-0.01,0.16,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV007160",null,null,{"v":24.8,"d":"24.80"},{"v":1185,"d":"1185.00"},{"v":208,"d":"208.00"},null,null,{"v":47.78225806451613,"d":"47.78"},{"$f":"F337/D337","v":{"v":8.387096774193548,"d":"8.39"}},null,null,"Mitochondrial electron transport chain (bc1 inhibitor) (Gamo)","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond, van Voorhis 2016",{"$nulls":8},0.8483333333333333,0.9800000000000001,0.8099999999999999,"Average",null,0.4530828604879675,1.7006577915597767,7.360729507627478,"gct V enriched","Average",0.2664162436067856,3.7535248844508895,null,"Detected",692838621.0520334,545915000,215905094.41200727,2.528495223731227,null,"Essential/Non essential"]
["MMV019066",null,null,104.54,{"v":5000,"d":"5000.00"},null,{"v":5000,"d":"5000.00"},null,{"v":47.82858236081882,"d":"47.83"},null,{"$f":"G338/D338","v":{"v":47.82858236081882,"d":"47.83"}},null,"protein farnesyltransferase subunit beta (FTB)","Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. Cowell. 2018","Eastman, R.T. et al. (2007) Resistance mutations at the lipid substrate binding site of Plasmodium falciparum protein farnesyltransferase. Mol. Biochem. Parasitol. 152, 66–71","Eastman, R.T. et al. (2005) Resistance to a protein farnesyltransferase inhibitor in Plasmodium falciparum. J. Biol. Chem. 280, 13554–13559","A broad analysis of resistance development in the malaria parasite VC Corey 2016","M.R. Luth, P. Gupta, S. Ottilie, E.A. Winzeler Using in vitro evolution and whole genome analysis to discover next generation targets for antimalarial drug discovery",null,null,"PF3D7_1147500",null,0.9,-0.08,-0.56,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV019066",null,null,104.54,{"v":5000,"d":"5000.00"},null,{"v":5000,"d":"5000.00"},null,{"v":47.82858236081882,"d":"47.83"},null,{"$f":"G339/D339","v":{"v":47.82858236081882,"d":"47.83"}},null,"protein farnesyltransferase subunit alpha","Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. Cowell. 2018","Eastman, R.T. et al. (2007) Resistance mutations at the lipid substrate binding site of Plasmodium falciparum protein farnesyltransferase. Mol. Biochem. Parasitol. 152, 66–71","Eastman, R.T. et al. (2005) Resistance to a protein farnesyltransferase inhibitor in Plasmodium falciparum. J. Biol. Chem. 280, 13554–13559","A broad analysis of resistance development in the malaria parasite VC Corey 2016","M.R. Luth, P. Gupta, S. Ottilie, E.A. Winzeler Using in vitro evolution and whole genome analysis to discover next generation targets for antimalarial drug discovery",null,null,"PF3D7_1242600",null,0.63,-0.21,-0.65,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV1580857","Mupirocin",null,100.49,{"v":5000,"d":"5000.00"},null,{"v":5000,"d":"5000.00"},null,{"v":49.75619464623346,"d":"49.76"},null,{"$f":"G340/D340","v":{"v":49.75619464623346,"d":"49.76"}},null,"isoleucine--tRNA ligase (cyto-IRS)","Validation of isoleucine utilization targets in Plasmodium falciparum. ES Istvan. 2011","Dual targeting of aminoacyl-tRNA synthetases to the apicoplast and cytosol in Plasmodium falciparum. KE Jackson. 2012",{"$nulls":5},"PF3D7_1332900",null,0.67,-0.18,-0.65,null,null,1.3845350808661399,2.2579551294528715,3.59886437939448,"shared 3 stages",null,0.6131809542210117,1.630839955344675,null,"Detected",1648061769.4163723,4102300000,877671904.8445911,4.674070090834674,null,"Essential"]
["MMV1580857","Mupirocin",null,100.49,{"v":5000,"d":"5000.00"},null,{"v":5000,"d":"5000.00"},null,{"v":49.75619464623346,"d":"49.76"},null,{"$f":"G341/D341","v":{"v":49.75619464623346,"d":"49.76"}},null,"isoleucine--tRNA ligase (api-IRS)","Validation of isoleucine utilization targets in Plasmodium falciparum. ES Istvan. 2011","Dual targeting of aminoacyl-tRNA synthetases to the apicoplast and cytosol in Plasmodium falciparum. KE Jackson. 2012",{"$nulls":5},"PF3D7_1225100",null,0.51,0.51,0.36,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Not essential"]
["MMV670402",null,null,25.74,{"v":1319.5,"d":"1319.50"},{"v":440.90000000000003,"d":"440.90"},null,null,{"v":51.26262626262626,"d":"51.26"},{"$f":"F342/D342","v":{"v":17.12898212898213,"d":"17.13"}},null,null,"PI4K"," Potent Plasmodium falciparum gametocytocidal compounds identified by exploring the kinase inhibitor chemical space for dual active antimalarials Mariëtte E van der Watt, ",{"$nulls":6},"PF3D7_0509800",null,0.29,-0.01,0.16,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV650381","KDU691",null,{"v":42.7,"d":"42.70"},{"v":2257,"d":"2257.00"},null,{"v":767.8,"d":"767.80"},null,{"v":52.857142857142854,"d":"52.86"},null,{"$f":"G343/D343","v":{"v":17.98126463700234,"d":"17.98"}},null,"PI4K","McNamara CW, et al. Targeting Plasmodium PI(4)K to eliminate malaria. Nature. 2013;504:248–253.",{"$nulls":6},"PF3D7_0509800",null,0.29,-0.01,0.16,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV006429",null,null,{"v":32.800000000000004,"d":"32.80"},{"v":1746,"d":"1746.00"},{"v":3317,"d":"3317.00"},null,null,{"v":53.231707317073166,"d":"53.23"},{"$f":"F344/D344","v":{"v":101.12804878048779,"d":"101.13"}},null,null,"ATP4","E.L. Allman, H.J. Painter, J. Samra, M. Carrasquilla, M. Llinas Metabolomic profiling of the malaria box reveals antimalarial target pathways 2016","Diverse chemotypes disrupt ion homeostasis in the malaria parasite AM Lehane 2014","Targeted Phenotypic Screening in Plasmodium falciparum and Toxoplasma gondii Reveals Novel Modes of Action of Medicines for Malaria Venture Malaria Box Molecules Gowtham Subramanian",{"$nulls":4},"PF3D7_1211900",null,0.33,-0.22,-0.49,null,null,1.7731908623980155,0.4394601472062679,2.59381366380463,"shared 3 stages",null,4.034929842149575,0.24783578379822793,null,"Detected",636393353.8483057,392860000,65708369.94269839,5.978842578846459,null,"Essential"]
["CLM17",null,null,{"v":14,"d":"14.00"},{"v":754,"d":"754.00"},{"v":237,"d":"237.00"},null,null,{"v":53.857142857142854,"d":"53.86"},{"v":16.928571428571427,"d":"16.93"},null,null,"PI4K","Identification of a potential antimalarial drug candidate from a series of 2-aminopyrazines by optimization of aqueous solubility and potency across the parasite life cycle Le Manach 2016",{"$nulls":6},"PF3D7_0509800",null,0.29,-0.01,0.16,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV642942",null,null,10.17,{"v":550,"d":"550.00"},{"v":134.7,"d":"134.70"},null,null,{"v":54.08062930186824,"d":"54.08"},{"v":13.244837758112093,"d":"13.24"},null,null,"PI4K"," Potent Plasmodium falciparum gametocytocidal compounds identified by exploring the kinase inhibitor chemical space for dual active antimalarials Mariëtte E van der Watt, ",{"$nulls":6},"PF3D7_0509800",null,0.29,-0.01,0.16,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV666023",null,null,{"v":36.8,"d":"36.80"},{"v":2000,"d":"2000.00"},{"v":183.5,"d":"183.50"},{"v":5000,"d":"5000.00"},null,{"v":54.34782608695652,"d":"54.35"},{"v":4.986413043478262,"d":"4.99"},{"$f":"G347/D347","v":{"v":135.8695652173913,"d":"135.87"}},null,"deoxyhypusine hydroxylase (DOHH)","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond, van Voorhis 2016","Screening the Medicines for Malaria Venture \"Malaria Box\" against the Plasmodium falciparum Aminopeptidases, M1, M17 and M18 A Paiardini","Malaria Box Compounds against Anopheles gambiae (Diptera: Culicidae) Carboxypeptidase B Activity to Block Malaria Transmission T Pomun","Metabolomics-based screening of the malaria box reveals both novel and established mechanisms of action DJ Creek",{"$nulls":3},"PF3D7_1302600",null,0.46,-0.08,-0.12,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV666023",null,null,{"v":36.8,"d":"36.80"},{"v":2000,"d":"2000.00"},{"v":183.5,"d":"183.50"},{"v":5000,"d":"5000.00"},null,{"v":54.34782608695652,"d":"54.35"},{"v":4.986413043478262,"d":"4.99"},{"v":135.8695652173913,"d":"135.87"},null,"PfA-M17 leucyl aminopeptidase","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond, van Voorhis 2016","Screening the Medicines for Malaria Venture \"Malaria Box\" against the Plasmodium falciparum Aminopeptidases, M1, M17 and M18 A Paiardini","Malaria Box Compounds against Anopheles gambiae (Diptera: Culicidae) Carboxypeptidase B Activity to Block Malaria Transmission T Pomun","Metabolomics-based screening of the malaria box reveals both novel and established mechanisms of action DJ Creek",{"$nulls":3},"PF3D7_1446200",null,0.54,0.07,-0.73,null,null,5.684407499026659,6.582454249212135,12.6500780654601,"shared 3 stages",null,0.8635696176250729,1.157984231485735,null,"Detected",1999628798.4753647,11380000000,1981315069.4565032,5.743659943555399,null,"Essential"]
["MMV666023",null,null,{"v":36.8,"d":"36.80"},{"v":2000,"d":"2000.00"},{"v":183.5,"d":"183.50"},{"v":5000,"d":"5000.00"},null,{"v":54.34782608695652,"d":"54.35"},{"v":4.986413043478262,"d":"4.99"},{"v":135.8695652173913,"d":"135.87"},null,"PfA-M1 alanyl aminopeptidase","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond, van Voorhis 2016","Screening the Medicines for Malaria Venture \"Malaria Box\" against the Plasmodium falciparum Aminopeptidases, M1, M17 and M18 A Paiardini","Malaria Box Compounds against Anopheles gambiae (Diptera: Culicidae) Carboxypeptidase B Activity to Block Malaria Transmission T Pomun","Metabolomics-based screening of the malaria box reveals both novel and established mechanisms of action DJ Creek",{"$nulls":3},"PF3D7_1311800",null,0.56,0.06,-0.86,null,null,15.969688689965796,9.989022559815394,32.8385515342823,"shared 3 stages",null,1.5987238585494725,0.6254988906635217,null,"Detected",2472328320.453194,15872000000,1421009325.403716,11.169525573303808,null,"Essential"]
["MMV666023",null,null,{"v":36.8,"d":"36.80"},{"v":2000,"d":"2000.00"},{"v":183.5,"d":"183.50"},{"v":5000,"d":"5000.00"},null,{"v":54.34782608695652,"d":"54.35"},{"v":4.986413043478262,"d":"4.99"},{"v":135.8695652173913,"d":"135.87"},null,"Mitochondrial electron transport chain (bc1 inhibitor)","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond, van Voorhis 2016","Screening the Medicines for Malaria Venture \"Malaria Box\" against the Plasmodium falciparum Aminopeptidases, M1, M17 and M18 A Paiardini","Malaria Box Compounds against Anopheles gambiae (Diptera: Culicidae) Carboxypeptidase B Activity to Block Malaria Transmission T Pomun","Metabolomics-based screening of the malaria box reveals both novel and established mechanisms of action DJ Creek",{"$nulls":5},0.8483333333333333,0.9800000000000001,0.8099999999999999,"Average",null,0.4530828604879675,1.7006577915597767,7.360729507627478,"gct V enriched","Average",0.2664162436067856,3.7535248844508895,null,"Detected",692838621.0520334,545915000,215905094.41200727,2.528495223731227,null,"Essential/Non essential"]
["MMV1557817","MIPS1778",null,32.83,{"v":1798,"d":"1798.00"},null,{"v":5000,"d":"5000.00"},null,{"v":54.76698141943345,"d":"54.77"},null,{"v":152.29972586049345,"d":"152.30"},null,"PfA-M17 leucyl aminopeptidase","Characterising the M1 and M17 aminopeptidases in Plasmodium falciparum. R Edgar. 2018",{"$nulls":6},"PF3D7_1446200",null,0.54,0.07,-0.73,null,null,5.684407499026659,6.582454249212135,12.6500780654601,"shared 3 stages",null,0.8635696176250729,1.157984231485735,null,"Detected",1999628798.4753647,11380000000,1981315069.4565032,5.743659943555399,null,"Essential"]
["MMV1557817","MIPS1778",null,32.83,{"v":1798,"d":"1798.00"},null,{"v":5000,"d":"5000.00"},null,{"v":54.76698141943345,"d":"54.77"},null,{"v":152.29972586049345,"d":"152.30"},null,"PfA-M1 alanyl aminopeptidase","Characterising the M1 and M17 aminopeptidases in Plasmodium falciparum. R Edgar. 2018",{"$nulls":6},"PF3D7_1311800",null,0.56,0.06,-0.86,null,null,15.969688689965796,9.989022559815394,32.8385515342823,"shared 3 stages",null,1.5987238585494725,0.6254988906635217,null,"Detected",2472328320.453194,15872000000,1421009325.403716,11.169525573303808,null,"Essential"]
["MMV006389",null,null,{"v":86.7,"d":"86.70"},{"v":5000,"d":"5000.00"},{"v":733,"d":"733.00"},null,null,{"v":57.67012687427912,"d":"57.67"},{"$f":"F353/D353","v":{"v":8.454440599769319,"d":"8.45"}},null,null,"Possible BC-1 inhibitor (structure similarity to cmpds reported in Dong C, Chem Biol. 2011; 18:1602-1610). Mitocondrial electron transport chain (bc1 inhibitor) (Gamo)","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond, van Voorhis 2016",{"$nulls":8},0.8483333333333333,0.9800000000000001,0.8099999999999999,"Average",null,0.4530828604879675,1.7006577915597767,7.360729507627478,"gct V enriched","Average",0.2664162436067856,3.7535248844508895,null,"Detected",692838621.0520334,545915000,215905094.41200727,2.528495223731227,null,"Essential/Non essential"]
["MMV674132",null,null,43.71,{"v":2604,"d":"2604.00"},{"v":1453.5,"d":"1453.50"},null,null,{"v":59.57446808510638,"d":"59.57"},{"v":33.25326012354152,"d":"33.25"},null,null,"CDPK1"," Potent Plasmodium falciparum gametocytocidal compounds identified by exploring the kinase inhibitor chemical space for dual active antimalarials Mariëtte E van der Watt, ",{"$nulls":6},"PF3D7_0217500",null,0.54,-0.07,0.86,null,null,1.8276642121903912,0.8228906159046369,5.07832312829723,"shared 3 stages",null,2.2210293529488925,0.4502416857626333,null,"Detected",1326801430.219953,360430000,3411452182.6706023,0.10565295384496434,null,"Essential","I S","A"]
["MMV674132",null,null,43.71,{"v":2604,"d":"2604.00"},{"v":1453.5,"d":"1453.50"},null,null,{"v":59.57446808510638,"d":"59.57"},{"v":33.25326012354152,"d":"33.25"},null,null,"PI4K"," Potent Plasmodium falciparum gametocytocidal compounds identified by exploring the kinase inhibitor chemical space for dual active antimalarials Mariëtte E van der Watt, ",{"$nulls":6},"PF3D7_0509800",null,0.29,-0.01,0.16,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV674132",null,null,43.71,{"v":2604,"d":"2604.00"},{"v":1453.5,"d":"1453.50"},null,null,{"v":59.57446808510638,"d":"59.57"},{"v":33.25326012354152,"d":"33.25"},null,null,"PKG"," Potent Plasmodium falciparum gametocytocidal compounds identified by exploring the kinase inhibitor chemical space for dual active antimalarials Mariëtte E van der Watt, ",{"$nulls":6},"PF3D7_1436600",null,0.47,-0.44,0.1,null,null,0,0.068244893498124,2.02530545710245,"gct V enriched",null,0.8,null,null,"Detected",187255751.4074903,109730000,295371702.85639864,0.37149801060444715,null,"Essential"]
["MMV674132",null,null,43.71,{"v":2604,"d":"2604.00"},{"v":1453.5,"d":"1453.50"},null,null,{"v":59.57446808510638,"d":"59.57"},{"v":33.25326012354152,"d":"33.25"},null,null,"PK7"," Potent Plasmodium falciparum gametocytocidal compounds identified by exploring the kinase inhibitor chemical space for dual active antimalarials Mariëtte E van der Watt, ",{"$nulls":6},"PF3D7_0213400",null,0.31,0.27,-0.31,null,null,0.2246523050636276,0,0.136463666385725,"not determined",null,1.2,0,null,"Not detected",{"$nulls":5},"Not essential","A D"]
["MMV668809",null,null,{"v":38.080000000000005,"d":"38.08"},{"v":2433,"d":"2433.00"},{"v":432.40000000000003,"d":"432.40"},null,null,{"v":63.89180672268907,"d":"63.89"},{"v":11.355042016806722,"d":"11.36"},null,null,"PI4K"," Potent Plasmodium falciparum gametocytocidal compounds identified by exploring the kinase inhibitor chemical space for dual active antimalarials Mariëtte E van der Watt, ",{"$nulls":6},"PF3D7_0509800",null,0.29,-0.01,0.16,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV672925",null,null,{"v":10.200000000000001,"d":"10.20"},693.35,{"v":476.8,"d":"476.80"},null,null,{"v":67.97549019607843,"d":"67.98"},{"v":46.745098039215684,"d":"46.75"},null,null,"CDPK1","Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): preparation and evaluation of pyrazole … JM Large","Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) TM Chapman","New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of Plasmodium Phosphatidylinositol-4-kinase and cGMP … PM Cheuka",{"$nulls":4},"PF3D7_0217500",null,0.54,-0.07,0.86,null,null,1.8276642121903912,0.8228906159046369,5.07832312829723,"shared 3 stages",null,2.2210293529488925,0.4502416857626333,null,"Detected",1326801430.219953,360430000,3411452182.6706023,0.10565295384496434,null,"Essential","I S","A"]
["MMV672925",null,null,{"v":10.200000000000001,"d":"10.20"},693.35,{"v":476.8,"d":"476.80"},null,null,{"v":67.97549019607843,"d":"67.98"},{"v":46.745098039215684,"d":"46.75"},null,null,"PI4K","Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): preparation and evaluation of pyrazole … JM Large","Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) TM Chapman","New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of Plasmodium Phosphatidylinositol-4-kinase and cGMP … PM Cheuka",{"$nulls":4},"PF3D7_0509800",null,0.29,-0.01,0.16,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV672925",null,null,{"v":10.200000000000001,"d":"10.20"},693.35,{"v":476.8,"d":"476.80"},null,null,{"v":67.97549019607843,"d":"67.98"},{"v":46.745098039215684,"d":"46.75"},null,null,"PKG","Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): preparation and evaluation of pyrazole … JM Large","Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) TM Chapman","New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of Plasmodium Phosphatidylinositol-4-kinase and cGMP … PM Cheuka",{"$nulls":4},"PF3D7_1436600",null,0.47,-0.44,0.1,null,null,0,0.068244893498124,2.02530545710245,"gct V enriched",null,0.8,null,null,"Detected",187255751.4074903,109730000,295371702.85639864,0.37149801060444715,null,"Essential"]
["MMV672925",null,null,{"v":10.200000000000001,"d":"10.20"},693.35,{"v":476.8,"d":"476.80"},null,null,{"v":67.97549019607843,"d":"67.98"},{"v":46.745098039215684,"d":"46.75"},null,null,"PK7","Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): preparation and evaluation of pyrazole … JM Large","Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) TM Chapman","New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of Plasmodium Phosphatidylinositol-4-kinase and cGMP … PM Cheuka",{"$nulls":4},"PF3D7_0213400",null,0.31,0.27,-0.31,null,null,0.2246523050636276,0,0.136463666385725,"not determined",null,1.2,0,null,"Not detected",{"$nulls":5},"Not essential","A D"]
["MMV000062","Pentamidine",null,{"v":10,"d":"10.00"},697.28,812.56,{"v":700,"d":"700.00"},null,{"v":69.728,"d":"69.73"},{"v":81.256,"d":"81.26"},{"$f":"G363/D363","v":{"v":70,"d":"70.00"}},null,"DNA topoisomerase2 (TOP2)","A. Stead, P.G. Bray, I.G. Edwards, H.P. DeKoning, B.C. Elford, P.A. Stocks, S.A. Ward Mol. Pharmacol., 59 (2001), pp. 1298-1306","A.E. Purfield, R.R. Tidwell, S.R. Meshnik Malar. J., 8 (2009), p. 104",{"$nulls":5},"PF3D7_1433500",null,0.79,-0.02,0.28,null,null,1.1250623353878415,0.9615132377040246,2.43332001828199,"shared 3 stages",null,1.1700955236709503,0.8546310790615554,null,"Detected",563713858.0970031,244090000,3133698280.5174513,0.07789199155436709,null,"Not essential"]
["MMV668807",null,null,26.16,{"v":1835,"d":"1835.00"},901.25,null,null,{"v":70.14525993883792,"d":"70.15"},{"v":34.45145259938838,"d":"34.45"},null,null,"PI4K"," Potent Plasmodium falciparum gametocytocidal compounds identified by exploring the kinase inhibitor chemical space for dual active antimalarials Mariëtte E van der Watt, ",{"$nulls":6},"PF3D7_0509800",null,0.29,-0.01,0.16,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV019555",null,null,{"v":20,"d":"20.00"},{"v":1428,"d":"1428.00"},{"v":1547.9,"d":"1547.90"},{"v":470,"d":"470.00"},null,{"v":71.4,"d":"71.40"},{"v":77.39500000000001,"d":"77.40"},{"$f":"G365/D365","v":{"v":23.5,"d":"23.50"}},null,"acetylcholinesterase?","Combining stage specificity and metabolomic profiling to advance antimalarial drug discovery JM Murithi","Antiapicoplast and gametocytocidal screening to identify the mechanisms of action of compounds within the malaria box JD Bowman"," Evaluation of short-tether bis-THA AChE inhibitors. A further test of the dual binding site hypothesis PR Carlier",{"$nulls":6},1.0166666666666666,-0.6,-0.7533333333333334,"Average",null,0,0,23.6209240149463,"gct V enriched","Average",1,null,null,"Detected",837699531.7690666,116700000,253740798.83660358,0.45991815480627135,null,"Essential"]
["MMV000642",null,null,{"v":20.2,"d":"20.20"},{"v":2000,"d":"2000.00"},{"v":596,"d":"596.00"},null,null,{"v":99.00990099009901,"d":"99.01"},{"v":29.504950495049506,"d":"29.50"},null,null,"ATP4","Biochemical characterization and chemical inhibition of PfATP4-associated Na+-ATPase activity in Plasmodium falciparum membranes James E.O. Rosling 2018",{"$nulls":6},"PF3D7_1211900",null,0.33,-0.22,-0.49,null,null,1.7731908623980155,0.4394601472062679,2.59381366380463,"shared 3 stages",null,4.034929842149575,0.24783578379822793,null,"Detected",636393353.8483057,392860000,65708369.94269839,5.978842578846459,null,"Essential"]
["MMV666810",null,null,5.42,{"v":602.5,"d":"602.50"},{"v":178.7,"d":"178.70"},null,null,{"v":111.16236162361623,"d":"111.16"},{"v":32.97047970479704,"d":"32.97"},null,null,"PI4K","Chemogenomic fingerprints associated with stage-specific gametocytocidal compound action against human malaria parasites J Niemand",{"$nulls":6},"PF3D7_0509800",null,0.29,-0.01,0.16,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["CLM9l2",null,null,{"v":5.4,"d":"5.40"},{"v":603,"d":"603.00"},{"v":179,"d":"179.00"},null,null,{"v":111.66666666666666,"d":"111.67"},{"v":33.148148148148145,"d":"33.15"},null,null,"PI4K","Identification of a potential antimalarial drug candidate from a series of 2-aminopyrazines by optimization of aqueous solubility and potency across the parasite life cycle Le Manach 2016",{"$nulls":6},"PF3D7_0509800",null,0.29,-0.01,0.16,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV670771",null,null,{"v":35.6,"d":"35.60"},{"v":4182.5,"d":"4182.50"},{"v":5000,"d":"5000.00"},null,null,{"v":117.48595505617978,"d":"117.49"},{"v":140.4494382022472,"d":"140.45"},null,null,"DHFR-TS","Rosowsky A., Chen K. K., Lin M.: 2,4-Diaminothieno(2,3-d)pyrimidines as antifolates and antimalarials.",{"$nulls":6},"PF3D7_0417200",null,0.11,0.52,0.13,null,null,1.15443469003188,0.6407679530676047,10.9377664171444,"gct V enriched",null,1.8016423644552657,0.5550491150347446,null,"Detected",3107354809.595412,901370000,1885999900.5903804,0.47792685445945216,null,"Essential","A"]
["MMV668648",null,null,{"v":6.0200000000000005,"d":"6.02"},{"v":731.3499999999999,"d":"731.35"},{"v":536.2,"d":"536.20"},null,null,{"v":121.48671096345512,"d":"121.49"},{"v":89.06976744186046,"d":"89.07"},null,null,"PI4K"," Potent Plasmodium falciparum gametocytocidal compounds identified by exploring the kinase inhibitor chemical space for dual active antimalarials Mariëtte E van der Watt, ",{"$nulls":6},"PF3D7_0509800",null,0.29,-0.01,0.16,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["DSM265","DSM265",null,{"v":7.8,"d":"7.80"},{"v":1000,"d":"1000.00"},{"v":5000,"d":"5000.00"},null,null,{"v":128.2051282051282,"d":"128.21"},{"$f":"F371/D371","v":{"v":641.025641025641,"d":"641.03"}},null,null,"PfDHODH","Phillips MA, Lotharius J, Marsh K, White J, Dayan A, White KL, Njoroge JW, El Mazouni F, Lao Y, Kokkonda S, Tomchick DR, Deng X, Laird T, Bhatia SN, March S, Ng CL, Fidock DA, Wittlin S, Lafuente-Monasterio M, Benito FJ, Alonso LM, Martinez MS, Jimenez-Diaz MB, Bazaga SF, Angulo-Barturen I, Haselden JN, Louttit J, Cui Y, Sridhar A, Zeeman AM, Kocken C, Sauerwein R, Dechering K, Avery VM, Duffy S, Delves M, Sinden R, Ruecker A, Wickham KS, Rochford R, Gahagen J, Iyer L, Riccio E, Mirsalis J, Bathhurst I, Rueckle T, Ding X, Campo B, Leroy D, Rogers MJ, etal. 2015. A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria. Sci Transl Med 7:296ra111.",{"$nulls":6},"PF3D7_0603300",null,0.75,-0.19,-0.43,null,null,1.15443469003188,0.7714114432536744,1.89426612471675,"shared 3 stages",null,1.4965226405803402,0.6682157508904827,null,"Detected",133919747.91061999,21091000,31021606.034033686,0.679880982849861,null,"Essential"]
["MMV688533","MMV533",null,{"v":1.9,"d":"1.90"},{"v":247.1,"d":"247.10"},null,{"v":5000,"d":"5000.00"},null,{"v":130.05263157894737,"d":"130.05"},null,{"$f":"G372/D372","v":{"v":2631.5789473684213,"d":"2631.58"}},null,"Plasmodium protein (PfACG1)"," The antimalarial MMV688533 provides potential for single-dose cures with a high barrier to Plasmodium falciparum parasite resistance James M Murithi 2021",{"$nulls":6},"PF3D7_0910300",null,1,1.02,0.36,null,null,0,1.0364555891885496,1.31012970008316,"gct V enriched",null,2,null,null,"Detected",76963909.60590272,43815000,30348724.240319505,1.4437180177013835,null,"Not essential"]
["MMV688533","MMV533",null,{"v":1.9,"d":"1.90"},{"v":247.1,"d":"247.10"},null,{"v":5000,"d":"5000.00"},null,{"v":130.05263157894737,"d":"130.05"},null,{"$f":"G373/D373","v":{"v":2631.5789473684213,"d":"2631.58"}},null,"EH domain-containing protein (EHD)"," The antimalarial MMV688533 provides potential for single-dose cures with a high barrier to Plasmodium falciparum parasite resistance James M Murithi 2021",{"$nulls":6},"PF3D7_0304200",null,0.52,-0.17,-0.37,null,null,0.8697210650705587,0.5334064717843519,1.97635144163132,"shared 3 stages",null,1.630503398583011,0.6133075226148256,null,"Detected",237537519.2852397,226920000,130246510.67893732,1.742234773255205,null,"Not essential"]
["MMV675052","TM2-115",null,10.71,{"v":1411,"d":"1411.00"},null,2399.33,null,{"v":131.74603174603175,"d":"131.75"},null,{"$f":"G374/D374","v":{"v":224.02707749766572,"d":"224.03"}},null,"Histone lysine methyltransferase","Small-molecule histone methyltransferase inhibitors display rapid antimalarial activity against all blood stage forms in Plasmodium falciparum. NA Malmquist. 2012","Development of Diaminoquinazoline Histone Lysine Methyltransferase Inhibitors as Potent Blood‐Stage Antimalarial Compounds. S Sundriyal. 2014",{"$nulls":16},"Not detected"]
["MMV027634",null,null,37.74,{"v":5000,"d":"5000.00"},null,{"v":5000,"d":"5000.00"},null,{"v":132.48542660307365,"d":"132.49"},null,{"$f":"G375/D375","v":{"v":132.48542660307365,"d":"132.49"}},null,"DHFR-TS","Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. Cowell. 2018","Using in Vitro Evolution and Whole Genome Analysis To Discover Next Generation Targets for Antimalarial Drug Discovery. MR Luth. 2018","Exploration of the Plasmodium falciparum Resistome and Druggable Genome Reveals New Mechanisms of Drug Resistance and Antimalarial Targets. A Cowell. 2018",{"$nulls":4},"PF3D7_0417200",null,0.11,0.52,0.13,null,null,1.15443469003188,0.6407679530676047,10.9377664171444,"gct V enriched",null,1.8016423644552657,0.5550491150347446,null,"Detected",3107354809.595412,901370000,1885999900.5903804,0.47792685445945216,null,"Essential","A"]
["MMV670654",null,null,{"v":35,"d":"35.00"},{"v":5000,"d":"5000.00"},{"v":5000,"d":"5000.00"},null,null,{"v":142.85714285714286,"d":"142.86"},{"$f":"F376/D376","v":{"v":142.85714285714286,"d":"142.86"}},null,null,"CDPK1"," Potent Plasmodium falciparum gametocytocidal compounds identified by exploring the kinase inhibitor chemical space for dual active antimalarials Mariëtte E van der Watt, ",{"$nulls":6},"PF3D7_0217500",null,0.54,-0.07,0.86,null,null,1.8276642121903912,0.8228906159046369,5.07832312829723,"shared 3 stages",null,2.2210293529488925,0.4502416857626333,null,"Detected",1326801430.219953,360430000,3411452182.6706023,0.10565295384496434,null,"Essential","I S","A"]
["MMV670654",null,null,{"v":35,"d":"35.00"},{"v":5000,"d":"5000.00"},{"v":5000,"d":"5000.00"},null,null,{"v":142.85714285714286,"d":"142.86"},{"v":142.85714285714286,"d":"142.86"},null,null,"PI4K"," Potent Plasmodium falciparum gametocytocidal compounds identified by exploring the kinase inhibitor chemical space for dual active antimalarials Mariëtte E van der Watt, ",{"$nulls":6},"PF3D7_0509800",null,0.29,-0.01,0.16,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV670654",null,null,{"v":35,"d":"35.00"},{"v":5000,"d":"5000.00"},{"v":5000,"d":"5000.00"},null,null,{"v":142.85714285714286,"d":"142.86"},{"v":142.85714285714286,"d":"142.86"},null,null,"PKG"," Potent Plasmodium falciparum gametocytocidal compounds identified by exploring the kinase inhibitor chemical space for dual active antimalarials Mariëtte E van der Watt, ",{"$nulls":6},"PF3D7_1436600",null,0.47,-0.44,0.1,null,null,0,0.068244893498124,2.02530545710245,"gct V enriched",null,0.8,null,null,"Detected",187255751.4074903,109730000,295371702.85639864,0.37149801060444715,null,"Essential"]
["MMV670654",null,null,{"v":35,"d":"35.00"},{"v":5000,"d":"5000.00"},{"v":5000,"d":"5000.00"},null,null,{"v":142.85714285714286,"d":"142.86"},{"v":142.85714285714286,"d":"142.86"},null,null,"PK7"," Potent Plasmodium falciparum gametocytocidal compounds identified by exploring the kinase inhibitor chemical space for dual active antimalarials Mariëtte E van der Watt, ",{"$nulls":6},"PF3D7_0213400",null,0.31,0.27,-0.31,null,null,0.2246523050636276,0,0.136463666385725,"not determined",null,1.2,0,null,"Not detected",{"$nulls":5},"Not essential","A D"]
["MMV666693",null,null,{"v":23.8,"d":"23.80"},{"v":5000,"d":"5000.00"},{"v":438,"d":"438.00"},{"v":730,"d":"730.00"},null,{"v":210.08403361344537,"d":"210.08"},{"v":18.403361344537814,"d":"18.40"},{"$f":"G380/D380","v":{"v":30.672268907563023,"d":"30.67"}},null,"PfDHODH","E.L. Allman, H.J. Painter, J. Samra, M. Carrasquilla, M. Llinas Metabolomic profiling of the malaria box reveals antimalarial target pathways 2016","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond, van Voorhis 2016","Small molecule screen for candidate antimalarials targeting Plasmodium Kinesin-5 L Liu","Metabolomics-based screening of the malaria box reveals both novel and established mechanisms of action DJ Creek","High-throughput luciferase-based assay for the discovery of therapeutics that prevent malaria J Swann",null,null,"PF3D7_0603300",null,0.75,-0.19,-0.43,null,null,1.15443469003188,0.7714114432536744,1.89426612471675,"shared 3 stages",null,1.4965226405803402,0.6682157508904827,null,"Detected",133919747.91061999,21091000,31021606.034033686,0.679880982849861,null,"Essential"]
["MMV666693",null,null,{"v":23.8,"d":"23.80"},{"v":5000,"d":"5000.00"},{"v":438,"d":"438.00"},{"v":730,"d":"730.00"},null,{"v":210.08403361344537,"d":"210.08"},{"v":18.403361344537814,"d":"18.40"},{"$f":"G381/D381","v":{"v":30.672268907563023,"d":"30.67"}},null,"kinesin-5 (EG5)","E.L. Allman, H.J. Painter, J. Samra, M. Carrasquilla, M. Llinas Metabolomic profiling of the malaria box reveals antimalarial target pathways 2016","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond, van Voorhis 2016","Small molecule screen for candidate antimalarials targeting Plasmodium Kinesin-5 L Liu","Metabolomics-based screening of the malaria box reveals both novel and established mechanisms of action DJ Creek","High-throughput luciferase-based assay for the discovery of therapeutics that prevent malaria J Swann",null,null,"PF3D7_0317500",null,0.55,0.12,0.11,{"$nulls":6},"Not detected",{"$nulls":3},"Detected",1724106.6035876258,71582000,6932437.81906581,10.325660592747463,null,"Not essential"]
["MMV666693",null,null,{"v":23.8,"d":"23.80"},{"v":5000,"d":"5000.00"},{"v":438,"d":"438.00"},{"v":730,"d":"730.00"},null,{"v":210.08403361344537,"d":"210.08"},{"v":18.403361344537814,"d":"18.40"},{"$f":"G382/D382","v":{"v":30.672268907563023,"d":"30.67"}},null,"Mitochondrial electron transport chain (bc1 inhibitor)","E.L. Allman, H.J. Painter, J. Samra, M. Carrasquilla, M. Llinas Metabolomic profiling of the malaria box reveals antimalarial target pathways 2016","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond, van Voorhis 2016","Small molecule screen for candidate antimalarials targeting Plasmodium Kinesin-5 L Liu","Metabolomics-based screening of the malaria box reveals both novel and established mechanisms of action DJ Creek","High-throughput luciferase-based assay for the discovery of therapeutics that prevent malaria J Swann",{"$nulls":4},0.8483333333333333,0.9800000000000001,0.8099999999999999,"Average",null,0.4530828604879675,1.7006577915597767,7.360729507627478,"gct V enriched","Average",0.2664162436067856,3.7535248844508895,null,"Detected",692838621.0520334,545915000,215905094.41200727,2.528495223731227,null,"Essential/Not essential"]
["MMV000024","Pyrimethamine",null,{"v":22,"d":"22.00"},{"v":5000,"d":"5000.00"},null,{"v":5000,"d":"5000.00"},null,{"v":227.27272727272728,"d":"227.27"},null,{"$f":"G383/D383","v":{"v":227.27272727272728,"d":"227.27"}},null,"DHFR-TS","Basco LK, Eldin de Pecoulas P, Wilson CM, Le Bras J, Mazabraud A. 1995. Point mutations in the dihydrofolate reductase-thymidylate synthase gene and pyrimethamine and cycloguanil resistance in Plasmodium falciparum. Mol Biochem Parasitol 69:135–138.","Sirawaraporn W, Sathitkul T, Sirawaraporn R, Yuthavong Y, Santi DV. (1997) Antifolate-resistant mutants of Plasmodium falciparum dihydrofolate reductase. ","Yuthavong Y, Tarnchompoo B, Vilaivan T, Chitnumsub P, Kamchonwongpaisan S, Charman SA, McLennan DN, White KL, Vivas L, Bongard E et al.. (2012) Malarial dihydrofolate reductase as a paradigm for drug development against a resistance-compromised target. ",{"$nulls":4},"PF3D7_0417200",null,0.11,0.52,0.13,null,null,1.15443469003188,0.6407679530676047,10.9377664171444,"gct V enriched",null,1.8016423644552657,0.5550491150347446,null,"Detected",3107354809.595412,901370000,1885999900.5903804,0.47792685445945216,null,"Essential","A"]
["MMV1793799","ML10",null,18.15,{"v":5000,"d":"5000.00"},null,{"v":5000,"d":"5000.00"},null,{"v":275.4820936639119,"d":"275.48"},null,{"$f":"G384/D384","v":{"v":275.4820936639119,"d":"275.48"}},null,"PKG"," A potent series targeting the malarial cGMP-dependent protein kinase clears infection and blocks transmission. DA Baker. 2017",{"$nulls":6},"PF3D7_1436600",null,0.47,-0.44,0.1,null,null,0,0.068244893498124,2.02530545710245,"gct V enriched",null,0.8,null,null,"Detected",187255751.4074903,109730000,295371702.85639864,0.37149801060444715,null,"Essential"]
["MMV000130","Ganaplacide/KAF156",null,{"v":6,"d":"6.00"},{"v":3300,"d":"3300.00"},null,{"v":5000,"d":"5000.00"},null,{"v":550,"d":"550.00"},null,{"v":833.3333333333334,"d":"833.33"},null,"Protein secretory pathway","Pan-active imidazolopiperazine antimalarials target the Plasmodium falciparum intracellular secretory pathway. GM LaMonte. 2020",{"$nulls":17},"Not detected"]
["MMV000130","Ganaplacide/KAF156",null,{"v":6,"d":"6.00"},{"v":3300,"d":"3300.00"},null,{"v":5000,"d":"5000.00"},null,{"v":550,"d":"550.00"},null,{"v":833.3333333333334,"d":"833.33"},null,"CARL","Pan-active imidazolopiperazine antimalarials target the Plasmodium falciparum intracellular secretory pathway. GM LaMonte. 2020",{"$nulls":6},"PF3D7_0321900",null,0.31,-0.21,-0.06,null,null,0,0,0.0537249727360731,"gct V enriched",null,1,null,null,"Not detected",{"$nulls":5},"Essential"]
["MMV1557821","SC83288",null,6.68,{"v":3903,"d":"3903.00"},null,{"v":5000,"d":"5000.00"},null,{"v":584.2814371257485,"d":"584.28"},null,{"v":748.502994011976,"d":"748.50"},null,"calcium-transporting ATPase (ATP6)","SC83288 is a clinical development candidate for the treatment of severe malaria S Pegoraro 2017","Target identification studies for SC83288: a novel drug for the treatment of severe malaria RV Celada 2022",{"$nulls":5},"PF3D7_0106300",null,0.39,-0.03,-0.13,null,null,1.6876027710717014,0.7605873874153525,3.93796931771435,"shared 3 stages",null,2.2188150881735713,0.4506910040994696,null,"Detected",1029579056.5443927,1600300000,889900800.0520924,1.7982903261872814,null,"Essential"]
["MMV1557821","SC83288",null,6.68,{"v":3903,"d":"3903.00"},null,{"v":5000,"d":"5000.00"},null,{"v":584.2814371257485,"d":"584.28"},null,{"v":748.502994011976,"d":"748.50"},null,"fumarate hydratase (FH)","SC83288 is a clinical development candidate for the treatment of severe malaria S Pegoraro 2017","Target identification studies for SC83288: a novel drug for the treatment of severe malaria RV Celada 2022",{"$nulls":5},"PF3D7_0927300",null,0.23,0.16,0.19,null,null,0.16576703731775866,0.3188409631490102,3.01945033361513,"gct V enriched",null,0.5199050827113688,1.9234280126381478,null,"Detected",289907290.8347029,323510000,31981193.98333044,10.115632335947906,null,"Essential"]
["MMV1557821","SC83288",null,6.68,{"v":3903,"d":"3903.00"},null,{"v":5000,"d":"5000.00"},null,{"v":584.2814371257485,"d":"584.28"},null,{"v":748.502994011976,"d":"748.50"},null,"mini-chromosome maintenance complex-binding protein","SC83288 is a clinical development candidate for the treatment of severe malaria S Pegoraro 2017","Target identification studies for SC83288: a novel drug for the treatment of severe malaria RV Celada 2022",{"$nulls":5},"PF3D7_1412100",null,1.16,0.17,0.19,null,null,0.22030595261377078,0.06444401261225294,0.0873356727196561,"enriched troph",null,3.418563551269049,{"$f":"AC389/AB389","v":0.2925205236066994},null,"Detected",477492.16995597084,2276900,32190079.896683455,0.07073297137838384,null,"Essential","A"]
["MMV1557821","SC83288",null,6.68,{"v":3903,"d":"3903.00"},null,{"v":5000,"d":"5000.00"},null,{"v":584.2814371257485,"d":"584.28"},null,{"v":748.502994011976,"d":"748.50"},null,"casein kinase 2, alpha subunit","SC83288 is a clinical development candidate for the treatment of severe malaria S Pegoraro 2017","Target identification studies for SC83288: a novel drug for the treatment of severe malaria RV Celada 2022",{"$nulls":5},"PF3D7_1108400",null,0.45,0.17,0.01,null,null,60.79064011727486,103.28083452179338,47.3293023857175,"shared 3 stages",null,{"$f":"AB390/AC390","v":0.5885955550102316},1.6989594832781518,null,"Detected",1725313191.9432108,3068800000,905698894.339295,3.388322564132842,null,"Essential","I","D"]
["MMV1557821","SC83288",null,6.68,{"v":3903,"d":"3903.00"},null,{"v":5000,"d":"5000.00"},null,{"v":584.2814371257485,"d":"584.28"},null,{"v":748.502994011976,"d":"748.50"},null,"casein kinase II beta chain","SC83288 is a clinical development candidate for the treatment of severe malaria S Pegoraro 2017","Target identification studies for SC83288: a novel drug for the treatment of severe malaria RV Celada 2022",{"$nulls":5},"PF3D7_1103700",null,0.9,0.14,-0.56,null,null,3.2187487937519563,1.8900861310663797,4.08021804691302,"shared 3 stages",null,1.7029640823489616,0.5872114452470794,null,"Detected",299234964.12211066,248990000,101464723.34606703,2.453956328750502,null,"Essential"]
["MMV1557821","SC83288",null,6.68,{"v":3903,"d":"3903.00"},null,{"v":5000,"d":"5000.00"},null,{"v":584.2814371257485,"d":"584.28"},null,{"v":748.502994011976,"d":"748.50"},null,"casein kinase II beta chain","SC83288 is a clinical development candidate for the treatment of severe malaria S Pegoraro 2017","Target identification studies for SC83288: a novel drug for the treatment of severe malaria RV Celada 2022",{"$nulls":5},"PF3D7_1103700",null,0.9,0.14,-0.56,null,null,3.2187487937519563,1.8900861310663797,4.08021804691302,"shared 3 stages",null,1.7029640823489616,0.5872114452470794,null,"Detected",299234964.12211066,248990000,101464723.34606703,2.453956328750502,null,"Essential"]
["MMV1557821","SC83288",null,6.68,{"v":3903,"d":"3903.00"},null,{"v":5000,"d":"5000.00"},null,{"v":584.2814371257485,"d":"584.28"},null,{"v":748.502994011976,"d":"748.50"},null,"iron-sulfur cluster assembly protein SufA","SC83288 is a clinical development candidate for the treatment of severe malaria S Pegoraro 2017","Target identification studies for SC83288: a novel drug for the treatment of severe malaria RV Celada 2022",{"$nulls":5},"PF3D7_0522700",null,0.46,0.62,0.91,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV1557821","SC83288",null,6.68,{"v":3903,"d":"3903.00"},null,{"v":5000,"d":"5000.00"},null,{"$f":"E394/D394","v":{"v":584.2814371257485,"d":"584.28"}},null,{"v":748.502994011976,"d":"748.50"},null,"iron-sulfur cluster assembly protein SufD","SC83288 is a clinical development candidate for the treatment of severe malaria S Pegoraro 2017","Target identification studies for SC83288: a novel drug for the treatment of severe malaria RV Celada 2022",{"$nulls":5},"PF3D7_1103400",null,0.4,0.62,0.39,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV1557821","SC83288",null,6.68,{"v":3903,"d":"3903.00"},null,{"v":5000,"d":"5000.00"},null,{"v":584.2814371257485,"d":"584.28"},null,{"v":748.502994011976,"d":"748.50"},null,"iron-sulfur cluster assembly protein SufC","SC83288 is a clinical development candidate for the treatment of severe malaria S Pegoraro 2017","Target identification studies for SC83288: a novel drug for the treatment of severe malaria RV Celada 2022",{"$nulls":5},"PF3D7_1413500",null,0.41,-0.05,0.12,null,null,0,0.36959173644292936,0,"gct I/II enriched",null,0.3,null,null,"Not detected",{"$nulls":5},"Essential"]
["MMV1557821","SC83288",null,6.68,{"v":3903,"d":"3903.00"},null,{"v":5000,"d":"5000.00"},null,{"v":584.2814371257485,"d":"584.28"},null,{"v":748.502994011976,"d":"748.50"},null,"iron-sulfur cluster assembly protein ISCU","SC83288 is a clinical development candidate for the treatment of severe malaria S Pegoraro 2017","Target identification studies for SC83288: a novel drug for the treatment of severe malaria RV Celada 2022",{"$nulls":5},"PF3D7_1454500",null,0.61,0.46,-0.06,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV1557821","SC83288",null,6.68,{"v":3903,"d":"3903.00"},null,{"v":5000,"d":"5000.00"},null,{"v":584.2814371257485,"d":"584.28"},null,{"v":748.502994011976,"d":"748.50"},null,"cytosolic iron-sulfur assembly component 2","SC83288 is a clinical development candidate for the treatment of severe malaria S Pegoraro 2017","Target identification studies for SC83288: a novel drug for the treatment of severe malaria RV Celada 2022",{"$nulls":5},"PF3D7_0703100",null,0.86,0.01,-0.27,null,null,0,0,0.701254279852589,"gct V enriched",null,1,null,null,"Detected",25954875.437983003,11308000,53060532.6792846,0.21311508627983985,null,"Essential"]
["MMV1557821","SC83288",null,6.68,{"v":3903,"d":"3903.00"},null,{"v":5000,"d":"5000.00"},null,{"v":584.2814371257485,"d":"584.28"},null,{"v":748.502994011976,"d":"748.50"},null,"cytosolic iron-sulfur protein assembly protein 1","SC83288 is a clinical development candidate for the treatment of severe malaria S Pegoraro 2017","Target identification studies for SC83288: a novel drug for the treatment of severe malaria RV Celada 2022",{"$nulls":5},"PF3D7_1209400",null,0.5,-0.02,0.36,{"$nulls":6},"Not detected",{"$nulls":3},"Detected",1273809.0091756743,203910,10904780.86039243,{"$f":"AL398/AM398","v":0.018699137801166405},null,"Essential (ortholog)"]
["MMV1557821","SC83288",null,6.68,{"v":3903,"d":"3903.00"},null,{"v":5000,"d":"5000.00"},null,{"v":584.2814371257485,"d":"584.28"},null,{"v":748.502994011976,"d":"748.50"},null,"Fe-S cluster assembly protein DRE2","SC83288 is a clinical development candidate for the treatment of severe malaria S Pegoraro 2017","Target identification studies for SC83288: a novel drug for the treatment of severe malaria RV Celada 2022",{"$nulls":5},"PF3D7_0824600",null,1.14,0.16,-0.15,null,null,1.2812367429334575,0.23330678076078387,1.05352502645715,"shared 3 stages",null,5.491639543246478,0.18209498131205323,null,"Detected",52525311.32636291,5585300,31361557.61851016,0.1780938328363976,null,"Essential"]
["MMV000147","P218",null,{"v":6,"d":"6.00"},{"v":5000,"d":"5000.00"},null,{"v":5000,"d":"5000.00"},null,{"v":833.3333333333334,"d":"833.33"},null,{"v":833.3333333333334,"d":"833.33"},null,"DHFR-TS","Yuthavong Y, Tarnchompoo B, Vilaivan T, Chitnumsub P, Kamchonwongpaisan S, Charman SA, McLennan DN, White KL, Vivas L, Bongard E, Thongphanchang C, Taweechai S, Vanichtanankul J, Rattanajak R, Arwon U, Fantauzzi P, Yuvaniyama J, Charman WN, Matthews D. 2012. Malarial dihydrofolate reductase as a paradigm for drug development against a resistance-compromised target. Proc Natl Acad Sci U S A 109:16823–16828",{"$nulls":6},"PF3D7_0417200",null,0.11,0.52,0.13,null,null,1.15443469003188,0.6407679530676047,10.9377664171444,"gct V enriched",null,1.8016423644552657,0.5550491150347446,null,"Detected",3107354809.595412,901370000,1885999900.5903804,0.47792685445945216,null,"Essential","A"]
["MMV1793038","BRD7539",null,5.54,{"v":5000,"d":"5000.00"},null,{"v":5000,"d":"5000.00"},null,{"v":902.5270758122743,"d":"902.53"},null,{"v":902.5270758122743,"d":"902.53"},null,"PfDHODH","Discovery of Antimalarial Azetidine-2-carbonitriles That Inhibit P. falciparum Dihydroorotate Dehydrogenase. M Maetani. 2017","Diversity-oriented synthesis yields novel multistage antimalarial inhibitors. Nobutaka Kato. 2016","Painter, H. J., Morrisey, J. M., Mather, M. W. & Vaidya, A. B. Specific role of mitochondrial electron transport in blood-stage Plasmodium falciparum. Nature 446",{"$nulls":4},"PF3D7_0603300",null,0.75,-0.19,-0.43,null,null,1.15443469003188,0.7714114432536744,1.89426612471675,"shared 3 stages",null,1.4965226405803402,0.6682157508904827,null,"Detected",133919747.91061999,21091000,31021606.034033686,0.679880982849861,null,"Essential"]
["MMV085203",null,null,{"v":5.3,"d":"5.30"},{"v":5000,"d":"5000.00"},{"v":235.6,"d":"235.60"},null,null,{"v":943.3962264150944,"d":"943.40"},{"$f":"F402/D402","v":{"v":44.45283018867924,"d":"44.45"}},null,null,"Thioredoxin Reductase (PfTrxR)","Preliminary LC-MS Based Screening for Inhibitors of Plasmodium falciparum Thioredoxin Reductase (PfTrxR) among a Set of Antimalarials from the Malaria Box NK Tiwari","PfMFR3: A Multidrug-Resistant Modulator in Plasmodium falciparum Frances Rocamora",{"$nulls":5},"PF3D7_0923800",null,0.25,0.12,0.31,null,null,0.2942965475215916,0.2694624621099895,3.77058269614393,"gct V enriched",null,1.0921615768561683,0.9156154374873183,null,"Not detected",{"$nulls":5},"Essential/Not essential"]
["MMV085203",null,null,{"v":5.3,"d":"5.30"},{"v":5000,"d":"5000.00"},{"v":235.6,"d":"235.60"},null,null,{"v":943.3962264150944,"d":"943.40"},{"$f":"F403/D403","v":{"v":44.45283018867924,"d":"44.45"}},null,null,"aconitate hydratase (IRP)","Preliminary LC-MS Based Screening for Inhibitors of Plasmodium falciparum Thioredoxin Reductase (PfTrxR) among a Set of Antimalarials from the Malaria Box NK Tiwari","PfMFR3: A Multidrug-Resistant Modulator in Plasmodium falciparum Frances Rocamora",{"$nulls":5},"PF3D7_1342100",null,0.34,0.08,0,null,null,0,0.37355356840714776,7.01394124150493,"gct V enriched",null,0.3,null,null,"Detected",800040052.4530545,1434200000,150380304.17607224,9.53715320538767,null,"Not essential","U","A"]
["MMV085203",null,null,{"v":5.3,"d":"5.30"},{"v":5000,"d":"5000.00"},{"v":235.6,"d":"235.60"},null,null,{"v":943.3962264150944,"d":"943.40"},{"$f":"F404/D404","v":{"v":44.45283018867924,"d":"44.45"}},null,null,"MFR3","Preliminary LC-MS Based Screening for Inhibitors of Plasmodium falciparum Thioredoxin Reductase (PfTrxR) among a Set of Antimalarials from the Malaria Box NK Tiwari","PfMFR3: A Multidrug-Resistant Modulator in Plasmodium falciparum Frances Rocamora",{"$nulls":5},"PF3D7_0312500",null,0.89,0.25,-0.19,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Not essential","U","U"]
["MMV085203",null,null,{"v":5.3,"d":"5.30"},{"v":5000,"d":"5000.00"},{"v":235.6,"d":"235.60"},null,null,{"v":943.3962264150944,"d":"943.40"},{"$f":"F405/D405","v":{"v":44.45283018867924,"d":"44.45"}},null,null,"glutathione reductase (GR)","Preliminary LC-MS Based Screening for Inhibitors of Plasmodium falciparum Thioredoxin Reductase (PfTrxR) among a Set of Antimalarials from the Malaria Box NK Tiwari","PfMFR3: A Multidrug-Resistant Modulator in Plasmodium falciparum Frances Rocamora",{"$nulls":5},"PF3D7_1419800",null,0.71,0.64,-0.14,null,null,1.15443469003188,1.0570182237640764,9,"gct V enriched",null,1.0921615768561685,0.9156154374873182,null,"Not detected",{"$nulls":5},"Essential"]
["MMV034055","ELQ-300",null,{"v":5,"d":"5.00"},{"v":5000,"d":"5000.00"},null,{"v":5000,"d":"5000.00"},null,{"v":1000,"d":"1000.00"},null,{"$f":"G406/D406","v":{"v":1000,"d":"1000.00"}},null,"mitochondrial cytochrome bc1 complex (Qi-site)","Nilsen A, LaCrue AN, White KL, Forquer IP, Cross RM, Marfurt J, Mather MW, Delves MJ, Shackleford DM, Saenz FE, Morrisey JM, Steuten J, Mutka T, Li Y, Wirjanata G, Ryan E, Duffy S, Kelly JX, Sebayang BF, Zeeman AM, Noviyanti R, Sinden RE, Kocken CH, Price RN, Avery VM, Angulo-Barturen I, Jimenez-Diaz MB, Ferrer S, Herreros E, Sanz LM, Gamo FJ, Bathurst I, Burrows JN, Siegl P, Guy RK, Winter RW, Vaidya AB, Charman SA, Kyle DE, Manetsch R, Riscoe MK. 2013. Quinolone-3-diarylethers: a new class of antimalarial drug. Sci Transl Med 5:177ra37.","Stickles AM, de Almeida MJ, Morrisey JM, Sheridan KA, Forquer IP, Nilsen A, Winter RW, Burrows JN, Fidock DA, Vaidya AB et al.. (2015) Subtle changes in endochin-like quinolone structure alter the site of inhibition within the cytochrome bc1 complex of Plasmodium falciparum. ",{"$nulls":7},0.8483333333333333,0.9800000000000001,0.8099999999999999,"Average",null,0.4530828604879675,1.7006577915597767,7.360729507627478,"gct V enriched","Average",0.2664162436067856,3.7535248844508895,null,"Detected",692838621.0520334,545915000,215905094.41200727,2.528495223731227,null,"Essential/Non essential"]
["MMV000445",null,null,1.97,{"v":2000,"d":"2000.00"},{"v":1611,"d":"1611.00"},{"v":3586.6600000000003,"d":"3586.66"},null,{"v":1015.2284263959391,"d":"1015.23"},{"$f":"F407/D407","v":{"v":817.7664974619289,"d":"817.77"}},{"v":1820.6395939086296,"d":"1820.64"},null,"phosphoethanolamine methyltransferase (PfPMT) ","Open Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and Beyond Wesley C. Van Open source drug discovery with the malaria box compound collection for neglected diseases and beyond, van Voorhis 2016 2016",{"$nulls":6},"PF3D7_1343000",null,0.77,1.48,0.61,null,null,336.4138014225539,83.2557979663136,10.5478198468946,"enriched troph",null,4.040725206413509,0.247480328138321,null,"Detected",114835488.61768718,1894500000,446647232.3754124,4.241602460905097,null,"Not essential/Essential","A"]
["P218","P218",null,{"v":4.6,"d":"4.60"},{"v":5000,"d":"5000.00"},{"v":5000,"d":"5000.00"},{"v":5000,"d":"5000.00"},null,{"v":1086.9565217391305,"d":"1086.96"},{"$f":"F408/D408","v":{"v":1086.9565217391305,"d":"1086.96"}},{"v":1086.9565217391305,"d":"1086.96"},null,"DHFR-TS","Yuthavong Y, Tarnchompoo B, Vilaivan T, Chitnumsub P, Kamchonwongpaisan S, Charman SA, McLennan DN, White KL, Vivas L, Bongard E, Thongphanchang C, Taweechai S, Vanichtanankul J, Rattanajak R, Arwon U, Fantauzzi P, Yuvaniyama J, Charman WN, Matthews D. 2012. Malarial dihydrofolate reductase as a paradigm for drug development against a resistance-compromised target. Proc Natl Acad Sci U S A 109:16823–16828",{"$nulls":6},"PF3D7_0417200",null,0.11,0.52,0.13,null,null,1.15443469003188,0.6407679530676047,10.9377664171444,"gct V enriched",null,1.8016423644552657,0.5550491150347446,null,"Detected",3107354809.595412,901370000,1885999900.5903804,0.47792685445945216,null,"Essential","A"]
["MMV018912","DSM265",null,{"v":4.3,"d":"4.30"},{"v":5000,"d":"5000.00"},null,{"v":5000,"d":"5000.00"},null,{"v":1162.7906976744187,"d":"1162.79"},null,{"v":1162.7906976744187,"d":"1162.79"},null,"PfDHODH","Phillips MA, Lotharius J, Marsh K, White J, Dayan A, White KL, Njoroge JW, El Mazouni F, Lao Y, Kokkonda S, Tomchick DR, Deng X, Laird T, Bhatia SN, March S, Ng CL, Fidock DA, Wittlin S, Lafuente-Monasterio M, Benito FJ, Alonso LM, Martinez MS, Jimenez-Diaz MB, Bazaga SF, Angulo-Barturen I, Haselden JN, Louttit J, Cui Y, Sridhar A, Zeeman AM, Kocken C, Sauerwein R, Dechering K, Avery VM, Duffy S, Delves M, Sinden R, Ruecker A, Wickham KS, Rochford R, Gahagen J, Iyer L, Riccio E, Mirsalis J, Bathhurst I, Rueckle T, Ding X, Campo B, Leroy D, Rogers MJ, etal. 2015. A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria. Sci Transl Med 7:296ra111.",{"$nulls":6},"PF3D7_0603300",null,0.75,-0.19,-0.43,null,null,1.15443469003188,0.7714114432536744,1.89426612471675,"shared 3 stages",null,1.4965226405803402,0.6682157508904827,null,"Detected",133919747.91061999,21091000,31021606.034033686,0.679880982849861,null,"Essential"]
["MMV1576861","49c",null,{"v":0.6,"d":"0.60"},{"v":1031,"d":"1031.00"},null,{"v":5000,"d":"5000.00"},null,{"v":1718.3333333333335,"d":"1718.33"},null,{"v":8333.333333333334,"d":"8333.33"},null,"Plasmepsin IX (PMIX)","Pino P, Caldelari R, Mukherjee B, Vahokoski J, Klages N, Maco B, Collins CR, Blackman MJ, Kursula I, Heussler V et al.. (2017) A multistage antimalarial targets the plasmepsins IX and X essential for invasion and egress. ","C.-L. Ciana, Novel in vivo active anti-malarials based on a hydroxy-ethyl-amine scaffold. 2013","W.A. Guiguemde, A.A. Shelat, D. Bouck, S. Duffy, G.J. Crowther, P.H. Davis, D.C. Smithson, M. Connelly, J. Clark, F. Zhu, M.B. Jiménez-Díaz, M.S. Martinez, E.B. Wilson, A.K. Tripathi, J. Gut, E.R. Sharlow. Chemical genetics of Plasmodium falciparum. 2010",{"$nulls":4},"PF3D7_1430200",null,0.33,1.1,0.72,{"$nulls":6},"Not detected",{"$nulls":3},"Translationally repressed",{"$nulls":5},"Essential","I"]
["MMV1576861","49c",null,{"v":0.6,"d":"0.60"},{"v":1031,"d":"1031.00"},null,{"v":5000,"d":"5000.00"},null,{"v":1718.3333333333335,"d":"1718.33"},null,{"v":8333.333333333334,"d":"8333.33"},null,"plasmepsin X (PMX)","Pino P, Caldelari R, Mukherjee B, Vahokoski J, Klages N, Maco B, Collins CR, Blackman MJ, Kursula I, Heussler V et al.. (2017) A multistage antimalarial targets the plasmepsins IX and X essential for invasion and egress. ","C.-L. Ciana, Novel in vivo active anti-malarials based on a hydroxy-ethyl-amine scaffold. 2013","W.A. Guiguemde, A.A. Shelat, D. Bouck, S. Duffy, G.J. Crowther, P.H. Davis, D.C. Smithson, M. Connelly, J. Clark, F. Zhu, M.B. Jiménez-Díaz, M.S. Martinez, E.B. Wilson, A.K. Tripathi, J. Gut, E.R. Sharlow. Chemical genetics of Plasmodium falciparum. 2010",{"$nulls":4},"PF3D7_0808200",null,1.26,-0.79,0.17,null,null,0,0,0.99526231496888,"gct V enriched",null,1,null,null,"Detected",90439310.2773018,149530000,3295189.911008856,45.37826469437687,null,"Essential Not essential","D I"]
["MMV000024","Pyrimethamine",null,{"v":2.5,"d":"2.50"},{"v":5000,"d":"5000.00"},{"v":5000,"d":"5000.00"},{"v":5000,"d":"5000.00"},null,{"v":2000,"d":"2000.00"},{"$f":"F412/D412","v":{"v":2000,"d":"2000.00"}},{"v":2000,"d":"2000.00"},null,"DHFR-TS","Basco LK, Eldin de Pecoulas P, Wilson CM, Le Bras J, Mazabraud A. 1995. Point mutations in the dihydrofolate reductase-thymidylate synthase gene and pyrimethamine and cycloguanil resistance in Plasmodium falciparum. Mol Biochem Parasitol 69:135–138.","Sirawaraporn W, Sathitkul T, Sirawaraporn R, Yuthavong Y, Santi DV. (1997) Antifolate-resistant mutants of Plasmodium falciparum dihydrofolate reductase. ","Yuthavong Y, Tarnchompoo B, Vilaivan T, Chitnumsub P, Kamchonwongpaisan S, Charman SA, McLennan DN, White KL, Vivas L, Bongard E et al.. (2012) Malarial dihydrofolate reductase as a paradigm for drug development against a resistance-compromised target. ",{"$nulls":4},"PF3D7_0417200",null,0.11,0.52,0.13,null,null,1.15443469003188,0.6407679530676047,10.9377664171444,"gct V enriched",null,1.8016423644552657,0.5550491150347446,null,"Detected",3107354809.595412,901370000,1885999900.5903804,0.47792685445945216,null,"Essential","A"]
["MMV000046","Atovaquone",null,{"v":1,"d":"1.00"},{"v":5000,"d":"5000.00"},null,{"v":5000,"d":"5000.00"},null,{"v":5000,"d":"5000.00"},null,{"v":5000,"d":"5000.00"},null,"bc1 complex (Qo site)","Fry M, Pudney M. 1992. Site of action of the antimalarial hydroxynaphthoquinone, 2-[trans-4-(4′-chlorophenyl) cyclohexyl]-3-hydroxy-1,4-naphthoquinone (566C80). Biochem Pharmacol 43:1545–1553.","Birth D, Kao WC, Hunte C. 2014. Structural analysis of atovaquone- inhibited cytochrome bc1 complex reveals the molecular basis of anti- malarial drug action. Nat Commun 5:4029.","Srivastava IK, Rottenberg H, Vaidya AB. (1997) Atovaquone, a broad spectrum antiparasitic drug, collapses mitochondrial membrane potential in a malarial parasite. ","Vaidya AB, Lashgari MS, Pologe LG, Morrisey J. (1993) Structural features of Plasmodium cytochrome b that may underlie susceptibility to 8-aminoquinolines and hydroxynaphthoquinones. ",{"$nulls":5},0.8483333333333333,0.9800000000000001,0.8099999999999999,"Average",null,0.4530828604879675,1.7006577915597767,7.360729507627478,"gct V enriched","Average",0.2664162436067856,3.7535248844508895,null,"Detected",692838621.0520334,545915000,215905094.41200727,2.528495223731227,null,"Essential/Non essential"]
["MMV000046","Atovaquone",null,0.27,{"v":5000,"d":"5000.00"},34.79,{"v":1000,"d":"1000.00"},null,{"v":18518.51851851852,"d":"18518.52"},{"$f":"F414/D414","v":{"v":128.85185185185185,"d":"128.85"}},{"v":3703.7037037037035,"d":"3703.70"},null,"bc1 complex (Qo site)","Fry M, Pudney M. 1992. Site of action of the antimalarial hydroxynaphthoquinone, 2-[trans-4-(4′-chlorophenyl) cyclohexyl]-3-hydroxy-1,4-naphthoquinone (566C80). Biochem Pharmacol 43:1545–1553.","Birth D, Kao WC, Hunte C. 2014. Structural analysis of atovaquone- inhibited cytochrome bc1 complex reveals the molecular basis of anti- malarial drug action. Nat Commun 5:4029.","Srivastava IK, Rottenberg H, Vaidya AB. (1997) Atovaquone, a broad spectrum antiparasitic drug, collapses mitochondrial membrane potential in a malarial parasite. ","Vaidya AB, Lashgari MS, Pologe LG, Morrisey J. (1993) Structural features of Plasmodium cytochrome b that may underlie susceptibility to 8-aminoquinolines and hydroxynaphthoquinones. ",{"$nulls":5},0.8483333333333333,0.9800000000000001,0.8099999999999999,"Average",null,0.4530828604879675,1.7006577915597767,7.360729507627478,"gct V enriched","Average",0.2664162436067856,3.7535248844508895,null,"Detected",692838621.0520334,545915000,215905094.41200727,2.528495223731227,null,"Essential/Non essential"]
["MMV884705","NMT-145",null,{"v":0.144,"d":"0.14"},{"v":5000,"d":"5000.00"},null,{"v":5000,"d":"5000.00"},null,{"v":34722.222222222226,"d":"34722.22"},null,{"v":34722.222222222226,"d":"34722.22"},null,"glycylpeptide N-tetradecanoyltransferase (NMT)","Selective Inhibitors of Protozoan Protein N-myristoyltransferases as Starting Points for Tropical Disease Medicinal Chemistry Programs Andrew S. Bell 2012",{"$nulls":6},"PF3D7_1412800",null,0.91,-0.29,-0.56,null,null,2.1250813598006153,1.3648237269808132,2.98107170553497,"shared 3 stages",null,1.5570372333001579,0.6422453995403108,null,"Detected",158075546.59579676,253280000,104045078.74631013,2.434329456538398,null,"Essential"]

{"sheet":"ABS mGc targets Supp FigS5","index":2,"n_rows":278,"n_cols":44,"rows_kept":278,"merged":[[0,13,0,18],[0,22,0,24],[0,27,0,30],[0,35,0,36],[0,42,0,43]]}
["Compound identifier","Trivial name",null,"Final ABS IC50 (nM)","Final iGc IC50 (nM)","Final LGc IC50 (nM)","Final mGc IC50 (nM)",null,"FC iGC-ABS","FC LGc-ABS","FC mGc-ABS",null,"Target (implied/confirmed)","References",{"$nulls":6},"GeneID",null,"transcript expression (microarray) (Bozdech 2003, van Biljon 2019)",{"$nulls":4},"Proteome expression (Silvestrini 2010)",{"$nulls":4},"FC proteom (ABS/mGc)","FC proteome (mGC/ABS)",null,"Proteome data (Lasonder 2016)",null,"Lasonder female","Lasonder male","F/M ratio",null,"Essential (P. falciparum data)","A = attenuated, difference in growth, D = different from wild type, U = no difference, I = invasion defect, S = cell cycle defect"]
[{"$nulls":22},"ABS","iGc","mGc",null,null,"T","iGc","mGc","classification",{"$nulls":5},"mGc (mixed)",{"$nulls":5},"ABS","Gc"]
["GP69",null,null,{"v":5000,"d":"5000.00"},null,null,555.35,{"$nulls":3},{"$f":"G3/D3","v":{"v":0.11107,"d":"0.1111"}},null,"MAPK1","Gametocyte-specific and all-blood-stage transmission-blocking chemotypes discovered from high throughput screening on Plasmodium falciparum gametocytes Paonessa 2022",{"$nulls":6},"PF3D7_1431500",null,0.39,0.68,0.76,{"$nulls":6},"Not detected",{"$nulls":3},"Translationally repressed",{"$nulls":5},"Non Essential"]
["GP69",null,null,{"v":5000,"d":"5000.00"},null,null,555.35,{"$nulls":3},{"v":0.11107,"d":"0.1111"},null,"MAPK2","Gametocyte-specific and all-blood-stage transmission-blocking chemotypes discovered from high throughput screening on Plasmodium falciparum gametocytes Paonessa 2022",{"$nulls":6},"PF3D7_1113900",null,0.53,1.03,0.24,null,null,0,0,3.89390091847749,"gct V enriched",null,0.3,null,null,"Detected",159395278.0361576,174890000,1931170747.9597151,{"$f":"AL4/AM4","v":0.09056164514959206},null,"Essential Non/Essential","U","A"]
["MMV1581373","KAE609 analog",null,0.55,1.14,null,0.11,null,{"$f":"E5/D5","v":{"v":2.0727272727272723,"d":"2.07"}},null,{"v":0.19999999999999998,"d":"0.2000"},null,"ATP4",{"$nulls":7},"PF3D7_1211900",null,0.33,-0.22,-0.49,null,null,1.7731908623980155,0.4394601472062679,2.59381366380463,"shared 3 stages",null,{"$f":"AB5/AD5","v":0.6836230709792325},{"$f":"AD5/AB5","v":1.462794400088903},null,"Detected",636393353.8483057,392860000,65708369.94269839,5.978842578846459,null,"Essential"]
["MMV643121","M5717 (DDD107498)",null,{"v":1,"d":"1.00"},3.57,null,0.25,null,{"$f":"E6/D6","v":3.57},null,{"v":0.25,"d":"0.2500"},null,"eEF2","Baragaña B, Hallyburton I, Lee MC, Norcross NR, Grimaldi R, Otto TD, Proto WR, Blagborough AM, Meister S, Wirjanata G et al.. (2015) A novel multiple-stage antimalarial agent that inhibits protein synthesis. ",{"$nulls":6},"PF3D7_1451100",null,0.72,-0.3,-1,null,null,36.215096568022325,20.79857304540562,60.2680478057332,"shared 3 stages",null,0.6009004420511069,1.6641691868067379,null,"Detected",8763016763.996223,19691000000,2265856301.007119,8.690312793113941,null,"Essential (ortholog)"]
["DDD107498","M5717",null,{"v":1,"d":"1.00"},3.57,{"v":1.606,"d":"1.61"},0.25,null,{"$f":"E7/D7","v":3.57},{"$f":"F7/D7","v":{"v":1.606,"d":"1.61"}},{"v":0.25,"d":"0.2500"},null,"eEF2","Baragaña B, Hallyburton I, Lee MC, Norcross NR, Grimaldi R, Otto TD, Proto WR, Blagborough AM, Meister S, Wirjanata G et al.. (2015) A novel multiple-stage antimalarial agent that inhibits protein synthesis. ",{"$nulls":6},"PF3D7_1451100",null,0.72,-0.3,-1,null,null,36.215096568022325,20.79857304540562,60.2680478057332,"shared 3 stages",null,0.6009004420511069,1.6641691868067379,null,"Detected",8763016763.996223,19691000000,2265856301.007119,8.690312793113941,null,"Essential (ortholog)"]
["MMV560185",null,null,{"v":2000,"d":"2000.00"},null,{"v":710,"d":"710.00"},{"v":510,"d":"510.00"},null,null,{"v":0.355,"d":"0.36"},{"v":0.255,"d":"0.2550"},null,"apoptosis-related protein","MMV560185 from pathogen box induces extrinsic pathway of apoptosis in Theileria annulata infected bovine leucocytes PB Araveti",{"$nulls":6},"PF3D7_0909300",null,1.55,0.84,-0.19,{"$nulls":6},"Not detected",{"$nulls":3},"Detected",18141122.64573207,49108000,20856995.146726865,2.354509825338221]
["MMV560185",null,null,{"v":2000,"d":"2000.00"},null,{"v":710,"d":"710.00"},{"v":510,"d":"510.00"},null,null,{"v":0.355,"d":"0.36"},{"v":0.255,"d":"0.2550"},null,"apoptosis-inducing factor","MMV560185 from pathogen box induces extrinsic pathway of apoptosis in Theileria annulata infected bovine leucocytes PB Araveti",{"$nulls":6},"PF3D7_0720400",null,0.55,0.08,-0.18,null,null,0.2942965475215916,0.8298062892038238,3.15956216307185,"gct V enriched",null,0.09314472459546895,10.735981069706714,null,"Detected",321133079.37895584,1053200000,290281205.8083001,3.628205956590682,null,"Non Essential"]
["MMV560185",null,null,{"v":2000,"d":"2000.00"},null,{"v":710,"d":"710.00"},{"v":510,"d":"510.00"},null,null,{"v":0.355,"d":"0.36"},{"v":0.255,"d":"0.2550"},null,"methionine aminopeptidase 1a (METAP1a)","MMV560185 from pathogen box induces extrinsic pathway of apoptosis in Theileria annulata infected bovine leucocytes PB Araveti",{"$nulls":6},"PF3D7_0527300",null,0.56,0.14,-0.3,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Non Essential"]
["MMV560185",null,null,{"v":2000,"d":"2000.00"},null,{"v":710,"d":"710.00"},{"v":510,"d":"510.00"},null,null,{"v":0.355,"d":"0.36"},{"v":0.255,"d":"0.2550"},null,"methionine aminopeptidase 1b (METAP1b)","MMV560185 from pathogen box induces extrinsic pathway of apoptosis in Theileria annulata infected bovine leucocytes PB Araveti",{"$nulls":6},"PF3D7_1015300",null,0.62,-0.49,-0.97,null,null,0,0,0.0700689556931748,"not determined",null,0.9,null,null,"Not detected",{"$nulls":5},"Non Essential"]
["MMV560185",null,null,{"v":2000,"d":"2000.00"},null,{"v":710,"d":"710.00"},{"v":510,"d":"510.00"},null,null,{"v":0.355,"d":"0.36"},{"v":0.255,"d":"0.2550"},null,"methionine aminopeptidase 2 (METAP2)","MMV560185 from pathogen box induces extrinsic pathway of apoptosis in Theileria annulata infected bovine leucocytes PB Araveti",{"$nulls":6},"PF3D7_1434600",null,0.95,0.2,-0.17,null,null,0.7701110966879913,0,1.29673617633864,"shared 3 stages",null,0.5938841768588696,1.6838300109107631,null,"Not detected",{"$nulls":5},"Essential"]
["MMV1029203",null,null,{"v":2000,"d":"2000.00"},null,null,{"v":840,"d":"840.00"},{"$nulls":3},{"v":0.42,"d":"0.4200"},null,"ferrochelatase","Screening the Pathogen Box for Identification of New Chemical Agents with Anti-Fasciola hepatica Activity C Machicado,",{"$nulls":6},"PF3D7_1364900",null,0.43,0.21,-0.07,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Non Essential","U","A"]
["MMV1029203",null,null,{"v":2000,"d":"2000.00"},null,null,{"v":840,"d":"840.00"},{"$nulls":3},{"v":0.42,"d":"0.4200"},null,"inosine-5'-monophosphate dehydrogenase","Screening the Pathogen Box for Identification of New Chemical Agents with Anti-Fasciola hepatica Activity C Machicado,",{"$nulls":6},"PF3D7_0920800",null,1.1,0.69,-0.34,null,null,4.173193961593051,1.0278816961781898,4.94557070854439,"shared 3 stages",null,0.843824546757179,1.1850804812955535,null,"Detected",263286422.35199496,1201100000,555735999.0015628,2.16127802078307,null,"Essential"]
["Epoxomycin","Epoxomycin",null,{"v":8,"d":"8.00"},{"v":12.1,"d":"12.10"},{"v":0.42000000000000004,"d":"0.42"},{"v":3.8,"d":"3.80"},null,{"$f":"E15/D15","v":{"v":1.5125,"d":"1.51"}},{"$f":"F15/D15","v":{"v":0.052500000000000005,"d":"0.05"}},{"v":0.475,"d":"0.4750"},null,"Proteosome subunit beta type-5","rasad R, Atul Kolla VK, Legac J, Singhal N, NavaleR, Rosenthal PJ & Sijwali PS (2013) BlockingPlasmodium falciparumdevelopment via dualinhibition of hemoglobin degradation and theubiquitin proteasome system by MG13",{"$nulls":6},"PF3D7_1011400",null,0.17,0.88,0.57,null,null,1.3957664804363776,5.489058493010015,6.35642254459642,"gct V enriched",null,0.21958365269831148,4.554073072889044,null,"Detected",863717094.4504669,2420200000,905523359.9583262,2.672708520861772,null,"Essential (ortholog)"]
["GP39",null,null,{"v":539.9699999999999,"d":"539.97"},null,null,{"v":308.40000000000003,"d":"308.40"},{"$nulls":3},{"v":0.5711428412689595,"d":"0.5711"},null,"K2","Gametocyte-specific and all-blood-stage transmission-blocking chemotypes discovered from high throughput screening on Plasmodium falciparum gametocytes Paonessa 2022",{"$nulls":6},"PF3D7_1465500",null,0.21,1.36,1.15,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential/Non Essential"]
["MMV023985",null,null,{"v":695.356363014862,"d":"695.36"},null,{"v":5000,"d":"5000.00"},{"v":410,"d":"410.00"},null,null,{"$f":"F17/D17","v":{"v":7.190557627633493,"d":"7.19"}},{"v":0.5896257254659464,"d":"0.5896"},null,"CDPK1","Screening the Medicines for Malaria Venture Pathogen Box across multiple pathogens reclassifies starting points for open-source drug discovery S Duffy","Targeting Plasmodium PI (4) K to eliminate malaria McNamara 2013",{"$nulls":5},"PF3D7_0217500",null,0.54,-0.07,0.86,null,null,1.8276642121903912,0.8228906159046369,5.07832312829723,"shared 3 stages",null,0.35989521856266954,2.7785865119124034,null,"Detected",1326801430.219953,360430000,3411452182.6706023,0.10565295384496434,null,"Essential","I S","A"]
["MMV023985",null,null,{"v":695.356363014862,"d":"695.36"},null,{"v":5000,"d":"5000.00"},{"v":410,"d":"410.00"},null,null,{"v":7.190557627633493,"d":"7.19"},{"v":0.5896257254659464,"d":"0.5896"},null,"PI4K","Screening the Medicines for Malaria Venture Pathogen Box across multiple pathogens reclassifies starting points for open-source drug discovery S Duffy","Targeting Plasmodium PI (4) K to eliminate malaria McNamara 2013",{"$nulls":5},"PF3D7_0509800",null,0.29,-0.01,0.16,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV023985",null,null,{"v":695.356363014862,"d":"695.36"},null,{"v":5000,"d":"5000.00"},{"v":410,"d":"410.00"},null,null,{"v":7.190557627633493,"d":"7.19"},{"v":0.5896257254659464,"d":"0.5896"},null,"PK7","Screening the Medicines for Malaria Venture Pathogen Box across multiple pathogens reclassifies starting points for open-source drug discovery S Duffy","Targeting Plasmodium PI (4) K to eliminate malaria McNamara 2013",{"$nulls":5},"PF3D7_0213400",null,0.31,0.27,-0.31,null,null,0.2246523050636276,0,0.136463666385725,"not determined",null,1.6462426300978217,0.6074438735319221,null,"Not detected",{"$nulls":5},"Non Essential","A D"]
["MMV010576",null,null,{"v":97.1290391498206,"d":"97.13"},null,{"v":150,"d":"150.00"},{"v":66,"d":"66.00"},null,null,{"v":1.5443373198475325,"d":"1.54"},{"v":0.6795084207329143,"d":"0.6795"},null,"PI4K","Screening the Medicines for Malaria Venture Pathogen Box across multiple pathogens reclassifies starting points for open-source drug discovery S Duffy","Hennessey KM, Rogiers IC, Shih HW, Hulverson MA, Choi R, McCloskey MC, Whitman GR, Barrett LK, Merritt EA, Paredez AR, Ojo KK. 2018. Screening of the Pathogen Box for inhibitors with dual efficacy against Giardia lamblia and Cryptosporidium parvum.",{"$nulls":5},"PF3D7_0509800",null,0.29,-0.01,0.16,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["GNF179","GNF179",null,4.31,19.92,9.15,{"v":3.3609999999999998,"d":"3.36"},null,{"$f":"E21/D21","v":{"v":4.621809744779584,"d":"4.6218"}},{"v":2.122969837587007,"d":"2.12"},{"v":0.779814385150812,"d":"0.78"},null,"inhibit protein trafficking, block the establishment of new permeation pathways, and cause ER expansion. - similar to KAF156","Pan-active imidazolopiperazine antimalarials target the Plasmodium falciparum intracellular secretory pathway GM LaMonte","Plasmodium falciparum Cyclic Amine Resistance Locus (PfCARL), a Resistance Mechanism for Two Distinct Compound Classes Pamela A. Magistrado","UDP-galactose and Acetyl-CoA transporters as Plasmodium multidrug resistance genes Michelle Yi-Xiu Lim",{"$nulls":9},"Not detected",{"$nulls":5},"Not detected",{"$nulls":3},"Not detected"]
["GNF179","GNF179",null,4.31,19.92,9.15,{"v":3.3609999999999998,"d":"3.36"},null,{"$f":"E22/D22","v":{"v":4.621809744779584,"d":"4.62"}},{"v":2.122969837587007,"d":"2.12"},{"v":0.779814385150812,"d":"0.7798"},null,"CARL","Pan-active imidazolopiperazine antimalarials target the Plasmodium falciparum intracellular secretory pathway GM LaMonte","Plasmodium falciparum Cyclic Amine Resistance Locus (PfCARL), a Resistance Mechanism for Two Distinct Compound Classes Pamela A. Magistrado","UDP-galactose and Acetyl-CoA transporters as Plasmodium multidrug resistance genes Michelle Yi-Xiu Lim",{"$nulls":4},"PF3D7_0321900",null,0.31,-0.21,-0.06,null,null,0,0,0.0537249727360731,"gct V enriched",null,0.8,null,null,"Not detected",{"$nulls":5},"Essential"]
["GNF179","GNF179",null,4.31,19.92,9.15,{"v":3.3609999999999998,"d":"3.36"},null,{"$f":"E23/D23","v":{"v":4.621809744779584,"d":"4.62"}},{"v":2.122969837587007,"d":"2.12"},{"v":0.779814385150812,"d":"0.7798"},null,"acetyl-CoA transporter 1","Pan-active imidazolopiperazine antimalarials target the Plasmodium falciparum intracellular secretory pathway GM LaMonte","Plasmodium falciparum Cyclic Amine Resistance Locus (PfCARL), a Resistance Mechanism for Two Distinct Compound Classes Pamela A. Magistrado","UDP-galactose and Acetyl-CoA transporters as Plasmodium multidrug resistance genes Michelle Yi-Xiu Lim",{"$nulls":4},"PF3D7_1036800",null,1.52,0,0.37,null,null,0,0,0.737800828749376,"gct V enriched",null,0.2,null,null,"Detected",15362145.29845788,3550600,31982949.32714013,0.11101540272857287,null,"Non Essential","A"]
["GNF179","GNF179",null,4.31,19.92,9.15,{"v":3.3609999999999998,"d":"3.36"},null,{"$f":"E24/D24","v":{"v":4.621809744779584,"d":"4.62"}},{"v":2.122969837587007,"d":"2.12"},{"v":0.779814385150812,"d":"0.7798"},null,"UDP-galactose transporter","Pan-active imidazolopiperazine antimalarials target the Plasmodium falciparum intracellular secretory pathway GM LaMonte","Plasmodium falciparum Cyclic Amine Resistance Locus (PfCARL), a Resistance Mechanism for Two Distinct Compound Classes Pamela A. Magistrado","UDP-galactose and Acetyl-CoA transporters as Plasmodium multidrug resistance genes Michelle Yi-Xiu Lim",{"$nulls":4},"PF3D7_1113300",null,1.64,-0.02,0.24,null,null,1.2812367429334575,0,1.61015721568254,"shared 3 stages",null,0.7957215174111714,1.2567210740428831,null,"Detected",44784143.763331816,138230000,1149223.5922035074,120.28120631857153,null,"Essential"]
["MMV024443",null,null,{"v":720.988829313838,"d":"720.99"},null,{"v":2710,"d":"2710.00"},{"v":570,"d":"570.00"},null,null,{"v":3.7587267511191476,"d":"3.76"},{"v":0.7905809033719241,"d":"0.7906"},null,"CDPK1","Ansell KH, Jones HM, Whalley D, Hearn A, Taylor DL, Patin EC, Chapman\nTM, Osborne SA, Wallace C, Birchall K, Large J, Bouloc N, Smiljanic-Hurley\nE, Clough B, Moon RW, Green JL, Holder AA. 2014. Biochemical and antiparasitic properties of inhibitors of the Plasmodium falciparum calcium-dependent protein kinase PfCDPK1","Bansal A, Singh S, More KR, Hans D, Nangalia K, Yogavel M, Sharma A,\nChitnis CE. 2013. Characterization of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) and its role in microneme secre-tion during erythrocyte invasion. J",{"$nulls":5},"PF3D7_0217500",null,0.54,-0.07,0.86,null,null,1.8276642121903912,0.8228906159046369,5.07832312829723,"shared 3 stages",null,0.35989521856266954,2.7785865119124034,null,"Detected",1326801430.219953,360430000,3411452182.6706023,0.10565295384496434,null,"Essential","I S","A"]
["MMV665852","NSC 35217",null,5171.67,{"v":3978,"d":"3978.00"},null,{"v":5000,"d":"5000.00"},null,{"$f":"E26/D26","v":{"v":0.7691906096096619,"d":"0.77"}},null,{"v":0.9668056933253668,"d":"0.9668"},null,"phospholipid-transporting ATPase 2 (ATP2)","Corey VC, Lukens AK, Istvan ES, et al. A broad analysis of resistance development in the malaria parasite. Nat Commun. 2016;7:11901.","Cowell AN, Istvan ES, Lukens AK, et al. Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. Science. 2018;359(6372):191-199.","Screening for potential prophylactics targeting sporozoite motility through the skin RG Douglas 2018",{"$nulls":4},"PF3D7_1219600",null,0.26,-0.16,-0.4,null,null,0,0,0.337940442708695,"gct V enriched",null,0.4,null,null,"Detected",38850536.94093786,30051000,36855198.62823407,0.8153802209324819,null,"Essential"]
["MMV665852","NSC 35217",null,5171.67,{"v":3978,"d":"3978.00"},null,{"v":5000,"d":"5000.00"},null,{"v":0.7691906096096619,"d":"0.77"},null,{"v":0.9668056933253668,"d":"0.9668"},null,"erythrocyte membrane protein 1 (PfEMP1)","Corey VC, Lukens AK, Istvan ES, et al. A broad analysis of resistance development in the malaria parasite. Nat Commun. 2016;7:11901.","Cowell AN, Istvan ES, Lukens AK, et al. Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. Science. 2018;359(6372):191-199.","Screening for potential prophylactics targeting sporozoite motility through the skin RG Douglas 2018",{"$nulls":4},"PF3D7_1219500",null,0.43,0.04,0.7,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Non Essential"]
["MMV665852","NSC 35217",null,5171.67,{"v":3978,"d":"3978.00"},null,{"v":5000,"d":"5000.00"},null,{"v":0.7691906096096619,"d":"0.77"},null,{"v":0.9668056933253668,"d":"0.9668"},null,"PKG","Corey VC, Lukens AK, Istvan ES, et al. A broad analysis of resistance development in the malaria parasite. Nat Commun. 2016;7:11901.","Cowell AN, Istvan ES, Lukens AK, et al. Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. Science. 2018;359(6372):191-199.","Screening for potential prophylactics targeting sporozoite motility through the skin RG Douglas 2018",{"$nulls":4},"PF3D7_1436600",null,0.47,-0.44,0.1,null,null,0,0.068244893498124,2.02530545710245,"gct V enriched",null,0.2,null,null,"Detected",187255751.4074903,109730000,295371702.85639864,0.37149801060444715,null,"Essential"]
["MMV667491",null,null,1230,891.5,696.4,1390.65,null,0.72479674796748,0.566178861788618,1.13060975609756,null,"phosphoethanolamine methyltransferase (PfPMT)","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond Voorhis 2016","Combining stage specificity and metabolomic profiling to advance antimalarial drug discovery JM Murithi",{"$nulls":5},"PF3D7_1343000",null,0.77,1.48,0.61,null,null,336.4138014225539,83.2557979663136,10.5478198468946,"enriched troph",null,31.89415502973328,0.03135370725663531,null,"Detected",114835488.61768718,1894500000,446647232.3754124,4.241602460905097,null,"Non/Essential","A"]
["MMV019918",null,null,280,824,406.9,320,null,2.94285714285714,1.45321428571429,1.14285714285714,null,"phosphoethanolamine methyltransferase (PfPMT)"," … and biological studies of the Malaria Box compound 1-[5-(4-bromo-2-chlorophenyl) furan-2-yl]-N-[(piperidin-4-yl) methyl] methanamine (MMV019918) and … A Vallone",{"$nulls":6},"PF3D7_1343000",null,0.77,1.48,0.61,null,null,336.4138014225539,83.2557979663136,10.5478198468946,"enriched troph",null,31.89415502973328,0.03135370725663531,null,"Detected",114835488.61768718,1894500000,446647232.3754124,4.241602460905097,null,"Non/Essential","A"]
["MMV020081",null,null,244.520638723368,null,680,310,null,null,2.78095134852523,1.26778664418062,null,"ATP4","Spillman NJ, Allen RJ, McNamara CW, Yeung BK, Winzeler EA, Diagana TT, Kirk K. 2013. Na(\u0005) regulation in the malaria parasite Plasmodium falciparum involves the cation ATPase PfATP4 and is a target of the spiroindolone antimalarials.",{"$nulls":6},"PF3D7_1211900",null,0.33,-0.22,-0.49,null,null,1.7731908623980155,0.4394601472062679,2.59381366380463,"shared 3 stages",null,0.6836230709792325,1.462794400088903,null,"Detected",636393353.8483057,392860000,65708369.94269839,5.978842578846459,null,"Essential"]
["MMV1542945","ACT-451840",null,8.34,9.9,null,11.1,null,1.18705035971223,null,1.33093525179856,null,"MDR1","CRISPR‐Cas9‐modified pfmdr1 protects Plasmodium falciparum asexual blood stages and gametocytes against a class of piperazine‐containing compounds. CL Ng 2016","Brunner R, Aissaoui H, Boss C, Bozdech Z, Brun R, Corminboeuf O, Delahaye S, Fischli C, Heidmann B, Kaiser M et al.. (2012) Identification of a new chemical class of antimalarials. ","Brunner R, Ng CL, Aissaoui H, Akabas MH, Boss C, Brun R, Callaghan PS, Corminboeuf O, Fidock DA, Frame IJ et al.. (2013) UV-triggered affinity capture identifies interactions between the Plasmodium falciparum multidrug resistance protein 1 (PfMDR1) and antimalarial agents in live parasitized cells",{"$nulls":4},"PF3D7_0523000",null,0.55,-0.14,-0.37,null,null,4.185382762981795,2.6120056276710084,5.55996328108289,"shared 3 stages",null,0.752771655385218,1.3284240882957625,null,"Detected",1075298324.2997518,2109100000,611327737.4544191,3.45003158008556,null,"Essential"]
["MMV396749",null,null,928,1384.56,5000,1354.33,null,1.49198275862069,5.38793103448276,1.45940732758621,null,"ATP4","E.L. Allman, H.J. Painter, J. Samra, M. Carrasquilla, M. Llinas Metabolomic profiling of the malaria box reveals antimalarial target pathways 2016","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond Voorhis 2016","Diverse chemotypes disrupt ion homeostasis in the malaria parasite AM Lehane","Targeted phenotypic screening in Plasmodium falciparum and Toxoplasma gondii reveals novel modes of action of medicines for malaria venture malaria box … G Subramanian",{"$nulls":3},"PF3D7_1211900",null,0.33,-0.22,-0.49,null,null,1.7731908623980155,0.4394601472062679,2.59381366380463,"shared 3 stages",null,0.6836230709792325,1.462794400088903,null,"Detected",636393353.8483057,392860000,65708369.94269839,5.978842578846459,null,"Essential"]
["MMV085499",null,null,94.9982354080629,null,550,140,null,null,5.78958122366681,1.4737115842061,null,"PI4K","Le Manach C, Identification of a potential anti-malarial drug candidate from a series of 2-aminopyrazines by optimization of aqueous solubility and potency across the parasite life-cycle.","Unpacking the Pathogen Box—an open source tool for fighting neglected tropical disease CGL Veale",{"$nulls":5},"PF3D7_0509800",null,0.29,-0.01,0.16,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["GNF-Pf-5386",null,null,114,null,null,212.97,{"$nulls":3},1.86815789473684,null,"ATP4"," High-throughput assay and discovery of small molecules that interrupt malaria transmission DM Plouffe",{"$nulls":6},"PF3D7_1211900",null,0.33,-0.22,-0.49,null,null,1.7731908623980155,0.4394601472062679,2.59381366380463,"shared 3 stages",null,0.6836230709792325,1.462794400088903,null,"Detected",636393353.8483057,392860000,65708369.94269839,5.978842578846459,null,"Essential"]
["MMV019266",null,null,255,596,324,520,null,2.33725490196078,1.27058823529412,2.03921568627451,null,"phosphatidylserine decarboxylase (PSD)","E.L. Allman, H.J. Painter, J. Samra, M. Carrasquilla, M. Llinas Metabolomic profiling of the malaria box reveals antimalarial target pathways 2016","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond Voorhis 2016","Characterization of Plasmodium phosphatidylserine decarboxylase expressed in yeast and application for inhibitor screening JY Choi",{"$nulls":4},"PF3D7_0927900",null,0.6,-0.61,0.16,null,null,0.9628761074834958,0,0.584893192461114,"shared 3 stages",null,1.6462426300978217,0.6074438735319221,null,"Not detected",{"$nulls":5},"Essential"]
["MMV019266",null,null,255,596,324,520,null,2.33725490196078,1.27058823529412,2.03921568627451,null,"PKG","E.L. Allman, H.J. Painter, J. Samra, M. Carrasquilla, M. Llinas Metabolomic profiling of the malaria box reveals antimalarial target pathways 2016","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond Voorhis 2016","Characterization of Plasmodium phosphatidylserine decarboxylase expressed in yeast and application for inhibitor screening JY Choi",{"$nulls":4},"PF3D7_1436600",null,0.47,-0.44,0.1,null,null,0,0.068244893498124,2.02530545710245,"gct V enriched",null,0.2,null,null,"Detected",187255751.4074903,109730000,295371702.85639864,0.37149801060444715,null,"Essential"]
["MMV010545",null,null,485.414337603676,null,1170,1030,null,null,2.41031199402945,2.12189859303447,null,"CDPK1","Screening the Medicines for Malaria Venture Pathogen Box across multiple pathogens reclassifies starting points for open-source drug discovery S Duffy","… and validation of a bioluminescence assay for high throughput screening of potent and rapidly cytocidal compounds against intraerythrocytic Plasmodium falciparum MT Famodimu","Unpacking the Pathogen Box—an open source tool for fighting neglected tropical disease CGL Veale",{"$nulls":4},"PF3D7_0217500",null,0.54,-0.07,0.86,null,null,1.8276642121903912,0.8228906159046369,5.07832312829723,"shared 3 stages",null,0.35989521856266954,2.7785865119124034,null,"Detected",1326801430.219953,360430000,3411452182.6706023,0.10565295384496434,null,"Essential","I S","A"]
["MMV010545",null,null,485.414337603676,null,1170,1030,null,null,2.41031199402945,2.12189859303447,null,"PI4K","Screening the Medicines for Malaria Venture Pathogen Box across multiple pathogens reclassifies starting points for open-source drug discovery S Duffy","… and validation of a bioluminescence assay for high throughput screening of potent and rapidly cytocidal compounds against intraerythrocytic Plasmodium falciparum MT Famodimu","Unpacking the Pathogen Box—an open source tool for fighting neglected tropical disease CGL Veale",{"$nulls":4},"PF3D7_0509800",null,0.29,-0.01,0.16,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV010545",null,null,485.414337603676,null,1170,1030,null,null,2.41031199402945,2.12189859303447,null,"PK7","Screening the Medicines for Malaria Venture Pathogen Box across multiple pathogens reclassifies starting points for open-source drug discovery S Duffy","… and validation of a bioluminescence assay for high throughput screening of potent and rapidly cytocidal compounds against intraerythrocytic Plasmodium falciparum MT Famodimu","Unpacking the Pathogen Box—an open source tool for fighting neglected tropical disease CGL Veale",{"$nulls":4},"PF3D7_0213400",null,0.31,0.27,-0.31,null,null,0.2246523050636276,0,0.136463666385725,"not determined",null,1.6462426300978217,0.6074438735319221,null,"Not detected",{"$nulls":5},"Non Essential","A D"]
["MMV019721","MMV019721",null,844.3,3379,null,1841.33,null,4.00213194362194,null,2.18089541632121,null,"acetyl-CoA synthetase (ACAS)","Chemogenomics identifies acetyl-coenzyme A synthetase as a target for malaria treatment and prevention. RL Summers. 2022",{"$nulls":6},"PF3D7_0627800",null,0.29,-0.51,-0.45,null,null,0.5239278103274543,0.22331568211144429,0.148153621496883,"enriched troph",null,3.5363820677071818,0.2827748758064344,null,"Detected",7752479.546805608,5327800,13142844.217746137,0.40537648561687534,null,"Essential","A"]
["MMV019721","MMV019721",null,844.3,3379,null,1841.33,null,4.00213194362194,null,2.18089541632121,null,"acyl-CoA synthetase (ACS11)","Chemogenomics identifies acetyl-coenzyme A synthetase as a target for malaria treatment and prevention. RL Summers. 2022",{"$nulls":6},"PF3D7_1238800",null,0.54,-0.04,-0.19,null,null,3.175016900592523,1.578121624064757,2.78248990638938,"shared 3 stages",null,1.1410704108222605,0.8763701087292198,null,"Detected",370910521.31342447,1014900000,531968643.8183713,1.9078192141462285]
["MMV019721","MMV019721",null,844.3,3379,null,1841.33,null,4.00213194362194,null,2.18089541632121,null,"acyl-CoA synthetase (ACS10)","Chemogenomics identifies acetyl-coenzyme A synthetase as a target for malaria treatment and prevention. RL Summers. 2022",{"$nulls":6},"PF3D7_0525100",null,0.84,-0.61,-0.77,null,null,6.499642624097776,6.443810658555231,5.39080484186031,"shared 3 stages",null,1.2056905814187884,0.829400192231125,null,"Detected",337785262.1603665,1807600000,394712460.1927418,4.579536199889236]
["MMV019881",null,null,646,740.91,287.6,1502,null,1.14691950464396,0.445201238390093,2.32507739938081,null,"Hsp90","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond Voorhis 2016","Malaria Box Compounds against Anopheles gambiae (Diptera: Culicidae) Carboxypeptidase B Activity to Block Malaria Transmission Tippawan Pomun",{"$nulls":5},"PF3D7_0708400",null,0.47,0.14,-0.37,null,null,391.244342138169,487.5030361563116,2642.7611857491,"gct V enriched",null,0.14804377491539,6.754758858125038,null,"Detected",28102267024.51306,93040000000,24304490388.95642,3.8280991911797466,null,"Essential"]
["MMV665953",null,null,2060,1645,5000,5000,null,0.798543689320388,2.42718446601942,2.42718446601942,null,"calmodulin (CAM)","The Medicines for Malaria Venture Malaria Box contains inhibitors of protein secretion in Plasmodium falciparum blood stage parasites O Looker","Comparison of ligand binding and conformational stability of human calmodulin with its homolog from the malaria parasite Plasmodium falciparum T Juhász,",{"$nulls":5},"PF3D7_1434200",null,0.66,-0.08,0.22,{"$nulls":6},"Not detected",{"$nulls":3},"Detected",10931146.987446235,236040000,342385661.2259073,0.6893980289795487,null,"Essential"]
["MMV669810",null,null,0.45,2,1.4,1.2,null,4.44444444444444,3.11111111111111,2.66666666666667,null,"CDPK1"," Potent Plasmodium falciparum gametocytocidal compounds identified by exploring the kinase inhibitor chemical space for dual active antimalarials Mariëtte E van der Watt, ",{"$nulls":6},"PF3D7_0217500",null,0.54,-0.07,0.86,null,null,1.8276642121903912,0.8228906159046369,5.07832312829723,"shared 3 stages",null,0.35989521856266954,2.7785865119124034,null,"Detected",1326801430.219953,360430000,3411452182.6706023,0.10565295384496434,null,"Essential","I S","A"]
["MMV669810",null,null,0.45,2,1.4,1.2,null,4.44444444444444,3.11111111111111,2.66666666666667,null,"PI4K"," Potent Plasmodium falciparum gametocytocidal compounds identified by exploring the kinase inhibitor chemical space for dual active antimalarials Mariëtte E van der Watt, ",{"$nulls":6},"PF3D7_0509800",null,0.29,-0.01,0.16,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV669810",null,null,0.45,2,1.4,1.2,null,4.44444444444444,3.11111111111111,2.66666666666667,null,"PKG"," Potent Plasmodium falciparum gametocytocidal compounds identified by exploring the kinase inhibitor chemical space for dual active antimalarials Mariëtte E van der Watt, ",{"$nulls":6},"PF3D7_1436600",null,0.47,-0.44,0.1,null,null,0,0.068244893498124,2.02530545710245,"gct V enriched",null,0.2,null,null,"Detected",187255751.4074903,109730000,295371702.85639864,0.37149801060444715,null,"Essential"]
["MMV669810",null,null,0.45,2,1.4,1.2,null,4.44444444444444,3.11111111111111,2.66666666666667,null,"PK7"," Potent Plasmodium falciparum gametocytocidal compounds identified by exploring the kinase inhibitor chemical space for dual active antimalarials Mariëtte E van der Watt, ",{"$nulls":6},"PF3D7_0213400",null,0.31,0.27,-0.31,null,null,0.2246523050636276,0,0.136463666385725,"not determined",null,1.6462426300978217,0.6074438735319221,null,"Not detected",{"$nulls":5},"Non Essential","A D"]
["MMV670325",null,null,1365,4492,null,3715.67,null,3.29084249084249,null,2.72210256410256,null,"leucine--tRNA ligase (LeuRS)","Provided from MMV",{"$nulls":6},"PF3D7_0622800",null,0.36,-0.2,-0.48,null,null,1.2020793536038865,1.2476120887779127,2.62680169079642,"shared 3 stages",null,0.4576208999010611,2.185214880299835,null,"Detected",595387412.6656642,382780000,1257820862.562945,0.3043199643071945,null,"Essential (ortholog)"]
["MMV693183","MMV183",null,9.4,113,null,26.2,null,12.0212765957447,null,2.78723404255319,null,"acetyl-CoA synthetase (ACAS)","Preclinical characterization and target validation of the antimalarial pantothenamide MMV693183. LE de Vries. 2022",{"$nulls":6},"PF3D7_0627800",null,0.29,-0.51,-0.45,null,null,0.5239278103274543,0.22331568211144429,0.148153621496883,"enriched troph",null,3.5363820677071818,0.2827748758064344,null,"Detected",7752479.546805608,5327800,13142844.217746137,0.40537648561687534,null,"Essential","A"]
["MMV019662",null,null,1729,4715.5,null,5000,null,2.7272990167727,null,2.89184499710816,null,"Niemann-Pick type C1-related protein (NCR1)","Diverse Chemical Compounds Target Plasmodium falciparum Plasma Membrane Lipid Homeostasis. S Bhatnagar. 2019","Plasmodium Niemann-Pick type C1-related protein is a druggable target required for parasite membrane homeostasis. ES Istvan. 2019","Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. Cowell. 2018",{"$nulls":4},"PF3D7_0107500",null,0.44,-0.6,-0.27,null,null,0.8720675920415234,0,0.0734188827013531,"enriched troph",null,11.877974166248805,0.0841894405564119,null,"Not detected",{"$nulls":5},"Essential"]
["MMV016838",null,null,1718,2000,null,5000,null,1.16414435389988,null,2.91036088474971,null,"eEF2","A novel multiple-stage antimalarial agent that inhibits protein synthesis. Beatriz Baragaña. 2015","Screening the Medicines for Malaria Venture Pathogen Box for invasion and egress inhibitors of the blood stage of Plasmodium falciparum reveals several inhibitory compounds\nAuthor links open overlay panelMadeline G.Dans. 2020",{"$nulls":5},"PF3D7_1451100",null,0.72,-0.3,-1,null,null,36.215096568022325,20.79857304540562,60.2680478057332,"shared 3 stages",null,0.6009004420511069,1.6641691868067379,null,"Detected",8763016763.996223,19691000000,2265856301.007119,8.690312793113941,null,"Essential (ortholog)"]
["MMV665882",null,null,337,252,63,983.63,null,0.747774480712166,0.186943620178042,2.91878338278932,null,"AP2 domain transcription factor","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond Voorhis 2016","Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics",{"$nulls":5},"PF3D7_0613800",null,0.3,0.16,0.69,null,null,0.03482332457788821,0,0,"enriched troph",null,null,0,null,"Not detected",{"$nulls":5},"Essential (ortholog)"]
["MMV665882",null,null,337,252,63,983.63,null,0.747774480712166,0.186943620178042,2.91878338278932,null,"Hsp90","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond Voorhis 2016","Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics",{"$nulls":5},"PF3D7_0708400",null,0.47,0.14,-0.37,null,null,391.244342138169,487.5030361563116,2642.7611857491,"gct V enriched",null,0.14804377491539,6.754758858125038,null,"Detected",28102267024.51306,93040000000,24304490388.95642,3.8280991911797466,null,"Essential"]
["MMV665943",null,null,190,2000,1099,570,null,10.5263157894737,5.78421052631579,3,null,"Cysteine protease","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond Voorhis 2016",{"$nulls":8},0.868333333333333,0.2925,0.5025,"Average",null,0.798641256081183,0.19433860091901342,0.31856282249165724,"enriched troph","Average",2.507013372855517,0.39888099953012557,null,"Detected",57370296.82134489,79529333.33333333,145189284.43913874,0.5477631055249872,null,"Essential/Non Essential","S U"]
["MMV396797",null,null,477,3934.38,1768.9,1431.09,null,8.24817610062893,3.7083857442348,3.00018867924528,null,"Thioredoxin Reductase (PfTrxR)","E.L. Allman, H.J. Painter, J. Samra, M. Carrasquilla, M. Llinas Metabolomic profiling of the malaria box reveals antimalarial target pathways 2016","Preliminary LC-MS Based Screening for Inhibitors of Plasmodium falciparum Thioredoxin Reductase (PfTrxR) among a Set of Antimalarials from the Malaria Box NK Tiwari","The Medicines for Malaria Venture Malaria Box contains inhibitors of protein secretion in Plasmodium falciparum blood stage parasites O Looker",{"$nulls":4},"PF3D7_0923800",null,0.25,0.12,0.31,null,null,0.2942965475215916,0.2694624621099895,3.77058269614393,"gct V enriched",null,0.07805068108506426,12.812188005254443,null,"Not detected",{"$nulls":5},"Essential/Non Essential"]
["MMV1578884","CRS-3123",null,1643.33,3776,null,5000,null,2.2977734234755,null,3.04260252049193,null,"methionine--tRNA ligase (cyto)","Inhibition of protein synthesis and malaria parasite development by drug targeting of methionyl-tRNA synthetases T Hussain 2015",{"$nulls":6},"PF3D7_1034900",null,0.43,0.01,0.05,null,null,2.488931895417541,5.890704031654335,15.5265353985669,"gct V enriched",null,0.16030182082006972,6.238232322528931,null,"Detected",3091188099.450991,3090600000,2027422100.1910057,1.5243988904475447,null,"Essential"]
["MMV1578884","CRS-3123",null,1643.33,3776,null,5000,null,2.2977734234755,null,3.04260252049193,null,"methionine--tRNA ligase (apic)","Inhibition of protein synthesis and malaria parasite development by drug targeting of methionyl-tRNA synthetases T Hussain 2015",{"$nulls":6},"PF3D7_1005000",null,0.42,0.36,0.4,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["GNF-Pf-5466",null,null,30.37,null,null,92.47,{"$nulls":3},3.04478103391505,null,"CARL","High-throughput luciferase-based assay for the discovery of therapeutics that prevent malaria J Swann,","Meister, S.,  (2011) Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.",{"$nulls":5},"PF3D7_0321900",null,0.31,-0.21,-0.06,null,null,0,0,0.0537249727360731,"gct V enriched",null,0.8,null,null,"Not detected",{"$nulls":5},"Essential"]
["MMV665941",null,null,255,769,157.9,843,null,3.0156862745098,0.61921568627451,3.30588235294118,null,"HT","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond Voorhis 2016","A novel fluorescence resonance energy transfer-based screen in high-throughput format to identify inhibitors of malarial and human glucose transporters TE Kraft",{"$nulls":5},"PF3D7_0204700",null,0.53,1.08,-0.46,null,null,3.0423154285688634,4.369138307018179,2.89860370254907,"shared 3 stages",null,1.0495796392909493,0.9527623846395846,null,"Detected",552024808.196664,783670000,843559723.476298,0.9290035763804686,null,"Essential"]
["MMV666597",null,null,551,819,465,1927,null,1.48638838475499,0.843920145190563,3.497277676951,null,"Saglin (thrombospondin-related anonymous protein?)","Transcriptome Analysis of Uninfected and Plasmodium vivax-infected Anopheles dirus at Ookinete and Oocyst Stages and Targeting Anopheles Carboxypeptidase B … T Boonkaew",{"$nulls":6},"PF3D7_1335900",null,0.82,0.91,0.81,{"$nulls":6},"Not detected",{"$nulls":3},"Translationally repressed",{"$nulls":5},"Non Essential"]
["GNF-Pf-3600",null,null,24.42,null,null,95.39,{"$nulls":3},3.90622440622441,null,"Thioredoxin Reductase (PfTrxR)","PfMFR3: A Multidrug-Resistant Modulator in Plasmodium falciparum Frances Rocamora",{"$nulls":6},"PF3D7_0923800",null,0.25,0.12,0.31,null,null,0.2942965475215916,0.2694624621099895,3.77058269614393,"gct V enriched",null,0.07805068108506426,12.812188005254443,null,"Not detected",{"$nulls":5},"Essential/Non Essential"]
["GNF-Pf-3600",null,null,24.42,null,null,95.39,{"$nulls":3},3.90622440622441,null,"multidrug-resistant modulator MFR3","PfMFR3: A Multidrug-Resistant Modulator in Plasmodium falciparum Frances Rocamora",{"$nulls":6},"PF3D7_0312500",null,0.89,0.25,-0.19,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Non Essential","U","U"]
["GNF-Pf-3600",null,null,24.42,null,null,95.39,{"$nulls":3},3.90622440622441,null,"glutathione reductase (GR)","PfMFR3: A Multidrug-Resistant Modulator in Plasmodium falciparum Frances Rocamora",{"$nulls":6},"PF3D7_1419800",null,0.71,0.64,-0.14,null,null,1.15443469003188,1.0570182237640764,9,"gct V enriched",null,0.12827052111465334,7.7960235236446875,null,"Not detected",{"$nulls":5},"Essential"]
["MMV007273",null,null,1278,1361,5000,5000,null,1.06494522691706,3.91236306729264,3.91236306729264,null,"6-phosphogluconate dehydrogenase","Identification of β-hematin inhibitors in the MMV Malaria Box KY Fong","Characterization of Plasmodium falciparum 6-phosphogluconate dehydrogenase as an antimalarial drug target K Haeussler",{"$nulls":5},"PF3D7_1454700",null,0.29,0.18,-0.08,null,null,1.7176232460629302,5.869374848204267,16.4332882219999,"gct V enriched",null,0.10452097126632753,9.567457974074145,null,"Detected",1936470222.4009511,2758600000,3486288340.423685,0.7912713265893406,null,"Essential"]
["MMV000011","Doxycycline hydrochloride",null,1258.92541179416,5000,5000,5000,null,3.97164117362143,3.97164117362143,3.97164117362143,null,"targets ribosomes"," Multiple antibiotics exert delayed effects against the Plasmodium falciparum apicoplast Erica L Dahl 2007",{"$nulls":8},0.801709677419355,0.480787096774194,0.155325806451613,"Average",null,24.71297769631029,85.40557604207882,1459.5331009753745,"gct V enriched","Average",0.016932111837542525,59.05937839264455,null,"Detected",1539680719.4419389,1132392260.2272727,592017901.0117464,1.9127669252771542,null,"Essential/Non Essential"]
["MMV000028","Trimethoprim",null,1258.92541179416,5000,5000,5000,null,3.97164117362143,3.97164117362143,3.97164117362143,null,"DHFR-TS","Antibacterial Agents That Interfere With Folate Synthesis. (2020). In Rang and Dale's Pharmacology (9th ed.). Edinburgh: Elsevier. ",{"$nulls":6},"PF3D7_0417200",null,0.11,0.52,0.13,null,null,1.15443469003188,0.6407679530676047,10.9377664171444,"gct V enriched",null,0.10554574361931532,9.474564920465403,null,"Detected",3107354809.595412,901370000,1885999900.5903804,{"$f":"AL68/AM68","v":0.47792685445945216},null,"Essential","A"]
["MMV643110",null,null,23.24,122.1,71.51,92.7,null,5.2538726333907,3.07702237521515,3.98881239242685,null,"PI4K"," Potent Plasmodium falciparum gametocytocidal compounds identified by exploring the kinase inhibitor chemical space for dual active antimalarials Mariëtte E van der Watt, ",{"$nulls":6},"PF3D7_0509800",null,0.29,-0.01,0.16,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV666125",null,null,120,720.32,745,480,null,6.00266666666667,6.20833333333333,4,null,"Hsp90","Sun W, Tanaka TQ, Magle CT, Huang W, Southall N, Huang R, Dehdashti SJ, McKew JC et al (2014) Chemical signatures and new drug targets for gametocytocidal drug development. "," Characterization of Plasmodium falciparum 6-phosphogluconate dehydrogenase as an antimalarial drug target K Haeussler",{"$nulls":5},"PF3D7_0708400",null,0.47,0.14,-0.37,null,null,391.244342138169,487.5030361563116,2642.7611857491,"gct V enriched",null,{"$f":"AB70/AD70","v":0.14804377491539},{"$f":"AD70/AB70","v":6.754758858125038},null,"Detected",28102267024.51306,93040000000,24304490388.95642,3.8280991911797466,null,"Essential"]
["MMV666125",null,null,120,720.32,745,480,null,6.00266666666667,6.20833333333333,4,null,"6-phosphogluconate dehydrogenase","Sun W, Tanaka TQ, Magle CT, Huang W, Southall N, Huang R, Dehdashti SJ, McKew JC et al (2014) Chemical signatures and new drug targets for gametocytocidal drug development. "," Characterization of Plasmodium falciparum 6-phosphogluconate dehydrogenase as an antimalarial drug target K Haeussler",{"$nulls":5},"PF3D7_1454700",null,0.29,0.18,-0.08,null,null,1.7176232460629302,5.869374848204267,16.4332882219999,"gct V enriched",null,0.10452097126632753,9.567457974074145,null,"Detected",1936470222.4009511,2758600000,3486288340.423685,0.7912713265893406,null,"Essential"]
["MMV023367",null,null,1192.27,2718,null,5000,null,2.27968497068617,null,4.19368096152717,null,"ABCI3","Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. Cowell. 2018",{"$nulls":6},"PF3D7_0319700",null,0.37,-0.27,-0.58,{"$nulls":6},"Not detected",{"$nulls":3},"Detected",2589313.0859880405,1486100,10695894.947039416,0.13894115521500583,null,"Essential (ortholog)"]
["MMV023367",null,null,1192.27,2718,null,5000,null,2.27968497068617,null,4.19368096152717,null,"AP2 domain transcription factor","Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. Cowell. 2018",{"$nulls":6},"PF3D7_0613800",null,0.3,0.16,0.69,null,null,0.03482332457788821,0,0,"enriched troph",null,1.1,0,null,"Not detected",{"$nulls":5},"Essential (ortholog)"]
["MMV023367",null,null,1192.27,2718,null,5000,null,2.27968497068617,null,4.19368096152717,null,"amino acid transporter AAT1","Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. Cowell. 2018",{"$nulls":6},"PF3D7_0629500",null,0.31,-0.31,-0.59,{"$nulls":6},"Not detected",{"$nulls":3},"Detected",3042923.6353463647,6972800,6511740.419343636,1.0708043550518,null,"Essential"]
["MMV023367",null,null,1192.27,2718,null,5000,null,2.27968497068617,null,4.19368096152717,null,"amino acid transporter A","Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. Cowell. 2018",{"$nulls":6},"PF3D7_1132500",null,0.34,0.73,0.67,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Non Essential"]
["MMV023367",null,null,1192.27,2718,null,5000,null,2.27968497068617,null,4.19368096152717,null,"amino acid transporter B","Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. Cowell. 2018",{"$nulls":6},"PF3D7_1208400",null,0.32,0.7,0.71,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Non Essential"]
["MMV390048","MMV0048",null,24,171,null,101.4,null,7.125,null,4.225,null,"PI4K"," Potent Plasmodium falciparum gametocytocidal compounds identified by exploring the kinase inhibitor chemical space for dual active antimalarials Mariëtte E van der Watt, ","Younis Y, Douelle F, Feng TS, Gonzalez Cabrera D, Le Manach C, Nchinda AT, Duffy S, White KL, Shackleford DM, Morizzi J, Mannila J, Katneni K, Bhamidipati R, Zabiulla KM, Joseph JT, Bashyam S, Waterson D, Witty MJ, Hardick D, Wittlin S, Avery V, Charman SA, Chibale K. 2012. 3,5-Diaryl-2-aminopyridines as a novel class of orally active antimalarials demonstrating single dose cure in mice and clinical candidate potential. J Med Chem 55:3479–3487.","Paquet T, Le Manach C, Cabrera DG, Younis Y, Henrich PP, Abraham TS, Lee MCS, Basak R, Ghidelli-Disse S, Lafuente-Monasterio MJ et al.. (2017)\nAntimalarial efficacy of MMV390048, an inhibitor of Plasmodium phosphatidylinositol 4-kinase. ",{"$nulls":4},"PF3D7_0509800",null,0.29,-0.01,0.16,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV390048","MMV0048",null,24,171,null,101.4,null,7.125,null,4.225,null,"PI3K"," Potent Plasmodium falciparum gametocytocidal compounds identified by exploring the kinase inhibitor chemical space for dual active antimalarials Mariëtte E van der Watt, ","Younis Y, Douelle F, Feng TS, Gonzalez Cabrera D, Le Manach C, Nchinda AT, Duffy S, White KL, Shackleford DM, Morizzi J, Mannila J, Katneni K, Bhamidipati R, Zabiulla KM, Joseph JT, Bashyam S, Waterson D, Witty MJ, Hardick D, Wittlin S, Avery V, Charman SA, Chibale K. 2012. 3,5-Diaryl-2-aminopyridines as a novel class of orally active antimalarials demonstrating single dose cure in mice and clinical candidate potential. J Med Chem 55:3479–3487.","Paquet T, Le Manach C, Cabrera DG, Younis Y, Henrich PP, Abraham TS, Lee MCS, Basak R, Ghidelli-Disse S, Lafuente-Monasterio MJ et al.. (2017)\nAntimalarial efficacy of MMV390048, an inhibitor of Plasmodium phosphatidylinositol 4-kinase. ",{"$nulls":4},"PF3D7_0515300",null,0.56,0.18,0.29,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV390048","MMV0048",null,24,171,null,101.4,null,7.125,null,4.225,null,"PKG"," Potent Plasmodium falciparum gametocytocidal compounds identified by exploring the kinase inhibitor chemical space for dual active antimalarials Mariëtte E van der Watt, ","Younis Y, Douelle F, Feng TS, Gonzalez Cabrera D, Le Manach C, Nchinda AT, Duffy S, White KL, Shackleford DM, Morizzi J, Mannila J, Katneni K, Bhamidipati R, Zabiulla KM, Joseph JT, Bashyam S, Waterson D, Witty MJ, Hardick D, Wittlin S, Avery V, Charman SA, Chibale K. 2012. 3,5-Diaryl-2-aminopyridines as a novel class of orally active antimalarials demonstrating single dose cure in mice and clinical candidate potential. J Med Chem 55:3479–3487.","Paquet T, Le Manach C, Cabrera DG, Younis Y, Henrich PP, Abraham TS, Lee MCS, Basak R, Ghidelli-Disse S, Lafuente-Monasterio MJ et al.. (2017)\nAntimalarial efficacy of MMV390048, an inhibitor of Plasmodium phosphatidylinositol 4-kinase. ",{"$nulls":4},"PF3D7_1436600",null,0.47,-0.44,0.1,null,null,0,0.068244893498124,2.02530545710245,"gct V enriched",null,0.2,null,null,"Detected",187255751.4074903,109730000,295371702.85639864,0.37149801060444715,null,"Essential"]
["MMV020438",null,null,1150.27,4554,null,5000,null,3.95907047910491,null,4.34680553261408,null,"HT","Provided from MMV",{"$nulls":6},"PF3D7_0204700",null,0.53,1.08,-0.46,null,null,3.0423154285688634,4.369138307018179,2.89860370254907,"shared 3 stages",null,1.0495796392909493,0.9527623846395846,null,"Detected",552024808.196664,783670000,843559723.476298,0.9290035763804686,null,"Essential"]
["MMV642944",null,null,20.16,46.8,51.9,96.8,null,2.32142857142857,2.57440476190476,4.8015873015873,null,"PI4K"," Potent Plasmodium falciparum gametocytocidal compounds identified by exploring the kinase inhibitor chemical space for dual active antimalarials Mariëtte E van der Watt, ","Probing the distinct chemosensitivity of Plasmodium vivax liver stage parasites and demonstration of 8-aminoquinoline radical cure activity in vitro SP Maher 2021","UCT943, a Next-Generation Plasmodium falciparum PI4K Inhibitor Preclinical Candidate for the Treatment of Malaria Christel Brunschwig 2018",{"$nulls":4},"PF3D7_0509800",null,0.29,-0.01,0.16,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV665852",null,null,1028,5000,5000,5000,null,4.86381322957198,4.86381322957198,4.86381322957198,null,"phospholipid-transporting ATPase 2 (ATP2)","Corey VC, Lukens AK, Istvan ES, et al. A broad analysis of resistance development in the malaria parasite. Nat Commun. 2016;7:11901.","Cowell AN, Istvan ES, Lukens AK, et al. Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. Science. 2018;359(6372):191-199.","Screening for potential prophylactics targeting sporozoite motility through the skin RG Douglas 2018",{"$nulls":4},"PF3D7_1219600",null,0.26,-0.16,-0.4,null,null,0,0,0.337940442708695,"gct V enriched",null,0.4,null,null,"Detected",38850536.94093786,30051000,36855198.62823407,0.8153802209324819,null,"Essential"]
["MMV665852",null,null,1028,5000,5000,5000,null,4.86381322957198,4.86381322957198,4.86381322957198,null,"erythrocyte membrane protein 1 (PfEMP1)","Corey VC, Lukens AK, Istvan ES, et al. A broad analysis of resistance development in the malaria parasite. Nat Commun. 2016;7:11901.","Cowell AN, Istvan ES, Lukens AK, et al. Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. Science. 2018;359(6372):191-199.","Screening for potential prophylactics targeting sporozoite motility through the skin RG Douglas 2018",{"$nulls":4},"PF3D7_1219500",null,0.43,0.04,0.7,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Non Essential"]
["MMV665852",null,null,1028,5000,5000,5000,null,4.86381322957198,4.86381322957198,4.86381322957198,null,"PKG","Corey VC, Lukens AK, Istvan ES, et al. A broad analysis of resistance development in the malaria parasite. Nat Commun. 2016;7:11901.","Cowell AN, Istvan ES, Lukens AK, et al. Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. Science. 2018;359(6372):191-199.","Screening for potential prophylactics targeting sporozoite motility through the skin RG Douglas 2018",{"$nulls":4},"PF3D7_1436600",null,0.47,-0.44,0.1,null,null,0,0.068244893498124,2.02530545710245,"gct V enriched",null,0.2,null,null,"Detected",187255751.4074903,109730000,295371702.85639864,0.37149801060444715,null,"Essential"]
["KDU691","KDU691",null,29.9,353.75,220.4,149.86,null,11.8311036789298,7.37123745819398,5.01204013377926,null,"PI4K","McNamara CW, et al. Targeting Plasmodium PI(4)K to eliminate malaria. Nature. 2013;504:248–253.",{"$nulls":6},"PF3D7_0509800",null,0.29,-0.01,0.16,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV665807",null,null,973.3,5000,5000,5000,null,5.13716223158327,5.13716223158327,5.13716223158327,null,"calcium-transporting ATPase (ATP6)","Selective Inhibition of Plasmodium falciparum ATPase 6 by Artemisinins and Identification of New Classes of Inhibitors after Expression in Yeast CM Moore","Screening of the open source malaria box reveals an early lead compound for the treatment of alveolar echinococcosis B Stadelmann",{"$nulls":5},"PF3D7_0106300",null,0.39,-0.03,-0.13,null,null,1.6876027710717014,0.7605873874153525,3.93796931771435,"shared 3 stages",null,0.4285464499381139,2.333469336041424,null,"Detected",1029579056.5443927,1600300000,889900800.0520924,1.7982903261872814,null,"Essential"]
["MMV007564",null,null,513,null,5000,2706,null,null,9.74658869395711,5.27485380116959,null,"CARL","E.L. Allman, H.J. Painter, J. Samra, M. Carrasquilla, M. Llinas Metabolomic profiling of the malaria box reveals antimalarial target pathways 2016","Metabolomics-based screening of the malaria box reveals both novel and established mechanisms of action DJ Creek","Pan-active imidazolopiperazine antimalarials target the Plasmodium falciparum intracellular secretory pathway Gregory M. LaMonte, ","Plasmodium falciparum Cyclic Amine Resistance Locus (PfCARL), a Resistance Mechanism for Two Distinct Compound Classes Pamela A. Magistrado",{"$nulls":3},"PF3D7_0321900",null,0.31,-0.21,-0.06,null,null,0,0,0.0537249727360731,"gct V enriched",null,0.8,null,null,"Not detected",{"$nulls":5},"Essential"]
["MMV019780",null,null,697,null,4176,3800,null,null,5.99139167862267,5.4519368723099,null,"Saglin (thrombospondin-related anonymous protein?)","Transcriptome Analysis of Uninfected and Plasmodium vivax-infected Anopheles dirus at Ookinete and Oocyst Stages and Targeting Anopheles Carboxypeptidase B T Boonkaew Thesis",{"$nulls":6},"PF3D7_1335900",null,0.82,0.91,0.81,{"$nulls":6},"Not detected",{"$nulls":3},"Translationally repressed",{"$nulls":5},"Non Essential"]
["MMV000848",null,null,660,1997,2000,3600,null,3.02575757575758,3.03030303030303,5.45454545454545,null,"ATP4","E.L. Allman, H.J. Painter, J. Samra, M. Carrasquilla, M. Llinas Metabolomic profiling of the malaria box reveals antimalarial target pathways 2016","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond Voorhis 2016","Identification of an inhibitory pocket in falcilysin provides a new avenue for malaria drug development G Wirjanata",{"$nulls":4},"PF3D7_1211900",null,0.33,-0.22,-0.49,null,null,1.7731908623980155,0.4394601472062679,2.59381366380463,"shared 3 stages",null,0.6836230709792325,1.462794400088903,null,"Detected",636393353.8483057,392860000,65708369.94269839,5.978842578846459,null,"Essential"]
["MMV000848",null,null,660,1997,2000,3600,null,3.02575757575758,3.03030303030303,5.45454545454545,null,"Hsp90","E.L. Allman, H.J. Painter, J. Samra, M. Carrasquilla, M. Llinas Metabolomic profiling of the malaria box reveals antimalarial target pathways 2016","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond Voorhis 2016","Identification of an inhibitory pocket in falcilysin provides a new avenue for malaria drug development G Wirjanata",{"$nulls":4},"PF3D7_0708400",null,0.47,0.14,-0.37,null,null,391.244342138169,487.5030361563116,2642.7611857491,"gct V enriched",null,0.14804377491539,6.754758858125038,null,"Detected",28102267024.51306,93040000000,24304490388.95642,3.8280991911797466,null,"Essential"]
["MMV000720",null,null,864.35955618131,5000,2427.4,5000,null,5.78462974608589,2.80832204912978,5.78462974608589,null,"6-phosphogluconate dehydrogenase","Characterization of Plasmodium falciparum 6-phosphogluconate dehydrogenase as an antimalarial drug target K Haeussler 2018",{"$nulls":6},"PF3D7_1454700",null,0.29,0.18,-0.08,null,null,1.7176232460629302,5.869374848204267,16.4332882219999,"gct V enriched",null,0.10452097126632753,9.567457974074145,null,"Detected",1936470222.4009511,2758600000,3486288340.423685,0.7912713265893406,null,"Essential"]
["MMV011895",null,null,842,1286.53,5000,5000,null,1.52794536817102,5.93824228028504,5.93824228028504,null,"chloroquine resistance transporter (CRT)","Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. Cowell. 2018","Identification of β-hematin inhibitors in the MMV Malaria Box KY Fong 2015","Characterization of Plasmodium falciparum 6-phosphogluconate dehydrogenase as an antimalarial drug target K Haeussler 2018",{"$nulls":4},"PF3D7_0709000",null,0.71,-0.13,-0.9,null,null,2.488931895417541,0.18392148688178012,0.584893192461114,"enriched troph",null,4.255361367679134,0.23499766849305168,null,"Detected",12619931.898450887,55641000,158501694.86890087,0.35104356484024674,null,"Essential","D"]
["MMV011895",null,null,842,1286.53,5000,5000,null,1.52794536817102,5.93824228028504,5.93824228028504,null,"amino acid transporter AAT1","Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. Cowell. 2018","Identification of β-hematin inhibitors in the MMV Malaria Box KY Fong 2015","Characterization of Plasmodium falciparum 6-phosphogluconate dehydrogenase as an antimalarial drug target K Haeussler 2018",{"$nulls":4},"PF3D7_0629500",null,0.31,-0.31,-0.59,{"$nulls":6},"Not detected",{"$nulls":3},"Detected",3042923.6353463647,6972800,6511740.419343636,1.0708043550518,null,"Essential"]
["MMV011895",null,null,842,1286.53,5000,5000,null,1.52794536817102,5.93824228028504,5.93824228028504,null,"6-phosphogluconate dehydrogenase","Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. Cowell. 2018","Identification of β-hematin inhibitors in the MMV Malaria Box KY Fong 2015","Characterization of Plasmodium falciparum 6-phosphogluconate dehydrogenase as an antimalarial drug target K Haeussler 2018",{"$nulls":4},"PF3D7_1454700",null,0.29,0.18,-0.08,null,null,1.7176232460629302,5.869374848204267,16.4332882219999,"gct V enriched",null,0.10452097126632753,9.567457974074145,null,"Detected",1936470222.4009511,2758600000,3486288340.423685,0.7912713265893406,null,"Essential"]
["MMV007224",null,null,320,654,948,1980,null,2.04375,2.9625,6.1875,null,"phospholipid-transporting ATPase 2 (ATP2)","Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. Cowell. 2018"," Lipid transport proteins in malaria, from Plasmodium parasites to their hosts M Ressurreição 2021"," Screening for potential prophylactics targeting sporozoite motility through the skin RG Douglas 2018","Generation of a mutator parasite to drive resistome discovery in Plasmodium falciparum K Kumpornsin",{"$nulls":3},"PF3D7_1219600",null,0.26,-0.16,-0.4,null,null,0,0,0.337940442708695,"gct V enriched",null,0.4,null,null,"Detected",38850536.94093786,30051000,36855198.62823407,0.8153802209324819,null,"Essential"]
["MMV007224",null,null,320,654,948,1980,null,2.04375,2.9625,6.1875,null,"amino acid transporter AAT1","Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. Cowell. 2018"," Lipid transport proteins in malaria, from Plasmodium parasites to their hosts M Ressurreição 2021"," Screening for potential prophylactics targeting sporozoite motility through the skin RG Douglas 2018","Generation of a mutator parasite to drive resistome discovery in Plasmodium falciparum K Kumpornsin",{"$nulls":3},"PF3D7_0629500",null,0.31,-0.31,-0.59,{"$nulls":6},"Not detected",{"$nulls":3},"Detected",3042923.6353463647,6972800,6511740.419343636,1.0708043550518,null,"Essential"]
["MMV007224",null,null,320,654,948,1980,null,2.04375,2.9625,6.1875,null,"CCR4-associated factor 16 (CAF16)","Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. Cowell. 2018"," Lipid transport proteins in malaria, from Plasmodium parasites to their hosts M Ressurreição 2021"," Screening for potential prophylactics targeting sporozoite motility through the skin RG Douglas 2018","Generation of a mutator parasite to drive resistome discovery in Plasmodium falciparum K Kumpornsin",{"$nulls":3},"PF3D7_1434000",null,0.74,0.24,0.02,{"$nulls":6},"Not detected",{"$nulls":3},"Detected",249143.5242036318,7014000,11440745.83695086,0.6130719185585318,null,"Essential"]
["MMV007224",null,null,320,654,948,1980,null,2.04375,2.9625,6.1875,null,"QRP1?","Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. Cowell. 2018"," Lipid transport proteins in malaria, from Plasmodium parasites to their hosts M Ressurreição 2021"," Screening for potential prophylactics targeting sporozoite motility through the skin RG Douglas 2018","Generation of a mutator parasite to drive resistome discovery in Plasmodium falciparum K Kumpornsin",{"$nulls":3},"PF3D7_1359900",null,0.59,-0.05,0.22,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Non Essential"]
["MMV007224",null,null,320,654,948,1980,null,2.04375,2.9625,6.1875,null,"thrombospondin-related anonymous protein (TRAP)","Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. Cowell. 2018"," Lipid transport proteins in malaria, from Plasmodium parasites to their hosts M Ressurreição 2021"," Screening for potential prophylactics targeting sporozoite motility through the skin RG Douglas 2018","Generation of a mutator parasite to drive resistome discovery in Plasmodium falciparum K Kumpornsin",{"$nulls":3},"PF3D7_1335900",null,0.82,0.91,0.81,{"$nulls":6},"Not detected",{"$nulls":3},"Translationally repressed",{"$nulls":5},"Non Essential"]
["MMV1558277",null,null,759.3,5000,null,5000,null,6.58501251152377,null,6.58501251152377,null,"plasmepsin X (PMX)","Provided from MMV",{"$nulls":6},"PF3D7_0808200",null,1.26,-0.79,0.17,null,null,0,0,0.99526231496888,"gct V enriched",null,0.5,null,null,"Detected",90439310.2773018,149530000,3295189.911008856,45.37826469437687,null,"Essential/Non Essential","D I"]
["MMV000788",null,null,697,2000,2000,5000,null,2.86944045911047,2.86944045911047,7.17360114777618,null,"Cysteine protease","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond Voorhis 2016",{"$nulls":8},0.868333333333333,0.2925,0.5025,"Average",null,0.798641256081183,0.19433860091901342,0.31856282249165724,"enriched troph","Average",2.507013372855517,0.39888099953012557,null,"Detected",57370296.82134489,79529333.33333333,145189284.43913874,0.5477631055249872,null,"Essential/Non Essential","S U"]
["MMV009952","(-)-Halofuginone",null,1.02,8.4,null,7.64,null,8.23529411764706,null,7.49019607843137,null,"proline--tRNA ligase (PRS)"," Elucidating the path to Plasmodium prolyl-tRNA synthetase inhibitors that overcome halofuginone resistance. MA Tye. 2022","Structure of prolyl-tRNA synthetase-halofuginone complex provides basis for development of drugs against malaria and toxoplasmosis. V Jain. 2015","Keller TL, Zocco D, Sundrud MS, Hendrick M, Edenius M, Yum J, Kim YJ, Lee HK, Cortese JF, Wirth DF et al.. (2012) Halofuginone and other febrifugine derivatives inhibit prolyl-tRNA synthetase. ",{"$nulls":4},"PF3D7_1213800",null,0.36,0.11,-0.31,null,null,1.5095069956043754,2.3943438818071816,10.0529514112602,"gct V enriched",null,0.1501556044440435,6.659758080309661,null,"Detected",943089513.9350281,1304100000,503052280.12675816,2.592374692490004,null,"Essential"]
["MMV009952","(-)-Halofuginone",null,1.02,8.4,null,7.64,null,8.23529411764706,null,7.49019607843137,null,"proline--tRNA ligase (aPRS)"," Elucidating the path to Plasmodium prolyl-tRNA synthetase inhibitors that overcome halofuginone resistance. MA Tye. 2022","Structure of prolyl-tRNA synthetase-halofuginone complex provides basis for development of drugs against malaria and toxoplasmosis. V Jain. 2015","Keller TL, Zocco D, Sundrud MS, Hendrick M, Edenius M, Yum J, Kim YJ, Lee HK, Cortese JF, Wirth DF et al.. (2012) Halofuginone and other febrifugine derivatives inhibit prolyl-tRNA synthetase. ",{"$nulls":4},"PF3D7_0925300",null,0.27,0.71,0.76,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV665794",null,null,90,656,416,680,null,7.28888888888889,4.62222222222222,7.55555555555556,null,"PKG","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond Voorhis 2016","Combining stage specificity and metabolomic profiling to advance antimalarial drug discovery JM Murithi","Malaria Box Compounds against Anopheles gambiae (Diptera: Culicidae) Carboxypeptidase B Activity to Block Malaria Transmission T Pomun","Generation of a mutator parasite to drive resistome discovery in Plasmodium falciparum K Kumpornsin",{"$nulls":3},"PF3D7_1436600",null,0.47,-0.44,0.1,null,null,0,0.068244893498124,2.02530545710245,"gct V enriched",null,0.2,null,null,"Detected",187255751.4074903,109730000,295371702.85639864,0.37149801060444715,null,"Essential"]
["MMV665794",null,null,90,656,416,680,null,7.28888888888889,4.62222222222222,7.55555555555556,null,"QRP1?","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond Voorhis 2016","Combining stage specificity and metabolomic profiling to advance antimalarial drug discovery JM Murithi","Malaria Box Compounds against Anopheles gambiae (Diptera: Culicidae) Carboxypeptidase B Activity to Block Malaria Transmission T Pomun","Generation of a mutator parasite to drive resistome discovery in Plasmodium falciparum K Kumpornsin",{"$nulls":3},"PF3D7_1359900",null,0.59,-0.05,0.22,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Non Essential"]
["MMV665924",null,null,649.2,5000,null,5000,null,7.70178681454097,null,7.70178681454097,null,"acetyl-CoA synthetase (ACAS)","Chemogenomics identifies acetyl-coenzyme A synthetase as a target for malaria treatment and prevention. RL Summers. 2022",{"$nulls":6},"PF3D7_0627800",null,0.29,-0.51,-0.45,null,null,0.5239278103274543,0.22331568211144429,0.148153621496883,"enriched troph",null,3.5363820677071818,0.2827748758064344,null,"Detected",7752479.546805608,5327800,13142844.217746137,0.40537648561687534,null,"Essential","A"]
["MMV665924",null,null,649.2,5000,null,5000,null,7.70178681454097,null,7.70178681454097,null,"acyl-CoA synthetase (ACS10)","Chemogenomics identifies acetyl-coenzyme A synthetase as a target for malaria treatment and prevention. RL Summers. 2022",{"$nulls":6},"PF3D7_0525100",null,0.84,-0.61,-0.77,null,null,6.499642624097776,6.443810658555231,5.39080484186031,"shared 3 stages",null,1.2056905814187884,0.829400192231125,null,"Detected",337785262.1603665,1807600000,394712460.1927418,4.579536199889236]
["MMV019721",null,null,496.512972476063,null,790,3910,null,null,1.59109639383709,7.87492012645954,null,"acetyl-CoA synthetase (ACAS)","Chemogenomics identifies acetyl-coenzyme A synthetase as a target for malaria treatment and prevention. RL Summers. 2022",{"$nulls":6},"PF3D7_0627800",null,0.29,-0.51,-0.45,null,null,0.5239278103274543,0.22331568211144429,0.148153621496883,"enriched troph",null,3.5363820677071818,0.2827748758064344,null,"Detected",7752479.546805608,5327800,13142844.217746137,0.40537648561687534,null,"Essential","A"]
["MMV019721",null,null,496.512972476063,null,790,3910,null,null,1.59109639383709,7.87492012645954,null,"acyl-CoA synthetase (ACS11)","Chemogenomics identifies acetyl-coenzyme A synthetase as a target for malaria treatment and prevention. RL Summers. 2022",{"$nulls":6},"PF3D7_1238800",null,0.54,-0.04,-0.19,null,null,3.175016900592523,1.578121624064757,2.78248990638938,"shared 3 stages",null,1.1410704108222605,0.8763701087292198,null,"Detected",370910521.31342447,1014900000,531968643.8183713,1.9078192141462285]
["MMV019721",null,null,496.512972476063,null,790,3910,null,null,1.59109639383709,7.87492012645954,null,"acyl-CoA synthetase (ACS10)","Chemogenomics identifies acetyl-coenzyme A synthetase as a target for malaria treatment and prevention. RL Summers. 2022",{"$nulls":6},"PF3D7_0525100",null,0.84,-0.61,-0.77,null,null,6.499642624097776,6.443810658555231,5.39080484186031,"shared 3 stages",null,1.2056905814187884,0.829400192231125,null,"Detected",337785262.1603665,1807600000,394712460.1927418,4.579536199889236]
["MMV665878",null,null,139,819,null,1100,null,5.89208633093525,null,7.9136690647482,null,"ATP4","E.L. Allman, H.J. Painter, J. Samra, M. Carrasquilla, M. Llinas Metabolomic profiling of the malaria box reveals antimalarial target pathways 2016","Metabolomics-based screening of the malaria box reveals both novel and established mechanisms of action DJ Creek","Targeted phenotypic screening in Plasmodium falciparum and Toxoplasma gondii reveals novel modes of action of medicines for malaria venture malaria box … G Subramanian",{"$nulls":4},"PF3D7_1211900",null,0.33,-0.22,-0.49,null,null,1.7731908623980155,0.4394601472062679,2.59381366380463,"shared 3 stages",null,0.6836230709792325,1.462794400088903,null,"Detected",636393353.8483057,392860000,65708369.94269839,5.978842578846459,null,"Essential"]
["GNF-Pf-3703",null,null,73.7,null,null,598.12,{"$nulls":3},8.11560379918589,null,"multidrug-resistant modulator MFR3","PfMFR3: A Multidrug-Resistant Modulator in Plasmodium falciparum Frances Rocamora",{"$nulls":6},"PF3D7_0312500",null,0.89,0.25,-0.19,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Non Essential","U","U"]
["MMV007384",null,null,100,949,1113.5,870,null,9.49,11.135,8.7,null,"6-phosphogluconate dehydrogenase","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond Voorhis 2016","New insights into novel inhibitors against deoxyhypusine hydroxylase from Plasmodium falciparum: compounds with an iron chelating potential I von Koschitzky","Identification of β-hematin inhibitors in the MMV Malaria Box KY Fong","Characterization of Plasmodium falciparum 6-phosphogluconate dehydrogenase as an antimalarial drug target K Haeussler,","Bilayer Effects of Antimalarial Compounds Nicole B. Ramsey",null,null,"PF3D7_1454700",null,0.29,0.18,-0.08,null,null,1.7176232460629302,5.869374848204267,16.4332882219999,"gct V enriched",null,0.10452097126632753,9.567457974074145,null,"Detected",1936470222.4009511,2758600000,3486288340.423685,0.7912713265893406,null,"Essential"]
["MMV007384",null,null,100,949,1113.5,870,null,9.49,11.135,8.7,null,"Hsp90","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond Voorhis 2016","New insights into novel inhibitors against deoxyhypusine hydroxylase from Plasmodium falciparum: compounds with an iron chelating potential I von Koschitzky","Identification of β-hematin inhibitors in the MMV Malaria Box KY Fong","Characterization of Plasmodium falciparum 6-phosphogluconate dehydrogenase as an antimalarial drug target K Haeussler,","Bilayer Effects of Antimalarial Compounds Nicole B. Ramsey",null,null,"PF3D7_0708400",null,0.47,0.14,-0.37,null,null,391.244342138169,487.5030361563116,2642.7611857491,"gct V enriched",null,0.14804377491539,6.754758858125038,null,"Detected",28102267024.51306,93040000000,24304490388.95642,3.8280991911797466,null,"Essential"]
["MMV007384",null,null,100,949,1113.5,870,null,9.49,11.135,8.7,null,"phosphoethanolamine methyltransferase (PfPMT)","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond Voorhis 2016","New insights into novel inhibitors against deoxyhypusine hydroxylase from Plasmodium falciparum: compounds with an iron chelating potential I von Koschitzky","Identification of β-hematin inhibitors in the MMV Malaria Box KY Fong","Characterization of Plasmodium falciparum 6-phosphogluconate dehydrogenase as an antimalarial drug target K Haeussler,","Bilayer Effects of Antimalarial Compounds Nicole B. Ramsey",null,null,"PF3D7_1343000",null,0.77,1.48,0.61,null,null,336.4138014225539,83.2557979663136,10.5478198468946,"enriched troph",null,31.89415502973328,0.03135370725663531,null,"Detected",114835488.61768718,1894500000,446647232.3754124,4.241602460905097,null,"Non/Essential","A"]
["MMV007384",null,null,100,949,1113.5,870,null,9.49,11.135,8.7,null,"deoxyhypusine hydroxylase (DOHH)","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond Voorhis 2016","New insights into novel inhibitors against deoxyhypusine hydroxylase from Plasmodium falciparum: compounds with an iron chelating potential I von Koschitzky","Identification of β-hematin inhibitors in the MMV Malaria Box KY Fong","Characterization of Plasmodium falciparum 6-phosphogluconate dehydrogenase as an antimalarial drug target K Haeussler,","Bilayer Effects of Antimalarial Compounds Nicole B. Ramsey",null,null,"PF3D7_1302600",null,0.46,-0.08,-0.12,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV007384",null,null,100,949,1113.5,870,null,9.49,11.135,8.7,null,"cysteine protease","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond Voorhis 2016","New insights into novel inhibitors against deoxyhypusine hydroxylase from Plasmodium falciparum: compounds with an iron chelating potential I von Koschitzky","Identification of β-hematin inhibitors in the MMV Malaria Box KY Fong","Characterization of Plasmodium falciparum 6-phosphogluconate dehydrogenase as an antimalarial drug target K Haeussler,","Bilayer Effects of Antimalarial Compounds Nicole B. Ramsey",{"$nulls":4},0.868333333333333,0.2925,0.5025,"Average",null,0.798641256081183,0.19433860091901342,0.31856282249165724,"enriched troph","Average",2.507013372855517,0.39888099953012557,null,"Detected",57370296.82134489,79529333.33333333,145189284.43913874,0.5477631055249872,null,"Essential/Non Essential","S U"]
["MMV1576861",null,null,519.35,5000,null,5000,null,9.62741888899586,null,9.62741888899586,null,"Plasmepsin IX (PMIX)","Pino P, Caldelari R, Mukherjee B, Vahokoski J, Klages N, Maco B, Collins CR, Blackman MJ, Kursula I, Heussler V et al.. (2017) A multistage antimalarial targets the plasmepsins IX and X essential for invasion and egress. ","C.-L. Ciana, Novel in vivo active anti-malarials based on a hydroxy-ethyl-amine scaffold. 2013","W.A. Guiguemde, A.A. Shelat, D. Bouck, S. Duffy, G.J. Crowther, P.H. Davis, D.C. Smithson, M. Connelly, J. Clark, F. Zhu, M.B. Jiménez-Díaz, M.S. Martinez, E.B. Wilson, A.K. Tripathi, J. Gut, E.R. Sharlow. Chemical genetics of Plasmodium falciparum. 2010",{"$nulls":4},"PF3D7_1430200",null,0.33,1.1,0.72,{"$nulls":6},"Not detected",{"$nulls":3},"Translationally repressed",{"$nulls":5},"Essential","I"]
["MMV1576861",null,null,519.35,5000,null,5000,null,9.62741888899586,null,9.62741888899586,null,"plasmepsin X (PMX)","Pino P, Caldelari R, Mukherjee B, Vahokoski J, Klages N, Maco B, Collins CR, Blackman MJ, Kursula I, Heussler V et al.. (2017) A multistage antimalarial targets the plasmepsins IX and X essential for invasion and egress. ","C.-L. Ciana, Novel in vivo active anti-malarials based on a hydroxy-ethyl-amine scaffold. 2013","W.A. Guiguemde, A.A. Shelat, D. Bouck, S. Duffy, G.J. Crowther, P.H. Davis, D.C. Smithson, M. Connelly, J. Clark, F. Zhu, M.B. Jiménez-Díaz, M.S. Martinez, E.B. Wilson, A.K. Tripathi, J. Gut, E.R. Sharlow. Chemical genetics of Plasmodium falciparum. 2010",{"$nulls":4},"PF3D7_0808200",null,1.26,-0.79,0.17,null,null,0,0,0.99526231496888,"gct V enriched",0.5,0.5,null,null,"Detected",90439310.2773018,149530000,3295189.911008856,45.37826469437687,null,"Essential/Non Essential","D I"]
["MMV006656",null,null,518.5,2420.18,5000,5000,null,4.66765670202507,9.64320154291225,9.64320154291225,null,"ATP4","Diverse chemotypes disrupt ion homeostasis in the malaria parasite AM Lehane 2014","A G358S mutation in the Plasmodium falciparum Na+ pump PfATP4 confers clinically-relevant resistance to cipargamin D Qiu",{"$nulls":5},"PF3D7_1211900",null,0.33,-0.22,-0.49,null,null,1.7731908623980155,0.4394601472062679,2.59381366380463,"shared 3 stages",null,0.6836230709792325,1.462794400088903,null,"Detected",636393353.8483057,392860000,65708369.94269839,5.978842578846459,null,"Essential"]
["MMV666054",null,null,499.444167,2000,1075,5000,null,4.00445161270649,2.15239274182974,10.0111290317662,null,"MAPK2","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond Voorhis 2016","Screening the Medicines for Malaria Venture \"Malaria Box\" against the Plasmodium falciparum Aminopeptidases, M1, M17 and M18 A Paiardini",{"$nulls":5},"PF3D7_1113900",null,0.53,1.03,0.24,null,null,0,0,3.89390091847749,"gct V enriched",null,0.05,null,null,"Detected",159395278.0361576,174890000,1931170747.9597151,0.09056164514959206,null,"Essential/Non Essential","U","A"]
["MMV666054",null,null,499.444167,2000,1075,5000,null,4.00445161270649,2.15239274182974,10.0111290317662,null,"PfA-M1 alanyl aminopeptidase","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond Voorhis 2016","Screening the Medicines for Malaria Venture \"Malaria Box\" against the Plasmodium falciparum Aminopeptidases, M1, M17 and M18 A Paiardini",{"$nulls":5},"PF3D7_1311800",null,0.56,0.06,-0.86,null,null,15.969688689965796,9.989022559815394,32.8385515342823,"shared 3 stages",null,0.4863091684568973,2.056305052140164,null,"Detected",2472328320.453194,15872000000,1421009325.403716,11.169525573303808,null,"Essential"]
["MMV665971",null,null,489,359,228,5000,null,0.734151329243354,0.466257668711656,10.2249488752556,null,"phosphatidylserine decarboxylase (PSD)","Characterization of Plasmodium phosphatidylserine decarboxylase expressed in yeast and application for inhibitor screening JY Choi",{"$nulls":6},"PF3D7_0927900",null,0.6,-0.61,0.16,null,null,0.9628761074834958,0,0.584893192461114,"shared 3 stages",null,1.6462426300978217,0.6074438735319221,null,"Not detected",{"$nulls":5},"Essential"]
["GNF-Pf-5179",null,null,119.1,null,null,1250,{"$nulls":3},10.495382031906,null,"CARL","High-throughput luciferase-based assay for the discovery of therapeutics that prevent malaria J Swann,",{"$nulls":6},"PF3D7_0321900",null,0.31,-0.21,-0.06,null,null,0,0,0.0537249727360731,"gct V enriched",null,0.8,null,null,"Not detected",{"$nulls":5},"Essential"]
["MMV006169",null,null,157.9,null,5000,1710,null,null,31.6656111462951,10.8296390120329,null,"Cysteine protease","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond Voorhis 2016"," Target identification strategies for mmv malaria box inhibitors of Toxoplasma gondii growth JE Foderaro",{"$nulls":7},0.868333333333333,0.2925,0.5025,"Average",null,0.798641256081183,0.19433860091901342,0.31856282249165724,"enriched troph","Average",2.507013372855517,0.39888099953012557,null,"Detected",57370296.82134489,79529333.33333333,145189284.43913874,0.5477631055249872,null,"Essential/Non Essential","S U"]
["MMV006169",null,null,157.9,null,5000,1710,null,null,31.6656111462951,10.8296390120329,null,"type II NADH:ubiquinone oxidoreductase","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond Voorhis 2016"," Target identification strategies for mmv malaria box inhibitors of Toxoplasma gondii growth JE Foderaro",{"$nulls":5},"PF3D7_0915000",null,0.23,0.12,0.11,null,null,0,0,2.62095835024592,"gct V enriched",null,0.1,null,null,"Detected",432631532.7831591,136270000,20237358.781906582,6.733586208978693,null,"Non Essential","U"]
["MMV000787",null,null,407,2000,584,4574.65,null,4.91400491400491,1.43488943488943,11.2399262899263,null,"PfDHODH","Combining stage specificity and metabolomic profiling to advance antimalarial drug discovery JM Murithi 2020","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond Voorhis 2016",{"$nulls":5},"PF3D7_0603300",null,0.75,-0.19,-0.43,null,null,1.15443469003188,0.7714114432536744,1.89426612471675,"shared 3 stages",null,0.6094363801202974,1.6408603631483383,null,"Detected",133919747.91061999,21091000,31021606.034033686,0.679880982849861,null,"Essential"]
["MMV000787",null,null,407,2000,584,4574.65,null,4.91400491400491,1.43488943488943,11.2399262899263,null,"Cysteine protease","Combining stage specificity and metabolomic profiling to advance antimalarial drug discovery JM Murithi 2020","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond Voorhis 2016",{"$nulls":7},0.868333333333333,0.2925,0.5025,"Average",null,0.798641256081183,0.19433860091901342,0.31856282249165724,"enriched troph","Average",2.507013372855517,0.39888099953012557,null,"Detected",57370296.82134489,79529333.33333333,145189284.43913874,0.5477631055249872,null,"Essential/Non Essential","S U"]
["MMV000787",null,null,407,2000,584,4574.65,null,4.91400491400491,1.43488943488943,11.2399262899263,null,"CytBC1","Combining stage specificity and metabolomic profiling to advance antimalarial drug discovery JM Murithi 2020","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond Voorhis 2016",{"$nulls":7},0.848333333333333,0.98,0.81,"Average",null,0.4530828604879675,1.7006577915597767,7.360729507627478,"gct V enriched","Average",0.06155407015275662,16.245879395437772,null,"Detected",692838621.0520334,545915000,215905094.41200727,2.528495223731227,null,"Essential/Non essential"]
["MMV007839",null,null,413.15,5000,null,5000,null,12.102142079148,null,12.102142079148,null,"formate nitrite transporter (PfFNT)"," Substrate-analogous inhibitors exert antimalarial action by targeting the Plasmodium lactate transporter PfFNT at nanomolar scale. A Golldack. 2017","Structural characterization of the Plasmodium falciparum lactate transporter PfFNT alone and in complex with antimalarial compound MMV007839 reveals its inhibition mechanism.    Xi Peng. 2021","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond Voorhis 2016",{"$nulls":4},"PF3D7_0316600",null,0.56,-0.12,-0.52,null,null,2.488931895417541,1.2779853366148883,1.51188643150958,"enriched troph",null,1.6462426300978217,0.6074438735319221,null,"Detected",102868352.44955763,394100000,150216472.08716792,2.6235471684577365,null,"Non Essential"]
["MMV007839",null,null,413.15,5000,null,5000,null,12.102142079148,null,12.102142079148,null,"PKG"," Substrate-analogous inhibitors exert antimalarial action by targeting the Plasmodium lactate transporter PfFNT at nanomolar scale. A Golldack. 2017","Structural characterization of the Plasmodium falciparum lactate transporter PfFNT alone and in complex with antimalarial compound MMV007839 reveals its inhibition mechanism.    Xi Peng. 2021","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond Voorhis 2016",{"$nulls":4},"PF3D7_1436600",null,0.47,-0.44,0.1,null,null,0,0.068244893498124,2.02530545710245,"gct V enriched",null,0.2,null,null,"Detected",187255751.4074903,109730000,295371702.85639864,0.37149801060444715,null,"Essential"]
["MMV390482","SJ733",null,30,102.7,null,367.5,null,3.42333333333333,null,12.25,null,"ATP4","Jimenez-Diaz MB, Ebert D, Salinas Y, Pradhan A, Lehane AM, Myrand-Lapierre ME, O'Loughlin KG, Shackleford DM, Justino de Almeida M, Carrillo AK, Clark JA, Dennis AS, Diep J, Deng X, Duffy S, Endsley AN, Fedewa G, Guiguemde WA, Gomez MG, Holbrook G, Horst J, Kim CC, Liu J, Lee MC, Matheny A, Martinez MS, Miller G, Rodriguez-Alejandre A, Sanz L, Sigal M, Spillman NJ, Stein PD, Wang Z, Zhu F, Waterson D, Knapp S, Shelat A, Avery VM, Fidock DA, Gamo FJ, Charman SA, Mirsalis JC, Ma H, Ferrer S, Kirk K, Angulo-Barturen I, Kyle DE, DeRisi JL, Floyd DM, Guy RK. 2014. (+)-SJ733, a clinical candidate for malaria that acts through ATP4 to induce rapid host-mediated clearance of Plasmodium. Proc Natl Acad Sci U S A 111:E5455–62.",{"$nulls":6},"PF3D7_1211900",null,0.33,-0.22,-0.49,null,null,1.7731908623980155,0.4394601472062679,2.59381366380463,"shared 3 stages",null,0.6836230709792325,1.462794400088903,null,"Detected",636393353.8483057,392860000,65708369.94269839,5.978842578846459,null,"Essential"]
["MMV665969",null,null,393,5000,1881,5000,null,12.7226463104326,4.78625954198473,12.7226463104326,null,"DHFR-TS","MMV Malaria Box Activity Screening in Dormant Plasmodium falciparum Phenotypes S Galusic",{"$nulls":6},"PF3D7_0417200",null,0.11,0.52,0.13,null,null,1.15443469003188,0.6407679530676047,10.9377664171444,"gct V enriched",null,0.10554574361931532,9.474564920465403,null,"Detected",3107354809.595412,901370000,1885999900.5903804,{"$f":"AL133/AM133","v":0.47792685445945216},null,"Essential","A"]
["MMV1645159",null,null,388.83,4379,null,5000,null,11.2619911015097,null,12.8590900907852,null,"Plasmepsin V (PMV)","Provided from MMV",{"$nulls":6},"PF3D7_1323500",null,0.44,-0.25,-0.59,null,null,0.5122019514535665,0.3395699984187145,0.311133937421564,"enriched troph",null,1.6462426300978215,0.6074438735319222,null,"Detected",15395138.5844669,16127000,287542.8694651849,56.08555006074537,null,"Essential","S"]
["MMV000031","Cycloheximide",null,198,912.61,476.67,2692.47,null,4.60914141414141,2.40742424242424,13.5983333333333,null,"60S ribosomal subunit","Geary TG, Jensen JB. 1983. Effects of antibiotics on Plasmodium falciparum in vitro. Am. J. Trop. Med. Hyg. 32:221–225.",{"$nulls":8},0.896,0.4648,0.1642,"Average",null,28.652939691617416,19.96706839095079,1136.2749488814245,"gct V enriched","Average",{"$f":"AB135/AD135","v":0.025216554954260003},{"$f":"AD135/AB135","v":39.65648764527461},null,"Detected",1241256245.4378562,846791520.4545455,502040263.24940014,1.6867004151694547,null,"Essential/Non Essential"]
["MMV029272",null,null,264.07,4042,null,3676,null,15.306547506343,null,13.9205513689552,null,"ABCI3","Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. Cowell. 2018",{"$nulls":6},"PF3D7_0319700",null,0.37,-0.27,-0.58,{"$nulls":6},"Not detected",{"$nulls":3},"Detected",2589313.0859880405,1486100,10695894.947039416,0.13894115521500583,null,"Essential (ortholog)"]
["MMV029272",null,null,264.07,4042,null,3676,null,15.306547506343,null,13.9205513689552,null,"Dipeptidyl aminopeptidase 1 (DPAP1)","Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. Cowell. 2018",{"$nulls":6},"PF3D7_1116700",null,0.66,-0.38,-0.99,null,null,2.93452527859505,0,0.668100537200059,"enriched troph",null,4.392340845725623,0.22766903460443955,null,"Not detected",{"$nulls":5},"Essential/Non Essential"]
["MMV007116",null,null,351,5000,253,5000,null,14.2450142450142,0.720797720797721,14.2450142450142,null,"Mitochondrial electron transport chain (bc1 inhibitor)","E.L. Allman, H.J. Painter, J. Samra, M. Carrasquilla, M. Llinas Metabolomic profiling of the malaria box reveals antimalarial target pathways 2016","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond Voorhis 2016","Metabolomics-based screening of the malaria box reveals both novel and established mechanisms of action DJ Creek",{"$nulls":6},0.848333333333333,0.98,0.81,"Average",null,0.4530828604879675,1.7006577915597767,7.360729507627478,"gct V enriched","Average",0.06155407015275662,16.245879395437772,null,"Detected",692838621.0520334,545915000,215905094.41200727,2.528495223731227,null,"Essential/Non essential"]
["MMV668399","MMV668399",null,339.43,1770,null,5000,null,5.21462451757358,null,14.7305777332587,null,"amino acid transporter AAT1","Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. Cowell. 2018",{"$nulls":6},"PF3D7_0629500",null,0.31,-0.31,-0.59,{"$nulls":6},"Not detected",{"$nulls":3},"Detected",3042923.6353463647,6972800,6511740.419343636,1.0708043550518,null,"Essential"]
["MMV668399","MMV668399",null,339.43,1770,null,5000,null,5.21462451757358,null,14.7305777332587,null,"Forkhead-associated domain (FHA)","Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. Cowell. 2018",{"$nulls":6},"PF3D7_0909700",null,0.98,1.04,0.42,null,null,0,0.2766043115290483,0,"gct I/II enriched",{"$nulls":4},"Not detected",{"$nulls":5},"Non Essential","V"]
["MMV668399","MMV668399",null,339.43,1770,null,5000,null,5.21462451757358,null,14.7305777332587,null,"inorganic anion exchanger, inorganic anion antiporter","Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. Cowell. 2018",{"$nulls":6},"PF3D7_1471200",null,0.26,0.44,-0.04,null,null,0,0,0.807768676963434,"gct V enriched",null,0.6,null,null,"Detected",64874226.94688254,78503000,147852609.0901198,0.5309544449915692,null,"Essential"]
["MMV674143","Cladosporin",null,65.89,199.4,null,1000.67,null,3.02625588101381,null,15.1869782971619,null,"lysine--tRNA ligase (KRS1)","Selective and Specific Inhibition of the Plasmodium falciparum Lysyl-tRNA Synthetase by the Fungal Secondary Metabolite Cladosporin. Hoepfner. 2012",{"$nulls":6},"PF3D7_1350100",null,0.52,-0.08,-0.33,null,null,2.488931895417541,4.157766611990654,5.68343917568615,"shared 3 stages",null,0.4379270752232617,2.283485211527936,null,"Detected",1071857595.901668,2153200000,1024886739.0171906,2.1009150748352927]
["MMV674143","Cladosporin",null,65.89,199.4,null,1000.67,null,3.02625588101381,null,15.1869782971619,null,"lysine--tRNA ligase (KRS2)","Selective and Specific Inhibition of the Plasmodium falciparum Lysyl-tRNA Synthetase by the Fungal Secondary Metabolite Cladosporin. Hoepfner. 2012",{"$nulls":6},"PF3D7_1416800",null,0.63,1.22,0.84,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV000753",null,null,326,627,2000,5000,null,1.92331288343558,6.13496932515337,15.3374233128834,null,"CDPK1","Identification of β-hematin inhibitors in the MMV Malaria Box KY Fong 2015","Allosteric regulation of the inactive to active state conformational transition in CDPK1 protein of Plasmodium falciparum P Gupta 2022","K.Y. Fong, R.D. Sandlin, D.W. Wright\nIdentification of beta-hematin inhibitors in the MMV Malaria Box. International journal for parasitology",{"$nulls":4},"PF3D7_0217500",null,0.54,-0.07,0.86,null,null,1.8276642121903912,0.8228906159046369,5.07832312829723,"shared 3 stages",null,0.35989521856266954,2.7785865119124034,null,"Detected",1326801430.219953,360430000,3411452182.6706023,0.10565295384496434,null,"Essential","I S","A"]
["MMV011438",null,null,50,1656,1129.5,820,null,33.12,22.59,16.4,null,"prodrug activation and resistance esterase (PARE)","Istvan, E. S., Mallari, J. P., Corey, V. C., Dharia, N. V., Marshall, G. R., Winzeler, E. A., and Goldberg, D. E. (2017) Esterase mutation is a mechanism of resistance to antimalarial compounds. Nat. Commu","A novel approach for the discovery of chemically diverse anti-malarial compounds targeting the Plasmodium falciparum Coenzyme A synthesis pathway Sabine Fletcher",{"$nulls":5},"PF3D7_0709700",null,0.74,0.63,0.46,null,null,2.9934994992897748,1.8671555457797142,1.23872113856834,"enriched troph",null,2.416604840335195,0.413803689916178,null,"Detected",24136474.046228625,42612000,32565723.47195694,1.3084923489169258,null,"Non Essential","U"]
["MMV011438",null,null,50,1656,1129.5,820,null,33.12,22.59,16.4,null,"phosphoethanolamine methyltransferase (PfPMT)","Istvan, E. S., Mallari, J. P., Corey, V. C., Dharia, N. V., Marshall, G. R., Winzeler, E. A., and Goldberg, D. E. (2017) Esterase mutation is a mechanism of resistance to antimalarial compounds. Nat. Commu","A novel approach for the discovery of chemically diverse anti-malarial compounds targeting the Plasmodium falciparum Coenzyme A synthesis pathway Sabine Fletcher",{"$nulls":5},"PF3D7_1343000",null,0.77,1.48,0.61,null,null,336.4138014225539,83.2557979663136,10.5478198468946,"enriched troph",null,31.89415502973328,0.03135370725663531,null,"Detected",114835488.61768718,1894500000,446647232.3754124,4.241602460905097,null,"Non/Essential","A"]
["MMV011438",null,null,50,1656,1129.5,820,null,33.12,22.59,16.4,null,"pantothenate kinase 1","Istvan, E. S., Mallari, J. P., Corey, V. C., Dharia, N. V., Marshall, G. R., Winzeler, E. A., and Goldberg, D. E. (2017) Esterase mutation is a mechanism of resistance to antimalarial compounds. Nat. Commu","A novel approach for the discovery of chemically diverse anti-malarial compounds targeting the Plasmodium falciparum Coenzyme A synthesis pathway Sabine Fletcher",{"$nulls":5},"PF3D7_1420600",null,0.26,0.36,0.59,null,null,0.68726376397451,0,0,"enriched troph",null,1.5,0,null,"Detected",266001.2984578802,721950,3593539.8471956938,0.2009021830002501,null,"Essential"]
["MMV011438",null,null,50,1656,1129.5,820,null,33.12,22.59,16.4,null,"pantothenate kinase 2","Istvan, E. S., Mallari, J. P., Corey, V. C., Dharia, N. V., Marshall, G. R., Winzeler, E. A., and Goldberg, D. E. (2017) Esterase mutation is a mechanism of resistance to antimalarial compounds. Nat. Commu","A novel approach for the discovery of chemically diverse anti-malarial compounds targeting the Plasmodium falciparum Coenzyme A synthesis pathway Sabine Fletcher",{"$nulls":5},"PF3D7_1437400",null,0.33,-0.07,-0.18,{"$nulls":6},"Not detected",{"$nulls":3},"Detected",1234946.8745992319,2466955.0532793016,1141968.171123459,2.1602660351315497,null,"Non Essential"]
["MMV011438",null,null,50,1656,1129.5,820,null,33.12,22.59,16.4,null,"phosphopantothenoylcysteine synthetase","Istvan, E. S., Mallari, J. P., Corey, V. C., Dharia, N. V., Marshall, G. R., Winzeler, E. A., and Goldberg, D. E. (2017) Esterase mutation is a mechanism of resistance to antimalarial compounds. Nat. Commu","A novel approach for the discovery of chemically diverse anti-malarial compounds targeting the Plasmodium falciparum Coenzyme A synthesis pathway Sabine Fletcher",{"$nulls":5},"PF3D7_0412300",null,0.72,-0.49,-0.31,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Non Essential"]
["MMV011438",null,null,50,1656,1129.5,820,null,33.12,22.59,16.4,null,"phosphopantothenoylcysteine decarboxylase","Istvan, E. S., Mallari, J. P., Corey, V. C., Dharia, N. V., Marshall, G. R., Winzeler, E. A., and Goldberg, D. E. (2017) Esterase mutation is a mechanism of resistance to antimalarial compounds. Nat. Commu","A novel approach for the discovery of chemically diverse anti-malarial compounds targeting the Plasmodium falciparum Coenzyme A synthesis pathway Sabine Fletcher",{"$nulls":5},"PF3D7_0816100",null,0.73,-0.05,0.35,null,null,0,2.1471274463127243,1.89426612471675,"gct I/II enriched",null,0.1,null,null,"Detected",61310952.05790817,26538000,43158638.24882792,0.6148942848242137,null,"Essential"]
["MMV011438",null,null,50,1656,1129.5,820,null,33.12,22.59,16.4,null,"phosphopantetheine adenylyltransferase (PPAT)","Istvan, E. S., Mallari, J. P., Corey, V. C., Dharia, N. V., Marshall, G. R., Winzeler, E. A., and Goldberg, D. E. (2017) Esterase mutation is a mechanism of resistance to antimalarial compounds. Nat. Commu","A novel approach for the discovery of chemically diverse anti-malarial compounds targeting the Plasmodium falciparum Coenzyme A synthesis pathway Sabine Fletcher",{"$nulls":5},"PF3D7_0704700",null,0.2,0.12,0.72,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Non Essential"]
["MMV011438",null,null,50,1656,1129.5,820,null,33.12,22.59,16.4,null,"dephospho-CoA kinase","Istvan, E. S., Mallari, J. P., Corey, V. C., Dharia, N. V., Marshall, G. R., Winzeler, E. A., and Goldberg, D. E. (2017) Esterase mutation is a mechanism of resistance to antimalarial compounds. Nat. Commu","A novel approach for the discovery of chemically diverse anti-malarial compounds targeting the Plasmodium falciparum Coenzyme A synthesis pathway Sabine Fletcher",{"$nulls":5},"PF3D7_1443700",null,0.27,0.6,0.55,{"$nulls":6},"Not detected",{"$nulls":3},"Detected",600796.7779038273,3685300,5879231.533252301,0.626833622584234,null,"Essential"]
["MMV008138",null,null,300,null,5000,5000,null,null,16.6666666666667,16.6666666666667,null,"2-C-Methyl-D-erythritol 4-Phosphate Cytidyltransferase (IspD)","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond Voorhis 2016","Biological Studies and Target Engagement of the 2-C-Methyl-d-Erythritol 4-Phosphate Cytidylyltransferase (IspD)-Targeting Antimalarial Agent (1R,3S)-MMV008138 and Analogs  Maryam Ghavami,","Plasmodium IspD (2-C-Methyl‑D‑erythritol 4‑Phosphate Cytidyltransferase), an Essential and Druggable Antimalarial Target Leah S. Imlay","Antiapicoplast and gametocytocidal screening to identify the mechanisms of action of compounds within the malaria box JD Bowman","Determination of the active stereoisomer of the MEP pathway-targeting antimalarial agent MMV008138, and initial structure–activity studies ZK Yao",null,null,"PF3D7_0106900",null,0.39,1.03,0.97,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV008138",null,null,300,null,5000,5000,null,null,16.6666666666667,16.6666666666667,null,"glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond Voorhis 2016","Biological Studies and Target Engagement of the 2-C-Methyl-d-Erythritol 4-Phosphate Cytidylyltransferase (IspD)-Targeting Antimalarial Agent (1R,3S)-MMV008138 and Analogs  Maryam Ghavami,","Plasmodium IspD (2-C-Methyl‑D‑erythritol 4‑Phosphate Cytidyltransferase), an Essential and Druggable Antimalarial Target Leah S. Imlay","Antiapicoplast and gametocytocidal screening to identify the mechanisms of action of compounds within the malaria box JD Bowman","Determination of the active stereoisomer of the MEP pathway-targeting antimalarial agent MMV008138, and initial structure–activity studies ZK Yao",null,null,"PF3D7_1453800",null,0.33,-0.18,-0.76,null,null,0.8826740544015893,1.4191345033752625,4.79044398060249,"shared 3 stages",null,0.18425725422856865,5.427194734810893,null,"Detected",532982968.84288555,1254400000,2247191145.164091,0.5582079667319101,null,"Essential"]
["MMV650381","KDU691",null,42.7,2257,null,767.8,null,52.8571428571429,null,17.9812646370023,null,"PI4K","McNamara CW, et al. Targeting Plasmodium PI(4)K to eliminate malaria. Nature. 2013;504:248–253.",{"$nulls":6},"PF3D7_0509800",null,0.29,-0.01,0.16,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV652103",null,null,7.25,59.6,5,133.3,null,8.22068965517241,0.689655172413793,18.3862068965517,null,"CDPK1","Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): preparation and evaluation of pyrazole … JM Large","Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) TM Chapman","New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of Plasmodium Phosphatidylinositol-4-kinase and cGMP … PM Cheuka","Exploring the transmission-blocking activity of antiplasmodial 3, 6-diarylated imidazopyridazines D Coertzen",{"$nulls":3},"PF3D7_0217500",null,0.54,-0.07,0.86,null,null,1.8276642121903912,0.8228906159046369,5.07832312829723,"shared 3 stages",null,0.35989521856266954,2.7785865119124034,null,"Detected",1326801430.219953,360430000,3411452182.6706023,0.10565295384496434,null,"Essential","I S","A"]
["MMV652103",null,null,7.25,59.6,5,133.3,null,8.22068965517241,0.689655172413793,18.3862068965517,null,"CDPK4","Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): preparation and evaluation of pyrazole … JM Large","Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) TM Chapman","New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of Plasmodium Phosphatidylinositol-4-kinase and cGMP … PM Cheuka","Exploring the transmission-blocking activity of antiplasmodial 3, 6-diarylated imidazopyridazines D Coertzen",{"$nulls":3},"PF3D7_0717500",null,0.32,0.52,0.27,null,null,0,0.40541168873881694,56.3615251044868,"gct V enriched",null,1E-3,null,null,"Detected",1686711047.3126552,891260000,11247658017.88505,0.07923960691041598,null,"Non Essential","U"]
["MMV652103",null,null,7.25,59.6,5,133.3,null,8.22068965517241,0.689655172413793,18.3862068965517,null,"PI4K","Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): preparation and evaluation of pyrazole … JM Large","Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) TM Chapman","New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of Plasmodium Phosphatidylinositol-4-kinase and cGMP … PM Cheuka","Exploring the transmission-blocking activity of antiplasmodial 3, 6-diarylated imidazopyridazines D Coertzen",{"$nulls":3},"PF3D7_0509800",null,0.29,-0.01,0.16,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV652103",null,null,7.25,59.6,5,133.3,null,8.22068965517241,0.689655172413793,18.3862068965517,null,"PKG","Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): preparation and evaluation of pyrazole … JM Large","Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) TM Chapman","New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of Plasmodium Phosphatidylinositol-4-kinase and cGMP … PM Cheuka","Exploring the transmission-blocking activity of antiplasmodial 3, 6-diarylated imidazopyridazines D Coertzen",{"$nulls":3},"PF3D7_1436600",null,0.47,-0.44,0.1,null,null,0,0.068244893498124,2.02530545710245,"gct V enriched",null,0.2,null,null,"Detected",187255751.4074903,109730000,295371702.85639864,0.37149801060444715,null,"Essential"]
["MMV006787",null,null,200.9,1645,1170,3713.2,null,8.18815331010453,5.82379293180687,18.4828272772524,null,"Hsp90","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond Voorhis 2016",{"$nulls":6},"PF3D7_0708400",null,0.47,0.14,-0.37,null,null,391.244342138169,487.5030361563116,2642.7611857491,"gct V enriched",null,0.14804377491539,6.754758858125038,null,"Detected",28102267024.51306,93040000000,24304490388.95642,3.8280991911797466,null,"Essential"]
["MMV1577530","MMV1577530",null,25.87,147.14,null,481.57,null,5.68766911480479,null,18.6149980672594,null,"proteosome","Provided from MMV",{"$nulls":8},0.414285714285714,0.289285714285714,0.119285714285714,"Average",null,4.371904224875087,14.744723143961812,53.195817261465585,"gct V enriched","Average",0.08218511247578938,12.167653847216995,null,"Detected",1385888365.4679062,3846228571.428571,1162706304.4179296,3.307996659873671,null,"Essential/Non essential"]
["MMV397264","21A092",null,10.58,62.1,null,213.3,null,5.8695652173913,null,20.1606805293006,null,"ATP4","Pyrazoleamide compounds are potent antimalarials that target Na+ homeostasis in intraerythrocytic Plasmodium falciparum. Akhil B. Vaidya. 2014",{"$nulls":6},"PF3D7_1211900",null,0.33,-0.22,-0.49,null,null,1.7731908623980155,0.4394601472062679,2.59381366380463,"shared 3 stages",null,0.6836230709792325,1.462794400088903,null,"Detected",636393353.8483057,392860000,65708369.94269839,5.978842578846459,null,"Essential"]
["MMV000061","Methylene Blue",null,21.7,62.7,null,457,null,2.88940092165899,null,21.0599078341014,null,"glutathione reductase (GR)","Buchholz K, Schirmer RH, Eubel JK, Akoachere MB, Dandekar T, Becker K, Gromer S. 2008. Interactions of methylene blue with human disulfide reductases and their orthologues from Plasmodium falciparum. Antimicrob. Agents Chemother. 52:183–191.","Vennerstrom JL, Makler MT, Angerhofer CK, Williams JA. 1995. Antimalarial dyes revisited: xanthenes, azines, oxazines, and thiazines. Antimicrob Agents Chemother 39:2671–2677. https://doi.org/10.1128/AAC.39 .12.2671",{"$nulls":5},"PF3D7_1419800",null,0.71,0.64,-0.14,null,null,1.15443469003188,1.0570182237640764,9,"gct V enriched",null,0.12827052111465334,7.7960235236446875,null,"Not detected",{"$nulls":5},"Essential"]
["MMV011895","MMV011895",null,233,2156,null,5000,null,9.25321888412017,null,21.4592274678112,null,"chloroquine resistance transporter (CRT)","Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. Cowell. 2018","Identification of β-hematin inhibitors in the MMV Malaria Box KY Fong 2015","Characterization of Plasmodium falciparum 6-phosphogluconate dehydrogenase as an antimalarial drug target K Haeussler 2018",{"$nulls":4},"PF3D7_0709000",null,0.71,-0.13,-0.9,null,null,2.488931895417541,0.18392148688178012,0.584893192461114,"enriched troph",null,4.255361367679134,0.23499766849305168,null,"Detected",12619931.898450887,55641000,158501694.86890087,0.35104356484024674,null,"Essential","D"]
["MMV011895","MMV011895",null,233,2156,null,5000,null,9.25321888412017,null,21.4592274678112,null,"amino acid transporter AAT1","Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. Cowell. 2018","Identification of β-hematin inhibitors in the MMV Malaria Box KY Fong 2015","Characterization of Plasmodium falciparum 6-phosphogluconate dehydrogenase as an antimalarial drug target K Haeussler 2018",{"$nulls":4},"PF3D7_0629500",null,0.31,-0.31,-0.59,{"$nulls":6},"Not detected",{"$nulls":3},"Detected",3042923.6353463647,6972800,6511740.419343636,1.0708043550518,null,"Essential"]
["MMV011895","MMV011895",null,233,2156,null,5000,null,9.25321888412017,null,21.4592274678112,null,"6-phosphogluconate dehydrogenase","Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. Cowell. 2018","Identification of β-hematin inhibitors in the MMV Malaria Box KY Fong 2015","Characterization of Plasmodium falciparum 6-phosphogluconate dehydrogenase as an antimalarial drug target K Haeussler 2018",{"$nulls":4},"PF3D7_1454700",null,0.29,0.18,-0.08,null,null,1.7176232460629302,5.869374848204267,16.4332882219999,"gct V enriched",null,0.10452097126632753,9.567457974074145,null,"Detected",1936470222.4009511,2758600000,3486288340.423685,0.7912713265893406,null,"Essential"]
["MMV1792684","TCMDC-135051",null,115.67,840,null,2526,null,7.26203855796663,null,21.8379873778854,null,"cyclin-dependent-like kinase (CLK3)","Development of Potent PfCLK3 Inhibitors Based on TCMDC-135051 as a New Class of Antimalarials. A Mahindra. 2020","Validation of the protein kinase PfCLK3 as a multistage cross-species malarial drug target. Mahmood M. Alam. 2019",{"$nulls":5},"PF3D7_1114700",null,0.25,0.09,-0.02,null,null,0,0,0.0624678308940412,"not determined",null,0.8,null,null,"Detected",2546751.7470364026,7551700,2549578.3721132143,2.9619407203163495,null,"Essential"]
["MMV642943",null,null,5.73,134,66,125.6,null,23.3856893542757,11.5183246073298,21.9197207678883,null,"PI4K","UCT943, a Next-Generation Plasmodium falciparum PI4K Inhibitor Preclinical Candidate for the Treatment of Malaria Christel Brunschwig 2018","Potent Plasmodium falciparum gametocytocidal compounds identified by exploring the kinase inhibitor chemical space for dual active antimalarials ME van der Wat",{"$nulls":5},"PF3D7_0509800",null,0.29,-0.01,0.16,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV642944","CC_642944",null,13.78,306.6,null,319.1,null,22.2496371552975,null,23.1567489114659,null,"PI4K"," Potent Plasmodium falciparum gametocytocidal compounds identified by exploring the kinase inhibitor chemical space for dual active antimalarials Mariëtte E van der Watt, ","Probing the distinct chemosensitivity of Plasmodium vivax liver stage parasites and demonstration of 8-aminoquinoline radical cure activity in vitro SP Maher 2021","UCT943, a Next-Generation Plasmodium falciparum PI4K Inhibitor Preclinical Candidate for the Treatment of Malaria Christel Brunschwig 2018",{"$nulls":4},"PF3D7_0509800",null,0.29,-0.01,0.16,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV675615",null,null,4.47,163.2,72.1,104.2,null,36.510067114094,16.1297539149888,23.3109619686801,null,"CDPK1","Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): preparation and evaluation of pyrazole … JM Large","Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) TM Chapman","New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of Plasmodium Phosphatidylinositol-4-kinase and cGMP … PM Cheuka"," Potent Plasmodium falciparum gametocytocidal compounds identified by exploring the kinase inhibitor chemical space for dual active antimalarials Mariëtte E van der Watt, ",{"$nulls":3},"PF3D7_0217500",null,0.54,-0.07,0.86,null,null,1.8276642121903912,0.8228906159046369,5.07832312829723,"shared 3 stages",null,0.35989521856266954,2.7785865119124034,null,"Detected",1326801430.219953,360430000,3411452182.6706023,0.10565295384496434,null,"Essential","I S","A"]
["MMV675615",null,null,4.47,163.2,72.1,104.2,null,36.510067114094,16.1297539149888,23.3109619686801,null,"PI4K","Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): preparation and evaluation of pyrazole … JM Large","Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) TM Chapman","New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of Plasmodium Phosphatidylinositol-4-kinase and cGMP … PM Cheuka"," Potent Plasmodium falciparum gametocytocidal compounds identified by exploring the kinase inhibitor chemical space for dual active antimalarials Mariëtte E van der Watt, ",{"$nulls":3},"PF3D7_0509800",null,0.29,-0.01,0.16,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV675615",null,null,4.47,163.2,72.1,104.2,null,36.510067114094,16.1297539149888,23.3109619686801,null,"PKG","Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): preparation and evaluation of pyrazole … JM Large","Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) TM Chapman","New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of Plasmodium Phosphatidylinositol-4-kinase and cGMP … PM Cheuka"," Potent Plasmodium falciparum gametocytocidal compounds identified by exploring the kinase inhibitor chemical space for dual active antimalarials Mariëtte E van der Watt, ",{"$nulls":3},"PF3D7_1436600",null,0.47,-0.44,0.1,null,null,0,0.068244893498124,2.02530545710245,"gct V enriched",null,0.2,null,null,"Detected",187255751.4074903,109730000,295371702.85639864,0.37149801060444715,null,"Essential"]
["MMV675615",null,null,4.47,163.2,72.1,104.2,null,36.510067114094,16.1297539149888,23.3109619686801,null,"PK7","Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): preparation and evaluation of pyrazole … JM Large","Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) TM Chapman","New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of Plasmodium Phosphatidylinositol-4-kinase and cGMP … PM Cheuka"," Potent Plasmodium falciparum gametocytocidal compounds identified by exploring the kinase inhibitor chemical space for dual active antimalarials Mariëtte E van der Watt, ",{"$nulls":3},"PF3D7_0213400",null,0.31,0.27,-0.31,null,null,0.2246523050636276,0,0.136463666385725,"not determined",null,1.6462426300978217,0.6074438735319221,null,"Not detected",{"$nulls":5},"Non Essential","A D"]
["MMV642943",null,null,5.38,208.7,null,125.6,null,38.7918215613383,null,23.3457249070632,null,"PI4K","UCT943, a Next-Generation Plasmodium falciparum PI4K Inhibitor Preclinical Candidate for the Treatment of Malaria Christel Brunschwig 2018","Potent Plasmodium falciparum gametocytocidal compounds identified by exploring the kinase inhibitor chemical space for dual active antimalarials ME van der Wat",{"$nulls":5},"PF3D7_0509800",null,0.29,-0.01,0.16,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV019555",null,null,20,1428,1547.9,470,null,71.4,77.395,23.5,null,"esterase","Combining stage specificity and metabolomic profiling to advance antimalarial drug discovery JM Murithi","Antiapicoplast and gametocytocidal screening to identify the mechanisms of action of compounds within the malaria box JD Bowman"," Evaluation of short-tether bis-THA AChE inhibitors. A further test of the dual binding site hypothesis PR Carlier",{"$nulls":6},1.01666666666667,-0.6,-0.753333333333333,"Average",null,0,0,23.6209240149463,"gct V enriched","Average",0.05,null,null,"Detected",837699531.7690666,116700000,253740798.83660358,0.45991815480627135,null,"Essential"]
["MMV665980",null,null,210.8,5000,5000,5000,null,23.719165085389,23.719165085389,23.719165085389,null,"phosphoethanolamine methyltransferase (PfPMT)","A novel approach for the discovery of chemically diverse anti-malarial compounds targeting the Plasmodium falciparum Coenzyme A synthesis pathway S Fletcher",{"$nulls":6},"PF3D7_1343000",null,0.77,1.48,0.61,null,null,336.4138014225539,83.2557979663136,10.5478198468946,"enriched troph",null,31.89415502973328,0.03135370725663531,null,"Detected",114835488.61768718,1894500000,446647232.3754124,4.241602460905097,null,"Non/Essential","A"]
["MMV665980",null,null,210.8,5000,5000,5000,null,23.719165085389,23.719165085389,23.719165085389,null,"pantothenate kinase 1","A novel approach for the discovery of chemically diverse anti-malarial compounds targeting the Plasmodium falciparum Coenzyme A synthesis pathway S Fletcher",{"$nulls":6},"PF3D7_1420600",null,0.26,0.36,0.59,null,null,0.68726376397451,0,0,"enriched troph",null,null,0,null,"Detected",266001.2984578802,721950,3593539.8471956938,0.2009021830002501,null,"Essential"]
["MMV665980",null,null,210.8,5000,5000,5000,null,23.719165085389,23.719165085389,23.719165085389,null,"pantothenate kinase 2","A novel approach for the discovery of chemically diverse anti-malarial compounds targeting the Plasmodium falciparum Coenzyme A synthesis pathway S Fletcher",{"$nulls":6},"PF3D7_1437400",null,0.33,-0.07,-0.18,{"$nulls":6},"Not detected",{"$nulls":3},"Detected",1234946.8745992319,2466955.0532793016,1141968.171123459,2.1602660351315497,null,"Non Essential"]
["MMV665980",null,null,210.8,5000,5000,5000,null,23.719165085389,23.719165085389,23.719165085389,null,"phosphopantothenoylcysteine synthetase","A novel approach for the discovery of chemically diverse anti-malarial compounds targeting the Plasmodium falciparum Coenzyme A synthesis pathway S Fletcher",{"$nulls":6},"PF3D7_0412300",null,0.72,-0.49,-0.31,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Non Essential"]
["MMV665980",null,null,210.8,5000,5000,5000,null,23.719165085389,23.719165085389,23.719165085389,null,"phosphopantothenoylcysteine decarboxylase","A novel approach for the discovery of chemically diverse anti-malarial compounds targeting the Plasmodium falciparum Coenzyme A synthesis pathway S Fletcher",{"$nulls":6},"PF3D7_0816100",null,0.73,-0.05,0.35,null,null,0,2.1471274463127243,1.89426612471675,"gct I/II enriched",null,0.1,null,null,"Detected",61310952.05790817,26538000,43158638.24882792,0.6148942848242137,null,"Essential"]
["MMV665980",null,null,210.8,5000,5000,5000,null,23.719165085389,23.719165085389,23.719165085389,null,"phosphopantetheine adenylyltransferase (PPAT)","A novel approach for the discovery of chemically diverse anti-malarial compounds targeting the Plasmodium falciparum Coenzyme A synthesis pathway S Fletcher",{"$nulls":6},"PF3D7_0704700",null,0.2,0.12,0.72,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Non Essential"]
["MMV665980",null,null,210.8,5000,5000,5000,null,23.719165085389,23.719165085389,23.719165085389,null,"dephospho-CoA kinase","A novel approach for the discovery of chemically diverse anti-malarial compounds targeting the Plasmodium falciparum Coenzyme A synthesis pathway S Fletcher",{"$nulls":6},"PF3D7_1443700",null,0.27,0.6,0.55,{"$nulls":6},"Not detected",{"$nulls":3},"Detected",600796.7779038273,3685300,5879231.533252301,0.626833622584234,null,"Essential"]
["MMV006427",null,null,78.2,1960,5000,2237.62,null,25.0639386189258,63.9386189258312,28.6140664961637,null,"ATP4","E.L. Allman, H.J. Painter, J. Samra, M. Carrasquilla, M. Llinas Metabolomic profiling of the malaria box reveals antimalarial target pathways 2016","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond Voorhis 2016","Diverse chemotypes disrupt ion homeostasis in the malaria parasite AM Lehane",{"$nulls":4},"PF3D7_1211900",null,0.33,-0.22,-0.49,null,null,1.7731908623980155,0.4394601472062679,2.59381366380463,"shared 3 stages",null,0.6836230709792325,1.462794400088903,null,"Detected",636393353.8483057,392860000,65708369.94269839,5.978842578846459,null,"Essential"]
["DDD01034957",null,null,171.5,null,5000,5000,null,null,29.1545189504373,29.1545189504373,null,"ABCI3","The antimalarial efficacy and mechanism of resistance of the novel chemotype DDD01034957 C Miguel-Blanco",{"$nulls":6},"PF3D7_0319700",null,0.37,-0.27,-0.58,{"$nulls":6},"Not detected",{"$nulls":3},"Detected",2589313.0859880405,1486100,10695894.947039416,0.13894115521500583,null,"Essential (ortholog)"]
["NITD246","KAF246",null,0.08,2.104,1.766,2.355,null,26.3,22.075,29.4375,null,"ATP4","McNamara CW, Lee MC, Lim CS, Lim SH, Roland J, Nagle A, Simon O, Yeung BK, Chatterjee AK, McCormack SL, Manary MJ, Zeeman AM, Dechering KJ, Kumar TR, Henrich PP, Gagaring K, Ibanez M, Kato N, Kuhen KL, Fischli C, Rottmann M, Plouffe DM, Bursulaya B, Meister S, Rameh L, Trappe J, Haasen D, Timmerman M, Sauerwein RW, Suwanarusk R, Russell B, Renia L, Nosten F, Tully DC, Kocken CH, Glynne RJ, Bodenreider C, Fidock DA, Diagana TT, Winzeler EA. 2013. Targeting Plasmodium PI(4)K to eliminate malaria. Nature 504:248–253.","Na+ extrusion imposes an acid load on the intraerythrocytic malaria parasite NJ Spillman",{"$nulls":5},"PF3D7_1211900",null,0.33,-0.22,-0.49,null,null,1.7731908623980155,0.4394601472062679,2.59381366380463,"shared 3 stages",null,0.6836230709792325,1.462794400088903,null,"Detected",636393353.8483057,392860000,65708369.94269839,5.978842578846459,null,"Essential"]
["MMV666693",null,null,23.8,5000,438,730,null,210.084033613445,18.4033613445378,30.672268907563,null,"PfDHODH","E.L. Allman, H.J. Painter, J. Samra, M. Carrasquilla, M. Llinas Metabolomic profiling of the malaria box reveals antimalarial target pathways 2016","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond Voorhis 2016","Small molecule screen for candidate antimalarials targeting Plasmodium Kinesin-5 L Liu","Metabolomics-based screening of the malaria box reveals both novel and established mechanisms of action DJ Creek","High-throughput luciferase-based assay for the discovery of therapeutics that prevent malaria J Swann",null,null,"PF3D7_0603300",null,0.75,-0.19,-0.43,null,null,1.15443469003188,0.7714114432536744,1.89426612471675,"shared 3 stages",null,0.6094363801202974,1.6408603631483383,null,"Detected",133919747.91061999,21091000,31021606.034033686,0.679880982849861,null,"Essential"]
["MMV666693",null,null,23.8,5000,438,730,null,210.084033613445,18.4033613445378,30.672268907563,null,"kinesin-5 (EG5)","E.L. Allman, H.J. Painter, J. Samra, M. Carrasquilla, M. Llinas Metabolomic profiling of the malaria box reveals antimalarial target pathways 2016","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond Voorhis 2016","Small molecule screen for candidate antimalarials targeting Plasmodium Kinesin-5 L Liu","Metabolomics-based screening of the malaria box reveals both novel and established mechanisms of action DJ Creek","High-throughput luciferase-based assay for the discovery of therapeutics that prevent malaria J Swann",null,null,"PF3D7_0317500",null,0.55,0.12,0.11,{"$nulls":6},"Not detected",{"$nulls":3},"Detected",1724106.6035876258,71582000,6932437.81906581,10.325660592747463,null,"Non Essential"]
["MMV666693",null,null,23.8,5000,438,730,null,210.084033613445,18.4033613445378,30.672268907563,null,"bc1 inhibitor","E.L. Allman, H.J. Painter, J. Samra, M. Carrasquilla, M. Llinas Metabolomic profiling of the malaria box reveals antimalarial target pathways 2016","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond Voorhis 2016","Small molecule screen for candidate antimalarials targeting Plasmodium Kinesin-5 L Liu","Metabolomics-based screening of the malaria box reveals both novel and established mechanisms of action DJ Creek","High-throughput luciferase-based assay for the discovery of therapeutics that prevent malaria J Swann",{"$nulls":4},0.848333333333333,0.98,0.81,"Average",null,0.4530828604879675,1.7006577915597767,7.360729507627478,"gct V enriched","Average",0.06155407015275662,16.245879395437772,null,"Detected",692838621.0520334,545915000,215905094.41200727,2.528495223731227,null,"Essential/Non essential"]
["MMV030084",null,null,160.17,5000,null,5000,null,31.2168321158769,null,31.2168321158769,null,"PKG","Inhibition of resistance-refractory P. falciparum kinase PKG delivers prophylactic, blood stage, and transmission-blocking antiplasmodial activity. M. Vanaerschot, 2020",{"$nulls":6},"PF3D7_1436600",null,0.47,-0.44,0.1,null,null,0,0.068244893498124,2.02530545710245,"gct V enriched",null,0.2,null,null,"Detected",187255751.4074903,109730000,295371702.85639864,0.37149801060444715,null,"Essential"]
["MMV030084",null,null,160.17,5000,null,5000,null,31.2168321158769,null,31.2168321158769,null,"tyrosine kinase-like protein (TKL3)","Inhibition of resistance-refractory P. falciparum kinase PKG delivers prophylactic, blood stage, and transmission-blocking antiplasmodial activity. M. Vanaerschot, 2020",{"$nulls":6},"PF3D7_1349300",null,0.11,0.43,0.37,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential/Non Essential"]
["MMV672652",null,null,0.56,10.8,3.3,18.1,null,19.2857142857143,5.89285714285714,32.3214285714286,null,"CDPK1","Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): preparation and evaluation of pyrazole … JM Large","Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) TM Chapman","New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of Plasmodium Phosphatidylinositol-4-kinase and cGMP … PM Cheuka",{"$nulls":4},"PF3D7_0217500",null,0.54,-0.07,0.86,null,null,1.8276642121903912,0.8228906159046369,5.07832312829723,"shared 3 stages",null,0.35989521856266954,2.7785865119124034,null,"Detected",1326801430.219953,360430000,3411452182.6706023,0.10565295384496434,null,"Essential","I S","A"]
["MMV672652",null,null,0.56,10.8,3.3,18.1,null,19.2857142857143,5.89285714285714,32.3214285714286,null,"CDPK4","Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): preparation and evaluation of pyrazole … JM Large","Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) TM Chapman","New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of Plasmodium Phosphatidylinositol-4-kinase and cGMP … PM Cheuka",{"$nulls":4},"PF3D7_0717500",null,0.32,0.52,0.27,null,null,0,0.40541168873881694,56.3615251044868,"gct V enriched",null,1E-3,null,null,"Detected",1686711047.3126552,891260000,11247658017.88505,0.07923960691041598,null,"Non Essential","U"]
["MMV672652",null,null,0.56,10.8,3.3,18.1,null,19.2857142857143,5.89285714285714,32.3214285714286,null,"PI4K","Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): preparation and evaluation of pyrazole … JM Large","Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) TM Chapman","New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of Plasmodium Phosphatidylinositol-4-kinase and cGMP … PM Cheuka",{"$nulls":4},"PF3D7_0509800",null,0.29,-0.01,0.16,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV672652",null,null,0.56,10.8,3.3,18.1,null,19.2857142857143,5.89285714285714,32.3214285714286,null,"PKG","Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): preparation and evaluation of pyrazole … JM Large","Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) TM Chapman","New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of Plasmodium Phosphatidylinositol-4-kinase and cGMP … PM Cheuka",{"$nulls":4},"PF3D7_1436600",null,0.47,-0.44,0.1,null,null,0,0.068244893498124,2.02530545710245,"gct V enriched",null,0.2,null,null,"Detected",187255751.4074903,109730000,295371702.85639864,0.37149801060444715,null,"Essential"]
["MMV892604",null,null,151.9,5000,null,5000,null,32.916392363397,null,32.916392363397,null,"serine hydroxymethyltransferase (SHMT)","Provided from MMV",{"$nulls":6},"PF3D7_1235600",null,0.21,0.33,0.63,null,null,3.3570103694626154,12.41539811512397,47.9390091847749,"gct V enriched",null,0.07002669488898779,14.280268425995033,null,"Detected",4524227910.619995,15584000000,9004913743.705505,1.7306106914009387,null,"Essential"]
["MMV892604",null,null,151.9,5000,null,5000,null,32.916392363397,null,32.916392363397,null,"serine hydroxymethyltransferase (SHMT)","Provided from MMV",{"$nulls":6},"PF3D7_1456100",null,0.35,0.22,-0.21,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Non Essential"]
["MMV674766",null,null,7.86,93.9,66.4,262.9,null,11.9465648854962,8.44783715012723,33.4478371501272,null,"CDPK1","Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): preparation and evaluation of pyrazole … JM Large","Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) TM Chapman","New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of Plasmodium Phosphatidylinositol-4-kinase and cGMP … PM Cheuka",{"$nulls":4},"PF3D7_0217500",null,0.54,-0.07,0.86,null,null,1.8276642121903912,0.8228906159046369,5.07832312829723,"shared 3 stages",null,{"$f":"AB197/AD197","v":0.35989521856266954},{"$f":"AD197/AB197","v":2.7785865119124034},null,"Detected",1326801430.219953,360430000,3411452182.6706023,{"$f":"AL197/AM197","v":0.10565295384496434},null,"Essential","I S","A"]
["MMV674766",null,null,7.86,93.9,66.4,262.9,null,11.9465648854962,8.44783715012723,33.4478371501272,null,"PI4K","Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): preparation and evaluation of pyrazole … JM Large","Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) TM Chapman","New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of Plasmodium Phosphatidylinositol-4-kinase and cGMP … PM Cheuka",{"$nulls":4},"PF3D7_0509800",null,0.29,-0.01,0.16,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV674766",null,null,7.86,93.9,66.4,262.9,null,11.9465648854962,8.44783715012723,33.4478371501272,null,"PKG","Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): preparation and evaluation of pyrazole … JM Large","Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) TM Chapman","New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of Plasmodium Phosphatidylinositol-4-kinase and cGMP … PM Cheuka",{"$nulls":4},"PF3D7_1436600",null,0.47,-0.44,0.1,null,null,0,0.068244893498124,2.02530545710245,"gct V enriched",null,0.2,null,null,"Detected",187255751.4074903,109730000,295371702.85639864,0.37149801060444715,null,"Essential"]
["MMV674766",null,null,7.86,93.9,66.4,262.9,null,11.9465648854962,8.44783715012723,33.4478371501272,null,"PK7","Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): preparation and evaluation of pyrazole … JM Large","Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) TM Chapman","New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of Plasmodium Phosphatidylinositol-4-kinase and cGMP … PM Cheuka",{"$nulls":4},"PF3D7_0213400",null,0.31,0.27,-0.31,null,null,0.2246523050636276,0,0.136463666385725,"not determined",null,1.6462426300978217,0.6074438735319221,null,"Not detected",{"$nulls":5},"Non Essential","A D"]
["MMV666620",null,null,11.59,68.4,78.9,428,null,5.9016393442623,6.80759275237273,36.9283865401208,null,"CDPK1","Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): preparation and evaluation of pyrazole … JM Large","Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) TM Chapman","New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of Plasmodium Phosphatidylinositol-4-kinase and cGMP … PM Cheuka",{"$nulls":4},"PF3D7_0217500",null,0.54,-0.07,0.86,null,null,1.8276642121903912,0.8228906159046369,5.07832312829723,"shared 3 stages",null,0.35989521856266954,2.7785865119124034,null,"Detected",1326801430.219953,360430000,3411452182.6706023,0.10565295384496434,null,"Essential","I S","A"]
["MMV666620",null,null,11.59,68.4,78.9,428,null,5.9016393442623,6.80759275237273,36.9283865401208,null,"CDPK4","Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): preparation and evaluation of pyrazole … JM Large","Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) TM Chapman","New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of Plasmodium Phosphatidylinositol-4-kinase and cGMP … PM Cheuka",{"$nulls":4},"PF3D7_0717500",null,0.32,0.52,0.27,null,null,0,0.40541168873881694,56.3615251044868,"gct V enriched",null,1E-3,null,null,"Detected",1686711047.3126552,891260000,11247658017.88505,0.07923960691041598,null,"Non Essential","U"]
["MMV666620",null,null,11.59,68.4,78.9,428,null,5.9016393442623,6.80759275237273,36.9283865401208,null,"PI4K","Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): preparation and evaluation of pyrazole … JM Large","Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) TM Chapman","New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of Plasmodium Phosphatidylinositol-4-kinase and cGMP … PM Cheuka",{"$nulls":4},"PF3D7_0509800",null,0.29,-0.01,0.16,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV666620",null,null,11.59,68.4,78.9,428,null,5.9016393442623,6.80759275237273,36.9283865401208,null,"PKG","Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): preparation and evaluation of pyrazole … JM Large","Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) TM Chapman","New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of Plasmodium Phosphatidylinositol-4-kinase and cGMP … PM Cheuka",{"$nulls":4},"PF3D7_1436600",null,0.47,-0.44,0.1,null,null,0,0.068244893498124,2.02530545710245,"gct V enriched",null,0.2,null,null,"Detected",187255751.4074903,109730000,295371702.85639864,0.37149801060444715,null,"Essential"]
["MMV020243",null,null,134.258604,1058.32,5000,5000,null,7.88269778225908,37.2415610697099,37.2415610697099,null,"phosphatidylserine decarboxylase (PSD)","Characterization of Plasmodium phosphatidylserine decarboxylase expressed in yeast and application for inhibitor screening JY Choi","Identification of Novel Ezrin Inhibitors Targeting Metastatic Osteosarcoma by Screening Open Access Malaria BoxScreening MMV Malaria Box to Identify Novel Ezrin … H Çelik",{"$nulls":5},"PF3D7_0927900",null,0.6,-0.61,0.16,null,null,0.9628761074834958,0,0.584893192461114,"shared 3 stages",null,1.6462426300978217,0.6074438735319221,null,"Not detected",{"$nulls":5},"Essential"]
["MMV667530",null,null,129.73,5000,null,5000,null,38.5415863716951,null,38.5415863716951,null,"2-C-Methyl-D-erythritol 4-Phosphate Cytidyltransferase (IspD)","Provided from MMV",{"$nulls":6},"PF3D7_0106900",null,0.39,1.03,0.97,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV669286",null,null,0.88,4.1,3,34.2,null,4.65909090909091,3.40909090909091,38.8636363636364,null,"CDPK1","Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): preparation and evaluation of pyrazole … JM Large","Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) TM Chapman","New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of Plasmodium Phosphatidylinositol-4-kinase and cGMP … PM Cheuka",{"$nulls":4},"PF3D7_0217500",null,0.54,-0.07,0.86,null,null,1.8276642121903912,0.8228906159046369,5.07832312829723,"shared 3 stages",null,0.35989521856266954,2.7785865119124034,null,"Detected",1326801430.219953,360430000,3411452182.6706023,0.10565295384496434,null,"Essential","I S","A"]
["MMV669286",null,null,0.88,4.1,3,34.2,null,4.65909090909091,3.40909090909091,38.8636363636364,null,"CDPK4","Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): preparation and evaluation of pyrazole … JM Large","Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) TM Chapman","New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of Plasmodium Phosphatidylinositol-4-kinase and cGMP … PM Cheuka",{"$nulls":4},"PF3D7_0717500",null,0.32,0.52,0.27,null,null,0,0.40541168873881694,56.3615251044868,"gct V enriched",null,1E-3,null,null,"Detected",1686711047.3126552,891260000,11247658017.88505,0.07923960691041598,null,"Non Essential","U"]
["MMV669286",null,null,0.88,4.1,3,34.2,null,4.65909090909091,3.40909090909091,38.8636363636364,null,"PI4K","Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): preparation and evaluation of pyrazole … JM Large","Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) TM Chapman","New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of Plasmodium Phosphatidylinositol-4-kinase and cGMP … PM Cheuka",{"$nulls":4},"PF3D7_0509800",null,0.29,-0.01,0.16,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV669286",null,null,0.88,4.1,3,34.2,null,4.65909090909091,3.40909090909091,38.8636363636364,null,"PKG","Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): preparation and evaluation of pyrazole … JM Large","Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) TM Chapman","New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of Plasmodium Phosphatidylinositol-4-kinase and cGMP … PM Cheuka",{"$nulls":4},"PF3D7_1436600",null,0.47,-0.44,0.1,null,null,0,0.068244893498124,2.02530545710245,"gct V enriched",null,0.2,null,null,"Detected",187255751.4074903,109730000,295371702.85639864,0.37149801060444715,null,"Essential"]
["Carmaphycin B","Carmaphycin B",null,4.1,null,null,160,{"$nulls":3},39.0243902439024,null,"Proteosome subunit beta type-5","LaMonte GM, Almaliti J, Bibo-Verdugo B, Keller L, Zou BY, Yang J, Antonova-Koch Y, Orjuela-Sanchez P, Boyle CA, Vigil E et al.. (2017) Development of a Potent Inhibitor of the Plasmodium Proteasome with Reduced Mammalian Toxicity.",{"$nulls":6},"PF3D7_1011400",null,0.17,0.88,0.57,null,null,1.3957664804363776,5.489058493010015,6.35642254459642,"gct V enriched",null,0.21958365269831148,4.554073072889044,null,"Detected",863717094.4504669,2420200000,905523359.9583262,2.672708520861772,null,"Essential (ortholog)"]
["GL Analog 18",null,null,3.27,null,null,130,{"$nulls":3},39.7553516819572,null,"Proteosome subunit beta type-5","LaMonte GM, Almaliti J, Bibo-Verdugo B, Keller L, Zou BY, Yang J, Antonova-Koch Y, Orjuela-Sanchez P, Boyle CA, Vigil E et al.. (2017) Development of a Potent Inhibitor of the Plasmodium Proteasome with Reduced Mammalian Toxicity.","Pan-active imidazolopiperazine antimalarials target the Plasmodium falciparum intracellular secretory pathway LaMonte 2020",{"$nulls":5},"PF3D7_1011400",null,0.17,0.88,0.57,null,null,1.3957664804363776,5.489058493010015,6.35642254459642,"gct V enriched",null,0.21958365269831148,4.554073072889044,null,"Detected",863717094.4504669,2420200000,905523359.9583262,2.672708520861772,null,"Essential (ortholog)"]
["MMV665827",null,null,119,5000,337,5000,null,42.0168067226891,2.83193277310924,42.0168067226891,null,"Mitochondrial electron transport chain (bc1 inhibitor)","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond Voorhis 2016","In vitro multistage malaria transmission blocking activity of selected malaria box compounds HM Malebo","Metabolomics-based screening of the malaria box reveals both novel and established mechanisms of action DJ Creek",{"$nulls":6},0.848333333333333,0.98,0.81,"Average",null,0.4530828604879675,1.7006577915597767,7.360729507627478,"gct V enriched","Average",0.06155407015275662,16.245879395437772,null,"Detected",692838621.0520334,545915000,215905094.41200727,2.528495223731227,null,"Essential/Non essential"]
["MMV019313",null,null,115.85,3928,null,5000,null,33.9059128182995,null,43.1592576607682,null,"bifunctional farnesyl/geranylgeranyl diphosphate synthase (FPPS/GGPPS)","Specific inhibition of the bifunctional farnesyl/geranylgeranyl diphosphate synthase in malaria parasites via a new small-molecule binding site. JE Gisselberg. 2018","E.L. Allman, H.J. Painter, J. Samra, M. Carrasquilla, M. Llinas Metabolomic profiling of the malaria box reveals antimalarial target pathways 2016",{"$nulls":5},"PF3D7_1128400",null,0.43,0.1,0.13,null,null,1.793245727412536,2.644193071403792,1.51188643150958,"shared 3 stages",null,1.186098168512582,0.8431005346328483,null,"Detected",242208425.91880268,194550000,99808849.0189269,1.9492259645545775,null,"Essential"]
["MMV019313",null,null,115.85,3928,null,5000,null,33.9059128182995,null,43.1592576607682,null,"protein farnesyltransferase subunit beta (FTB)","Specific inhibition of the bifunctional farnesyl/geranylgeranyl diphosphate synthase in malaria parasites via a new small-molecule binding site. JE Gisselberg. 2018","E.L. Allman, H.J. Painter, J. Samra, M. Carrasquilla, M. Llinas Metabolomic profiling of the malaria box reveals antimalarial target pathways 2016",{"$nulls":5},"PF3D7_1147500",null,0.9,-0.08,-0.56,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV019313",null,null,115.85,3928,null,5000,null,33.9059128182995,null,43.1592576607682,null,"protein farnesyltransferase subunit alpha","Specific inhibition of the bifunctional farnesyl/geranylgeranyl diphosphate synthase in malaria parasites via a new small-molecule binding site. JE Gisselberg. 2018","E.L. Allman, H.J. Painter, J. Samra, M. Carrasquilla, M. Llinas Metabolomic profiling of the malaria box reveals antimalarial target pathways 2016",{"$nulls":5},"PF3D7_1242600",null,0.63,-0.21,-0.65,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV019066",null,null,104.54,5000,null,5000,null,47.8285823608188,null,47.8285823608188,null,"protein farnesyltransferase subunit beta (FTB)","Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. Cowell. 2018","Eastman, R.T. et al. (2007) Resistance mutations at the lipid substrate binding site of Plasmodium falciparum protein farnesyltransferase. Mol. Biochem. Parasitol. 152, 66–71","Eastman, R.T. et al. (2005) Resistance to a protein farnesyltransferase inhibitor in Plasmodium falciparum. J. Biol. Chem. 280, 13554–13559","A broad analysis of resistance development in the malaria parasite VC Corey 2016","M.R. Luth, P. Gupta, S. Ottilie, E.A. Winzeler Using in vitro evolution and whole genome analysis to discover next generation targets for antimalarial drug discovery",null,null,"PF3D7_1147500",null,0.9,-0.08,-0.56,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV019066",null,null,104.54,5000,null,5000,null,47.8285823608188,null,47.8285823608188,null,"protein farnesyltransferase subunit alpha","Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. Cowell. 2018","Eastman, R.T. et al. (2007) Resistance mutations at the lipid substrate binding site of Plasmodium falciparum protein farnesyltransferase. Mol. Biochem. Parasitol. 152, 66–71","Eastman, R.T. et al. (2005) Resistance to a protein farnesyltransferase inhibitor in Plasmodium falciparum. J. Biol. Chem. 280, 13554–13559","A broad analysis of resistance development in the malaria parasite VC Corey 2016","M.R. Luth, P. Gupta, S. Ottilie, E.A. Winzeler Using in vitro evolution and whole genome analysis to discover next generation targets for antimalarial drug discovery",null,null,"PF3D7_1242600",null,0.63,-0.21,-0.65,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV1580857","Mupirocin",null,100.49,5000,null,5000,null,49.7561946462335,null,49.7561946462335,null,"isoleucine--tRNA ligase (cyto-IRS)","Validation of isoleucine utilization targets in Plasmodium falciparum. ES Istvan. 2011","Dual targeting of aminoacyl-tRNA synthetases to the apicoplast and cytosol in Plasmodium falciparum. KE Jackson. 2012",{"$nulls":5},"PF3D7_1332900",null,0.67,-0.18,-0.65,null,null,1.3845350808661399,2.2579551294528715,3.59886437939448,"shared 3 stages",null,0.3847144362519968,2.5993305833342237,null,"Detected",1648061769.4163723,4102300000,877671904.8445911,4.674070090834674,null,"Essential"]
["MMV1580857","Mupirocin",null,100.49,5000,null,5000,null,49.7561946462335,null,49.7561946462335,null,"isoleucine--tRNA ligase (api-IRS)","Validation of isoleucine utilization targets in Plasmodium falciparum. ES Istvan. 2011","Dual targeting of aminoacyl-tRNA synthetases to the apicoplast and cytosol in Plasmodium falciparum. KE Jackson. 2012",{"$nulls":5},"PF3D7_1225100",null,0.51,0.51,0.36,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Non Essential"]
["MMV666021",null,null,94.4,819,603,5000,null,8.67584745762712,6.38771186440678,52.9661016949153,null,"Mitochondrial electron transport chain (bc1 inhibitor) (Gamo)","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond Voorhis 2016","The relative rate of kill of the MMV Malaria Box compounds provides links to the mode of antimalarial action and highlights scaffolds of medicinal chemistry interest I Ullah",{"$nulls":7},0.848333333333333,0.98,0.81,"Average",null,0.4530828604879675,1.7006577915597767,7.360729507627478,"gct V enriched","Average",0.06155407015275662,16.245879395437772,null,"Detected",692838621.0520334,545915000,215905094.41200727,2.528495223731227,null,"Essential/Non essential"]
["MMV000025","Pyronaridine",null,17,27,null,938.4,null,1.58823529411765,null,55.2,null,"DNA topoisomerase2 (TOP2)","Pyronaridine: An update of its pharmacological activities andmechanisms of action Christian Bailly 2021","Review of pyronaridine anti-malarial properties and product characteristics Simon L Croft 2012",{"$nulls":5},"PF3D7_1433500",null,0.79,-0.02,0.28,null,null,1.1250623353878415,0.9615132377040246,2.43332001828199,"shared 3 stages",null,0.46235691439475163,2.162831286537696,null,"Detected",563713858.0970031,244090000,3133698280.5174513,0.07789199155436709,null,"Non Essential"]
["MMV000073","Cipargamin/KAE609/NITD609",null,0.5,1.03,null,27.7,null,2.06,null,55.4,null,"ATP4","Rottmann M, McNamara C, Yeung BK, Lee MC, Zou B, Russell B, Seitz P, Plouffe DM, Dharia NV, Tan J, Cohen SB, Spencer KR, Gonzalez-Paez GE, Lakshminarayana SB, Goh A, Suwanarusk R, Jegla T, Schmitt EK, Beck HP, Brun R, Nosten F, Renia L, Dartois V, Keller TH, Fidock DA, Winzeler EA, Diagana TT. 2010. Spiroindolones, a potent compound class for the treatment of malaria. Science 329:1175–1180.","N.J. Spillman, R.J. Allen, C.W. McNamara, B.K.S. Yeung, E.A. Winzeler, et al. Na+ regulation in the malaria parasite Plasmodium falciparum involves the cation ATPase PfATP4 and is a target of the spiroindolone antimalarials 2013","J.C. Van Pelt-Koops, H.E. Pett, W. Graumans, M. van der Vegte-Bolmer, G.J. van Gemert, M. Rottmann, et al. The spiroindolone drug candidate NITD609 potently inhibits gametocytogenesis and blocks Plasmodium falciparum transmission to anopheles mosquito vector 2012",{"$nulls":4},"PF3D7_1211900",null,0.33,-0.22,-0.49,null,null,1.7731908623980155,0.4394601472062679,2.59381366380463,"shared 3 stages",null,0.6836230709792325,1.462794400088903,null,"Detected",636393353.8483057,392860000,65708369.94269839,5.978842578846459,null,"Essential"]
["MMV000062","Pentamidine",null,10,697.28,812.56,700,null,69.728,81.256,70,null,"DNA topoisomerase2 (TOP2)","A. Stead, P.G. Bray, I.G. Edwards, H.P. DeKoning, B.C. Elford, P.A. Stocks, S.A. Ward Mol. Pharmacol., 59 (2001), pp. 1298-1306","A.E. Purfield, R.R. Tidwell, S.R. Meshnik Malar. J., 8 (2009), p. 104",{"$nulls":5},"PF3D7_1433500",null,0.79,-0.02,0.28,null,null,1.1250623353878415,0.9615132377040246,2.43332001828199,"shared 3 stages",null,0.46235691439475163,2.162831286537696,null,"Detected",563713858.0970031,244090000,3133698280.5174513,0.07789199155436709,null,"Non Essential"]
["MMV000062","Pentamidine",null,10,697.28,812.56,700,null,69.728,81.256,70,null,"calcium-transporting ATPase (ATP6)","A. Stead, P.G. Bray, I.G. Edwards, H.P. DeKoning, B.C. Elford, P.A. Stocks, S.A. Ward Mol. Pharmacol., 59 (2001), pp. 1298-1306","A.E. Purfield, R.R. Tidwell, S.R. Meshnik Malar. J., 8 (2009), p. 104",{"$nulls":5},"PF3D7_0106300",null,0.39,-0.03,-0.13,null,null,1.6876027710717014,0.7605873874153525,3.93796931771435,"shared 3 stages",null,0.4285464499381139,2.333469336041424,null,"Detected",1029579056.5443927,1600300000,889900800.0520924,1.7982903261872814,null,"Essential"]
["MMV674850",null,null,2.65,4.47,28.7,208.8,null,1.68679245283019,10.8301886792453,78.7924528301887,null,"CDPK1","Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): preparation and evaluation of pyrazole … JM Large","Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) TM Chapman","New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of Plasmodium Phosphatidylinositol-4-kinase and cGMP … PM Cheuka",{"$nulls":4},"PF3D7_0217500",null,0.54,-0.07,0.86,null,null,1.8276642121903912,0.8228906159046369,5.07832312829723,"shared 3 stages",null,0.35989521856266954,2.7785865119124034,null,"Detected",1326801430.219953,360430000,3411452182.6706023,0.10565295384496434,null,"Essential","I S","A"]
["MMV674850",null,null,2.65,4.47,28.7,208.8,null,1.68679245283019,10.8301886792453,78.7924528301887,null,"CDPK4","Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): preparation and evaluation of pyrazole … JM Large","Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) TM Chapman","New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of Plasmodium Phosphatidylinositol-4-kinase and cGMP … PM Cheuka",{"$nulls":4},"PF3D7_0717500",null,0.32,0.52,0.27,null,null,0,0.40541168873881694,56.3615251044868,"gct V enriched",null,1E-3,null,null,"Detected",1686711047.3126552,891260000,11247658017.88505,0.07923960691041598,null,"Non Essential","U"]
["MMV674850",null,null,2.65,4.47,28.7,208.8,null,1.68679245283019,10.8301886792453,78.7924528301887,null,"PI4K","Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): preparation and evaluation of pyrazole … JM Large","Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) TM Chapman","New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of Plasmodium Phosphatidylinositol-4-kinase and cGMP … PM Cheuka",{"$nulls":4},"PF3D7_0509800",null,0.29,-0.01,0.16,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV674850",null,null,2.65,4.47,28.7,208.8,null,1.68679245283019,10.8301886792453,78.7924528301887,null,"PKG","Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): preparation and evaluation of pyrazole … JM Large","Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) TM Chapman","New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of Plasmodium Phosphatidylinositol-4-kinase and cGMP … PM Cheuka",{"$nulls":4},"PF3D7_1436600",null,0.47,-0.44,0.1,null,null,0,0.068244893498124,2.02530545710245,"gct V enriched",null,0.2,null,null,"Detected",187255751.4074903,109730000,295371702.85639864,0.37149801060444715,null,"Essential"]
["MMV000662",null,null,36.7,1388,2000,3324.48,null,37.8201634877384,54.4959128065395,90.5852861035422,null,"ATP4","E.L. Allman, H.J. Painter, J. Samra, M. Carrasquilla, M. Llinas Metabolomic profiling of the malaria box reveals antimalarial target pathways 2016","Diverse chemotypes disrupt ion homeostasis in the malaria parasite AM Lehane 2014","Biochemical characterization and chemical inhibition of PfATP4-associated Na+-ATPase activity in Plasmodium falciparum membranes JEO Rosling 2018",{"$nulls":4},"PF3D7_1211900",null,0.33,-0.22,-0.49,null,null,1.7731908623980155,0.4394601472062679,2.59381366380463,"shared 3 stages",null,0.6836230709792325,1.462794400088903,null,"Detected",636393353.8483057,392860000,65708369.94269839,5.978842578846459,null,"Essential"]
["GNF-Pf-5640",null,null,9.98,null,null,994.14,{"$nulls":3},99.6132264529058,null,"MDR1","Genetic resistance to purine nucleoside phosphorylase inhibition in Plasmodium falciparum Proc. Natl. Acad. Sci. U. S. A., 115 (2018),","Hexahydroquinolines are Antimalarial Candidates with Potent Blood Stage and Transmission-Blocking Activity Manu Vanaerschot",{"$nulls":5},"PF3D7_0523000",null,0.55,-0.14,-0.37,null,null,4.185382762981795,2.6120056276710084,5.55996328108289,"shared 3 stages",null,0.752771655385218,1.3284240882957625,null,"Detected",1075298324.2997518,2109100000,611327737.4544191,3.45003158008556,null,"Essential"]
["MMV652007","AN3661",null,46.26,1086,null,5000,null,23.4760051880674,null,108.084738434933,null,"Cleavage and polyadenylation specificity factor subunit 3 (CPSF3)","A potent antimalarial benzoxaborole targets a Plasmodium falciparum cleavage and polyadenylation specificity factor homologue. Ebere Sonoiki. 2017",{"$nulls":6},"PF3D7_1438500",null,0.77,0.29,0.06,null,null,0.19077316861219132,0.1746748582396935,0,"enriched troph",null,1.2,0,null,"Detected",2165066.561177746,11106000,3262072.4244660535,3.4045841277781763,null,"Essential"]
["MMV027634",null,null,37.74,5000,null,5000,null,132.485426603074,null,132.485426603074,null,"DHFR-TS","Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. Cowell. 2018","Using in Vitro Evolution and Whole Genome Analysis To Discover Next Generation Targets for Antimalarial Drug Discovery. MR Luth. 2018","Exploration of the Plasmodium falciparum Resistome and Druggable Genome Reveals New Mechanisms of Drug Resistance and Antimalarial Targets. A Cowell. 2018",{"$nulls":4},"PF3D7_0417200",null,0.11,0.52,0.13,null,null,1.15443469003188,0.6407679530676047,10.9377664171444,"gct V enriched",null,0.10554574361931532,9.474564920465403,null,"Detected",3107354809.595412,901370000,1885999900.5903804,0.47792685445945216,null,"Essential","A"]
["MMV666023",null,null,36.8,2000,183.5,5000,null,54.3478260869565,4.98641304347826,135.869565217391,null,"deoxyhypusine hydroxylase (DOHH)","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond Voorhis 2016","Screening the Medicines for Malaria Venture \"Malaria Box\" against the Plasmodium falciparum Aminopeptidases, M1, M17 and M18 A Paiardini","Malaria Box Compounds against Anopheles gambiae (Diptera: Culicidae) Carboxypeptidase B Activity to Block Malaria Transmission T Pomun","Metabolomics-based screening of the malaria box reveals both novel and established mechanisms of action DJ Creek",{"$nulls":3},"PF3D7_1302600",null,0.46,-0.08,-0.12,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV666023",null,null,36.8,2000,183.5,5000,null,54.3478260869565,4.98641304347826,135.869565217391,null,"PfA-M17 leucyl aminopeptidase","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond Voorhis 2016","Screening the Medicines for Malaria Venture \"Malaria Box\" against the Plasmodium falciparum Aminopeptidases, M1, M17 and M18 A Paiardini","Malaria Box Compounds against Anopheles gambiae (Diptera: Culicidae) Carboxypeptidase B Activity to Block Malaria Transmission T Pomun","Metabolomics-based screening of the malaria box reveals both novel and established mechanisms of action DJ Creek",{"$nulls":3},"PF3D7_1446200",null,0.54,0.07,-0.73,null,null,5.684407499026659,6.582454249212135,12.6500780654601,"shared 3 stages",null,0.4493575035356835,2.2253995808052416,null,"Detected",1999628798.4753647,11380000000,1981315069.4565032,5.743659943555399,null,"Essential"]
["MMV666023",null,null,36.8,2000,183.5,5000,null,54.3478260869565,4.98641304347826,135.869565217391,null,"PfA-M1 alanyl aminopeptidase","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond Voorhis 2016","Screening the Medicines for Malaria Venture \"Malaria Box\" against the Plasmodium falciparum Aminopeptidases, M1, M17 and M18 A Paiardini","Malaria Box Compounds against Anopheles gambiae (Diptera: Culicidae) Carboxypeptidase B Activity to Block Malaria Transmission T Pomun","Metabolomics-based screening of the malaria box reveals both novel and established mechanisms of action DJ Creek",{"$nulls":3},"PF3D7_1311800",null,0.56,0.06,-0.86,null,null,15.969688689965796,9.989022559815394,32.8385515342823,"shared 3 stages",null,0.4863091684568973,2.056305052140164,null,"Detected",2472328320.453194,15872000000,1421009325.403716,11.169525573303808,null,"Essential"]
["MMV666023",null,null,36.8,2000,183.5,5000,null,54.3478260869565,4.98641304347826,135.869565217391,null,"(bc1 inhibitor","Open source drug discovery with the malaria box compound collection for neglected diseases and beyond Voorhis 2016","Screening the Medicines for Malaria Venture \"Malaria Box\" against the Plasmodium falciparum Aminopeptidases, M1, M17 and M18 A Paiardini","Malaria Box Compounds against Anopheles gambiae (Diptera: Culicidae) Carboxypeptidase B Activity to Block Malaria Transmission T Pomun","Metabolomics-based screening of the malaria box reveals both novel and established mechanisms of action DJ Creek",{"$nulls":5},0.848333333333333,0.98,0.81,"Average",null,0.4530828604879675,1.7006577915597767,7.360729507627478,"gct V enriched","Average",0.06155407015275662,16.245879395437772,null,"Detected",692838621.0520334,545915000,215905094.41200727,2.528495223731227,null,"Essential/Non essential"]
["MMV1557817","MIPS1778",null,32.83,1798,null,5000,null,54.7669814194334,null,152.299725860493,null,"PfA-M17 leucyl aminopeptidase","Characterising the M1 and M17 aminopeptidases in Plasmodium falciparum. R Edgar. 2018",{"$nulls":6},"PF3D7_1446200",null,0.54,0.07,-0.73,null,null,5.684407499026659,6.582454249212135,12.6500780654601,"shared 3 stages",null,0.4493575035356835,2.2253995808052416,null,"Detected",1999628798.4753647,11380000000,1981315069.4565032,5.743659943555399,null,"Essential"]
["MMV1557817","MIPS1778",null,32.83,1798,null,5000,null,54.7669814194334,null,152.299725860493,null,"PfA-M1 alanyl aminopeptidase","Characterising the M1 and M17 aminopeptidases in Plasmodium falciparum. R Edgar. 2018",{"$nulls":6},"PF3D7_1311800",null,0.56,0.06,-0.86,null,null,15.969688689965796,9.989022559815394,32.8385515342823,"shared 3 stages",null,0.4863091684568973,2.056305052140164,null,"Detected",2472328320.453194,15872000000,1421009325.403716,11.169525573303808,null,"Essential"]
["MMV000054","Quinine",null,29.25,374.94,1000,5000,null,12.8184615384615,34.1880341880342,170.940170940171,null,"purine nucleoside phosphorylase (PNP)","A. F. Cowman, D. Galatis, J. K. Thompson, Selection for mefloquine resistance in Plasmodium falciparum is linked to amplification of the pfmdr1 gene and cross-resistance to halofantrine and quinine. Proc. Natl. Acad. Sci. U.S.A. 91, 1143–1147 (1994).","K. N. Olafson, T. Q. Nguyen, J. D. Rimer, P. G. Vekilov, Antimalarials inhibit hematin crystallization by unique drug–surface site interactions. Proc. Natl. Acad. Sci. U.S.A. 114, 7531–7536 (2017).","M. W. Davidson, B. G. Griggs, D. W. Boykin, W. D. Wilson, Molecular structural effects involved in the interaction of quinolinemethanolamines with DNA. Implications for antimalarial action. J. Med. Chem. 20, 1117–1122 (1977).","Identifying purine nucleoside phosphorylase as the target of quinine using cellular thermal shift assay Jerzy M. Dziekan 2020",{"$nulls":3},"PF3D7_0513300",null,0.88,0.31,-0.78,null,null,59.71899427057608,106.97270748410696,226.584592607479,"gct V enriched",null,0.2635615845867752,3.794179647113023,null,"Detected",3876334039.934259,5361900000,1379349165.6537595,3.887268092454793,null,"Non Essential"]
["GNF-Pf-5660",null,null,5.05,null,null,945.42,{"$nulls":3},187.211881188119,null,"MDR1","Genetic resistance to purine nucleoside phosphorylase inhibition in Plasmodium falciparum Proc. Natl. Acad. Sci. U. S. A., 115 (2018),","Hexahydroquinolines are Antimalarial Candidates with Potent Blood Stage and Transmission-Blocking Activity Manu Vanaerschot"," Combining stage specificity and metabolomic profiling to advance antimalarial drug discovery JM Murithi",{"$nulls":4},"PF3D7_0523000",null,0.55,-0.14,-0.37,null,null,4.185382762981795,2.6120056276710084,5.55996328108289,"shared 3 stages",null,0.752771655385218,1.3284240882957625,null,"Detected",1075298324.2997518,2109100000,611327737.4544191,3.45003158008556,null,"Essential"]
["MMV000025","Pyronaridine",null,4.5,27,1866,938,null,6,414.666666666667,208.444444444444,null,"DNA topoisomerase2 (TOP2)","Pyronaridine: An update of its pharmacological activities andmechanisms of action Christian Bailly 2021","Review of pyronaridine anti-malarial properties and product characteristics Simon L Croft 2012",{"$nulls":5},"PF3D7_1433500",null,0.79,-0.02,0.28,null,null,1.1250623353878415,0.9615132377040246,2.43332001828199,"shared 3 stages",null,0.46235691439475163,2.162831286537696,null,"Detected",563713858.0970031,244090000,3133698280.5174513,0.07789199155436709,null,"Non Essential"]
["MMV000024","Pyrimethamine",null,22,5000,null,5000,null,227.272727272727,null,227.272727272727,null,"DHFR-TS","Basco LK, Eldin de Pecoulas P, Wilson CM, Le Bras J, Mazabraud A. 1995. Point mutations in the dihydrofolate reductase-thymidylate synthase gene and pyrimethamine and cycloguanil resistance in Plasmodium falciparum. Mol Biochem Parasitol 69:135–138.","Sirawaraporn W, Sathitkul T, Sirawaraporn R, Yuthavong Y, Santi DV. (1997) Antifolate-resistant mutants of Plasmodium falciparum dihydrofolate reductase. ","Yuthavong Y, Tarnchompoo B, Vilaivan T, Chitnumsub P, Kamchonwongpaisan S, Charman SA, McLennan DN, White KL, Vivas L, Bongard E et al.. (2012) Malarial dihydrofolate reductase as a paradigm for drug development against a resistance-compromised target. ",{"$nulls":4},"PF3D7_0417200",null,0.11,0.52,0.13,null,null,1.15443469003188,0.6407679530676047,10.9377664171444,"gct V enriched",null,0.10554574361931532,9.474564920465403,null,"Detected",3107354809.595412,901370000,1885999900.5903804,0.47792685445945216,null,"Essential","A"]
["MMV000061","Methylene blue",null,0.3,13.3,30,80,null,44.3333333333333,100,266.666666666667,null,"glutathione reductase (GR)","Buchholz K, Schirmer RH, Eubel JK, Akoachere MB, Dandekar T, Becker K, Gromer S. 2008. Interactions of methylene blue with human disulfide reductases and their orthologues from Plasmodium falciparum. Antimicrob. Agents Chemother. 52:183–191.","Vennerstrom JL, Makler MT, Angerhofer CK, Williams JA. 1995. Antimalarial dyes revisited: xanthenes, azines, oxazines, and thiazines. Antimicrob Agents Chemother 39:2671–2677. https://doi.org/10.1128/AAC.39 .12.2671",{"$nulls":5},"PF3D7_1419800",null,0.71,0.64,-0.14,null,null,1.15443469003188,1.0570182237640764,9,"gct V enriched",null,0.12827052111465334,7.7960235236446875,null,"Not detected",{"$nulls":5},"Essential"]
["MMV1793799","ML10",null,18.15,5000,null,5000,null,275.482093663912,null,275.482093663912,null,"PKG"," A potent series targeting the malarial cGMP-dependent protein kinase clears infection and blocks transmission. DA Baker. 2017",{"$nulls":6},"PF3D7_1436600",null,0.47,-0.44,0.1,null,null,0,0.068244893498124,2.02530545710245,"gct V enriched",null,0.2,null,null,"Detected",187255751.4074903,109730000,295371702.85639864,0.37149801060444715,null,"Essential"]
["MMV674253","AZ412/MMV253",null,9,141.97,null,5000,null,15.7744444444444,null,555.555555555556,null,"Vacuolar ATP synthase (V-type H+-ATPase) subunit D","Hameed PS, Solapure S, Patil V, Henrich PP, Magistrado PA, Bharath S, Murugan K, Viswanath P, Puttur J, Srivastava A, Bellale E, Panduga V, Shanbag G, Awasthy D, Landge S, Morayya S, Koushik K, Saralaya R, Raichurkar A, Rautela N, Roy Choudhury N, Ambady A, Nandishaiah R, Reddy J, Prabhakar KR, Menasinakai S, Rudrapatna S, Chatterji M, Jimenez-Diaz MB, Martinez MS, Sanz LM, Coburn-Flynn O, Fidock DA, Lukens AK, Wirth DF, Bandodkar B, Mukherjee K, McLaughlin RE, Waterson D, Rosenbrier-Ribeiro L, Hickling K, Balasubramanian V, Warner P, Hosagrahara V, Dudley A, Iyer PS, Narayanan S, Kavanagh S, Sambandamurthy VK. 2015. Triaminopyrimidine is a fast-killing and long-acting antimalarial clinical candidate. Nat Commun 6:6715.",{"$nulls":6},"PF3D7_1341900",null,0.35,0.76,0.31,null,null,1.76006068659215,1.255572788203053,28.7635144163132,"gct V enriched",null,0.06119073841664958,16.34234241775234,null,"Detected",717038371.5075008,250510000,745494515.9749957,0.3360319823042162,null,"Essential"]
["MMV1557821","SC83288",null,6.68,3903,null,5000,null,584.281437125749,null,748.502994011976,null,"calcium-transporting ATPase (ATP6)","SC83288 is a clinical development candidate for the treatment of severe malaria S Pegoraro 2017","Target identification studies for SC83288: a novel drug for the treatment of severe malaria RV Celada 2022",{"$nulls":5},"PF3D7_0106300",null,0.39,-0.03,-0.13,null,null,1.6876027710717014,0.7605873874153525,3.93796931771435,"shared 3 stages",null,0.4285464499381139,2.333469336041424,null,"Detected",1029579056.5443927,1600300000,889900800.0520924,1.7982903261872814,null,"Essential"]
["MMV1557821","SC83288",null,6.68,3903,null,5000,null,584.281437125749,null,748.502994011976,null,"fumarate hydratase (FH)","SC83288 is a clinical development candidate for the treatment of severe malaria S Pegoraro 2017","Target identification studies for SC83288: a novel drug for the treatment of severe malaria RV Celada 2022",{"$nulls":5},"PF3D7_0927300",null,0.23,0.16,0.19,null,null,0.16576703731775866,0.3188409631490102,3.01945033361513,"gct V enriched",null,0.054899739688477986,18.21502261530529,null,"Detected",289907290.8347029,323510000,31981193.98333044,10.115632335947906,null,"Essential"]
["MMV1557821","SC83288",null,6.68,3903,null,5000,null,584.281437125749,null,748.502994011976,null,"mini-chromosome maintenance complex-binding protein","SC83288 is a clinical development candidate for the treatment of severe malaria S Pegoraro 2017","Target identification studies for SC83288: a novel drug for the treatment of severe malaria RV Celada 2022",{"$nulls":5},"PF3D7_1412100",null,1.16,0.17,0.19,null,null,0.22030595261377078,0.06444401261225294,0.0873356727196561,"enriched troph",null,2.522519673271926,0.3964290192047991,null,"Detected",477492.16995597084,2276900,32190079.896683455,0.07073297137838384,null,"Essential","A"]
["MMV1557821","SC83288",null,6.68,3903,null,5000,null,584.281437125749,null,748.502994011976,null,"casein kinase 2, alpha subunit","SC83288 is a clinical development candidate for the treatment of severe malaria S Pegoraro 2017","Target identification studies for SC83288: a novel drug for the treatment of severe malaria RV Celada 2022",{"$nulls":5},"PF3D7_1108400",null,0.45,0.17,0.01,null,null,60.79064011727486,103.28083452179338,47.3293023857175,"shared 3 stages",null,1.2844186804582942,0.7785623295693499,null,"Detected",1725313191.9432108,3068800000,905698894.339295,3.388322564132842,null,"Essential","I","D"]
["MMV1557821","SC83288",null,6.68,3903,null,5000,null,584.281437125749,null,748.502994011976,null,"casein kinase II beta chain","SC83288 is a clinical development candidate for the treatment of severe malaria S Pegoraro 2017","Target identification studies for SC83288: a novel drug for the treatment of severe malaria RV Celada 2022",{"$nulls":5},"PF3D7_1103700",null,0.9,0.14,-0.56,null,null,3.2187487937519563,1.8900861310663797,4.08021804691302,"shared 3 stages",null,0.7888668587668183,1.2676410333211763,null,"Detected",299234964.12211066,248990000,101464723.34606703,2.453956328750502,null,"Essential"]
["MMV1557821","SC83288",null,6.68,3903,null,5000,null,584.281437125749,null,748.502994011976,null,"casein kinase II beta chain","SC83288 is a clinical development candidate for the treatment of severe malaria S Pegoraro 2017","Target identification studies for SC83288: a novel drug for the treatment of severe malaria RV Celada 2022",{"$nulls":5},"PF3D7_1342400",null,0.4,0.07,-0.15,null,null,2.257613856055447,1.1731201409058445,1.37137370566166,"enriched troph",null,1.6462426300978217,0.6074438735319221,null,"Detected",448793529.6010071,86727000,75538295.27695781,1.148119634974807,null,"Non Essential"]
["MMV1557821","SC83288",null,6.68,3903,null,5000,null,584.281437125749,null,748.502994011976,null,"iron-sulfur cluster assembly protein SufA","SC83288 is a clinical development candidate for the treatment of severe malaria S Pegoraro 2017","Target identification studies for SC83288: a novel drug for the treatment of severe malaria RV Celada 2022",{"$nulls":5},"PF3D7_0522700",null,0.46,0.62,0.91,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV1557821","SC83288",null,6.68,3903,null,5000,null,584.281437125749,null,748.502994011976,null,"iron-sulfur cluster assembly protein SufD","SC83288 is a clinical development candidate for the treatment of severe malaria S Pegoraro 2017","Target identification studies for SC83288: a novel drug for the treatment of severe malaria RV Celada 2022",{"$nulls":5},"PF3D7_1103400",null,0.4,0.62,0.39,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV1557821","SC83288",null,6.68,3903,null,5000,null,584.281437125749,null,748.502994011976,null,"iron-sulfur cluster assembly protein SufC","SC83288 is a clinical development candidate for the treatment of severe malaria S Pegoraro 2017","Target identification studies for SC83288: a novel drug for the treatment of severe malaria RV Celada 2022",{"$nulls":5},"PF3D7_1413500",null,0.41,-0.05,0.12,null,null,0,0.36959173644292936,0,"gct I/II enriched",{"$nulls":4},"Not detected",{"$nulls":5},"Essential"]
["MMV1557821","SC83288",null,6.68,3903,null,5000,null,584.281437125749,null,748.502994011976,null,"iron-sulfur cluster assembly protein ISCU","SC83288 is a clinical development candidate for the treatment of severe malaria S Pegoraro 2017","Target identification studies for SC83288: a novel drug for the treatment of severe malaria RV Celada 2022",{"$nulls":5},"PF3D7_1454500",null,0.61,0.46,-0.06,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV1557821","SC83288",null,6.68,3903,null,5000,null,584.281437125749,null,748.502994011976,null,"cytosolic iron-sulfur assembly component 2","SC83288 is a clinical development candidate for the treatment of severe malaria S Pegoraro 2017","Target identification studies for SC83288: a novel drug for the treatment of severe malaria RV Celada 2022",{"$nulls":5},"PF3D7_0703100",null,0.86,0.01,-0.27,null,null,0,0,0.701254279852589,"gct V enriched",null,0.4,null,null,"Detected",25954875.437983003,11308000,53060532.6792846,0.21311508627983985,null,"Essential"]
["MMV1557821","SC83288",null,6.68,3903,null,5000,null,584.281437125749,null,748.502994011976,null,"cytosolic iron-sulfur protein assembly protein 1","SC83288 is a clinical development candidate for the treatment of severe malaria S Pegoraro 2017","Target identification studies for SC83288: a novel drug for the treatment of severe malaria RV Celada 2022",{"$nulls":5},"PF3D7_1209400",null,0.5,-0.02,0.36,{"$nulls":6},"Not detected",{"$nulls":3},"Detected",1273809.0091756743,203910,10904780.86039243,0.018699137801166405,null,"Essential (ortholog)"]
["MMV1557821","SC83288",null,6.68,3903,null,5000,null,584.281437125749,null,748.502994011976,null,"Fe-S cluster assembly protein DRE2","SC83288 is a clinical development candidate for the treatment of severe malaria S Pegoraro 2017","Target identification studies for SC83288: a novel drug for the treatment of severe malaria RV Celada 2022",{"$nulls":5},"PF3D7_0824600",null,1.14,0.16,-0.15,null,null,1.2812367429334575,0.23330678076078387,1.05352502645715,"shared 3 stages",null,1.216142674125235,0.8222719433139658,null,"Detected",52525311.32636291,5585300,31361557.61851016,0.1780938328363976,null,"Essential"]
["MMV000147","P218",null,6,5000,null,5000,null,833.333333333333,null,833.333333333333,null,"DHFR-TS","Yuthavong Y, Tarnchompoo B, Vilaivan T, Chitnumsub P, Kamchonwongpaisan S, Charman SA, McLennan DN, White KL, Vivas L, Bongard E, Thongphanchang C, Taweechai S, Vanichtanankul J, Rattanajak R, Arwon U, Fantauzzi P, Yuvaniyama J, Charman WN, Matthews D. 2012. Malarial dihydrofolate reductase as a paradigm for drug development against a resistance-compromised target. Proc Natl Acad Sci U S A 109:16823–16828",{"$nulls":6},"PF3D7_0417200",null,0.11,0.52,0.13,null,null,1.15443469003188,0.6407679530676047,10.9377664171444,"gct V enriched",null,0.10554574361931532,9.474564920465403,null,"Detected",3107354809.595412,901370000,1885999900.5903804,0.47792685445945216,null,"Essential","A"]
["MMV000130","Ganaplacide/KAF156",null,{"v":6,"d":"6.00"},{"v":3300,"d":"3300.00"},null,{"v":5000,"d":"5000.00"},null,{"$f":"E261/D261","v":{"v":550,"d":"550.0000"}},null,{"$f":"G261/D261","v":{"v":833.3333333333334,"d":"833.33"}},null,"Protein secretory pathway","Pan-active imidazolopiperazine antimalarials target the Plasmodium falciparum intracellular secretory pathway. GM LaMonte. 2020",{"$nulls":11},"Not detected",{"$nulls":5},"Not detected",{"$nulls":3},"Not detected"]
["MMV000130","Ganaplacide/KAF156",null,{"v":6,"d":"6.00"},{"v":3300,"d":"3300.00"},null,{"v":5000,"d":"5000.00"},null,{"v":550,"d":"550.0000"},null,{"v":833.3333333333334,"d":"833.33"},null,"CARL","Pan-active imidazolopiperazine antimalarials target the Plasmodium falciparum intracellular secretory pathway. GM LaMonte. 2020",{"$nulls":6},"PF3D7_0321900",null,0.31,-0.21,-0.06,null,null,0,0,0.0537249727360731,"gct V enriched",null,0.8,null,null,"Not detected"]
["MMV1793038","BRD7539",null,5.54,5000,null,5000,null,902.527075812274,null,902.527075812274,null,"PfDHODH","Discovery of Antimalarial Azetidine-2-carbonitriles That Inhibit P. falciparum Dihydroorotate Dehydrogenase. M Maetani. 2017","Diversity-oriented synthesis yields novel multistage antimalarial inhibitors. Nobutaka Kato. 2016","Painter, H. J., Morrisey, J. M., Mather, M. W. & Vaidya, A. B. Specific role of mitochondrial electron transport in blood-stage Plasmodium falciparum. Nature 446",{"$nulls":4},"PF3D7_0603300",null,0.75,-0.19,-0.43,null,null,1.15443469003188,0.7714114432536744,1.89426612471675,"shared 3 stages",null,{"$f":"AB263/AD263","v":0.6094363801202974},{"$f":"AD263/AB263","v":1.6408603631483383},null,"Detected",133919747.91061999,21091000,31021606.034033686,{"$f":"AL263/AM263","v":0.679880982849861},null,"Essential"]
["MMV034055","ELQ-300",null,5,5000,null,5000,null,1000,null,1000,null,"mitochondrial cytochrome bc1 complex (Qi-site)","Nilsen A, LaCrue AN, White KL, Forquer IP, Cross RM, Marfurt J, Mather MW, Delves MJ, Shackleford DM, Saenz FE, Morrisey JM, Steuten J, Mutka T, Li Y, Wirjanata G, Ryan E, Duffy S, Kelly JX, Sebayang BF, Zeeman AM, Noviyanti R, Sinden RE, Kocken CH, Price RN, Avery VM, Angulo-Barturen I, Jimenez-Diaz MB, Ferrer S, Herreros E, Sanz LM, Gamo FJ, Bathurst I, Burrows JN, Siegl P, Guy RK, Winter RW, Vaidya AB, Charman SA, Kyle DE, Manetsch R, Riscoe MK. 2013. Quinolone-3-diarylethers: a new class of antimalarial drug. Sci Transl Med 5:177ra37.","Stickles AM, de Almeida MJ, Morrisey JM, Sheridan KA, Forquer IP, Nilsen A, Winter RW, Burrows JN, Fidock DA, Vaidya AB et al.. (2015) Subtle changes in endochin-like quinolone structure alter the site of inhibition within the cytochrome bc1 complex of Plasmodium falciparum. ",{"$nulls":7},0.848333333333333,0.98,0.81,"Average",null,0.4530828604879675,1.7006577915597767,7.360729507627478,"gct V enriched","Average",0.06155407015275662,16.245879395437772,null,"Detected",692838621.0520334,545915000,215905094.41200727,2.528495223731227,null,"Essential/Non essential"]
["P218","P218",null,4.6,5000,5000,5000,null,1086.95652173913,1086.95652173913,1086.95652173913,null,"DHFR-TS","Yuthavong Y, Tarnchompoo B, Vilaivan T, Chitnumsub P, Kamchonwongpaisan S, Charman SA, McLennan DN, White KL, Vivas L, Bongard E, Thongphanchang C, Taweechai S, Vanichtanankul J, Rattanajak R, Arwon U, Fantauzzi P, Yuvaniyama J, Charman WN, Matthews D. 2012. Malarial dihydrofolate reductase as a paradigm for drug development against a resistance-compromised target. Proc Natl Acad Sci U S A 109:16823–16828",{"$nulls":6},"PF3D7_0417200",null,0.11,0.52,0.13,null,null,1.15443469003188,0.6407679530676047,10.9377664171444,"gct V enriched",null,0.10554574361931532,9.474564920465403,null,"Detected",3107354809.595412,901370000,1885999900.5903804,0.47792685445945216,null,"Essential","A"]
["MMV018912","DSM265",null,4.3,5000,null,5000,null,1162.79069767442,null,1162.79069767442,null,"PfDHODH","Phillips MA, Lotharius J, Marsh K, White J, Dayan A, White KL, Njoroge JW, El Mazouni F, Lao Y, Kokkonda S, Tomchick DR, Deng X, Laird T, Bhatia SN, March S, Ng CL, Fidock DA, Wittlin S, Lafuente-Monasterio M, Benito FJ, Alonso LM, Martinez MS, Jimenez-Diaz MB, Bazaga SF, Angulo-Barturen I, Haselden JN, Louttit J, Cui Y, Sridhar A, Zeeman AM, Kocken C, Sauerwein R, Dechering K, Avery VM, Duffy S, Delves M, Sinden R, Ruecker A, Wickham KS, Rochford R, Gahagen J, Iyer L, Riccio E, Mirsalis J, Bathhurst I, Rueckle T, Ding X, Campo B, Leroy D, Rogers MJ, etal. 2015. A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria. Sci Transl Med 7:296ra111.",{"$nulls":6},"PF3D7_0603300",null,0.75,-0.19,-0.43,null,null,1.15443469003188,0.7714114432536744,1.89426612471675,"shared 3 stages",null,0.6094363801202974,1.6408603631483383,null,"Detected",133919747.91061999,21091000,31021606.034033686,0.679880982849861,null,"Essential"]
["MMV000004","Artenimol (DHA)",null,1.45,20.5,null,2103.3,null,14.1379310344828,null,1450.55172413793,null,"PI3K","Wang J, Zhang CJ, Chia WN, Loh CCY, Li Z, Lee YM, et al. Haem-activated promiscuous targeting of artemisinin in Plasmodium falciparum. Nat Commun. 2015;6:10111.","Tilley L, Straimer J, Gnädig NF, Ralph SA, Fidock DA. Artemisinin action and resistance in Plasmodium falciparum. Trends Parasitol. 2016;32:682–96."," High-throughput assay and discovery of small molecules that interrupt malaria transmission DM Plouffe 2016","Antimalarial and anticancer properties of artesunate and other artemisinins: current development P Khanal 2021","Coertzen, D., Reader, J., van der Watt, M., Nondaba, S. H., Gibhard, L., Wiesner, L., et al. (2018). Artemisone and Artemiside Are Potent Panreactive Antimalarial Agents That Also Synergize Redox Imbalance in Plasmodium Falciparum Transmissible Gametocyte Stages. Antimicrob. Agents Chemother. 62, 1–17. doi: 10.1128/AAC.02214-17","Klonis, N., Crespo-Ortiz, M. P., Bottova, I., Abu-Bakar, N., Kenny, S., Rosenthal, P. J., et al. (2011). Artemisinin Activity Against Plasmodium Falciparum Requires Hemoglobin Uptake and Digestion. Proc. Natl. Acad. Sci. U.S.A. 108, 11405–11410. doi: 10.1073/pnas.1104063108",null,"PF3D7_0515300",null,0.56,0.18,0.29,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV000445",null,null,1.97,2000,1611,3586.66,null,1015.22842639594,817.766497461929,1820.63959390863,null,"phosphoethanolamine methyltransferase (PfPMT)","Open Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and Beyond Wesley C. Van Voorhis 2016",{"$nulls":6},"PF3D7_1343000",null,0.77,1.48,0.61,null,null,336.4138014225539,83.2557979663136,10.5478198468946,"enriched troph",null,31.89415502973328,0.03135370725663531,null,"Detected",114835488.61768718,1894500000,446647232.3754124,4.241602460905097,null,"Non/Essential","A"]
["MMV000024","Pyrimethamine",null,2.5,5000,5000,5000,null,2000,2000,2000,null,"DHFR-TS","Basco LK, Eldin de Pecoulas P, Wilson CM, Le Bras J, Mazabraud A. 1995. Point mutations in the dihydrofolate reductase-thymidylate synthase gene and pyrimethamine and cycloguanil resistance in Plasmodium falciparum. Mol Biochem Parasitol 69:135–138.","Sirawaraporn W, Sathitkul T, Sirawaraporn R, Yuthavong Y, Santi DV. (1997) Antifolate-resistant mutants of Plasmodium falciparum dihydrofolate reductase. ","Yuthavong Y, Tarnchompoo B, Vilaivan T, Chitnumsub P, Kamchonwongpaisan S, Charman SA, McLennan DN, White KL, Vivas L, Bongard E et al.. (2012) Malarial dihydrofolate reductase as a paradigm for drug development against a resistance-compromised target. ",{"$nulls":4},"PF3D7_0417200",null,0.11,0.52,0.13,null,null,1.15443469003188,0.6407679530676047,10.9377664171444,"gct V enriched",null,0.10554574361931532,9.474564920465403,null,"Detected",3107354809.595412,901370000,1885999900.5903804,0.47792685445945216,null,"Essential","A"]
["MMV688533","MMV533",null,1.9,247.1,null,5000,null,130.052631578947,null,2631.57894736842,null,"Plasmodium protein (PfACG1)"," The antimalarial MMV688533 provides potential for single-dose cures with a high barrier to Plasmodium falciparum parasite resistance James M Murithi 2021",{"$nulls":6},"PF3D7_0910300",null,1,1.02,0.36,null,null,0,1.0364555891885496,1.31012970008316,"gct V enriched",null,2,null,null,"Detected",76963909.60590272,43815000,30348724.240319505,1.4437180177013835,null,"Non Essential"]
["MMV688533","MMV533",null,1.9,247.1,null,5000,null,130.052631578947,null,2631.57894736842,null,"EH domain-containing protein (EHD)"," The antimalarial MMV688533 provides potential for single-dose cures with a high barrier to Plasmodium falciparum parasite resistance James M Murithi 2021",{"$nulls":6},"PF3D7_0304200",null,0.52,-0.17,-0.37,null,null,0.8697210650705587,0.5334064717843519,1.97635144163132,"shared 3 stages",null,0.4400639717967739,2.2723968879274903,null,"Detected",237537519.2852397,226920000,130246510.67893732,1.742234773255205,null,"Non Essential"]
["MMV000046","Atovaquone",null,0.27,5000,34.79,1000,null,18518.5185185185,128.851851851852,3703.7037037037,null,"bc1 complex (Qo site)","Fry M, Pudney M. 1992. Site of action of the antimalarial hydroxynaphthoquinone, 2-[trans-4-(4′-chlorophenyl) cyclohexyl]-3-hydroxy-1,4-naphthoquinone (566C80). Biochem Pharmacol 43:1545–1553.","Birth D, Kao WC, Hunte C. 2014. Structural analysis of atovaquone- inhibited cytochrome bc1 complex reveals the molecular basis of anti- malarial drug action. Nat Commun 5:4029.","Srivastava IK, Rottenberg H, Vaidya AB. (1997) Atovaquone, a broad spectrum antiparasitic drug, collapses mitochondrial membrane potential in a malarial parasite. ","Vaidya AB, Lashgari MS, Pologe LG, Morrisey J. (1993) Structural features of Plasmodium cytochrome b that may underlie susceptibility to 8-aminoquinolines and hydroxynaphthoquinones. ",{"$nulls":5},0.848333333333333,0.98,0.81,"Average",null,0.4530828604879675,1.7006577915597767,7.360729507627478,"gct V enriched","Average",0.06155407015275662,16.245879395437772,null,"Detected",692838621.0520334,545915000,215905094.41200727,2.528495223731227,null,"Essential/Non essential"]
["MMV687815","BRD7929",null,1.07,12.45,null,5000,null,11.6355140186916,null,4672.89719626168,null,"phenylalanine-tRNA synthetase (PheRS/FRS)","Inhibition of Plasmodium falciparum phenylalanine tRNA synthetase provides opportunity for antimalarial drug development. Sharma. 2022","Novel antimalarial target identified. Crunkhorn. 2016","Kato N, Comer E, Sakata-Kato T, Sharma A, Sharma M, Maetani M, Bastien J, Brancucci NM, Bittker JA, Corey V et al.. (2016) Diversity-oriented synthesis yields novel multistage antimalarial inhibitors. ",{"$nulls":4},"PF3D7_1104000",null,0.3,0.21,0.02,null,null,1.2020793536038865,1.1006424132444954,3.64158883361278,"shared 3 stages",null,0.33009749549657885,3.0294080192752144,null,"Detected",370151675.735217,365270000,275899088.8609134,1.3239260829315038,null,"Essential"]
["MMV000046","Atovaquone",null,1,5000,null,5000,null,5000,null,5000,null,"bc1 complex (Qo site)","Fry M, Pudney M. 1992. Site of action of the antimalarial hydroxynaphthoquinone, 2-[trans-4-(4′-chlorophenyl) cyclohexyl]-3-hydroxy-1,4-naphthoquinone (566C80). Biochem Pharmacol 43:1545–1553.","Birth D, Kao WC, Hunte C. 2014. Structural analysis of atovaquone- inhibited cytochrome bc1 complex reveals the molecular basis of anti- malarial drug action. Nat Commun 5:4029.","Srivastava IK, Rottenberg H, Vaidya AB. (1997) Atovaquone, a broad spectrum antiparasitic drug, collapses mitochondrial membrane potential in a malarial parasite. ","Vaidya AB, Lashgari MS, Pologe LG, Morrisey J. (1993) Structural features of Plasmodium cytochrome b that may underlie susceptibility to 8-aminoquinolines and hydroxynaphthoquinones. ",{"$nulls":5},0.848333333333333,0.98,0.81,"Average",null,0.4530828604879675,1.7006577915597767,7.360729507627478,"gct V enriched","Average",0.06155407015275662,16.245879395437772,null,"Detected",692838621.0520334,545915000,215905094.41200727,2.528495223731227,null,"Essential/Non essential"]
["MMV000004","DHA",null,0.24,0.9,2.17,1500,null,3.75,9.04166666666667,6250,null,"PI3K","Wang J, Zhang CJ, Chia WN, Loh CCY, Li Z, Lee YM, et al. Haem-activated promiscuous targeting of artemisinin in Plasmodium falciparum. Nat Commun. 2015;6:10111.","Tilley L, Straimer J, Gnädig NF, Ralph SA, Fidock DA. Artemisinin action and resistance in Plasmodium falciparum. Trends Parasitol. 2016;32:682–96."," High-throughput assay and discovery of small molecules that interrupt malaria transmission DM Plouffe 2016","Antimalarial and anticancer properties of artesunate and other artemisinins: current development P Khanal 2021","Coertzen, D., Reader, J., van der Watt, M., Nondaba, S. H., Gibhard, L., Wiesner, L., et al. (2018). Artemisone and Artemiside Are Potent Panreactive Antimalarial Agents That Also Synergize Redox Imbalance in Plasmodium Falciparum Transmissible Gametocyte Stages. Antimicrob. Agents Chemother. 62, 1–17. doi: 10.1128/AAC.02214-17","Klonis, N., Crespo-Ortiz, M. P., Bottova, I., Abu-Bakar, N., Kenny, S., Rosenthal, P. J., et al. (2011). Artemisinin Activity Against Plasmodium Falciparum Requires Hemoglobin Uptake and Digestion. Proc. Natl. Acad. Sci. U.S.A. 108, 11405–11410. doi: 10.1073/pnas.1104063108",null,"PF3D7_0515300",null,0.56,0.18,0.29,{"$nulls":6},"Not detected",{"$nulls":3},"Not detected",{"$nulls":5},"Essential"]
["MMV1576861","49c",null,0.6,1031,null,5000,null,1718.33333333333,null,8333.33333333333,null,"plasmepsin X (PMX)","Pino P, Caldelari R, Mukherjee B, Vahokoski J, Klages N, Maco B, Collins CR, Blackman MJ, Kursula I, Heussler V et al.. (2017) A multistage antimalarial targets the plasmepsins IX and X essential for invasion and egress. ","C.-L. Ciana, Novel in vivo active anti-malarials based on a hydroxy-ethyl-amine scaffold. 2013","W.A. Guiguemde, A.A. Shelat, D. Bouck, S. Duffy, G.J. Crowther, P.H. Davis, D.C. Smithson, M. Connelly, J. Clark, F. Zhu, M.B. Jiménez-Díaz, M.S. Martinez, E.B. Wilson, A.K. Tripathi, J. Gut, E.R. Sharlow. Chemical genetics of Plasmodium falciparum. 2010",{"$nulls":4},"PF3D7_0808200",null,1.26,-0.79,0.17,null,null,0,0,0.99526231496888,"gct V enriched",null,2,null,null,"Detected",90439310.2773018,149530000,3295189.911008856,45.37826469437687,null,"Essential Non/Essential","D I"]
["MMV1576861","49c",null,0.6,1031,null,5000,null,1718.33333333333,null,8333.33333333333,null,"Plasmepsin IX (PMIX)","Pino P, Caldelari R, Mukherjee B, Vahokoski J, Klages N, Maco B, Collins CR, Blackman MJ, Kursula I, Heussler V et al.. (2017) A multistage antimalarial targets the plasmepsins IX and X essential for invasion and egress. ","C.-L. Ciana, Novel in vivo active anti-malarials based on a hydroxy-ethyl-amine scaffold. 2013","W.A. Guiguemde, A.A. Shelat, D. Bouck, S. Duffy, G.J. Crowther, P.H. Davis, D.C. Smithson, M. Connelly, J. Clark, F. Zhu, M.B. Jiménez-Díaz, M.S. Martinez, E.B. Wilson, A.K. Tripathi, J. Gut, E.R. Sharlow. Chemical genetics of Plasmodium falciparum. 2010",{"$nulls":4},"PF3D7_1430200",null,0.33,1.1,0.72,{"$nulls":6},"Not detected",{"$nulls":3},"Translationally repressed",{"$nulls":5},"Essential","I"]
["MMV884705","NMT-145",null,0.144,5000,null,5000,null,34722.2222222222,null,34722.2222222222,null,"glycylpeptide N-tetradecanoyltransferase (NMT)","Selective Inhibitors of Protozoan Protein N-myristoyltransferases as Starting Points for Tropical Disease Medicinal Chemistry Programs Andrew S. Bell 2012",{"$nulls":6},"PF3D7_1412800",null,0.91,-0.29,-0.56,null,null,2.1250813598006153,1.3648237269808132,2.98107170553497,"shared 3 stages",null,0.7128581831342623,1.402803564101973,null,"Detected",158075546.59579676,253280000,104045078.74631013,2.434329456538398,null,"Essential"]